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General information on the European network for Health Technology Assessment, 
EUnetHTA 
 
Background 
Health Technology Assessment (HTA) is increasingly used in European countries to inform 
decision- and policy-making in the health care sector. Several countries have integrated HTA into 
policy, governance, reimbursement or regulatory processes. Therefore, the EU and Member States 
in 2004 expressed the need for a sustainable European network for HTA. 
 
EUnetHTA was established to respond to this need. The European Commission and Member States 
co-funded the three year project (2006–2008) with the aim to develop a sustainable network and 
information resources to inform health policy making (1, 2, 3). The project, which was based on 
three prior projects, connected national HTA agencies, research institutions and health ministries 
and enabled an effective exchange of information and support to policy decisions (4).  
  
What is health technology assessment? 
EUnetHTA used the definition of health technology offered by the International Network of 
Agencies for Health Technology Assessment (INAHTA): “Any intervention that may be used to 
promote health, prevent, diagnose or treat disease, or for rehabilitation or long-term care. This 
includes pharmaceuticals, devices, procedures and organisational systems used in health care‖ (5). 
 
EUnetHTA defined health technology assessment (HTA) as ―a multidisciplinary process that 
summarizes information about the medical, social, economic and ethical issues related to the use of 
a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the 
formulation of safe effective, health policies that are patient focused and seek to achieve best 
value‖. 
 
EUnetHTA aims and strategic objectives 
The EUnetHTA project was established to create an effective and sustainable network for HTA 
across Europe that could develop and implement practical tools to provide reliable, timely, 
transparent and transferable information to contribute to HTAs in Members States.  
 
The strategic objectives of the EUnetHTA project were to: 
 reduce duplication of effort in order to promote more effective use of resources 
 increase HTA input to decision making in Member States and the EU in order to increase 
the impact of HTA 
 strengthen the link between HTA and health care policy making in the EU and its member 
states 
 support countries with limited experience of HTA. 
 
Structure of EUnetHTA 
The EUnetHTA Partnership involved 64 organisations:  1 Main Partner, 33 Associated Partners, 
and 30 Collaborating Partners. In total, 33 countries (Europe: 25 EU and 2 EEA countries (Norway, 
Iceland), Switzerland and Serbia; outside Europe: Australia, Canada, Israel, USA) participated in 
the project. The list of partners is accessible at: www.eunethta.net . 
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Management and leadership 
EUnetHTA governance structure consisted of 
 the Steering Committee which comprised the heads of each of the Associated Partners or 
representatives appointed by the head. The head of the Main Partner chaired the Steering 
Committee. The Steering committee mandated the the management of the network to: 
 the Executive Committee representing the Main Partner and Work Package Lead Partners,  
 the Secretariat under the leadership of the Main Partner which provided managerial support 
to the overall project and ensured ongoing contact to the DG SANCO. 
 
Collaborating Partners participated in the work packages and received internal communication on a 
regular basis. 
 
The modes of operation of the network were described in a standard operating procedures (SOP) 
manual, a communication strategy, and supported by virtual and face-to-face meetings, website 
(with the Members Only work area), regular e-newsletter and other types of communication tools. 
The Associated Partners agreed on 3-year work plan during the first Steering Committee meeting 
and project results were presented at the EUnetHTA Conference ―HTA‘s Future in Europe‖, in 
journal articles and conference presentations. 
 
Work Packages and major results 
The scientific work in the EUnetHTA project took place in separately managed Work Packages 
(WPs), each led by a Lead Partner. The following major results were achieved: 
 A well functioning network of partners and colleagues from HTA agencies, research 
institutions and health ministries (WP1 - DACEHTA/National Board of Health, Denmark) 
 A well functioning Information platform and website (www.eunethta.net) (WP2 - SBU, 
Sweden and Co-Lead Partner – DIMDI, Germany) 
 Internal evaluations that helped to adjust work plans (WP3 – NOKC, Norway) 
 A comprehensive, evidence-based and validated common framework for HTA information 
(HTA Core Model) applied to two types of technology to produce generic Core HTAs a) on 
medical and surgical interventions (Drug Eluting Stents) and b) on diagnostic technology 
(Multislice CT coronary angiography) (WP4 - FinOHTA, Finland) 
 A handbook instructing in the use of the Core HTA Model (WP4 -  FinOHTA, Finland) 
 An Adaptation Toolkit (and a guidance document) composed of a series of checklists and 
resources which address the relevance, reliability and transferability of data and information 
from existing reports (WP5 - NCCHTA, UK) 
 A book ‖Health technology assessment and health policy-making in Europe‖ (WP6 - 
DACEHTA/National Board of Health, Denmark) 
 A web-based Stakeholder Open Forum, a Draft Stakeholder Policy and Discussion Topic 
Catalogue; (WP6 - DACEHTA/National Board of Health, Denmark) 
 Web-based tools for information sharing on the monitoring of new promising technologies 
and information service on emerging technologies (WP7 – HAS, France, and Co-Lead 
Partner- LBI/HTA, Austria) 
 A handbook on HTA capacity building (WP8 - CAHTA, Spain) 
 A proposal for a permanent EUnetHTA Collaboration after two rounds of public 
consultation (WP1 - DACEHTA/National Board of Health, Denmark) 
 
Based on best practice each Work Package developed the methods suitable for their purpose, which 
is described in WP-specific products. The Lead Partners were responsible for coordination within 
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the WP, for bringing work forward, producing and reporting results, for sending management 
information reports to the Main Partner and for responding to internal evaluation questionnaires.  
 
The next phase 
Through a series of internal and public consultation rounds, the network developed a Proposal for 
the EUnetHTA Collaboration (published June 16, 2008) detailing the approaches for the future 
development of the network. A group of founding partners was established after this to implement 
the proposal for EUnetHTA Collaboration. 
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Editors' Notes 
This is the final deliverable of this document, Core HTA on multislice computed tomography 
(MSCT) coronary angiography. This Core HTA is based on the HTA Core Model for diagnostic 
technologies, developed by EUnetHTA Work Package 4. Readers of this document are urged to 
familiarize themselves with the Core Model as well.  
 
The aim of preparing this document was to test the diagnostic HTA Core Model. We wanted to 
gather experiences from a novel way of preparing of health technology assessment work, rather 
than prepare a valid assessment on MSCT. Instead of preparing a traditional HTA-report in a single 
HTA-unit, the relevant assessment elements were defined and the work distributed into several 
research units around Europe. Because of this piloting function, not every research question is 
assessed with full thoroughness. Therefore we suggest that the results described in this document 
should not be used as a basis of decision making as such. 
 
The current document represents a considerable amount of work by many people across Europe. It 
is divided into chapters, most of which present one domain of work within HTA. In the beginning 
of each chapter the main authors have been listed. Several others, however, have contributed to the 
work. Their names can be found in the chapter "Teams" of this report. Feedback from other 
EUnetHTA work packages, collaborators and the public was received in the validation round.  
 
Each chapter describing domains of the model contains the following sections: 
 
 Introduction: why is it important to assess the technology from the viewpoint of this 
domain? 
 Methodology: what methodology was used to answer the research questions of this HTA? 
 Assessment elements: answers to the issues that are defined for this domain in the Core 
Model.  
 References 
 Assessment elements table: the relevance of each assessment element in this domain and 
issues translated into research questions. First column contains an identification code (ID) 
that refers to the element in the model. 
 
Notice that this assessment is based on a draft version of the HTA Core Model (available at 
http://www.eunethta.net/Work_Packages/WP_4/Activities/). Hence it does not address all the same 
assessment elements as the final version 1.0 of the Model.  
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WP4 Teams 
The work on different domains has been done as a collaborative effort of WP4 teams. Each team 
consists of investigators that are responsible for writing the sections of the report and reviewers 
whose task is to provide support and feedback to investigators in their team. Each team has also a 
coordinator on behalf of FinOHTA. 
 
DOMAIN Coordinator Investigators Reviewers 
 Primary investigators for the Core Model for diagnostic 
technologies (CM)  and MSCT Core HTA (MSCT) in italics 
 
General design of 
the core model 
Kristian Lampe (CM) 
Iris Pasternack (MSCT) 
 
Finn Børlum Kristensen, 
DACEHTA 
Marjukka Mäkelä, Finohta 
Katrine Bjørnebek Frønsdal, NOKC 
Alberto Ruano-Ravina, AVALIA-T 
Marcial Velasco Garrido, TU Berlin 
Irina Cleemput, KCE 
Måns Rosén, SBU 
Marco Marchetti, UCSC 
Dagmar Lühmann, U Lübeck 
Current use of the 
technology 
(implementation 
level) 
Iris Pasternack (MSCT) 
 
Marcial Velasco Garrido (CM), TU 
Berlin 
Lorenzo Leogrande, UCSC 
Marta Lopez de Argumedo, 
OSTEBA 
Paolo Oppedisano, UCSC 
Måns Rosén, SBU 
Nieves Sobradillo, OSTEBA; 
Heikki Ukkonen, TYKS (through 
Finohta) 
Leonor Varela Lema, AVALIA-T 
Ritva Bly, STUK (through Finohta) 
Nick Hicks, NCCHTA 
Marco Marchetti, UCSC 
Kersti Meiesaar, U Tartu 
Description and 
technical 
characteristics of 
technology 
Iris Pasternack 
 
Iris Pasternack (CM, MSCT), 
Finohta 
Sami Kajander, TYKS (through 
Finohta) 
Sigurdur Helgason, MoH Iceland 
Lorenzo Leogrande, UCSC 
Paolo Oppedisano, UCSC 
Heikki Ukkonen, TYKS (through 
Finohta) 
Ritva Bly, STUK (through Finohta) 
Marta Lopez de Argumedo, OSTEBA 
Leonor Varela Lema, AVALIA-T 
Monika Reesev, U Tartu 
Nieves Sobradillo, OSTEBA 
Marcial Velasco Garrido, TU Berlin 
Accuracy and 
effectiveness 
Iris Pasternack (CM) 
 
Tuija Ikonen (MSCT), Finohta    
Sigurdur Helgason, MoH Iceland 
Marjukka Mäkelä, Finohta 
Heikki Ukkonen, TYKS (through 
Finohta) 
Sami Kajander, TYKS (through 
Finohta) 
Alberto Ruano-Ravina, AVALIA-T 
Marta Lopez de Argumedo, OSTEBA 
Kåre Hansen, DACEHTA 
Marco Marchetti, UCSC 
Kersti Meiesaar, U Tartu 
Katrine Bjørnebek Frønsdal, NOKC 
Monika Reesev, U Tartu 
Måns Rosén, SBU 
Nieves Sobradillo, OSTEBA 
Leonor Varela Lema, AVALIA-T 
Neringa Kuliesuite, StaHeCCA 
Luana Vaikutyte, StaHeCCA  
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Safety Iris Pasternack 
 
Iris Pasternack (CM, MSCT) 
Sami Kajander, TYKS (through 
Finohta) 
Ritva Bly, STUK (through Finohta) 
Leonor Varela Lema, AVALIA-T 
Alberto Ruano-Ravina, AVALIA-T 
Nick Hicks, NCCHTA 
Sigurður Helgason, MoH Iceland 
Marta Lopez de Argumedo, OSTEBA 
Katrine Bjørnebek Frønsdal, NOKC 
Nieves Sobradillo, OSTEBA 
Heikki Ukkonen, TYKS (through 
Finohta) 
Luana Vaikutyte, StaHeCCA 
Costs, economic 
evaluation 
 
Pirjo Räsänen  
 
Kersti Meiesaar (CM), U Tartu 
Irina Cleemput (MSCT), KCE 
Jose Antonio Navarro, AETSA 
Cecile Camberlin KCE 
Belén Corbacho, AETSA 
Henrik Hauschildt-Juhl, DSI 
Aurora Llanos Mendez, AETSA 
Sergio Márquez, AETSA 
Monika Reesev, U Tartu 
Victor Sarmiento, AETSA 
Harri Sintonen, Finohta 
Sigurður Helgason, MoH Iceland 
Marco Marchetti, UCSC 
Katrine Bjørnebek Frønsdal, NOKC 
Heikki Ukkonen, TYKS (through Finohta) 
Torbjørn Wisløff, NOKC 
Neringa Kuliesuite, StaHeCCA 
Ethical aspects 
 
Ilona Autti-Rämö  
 
Samuli Saarni (CM), Finohta 
Pietro Refolo (MSCT), UCSC 
Dario Sacchini (CT), UCSC 
Dagmar Lühmann, U Lübeck 
Bjørn Hofmann, U Oslo 
Marco Marchetti, UCSC 
Marcial Velasco Garrido, TU Berlin 
Nieves Sobradillo, OSTEBA 
Marta Lopez de Argumedo, OSTEBA 
Organisational 
aspects 
 
Päivi Reiman-Möttönen 
 
Ulla Saalasti-Koskinen (CM), Finohta 
Marco Marchetti (MSCT), UCSC 
Mirella Corio, UCSC 
Carmen Furno, UCSC 
Juha Koivisto, FinSoc 
Marco Oradei, UCSC 
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Legal aspects 
 
Kristian Lampe 
 
Laura Walin (CM), Finohta 
Marco Marchetti (MSCT), UCSC 
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General design 
Iris Pasternack, Kristian Lampe, Finn Børlum Kristensen, Marjukka Mäkelä, Katrine Bjørnebek 
Frønsdal, Alberto Ruano Ravina, Marcial Velasco Garrido 
Introduction 
The EUnetHTA project aims at facilitating HTA information sharing within Europe. In order to 
achieve this, the development of a standardised structure for the conduction and reporting of HTAs, 
a HTA Core Model, was considered essential. Work Package (WP) 4 of the EUnetHTA Project 
developed two applications of the HTA Core Model - one for medical and surgical interventions 
and the other for diagnostic technologies – which describe the structure, means of rigorously 
developing, and transparently presenting information in HTA (1, 2).  
 
In this document the feasibility of the HTA Core Model on diagnostic technologies was piloted in 
an assessment of multislice computed tomography (MSCT) angiography. The pilot Core HTA on 
MSCT focused on the use of the MSCT angiography in patients with low or moderate risk for 
coronary artery disease. Patients with the history of acute myocardial infarction or with acute or 
severe symptoms, as well as screening of asymptomatic patients, were not included in the 
assessment.  
 
Policy questions related to the use of MSCT coronary angiography can vary markedly between 
countries. The Core HTA covers a wide range of questions to fulfil the different needs.  The HTA 
Core Model can be seen, among other things, as a checklist for producing an HTA on any single 
topic. The resulting Core HTA may in turn acts either as a stand-alone report that can be utilized in 
various settings, or as a base from which HTA producers can pick out building blocks for their own 
national or regional assessments. National, regional or local technology assessments based on a 
Core HTA may therefore come out differently with different sets of issues included depending on 
the country and the policy question.  
 
Reports on MSCT that have utilized the Core HTA or a local HTA that is based on the Core HTA 
may provide different answers to one and the same question, for instance due to the price of stents, 
salaries of health professionals, or reimbursement systems that may vary notably from country to 
country. However, regardless of those differences, a thoroughly performed Core HTA should 
provide a useful starting point for preparing a context-specific report more rapidly than would be 
possible by starting the whole assessment from scratch or by adapting from a traditional full-text 
report from another country. 
Methodology 
The assessment of MSCT coronary angiography was based on the HTA Core Model for diagnostic 
technologies (2) developed by the participants in EUnetHTA Work Package 4 (WP4). The Model 
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employs ten domains, nine of them originally established in the EUR-ASSESS project (3) and one 
added regarding diagnostic accuracy. 
 
The domains  
 
1. Current use of the technology (implementation level) 
2. Description and technical characteristics of technology 
3. Safety 
4. Diagnostic accuracy 
5. Effectiveness 
6. Costs, economic evaluation 
7. Ethical aspects 
8. Organisational aspects 
9. Social aspects 
10. Legal aspects  
 
There has been discussion about the position of the Accuracy domain. Taking into account the 
opinions of several investigators in WP4 and the validation feedback, it is possible that the accuracy 
issues will be incorporated in the Effectiveness domain in the next version of the HTA Core Model 
for diagnostic technologies. 
Selection of topic 
An invitation to participate in the web-based survey was sent by email to the participating 
organisations of WP4 in 17 European countries. From among 14 proposals, a two-step voting 
process in December 2006- February 2007 identified the multislice computed tomography (MSCT) 
coronary angiography as a topic of high interest.  
 
The selection of MSCT coronary angiography as the piloting theme was motivated with following 
reasons: 
– As MSCT is a non-invasive technology, there is a risk that it will be inappropriately used. 
– MSCT has the potential to reduce the number of invasive coronary angiographies 
– Information on the cost-effectiveness of MSCT compared to other non-invasive procedures, 
e.g. MRI, would be useful. 
– There are several safety and patient issues of relevance, e.g. radiation, contrast agents, and 
beta-blockade. 
The work process 
The working teams were re-built in April-Sept 2007 from the previous WP4 teams that had 
developed the first HTA Core Model for medical and surgical interventions, and produced the Core 
HTA on drug eluting stents. Substantial changes took place in the description of the technology and 
safety domain teams. Also in the current use and social aspects domains more than half of the 
investigators were new. 
 
The ten domain teams all had a coordinator and a primary investigator whose responsibility was to 
elaborate the document in due time. Each domain team worked independently in their own fashion. 
In most cases, the primary investigator produced a draft text which was commented and amended 
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by the other investigators in team. Some teams distributed tasks to their members, thus sharing 
active authorship more evenly. 
 
The investigators in the domain teams started their work with the preparation of the HTA Core 
Model on diagnostic technologies in October 2007. In January 2008 the generic research questions 
in the HTA Core Model were created and the teams could start considering specific questions for 
the MSCT Core HTA. Basic literature database searches were performed in December 2007, using 
disease-specific (coronary artery disease) and technology-specific (MSCT) search terms. No 
restrictions of study designs were used. The detailed search strategies are in Appendix 1. The teams 
were advised to combine their domain specific search terms to the basic search. Additionally, each 
team searched additional databases and other information sources.  
 
In February 2008 there was a general discussion on the framing or focusing of the MSCT Core 
HTA. Investigators in various teams encountered the typical problem of diagnostic tests research; 
the research questions turned out to be highly context-specific. A simple PICO (patient-
intervention-comparison-outcome) was not enough to define the scope of the HTA of this 
diagnostic procedure. The research questions were very different if we were dealing with the value 
of MSCT in comparison to conventional invasive coronary angiography, or if we were interested in 
the ability of MSCT to reliably rule out the diagnosis of coronary artery disease in patients, thus 
reducing the need for invasive angiographies. We decided to consider the latter: the added value of 
a management pathway with MSCT in ruling out coronary artery disease in patients with low to 
intermediate risk of having the disease, compared to a pathway without MSCT. We chose this 
clinically relevant comparison, although we knew that the majority of published research was done 
with the view of comparing MSCT with invasive coronary angiography in high risk patients. The 
next chapter and appendix 2 contain a more detailed description of the framing problem. 
 
The first internal (not public) draft of the Core HTA on MSCT was delivered to all investigators in 
July 2008. In August 2008 the primary investigators of each domain were asked to produce a brief 
summary, less than 700 characters long, of the main results from their domain. The editors of the 
MSCT Core HTA then prepared, on the basis of the domain summaries, a common summary for the 
whole Core HTA. In October 2008 all EUnetHTA and INAHTA members were called to participate 
in the validation of the MSCT Core HTA document. There were 17 respondents in the 
comprehensive multi-element validation questionnaire. Final changes to both project deliverables, 
The HTA Core Model on diagnostic technologies and Core HTA on MSCT, were made according 
to the validation feedback. The development of the HTA Core Model will continue and consequent 
versions published.  
Framing the topic 
In the present clinical diagnostic setting of coronary artery disease (CAD), it is not straightforward 
to decide how to compare the costs and effectiveness of MSCT coronary angiography. In the 
literature, MSCT has mainly been compared to invasive coronary angiography (ICA) due to the 
similarity of information obtained by these two methods (anatomical or structural imaging). 
However, in the current use as a rule-out test in low or moderate likelihood CAD patients, this 
comparison does not represent clinical decision making since ICA is seldom justified solely as a 
rule-out test for CAD. Widely used early diagnostic tests for CAD, on the other hand, measure other 
aspects of the CAD: stress tests (ergometry, dobutamine echo, SPECT, PET etc) look at ischemia as 
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a sign of functional performance of the heart, whereas currently the information obtained from 
MSCT is purely structural.  
Selection of the reference test is also dependent on the indications for diagnostic procedures, which 
have not been well established. The use of different diagnostic methods depends on physician's and 
patient's preference, health care system, local facilities, reimbursement and insurance systems, etc. 
rather than on clinical relevance, making this field even more complex. MSCT has even been used 
as a screening test for CAD in patients without CAD symptoms. 
 
Current use of the MSCT in Europe is becoming more and more established as a diagnostic test for 
ruling out significant coronary artery disease in patients with low or moderate risk and specific or 
unspecific symptoms of coronary disease (see appendix 2). For this purpose there is no other 
diagnostic method that could totally replace it or could be nominated as the control or reference 
diagnostic test for MSCT at the moment. 
 
Therefore it might be reasonable to compare the whole diagnostic path (including the selection of 
treatment options) of defined patient populations with a situation where the treatment decisions are 
made without the information obtained from MSCT. Pre-assumptions for this path are 1) low or 
moderate likelihood of CAD related to factors such as age, gender, symptoms, risk factors for CAD, 
2) the clinician's suspicion of coronary disease and 3) esteemed usefulness of established CAD 
diagnosis for decision-making concerning the treatment options.  
 
Information obtained from MSCT should always have clinical impact, either in the sense of ruling 
out CAD and consequent unnecessary medical treatment, or verifying the diagnosis of CAD with 
optimal treatment protocol and possibility to avoid coronary disease end-points such as acute 
myocardial infarction, invasive treatment or death. Costs and effectiveness depend on these. 
 
In patients with high risk for CAD, the use of MSCT does not usually provide any clinically 
relevant additional information. Ruling out CAD in diabetic patient for instance does not change 
patient's medical therapy. Therefore, the diagnostic path should proceed either to functional 
imaging (Stress echo, SPECT etc.) in search for ischemia, or directly to ICA and invasive treatment 
of the CAD, whenever the patient is judged to benefit from interventional treatment. If invasive 
treatment is out of the question in these patients, the anatomical CAD diagnosis does not provide 
any useful information for decision making.  
 
On the other hand, a low-risk patient with atypical symptoms might benefit from the MSCT: if 
significant CAD can be ruled out, there is no need for medical treatment, no treatment costs and no 
possible side-effects from the medication. If the diagnosis of CAD can be verified by MSCT, the 
consequent use of optimal medical treatment will decrease the risk for acute myocardial infarction 
and probability for invasive treatment. 
 
Modelling of different diagnostic paths and treatment options either with or without the use of 
MSCT might provide useful information for costs and economic evaluation as well as effectiveness 
domains. It would be a challenge for HTA, but of higher clinical relevance compared to the 
traditional approach where ICA is used as the control test for MSCT. In this situation, the costs 
caused by MSCT would be compared either with assumed costs of the unnecessary medical 
treatment of subjects without CAD, or with the costs of acute myocardial infarction etc. in the 
population that did not get medical treatment for CAD due to failed diagnosis. In this way we could 
obtain relevant information for the definition of indications and use of MSCT that might also 
benefit clinical decision making. 
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Research questions and exclusion criteria 
 
The following important questions and study exclusion criteria were jointly considered during the 
assessment process: 
 
What are the questions? 
 
– What is the accuracy of MSCT coronary angiography in the diagnosis of coronary artery 
disease (CAD) (or exclusion of the disease) in patients with suspected or stable angina 
pectoris. 
– Does MSCT diminish the need for invasive coronary angiography? 
– What is the added value of MSCT coronary angiography in selecting proper treatment, e.g. 
risk factor reduction, medical treatment, invasive treatment?  
– What is the added value of MSCT coronary angiography in patient health outcomes and 
quality of life?   
– What are the harms that rise using MSCT coronary angiography? 
– What are the legal premises and organisational, ethical, social and economical consequences 
of the use of MSCT coronary angiography?  
 
What kind of studies will be excluded? 
– Diagnosis of acute chest pain, myocardial infarction/acute coronary syndrome. 
– Monitoring treatment effect after PTCA, stent or CABG. 
– Assessment of coronary arteries in adjunction with other diseases of the myocardium, heart 
valves or ascending aorta. 
– Assessment of coronary anomalies. 
– Screening of asymptomatic high-risk or low-risk populations. 
 
Application of the HTA Core Model 
Translating issues into research questions 
The HTA Core Model is structured into ten domains, and each domain is further divided into more 
specific topic areas. Each topic is further divided into one or more issues, i.e. generic questions to 
be answered in an assessment. Combinations of a domain, topic and issue define the context of 
assessment elements, which are the basic units of a Core HTA.  
 
First, all domain teams started with their respective assessment element table from the HTA Core 
Model on diagnostic technologies. The teams went through the generic research questions of each 
assessment element (i.e. the issues) and considered their relevance for MSCT Core HTA. After 
selecting the relevant ones, the teams translated the issues into MSCT-specific research questions. 
For example, in the domain of Safety, under the topic of Technology dependent safety issues, the 
issue asks: What is the timing of onset of harms: immediate, early or late? For MSCT Core HTA 
this was translated into a specific question: What are the immidiate and long term consequences of 
the radiation exposure from MSCT coronary angiography? Some issues were translated into several 
related research questions. Omitted issues (and reasons for omission) were recorded in the Core 
HTA report, as it may provide useful information.  
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Finding answers to the research questions 
After defining relevant issues and translating them into answerable questions, the teams proceeded 
in finding answers to the questions. The Methodology sections of the respective domains in the 
HTA Core Model on diagnostic technologies give guidance on where to find published literature or 
other relevant information, how to search for it, assess its quality, synthesize, and report the 
findings of published literature or other information. If other sources or means of assessment were 
used with a certain research question, the teams were asked to report this in the Methods section of 
the respective assessment element in the MSCT Core HTA report.  
 
A Systematic review of published primary and secondary literature and other information sources 
are usually the method of choice in finding evidence for a specific research question. For every 
assessment element this was not a feasible approach, and even not necessary. For example there is 
an assessment element in the domain "Health problem and current use of technology" called "What 
are the potential indications and aims of MSCT in diagnostic cardiology?" where systematic review 
was not intended. Instead, information was retrieved from earlier HTA reports and consensus 
statements. Most important is that the authors are transparent and state in the methods section of the 
assessment element whether they intended to do a thorough search of primary publications with 
predefined inclusion criteria, or if they were just considering some recent information sources, in 
order to be convinced about the trustworthiness of the information. 
 
Sometimes there are no published studies that answer the issue. This was the case in the Social 
aspects domain where no relevant literature on patient experiences of MSCT coronary angiography 
was found. In this case the solution was that the investigators interviewed patients and professionals 
in order to gather original data for the assessment. 
 
Assessment elements from previous Core HTAs will be increasingly available when the number of 
Core HTAs rise. These will be useful sources of information for Core HTA authors in future. Even 
in MSCT Core HTA, where there was only one prior Core HTA, namely that of drug eluting stents 
(DES), some domain teams were able to use the results of some assessment elements of the 
previous Core HTA as such, or updating, or modifying them. This was due to the fact that both 
reports deal with coronary artery disease. For transparency the original work and authors were 
referred in the methods section of the corresponding elements in the Core HTA on MSCT. 
 
Assessing the quality of information 
The domain teams were asked to assess and report the quality of information retrieved and used in 
the assessment. They were also asked to report the tool or the specific quality assessment criteria in 
the methodology section of the domain, or in the Methods section of the single assessment element 
if the tool differs from that explained in the methodology section. It should be also stated in what 
way the quality of information will be used (e.g. in the exclusion process, or looking at studies in 
quality adjusted subgroups). A comment should also be included if no formal quality assessment 
criteria was used. 
 
Reporting answers to the questions 
The issues and answers to them can be presented in a traditional way as text in chapters. Tables and 
figures are also possible. For the purposes of this report we chose the same standard structure for 
each domain that was used already in the Core HTA on drug eluting stents. The following main 
chapters are included: 
– Introduction 
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puts the assessment in context within the domain. It provides information on the reasons for 
assessing MSCT (and perhaps similar technologies) from the viewpoint of the domain. 
– Methodology 
reports what kind of research methodologies, paradigms and theories have been used in the 
analysis. 
– Assessment elements 
is a chapter that contains information on those assessment elements that have been regarded 
as relevant in the context of this particular technology. The elements are organised based on 
topic and the generic issues of the model are replaced by topic-specific research questions. 
The main findings are reported under subheading "Results". Two other (optional) 
subheadings exist in this section. In "Methods" researchers may provide additional 
information on the research methodology that was used when answering this issue. In 
"Comment" researchers may comment on their findings. If the two optional headings have 
not been used, also the heading "Results" has been left out. 
– Discussion 
contains an overview of findings in this domain as well as reflections on them.   
– References 
used within the domain are listed here. 
– Assessment element table 
is an overview of all assessment elements defined in the Core Model as well as of the topic-
specific judgements that have been made in this particular HTA. The relevance of 
assessment elements and the translated research questions are included here. 
 
In the future and online version of the HTA Core Model will support the presentation of the results 
of Core HTAs that could be stored in an electronic database and accessed for only those elements 
that are relevant for the user. In the next steps of the EUnetHTA project, we will still pilot with 
various modes of using the Core Model and presenting the results.  
 
Overlapping issues 
Some of the issues defined in the Core Model are relevant for two or more domains. For example, 
the issue of approval of the technology by national or other authorities may be relevant from the 
viewpoint of the following domains: Health problem and current use of technology, Organisational 
aspects and Legal aspects. Although the simple reply to the question - yes or no- is the same, the 
issue is discussed from different viewpoints under each domain. In the current version of the Core 
Model, it has not yet been possible to consider extensively the overlaps between domains and 
indicate these in the structure.  
 
There were some overlapping issues in the MSCT Core HTA as well and probably also some 
double work done too. This information will be used to further improve the HTA Core Model to 
guide its users in the future to careful coordination between domains to avoid the identified overlap.  
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Appendix 1 Basic search strategy 
  
Database: CRD (= HTA, EED, DARE) 
Search date: 4.12.2007 
Name of search performer: Jaana Isojärvi, information specialist, Finohta 
Search strategy: 
 
#1 MeSH Coronary Disease EXPLODE 1 2 
#2 ( coronary AND ( disease* OR arter* OR aneurysm* OR stenos* OR restenos* OR thrombos* 
OR vasospasm* OR vessel* ) ) OR "angina pectoris" OR "chest pain" OR atherosclero* 
#3 #1 OR #2 
#4 MeSH Coronary Angiography EXPLODE 1 2 3 
#5 MeSH Tomography, X-Ray Computed EXPLODE 1 2 3 4 5 6 
#6 #4 AND #5 
#7 angiograph* AND tomograph* 
#8 #6 OR #7 
#9 #3 AND #8 
#10 msct OR mdct 
#11 ( multislice OR "multi-slice" OR "multi slice" OR multirow OR multidetect* OR "multi-
detect*" OR "multi detect*" OR multiselect* ) 
#12 ( 4 OR 16 OR 32 OR 40 OR 64 ) AND ( slice* OR row* ) 
#13 #10 OR #11 OR #12 
#14 #9 AND 13  24 
 
Database: Ovid MEDLINE(R) <1950 to November Week 2 2007> 
Search date: 7.12.2007 
Name of search performer: Jaana Isojärvi, information specialist, Finohta 
Search strategy: 
 
1 exp Coronary Disease/di, ra [Diagnosis, Radiography] (36545) 
2 (coronary adj2 (disease$ or occlus$ or vessel$ or arter$ or stenos$ or restenos$ or aneurysm$ 
or thrombos$ or vasospasm$ or obstruct$)).tw. (147726) 
3 calcinosis/di, ra or myocardial ischemia/di, ra (13707) 
4 1 or 2 or 3 (174520) 
5 exp Coronary Angiography/ (32102) 
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6 exp Tomography, X-Ray Computed/ (191788) 
7 5 and 6 (2083) 
8 (angiograph$ and tomograph$).tw. (12150) 
9  7 or 8 (13378) 
10  4 and 9 (3087) 
11 (msct or mdct).tw. (2055) 
12  (("8" or "16" or "32" or "40" or "64") adj2 (slice$ or row$)).tw. (1262) 
13 (multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or "multi-detect$" or 
"multi detect$" or multisect$ or "multi-sect$" or "multi sect$").tw. (6255) 
14 11 or 12 or 13 (7422) 
15 10 and 14 (944) 
16 animals/ (4261058) 
17 humans/ (10120566) 
18 16 not (16 and 17) (3224038) 
19  15 not 18 (937) 
20 limit 19 to yr="1990 - 2008" (936) 
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 03, 2007> 
Search date: 5.12.2007 
Name of search performer: Jaana Isojärvi, information specialist, Finohta 
Search strategy: 
 
1  (coronary adj2 (disease$ or vessel$ or arter$ or stenos$ or obstruct$ or restenos$ or 
thrombos$ or vasospasm$ or occlus$)).ti,ab. (3498) 
2  (angina pectoris or calcinos$ or myocardial ischem$).ti,ab. (499) 
3 1 or 2 (3795) 
4 coronary angiograp$.ti,ab. (417) 
5  (ct or computer tomograph$ or computed tomograp$ or computerized tomograph$).ti,ab. 
(6058) 
6 4 and 5 (102) 
7  (angiograph$ adj5 tomograp$).ti,ab. (216) 
8  6 or 7 (284) 
9 (mdct or msct).ti,ab. (227) 
10  (multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or "multi detect$ or 
multi-detect$" or multiselect$ or "multi-select$" or "multi select$").ti,ab. (440) 
11  (("8" or "32" or "16" or "64" or "40") adj2 (slice$ or row$)).ti,ab. (137) 
12  9 or 10 (519) 
13  3 and 8 and 12 (50) 
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Appendix 2 Diagnostic pathway 
 
FIGURE 1. DIAGNOSTIC PATHWAY FOR STABLE CORONARY ARTERY DISEASE
CAD suspicion 
No symptoms AND 
Family history + AND  
risk factors  
Mild symptoms AND  
no AMI in history  
AND risk factors  
Severe symptoms OR  
AMI in history AND  
multiple risk factors  
ECG 
Exercise ECG Risk factor control 
Exercise ECG 
Other diagnostic 
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Coronary 
angiography 
 Medical treatment PTCA CABG 
Diagnostic tests to  
  exclude severe  
CAD, Fig 2 
Medical treatment 
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- 
- - 
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FIGURE 2. DIAGNOSTIC PATHWAY FOR MILD TO MODERATE CORONARY 
SYMPTOMS IN PATIENTS WITH LOW PROBABILITY FOR SEVERE CORONARY 
ARTERY DISEASE 
 
 
-+
Mild AP symptoms, stabile, no AMI in history, ECG not specific for
ischemia
Exercise ECG Exercise ECG not possible
Specific medical treatment
Stress-ECHO
CORONARY ANGIOGRAPHY (+PTCA)
MSCT
Consider medical treatment: ASA, status
IVUS
Options:
MRI
SPECT
PET
 
  
 
 
 
 
Glossary: 
MSCT Multi-slice Computed Tomography 
CAD Coronary Artery Disease 
AP Angina pectoris, chest pain with cardiac origin 
PTCA Percutaneous Transluminal Coronary Angioplasty (usually balloon  angioplasty or 
 stenting) 
CABG Coronary Artery Bypass Surgery 
AMI Acute myocardial infarction 
ECG Electrocardiogram 
MRI Magnetic resonance imaging 
PET Positron emission tomography 
SPECT Single photon emission computed tomography 
IVU Intra vascular ultrasound 
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Summary 
Coronary artery disease (CAD) is the single most common cause of death in the Europe. In 
developed European countries, 17% of all DALYs (Disability Adjusted Life Year) lost are due to 
cardiovascular diseases. The golden standard for the diagnosis of coronary artery disease (CAD) is 
invasive coronary angiography (ICA). In past decades non-invasive imaging has been developed to 
serve as first-line diagnostic tool instead of or alongside ICA. Computed tomography angiography, 
and especially its advanced multi-slice versions (MSCT), has been suggested as a promising non-
invasive imaging modality which could triage patients for ICA. In 2004 only early adopters were 
using 64-slice CT. Since then it has become increasingly available in many European countries.  
 
MSCT is a rapidly evolving technology; completely new generations, with added image slices or 
dual X-ray tube sources, with new features are entering market. The use of MSCT in coronary 
angiography requires close cooperation between radiologists and cardiologists. There are guidelines 
that define the training requirements and proper user conditions for cardiac computed tomography. 
There are consensus statements about appropriate indications for MSCT. According to them one of 
the indications for cardiac imaging is to rule out CAD in patients with suspicion but with low to 
moderate risk of having the disease.  
 
Radioactivity and the use of iodinated contrast media are the major safety issues in the use of 
MSCT. Induction of cancer especially in the young and women, and contrast induced nephropathy 
in patients with impaired renal function are the principal concerns. There are technical means to 
reduce the radiation dose received, but this is usually with the cost of image quality. The risk of 
contrast induced nephropathy may be reduced with careful patient assessment prior to MSCT.  
 
The sensitivity of 64-slice CT against ICA for the diagnosis of CAD is excellent, and specificity is 
good. The values do not seem to be affected by the pre-test likelihood of CAD in a patient group 
where the risk of having the disease is low to intermediate. Research results support the use of 64-
slice MSCT for exclusion of CAD in patients with low or intermediate risk of the disease. The 
negative predictive value (NPV) of MSCT is excellent in this group, which means that a negative 
test result reliably excludes CAD and the need for ICA. The positive predictive value (PPV) is 
therefore only modest to good. The accuracy of MSCT to detect CAD is better than in another non-
invasive imaging test, single photon emission computed tomography (SPECT), when ICA is 
considered as the common reference test. 
 
Assessment of effectiveness for a diagnostic test requires different approach from the basic 
accuracy assessment and leads to a more complex study design. Very few studies were identified 
that dealt with the usefulness of 64-slice CT in the diagnostic path of patients with stable chest pain 
and low to intermediate risk of coronary artery disease (CAD). Based on accuracy data and what is 
known from large population studies of CAD prevention, 64-slice CT helps to indentify and classify 
the patients between groups of primary and secondary prevention and patients between obstructive 
and non-obstructive disease. Further studies are needed to find more specific and direct evidence to 
the questions asked in the elements of EUnetHTA effectiveness domain. These questions are of 
major interest and they are essential requirements in the core of clinical work: does the effort paid 
for diagnostic work-up really benefit the patients?  
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A full economic evaluation of MSCT coronary angiography requires more data on the clinical 
effectiveness of this diagnostic technique in preventing morbidity and mortality. It is yet impossible 
to conclude whether MSCT is cost-effective compared to the standard diagnostic protocols in low to 
intermediate pre-test likelihood patients. Nevertheless, a specific economic evaluation alongside a 
randomised controlled trial (RCT) is frequently cited to demonstrate the technique's cost-
effectiveness. We challenge the conclusion drawn from the one RCT available in this assessment 
saying that MSCT is cost-effective relative to standard of care. A basic economic evaluation, based 
on this data showed that taking treatment or patient outcomes into account might reverse the 
conclusion about the cost-effectiveness of MSCT. However, given the small number of patients in 
the RCT, firm conclusions about cost-effectiveness cannot be drawn. 
 
From an ethical point of view following points should be taken into consideration. The relation of 
benefits and harms in all potential clinical applications is still unclear. While typical patients in 
cardiac MSCT present mild and stable symptoms, they are probably capable of making their own 
decision about testing. Nevertheless, there may be some important but complex trade-offs between 
MSCT and other diagnostic technologies (such as stress testing or ICA), the consequences of which 
may be difficult to comprehend regardless of thorough information.  
 
The investigation of MSCT's impact on management and structure of organization was very 
complex, because organisational aspects are rarely analysed within clinical studies and HTA reports 
and hence little evidence is available in the scientific literature. The traditional systematic literature 
review was not completely suitable to obtain full information on organisational aspects, and it was 
necessary to complement the search with analysis of other sources. The impact of MSCT-64 on 
clinical pathways of patients could lead into reduced length of stay and avoidance of unnecessary 
further investigations for chest pain. Introducing MSCT-64 into practice does not lead into 
completely novel organisational challenges. Comparative imaging systems have been introduced 
before. Closer co-operation across the disciplines of cardiology and radiology is probably a new or 
incremental feature brought by the introduction of cardiac CT.  
 
Social and patient related aspects of MSCT were analysed from the published scientific literature as 
well as from semi-structured interviews of patients and experts. Major life areas where change may 
be generated by MSCT are life at home and working life. While the direct social consequences by 
technology use seem to be minor, larger consequences are to be expected by a diagnosis of CAD. 
Individuals report only minor physical and psychosocial consequences of MSCT, with conflicting 
information regarding the experience of pain and uneasiness during the waiting time for the results 
being the major components. According to the limited data available, communication regarding the 
conduct of the examination and the meaning of results seem to be satisfactory - as it was expressed 
in patients and experts interviews as well as in the literature. These preliminary results need 
confirmation in further research. 
 
The objective of legal domain was to point out questions on basic rights of patients (autonomy, 
informed consent, privacy and confidentiality) and legal requirements of the new technology 
(authorisation, guarantee, and regulation of market). It was very difficult to find specific 
information on MSCT on legal issues, because usually the literature and the laws use the general 
concept of CT. As a consequence, the MSCT, from this point of view is not a completely new 
technology, because its use, as far as legal issues are concerned, is similar to traditional CT. The 
main issues are about legal requirement to guarantee the safety (health protection of individuals 
against the dangers of ionizing radiation). 
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Health problem and current use of the 
technology 
 
Iris Pasternack, Marta Lopez de Argumedo, 
Nieves Sobradillo, Nick Hicks, Leonor Varela Lema, Marcial Velasco Garrido 
 
Introduction  
Coronary artery disease (CAD) is caused by impaired blood flow and deficient oxygen supply to 
myocardium, mostly induced by atherosclerosis or build up of plaque in the arteries. CAD may be 
manifested by stable angina pectoris, acute coronary syndromes - including myocardial infarction 
and unstable angina, or sudden death. CAD is one of the leading causes of death in Europe. The 
reference standard for the diagnosis of CAD is conventional coronary angiography which enables 
visualisation of the coronary lumen. Due to its invasiveness, coronary angiography is less suitable 
for first line diagnostic test.  In past decades non-invasive imaging has been developed for this 
purpose.  
 
Several non-invasive technologies such as stress echo cardiography, myocardial perfusion imaging 
and single photon emission computed tomography (SPECT) have become available to assess 
cardiac function. The anatomical assessment of coronary arteries has become possible with the 
introduction of multi-slice computed tomography (MSCT) coronary angiography. Other anatomical 
non-invasive modalities, magnetic resonance imaging (MRI) and electron beam computed 
tomography (EBCT), have not yet gained a role in routine clinical practice (1).  
 
The 64-slice computed tomography (CT) application came to market in 2004. Since then several 
trials have been performed. The first trials using dual-source 64-slice CT scanners were published 
in 2007, at which time also 256- and 320-slice devices became available. Because of the rapid 
development and the penetration of next generation scanners into use, the assessment in this domain 
focuses on 64 or more slice CT-scanners. 
 
MSCT can be used for risk stratification in evaluating CAD by assessing calcifications in coronary 
arteries, and coupled with intravenous contrast administration, as diagnostic coronary angiography. 
The assessment elements in this domain may briefly describe risk assessment, screening and other 
uses of the technology, but they concentrate on the diagnostic use of MSCT in native coronary 
arteries (no stents or bypass grafts) in a population with no known heart disease. 
 
Currently MSCT coronary angiography is becoming increasingly established in Europe as a 
diagnostic test for ruling out significant coronary artery disease in patients with low or moderate 
risk and specific or non-specific symptoms of CAD. There is no other diagnostic method available 
that could totally replace it in this role. 
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As MSCT is a non-invasive technology there is a risk that it will be inappropriately used beyond its 
original indications.  While it is an expensive and rapidly evolving technology with potentially 
harmful effects (from ionizing radiation), frequent and comprehensive assessments of its role and 
effectiveness are important. 
 
Methodology 
Information for this domain comes from epidemiological research, reviews and registries. We did a 
basic search for HTA-reports and systematic reviews, and an additional search in Medline. Details 
of search strategies are described in Appendix 1. Further information was sought from the 
bibliographies of relevant documents and the Internet.  
 
We did not intend to conduct a systematic review of issues like current indications or diagnostic 
pathways. Rather, information was retrieved from earlier HTA reports, consensus statements, and 
introduction sections of guidelines, reviews and original articles. 
 
The disease (i.e. CAD) that the technology is used for is essentially the same as in the other Core 
HTA (on drug eluting stents) that has been prepared within the EUnetHTA project. Therefore we 
utilized results of several corresponding assessment elements from the earlier work as such or as a 
base for more focused text. This is mentioned and original work referred to in the methods section 
of the elements. 
 
There is no standard, straightforward way to assess the quality of sources and information used in 
this domain. Due to restrictions in time during this project we did not use any formal quality 
assessment.  
Assessment elements 
Target condition 
What are the potential indications and aims of MSCT in diagnostic cardiology? 
Results 
Potential uses of cardiac MSCT angiography include diagnosing CAD and other conditions, 
screening vessel calcium as a risk factor for CAD, and monitoring patency of stents and bypass 
grafts.  
 
Diagnosing coronary artery disease 
 
MSCT coronary angiography (MSCT) can be used to visualize narrowing of coronary arteries and 
to diagnose CAD.  In intermediate risk patients, in whom there is diagnostic uncertainty after 
resting ECG and exercise testing, further assessment is generally required. Patients may be referred 
for myocardial perfusion scanning, while some go directly to invasive coronary angiography (ICA). 
MSCT coronary angiography is one option for such further assessment, and offers the possibility of 
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reducing the number of unnecessary ICAs and the risks associated with them. High risk patients 
(several risk factors, typical syndromes, and positive ECG and lab findings) are referred directly to 
ICA.  
 
Several recent reviews and recommendations state that MSCT is best indicated in patients with 
intermediate risk of coronary artery disease (a 10-year risk of cardiovascular disease of 10-20%) 
(1, 2,3). The American College of Cardiology Foundation (ACCF) gives appropriateness criteria for 
the use of cardiac computed tomography in patients with the following indications (3): 
 
– Evaluating patients with chest pain and intermediate pre-test probability of coronary artery 
disease AND uninterpretable electrocardiogram OR unable to exercise. 
– Evaluating acute chest pain in patients with intermediate pre-test probability of coronary 
artery disease AND no ECG-changes and serial enzymes negative. 
– Evaluation of chest pain syndrome in patients with uninterpretable or equivocal stress test 
(exercise, perfusion, or stress echo). 
 
In low risk patients using MSCT as triage for further examinations might be useful (1,4). This is a 
large group of people, who have chest pain, with normal ECG and blood test and few risk factors or 
other convincing evidence of acute coronary syndrome.   
 
MSCT has been used to rule out CAD in patients with heart failure and patient who are going to 
valvular surgery (3).  
 
Diagnosing other intra- and extra-cardiac conditions 
 
According to American College of Cardiology Foundation (ACCF) appropriateness criteria for 
cardiac computed tomography (3), following indications (other than CAD) are deemed appropriate 
for MSCT coronary angiography:  
- Assessment of complex congenital heart disease including anomalies of coronary 
circulation, great vessels, and cardiac chambers and valves. 
- Evaluation of coronary arteries in patients with new onset heart failure to assess etiology. 
- Evaluation of suspected aortic dissection or thoracic aortic aneurysm 
- Evaluation of suspected pulmonary embolism. 
  
Although coronary anomalies are rare, their possible consequences include myocardial infarction 
and sudden death. Numerous case reports and several research papers have shown that MSCT 
analysis of coronary anatomy is a reliable way to detect anomalies (5). In a recent study MSCT has 
been shown to be useful in the differentiation of the idiopathic from ischemic etiology in dilated 
cardiomyopathy (6).  
 
Guiding treatment decisions in patients with definite CAD 
 
Patients with a high pre-test probability of CAD (typical symptoms and findings in previous tests 
e.g. positive rest and stress ECG and enzymes), at least those with severe or persistent symptoms, 
go directly to invasive coronary angiography (ICA). Treatment options are medical treatment only, 
angioplasty (vessel dilatation with or without stent) or coronary artery bypass graft (CABG). ICA 
allows immediate intervention with angioplasty. MSCT may not have a large role in this group, 
unless it could identify those in whom CABG is required (1).  
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Calcium screening 
 
Coronary calcium is a surrogate marker for the presence and amount of coronary plaques. 
Calcifications occur in the context of atherosclerotic lesions. However not every atherosclerotic 
coronary plaque is calcified, and calcification is neither a sign of stability nor of instability of an 
individual plaque.  In several studies the absence of coronary calcium has ruled out significant 
coronary stenosis. However, even pronounced coronary calcification is not necessarily associated 
with hemodynamically relevant luminal narrowing. Numerous prospective trials have demonstrated 
that coronary calcium in asymptomatic individuals is a strong prognostic parameter for future heart 
events. Patient management approaches based on calcium score have not been prospectively 
investigated (5). In the guidelines of American heart Association, repeated imaging assessment of 
progression of coronary calcification is not recommended (7). 
 
Knowledge of the presence or absence of coronary artery calcification and atherosclerosis may add 
value in a risk assessment and potential to improve the targeting of cardiovascular preventive 
activities such as lifestyle modification and lipid lowering therapies (2). 
 
Monitoring coronary artery stents and bypass grafts 
 
In patients with previous revascularisation (angioplasty or bypass grafting) imaging with MSCT is 
possible but challenging.  Imaging of bypass grafts is less affected by motion than the coronary 
arteries but it may be affected by surgical metal clips. Assessment of the native coronary arteries 
distal to the anastomosis may be difficult due to the frequent presence of extensive calcification. 
Studies that have investigated the accuracy of MSCT in detecting stenosis in native arteries in 
patients with bypass grafts have reported low accuracies, which severely limits the use of MSCT in 
these patients (5). 
 
Assessment of in-stent re-stenosis is usually not recommended because of metal artefacts caused by 
the stent. However, in selected patients with larger stent diameter, results with 64-slice CT have 
been promising (5,7,8). 
 
Screening 
 
MSCT has been proposed as a screening tool in asymptomatic subjects. Currently there is global 
consensus that is should not be used for this purpose, both because of the radiation burden and lack 
of accuracy in this population, and because WHO criteria for screening are not met. No evidence 
was found for the impact of screening on patient management (7,9).  
 
In summary: 
 
In 2006 the American College of Cardiology Foundation produced recommendations on the 
appropriate uses of cardiac computed tomography (3). The indications include: 
– evaluation of chest pain where there is intermediate pre-test probability of CAD and either 
an uninterpretable ECG or inability exercise; or after an uninterpretable or equivocal stress 
test; 
– evaluation of suspected coronary anomalies in symptomatic CAD; 
– acute chest pain with intermediate pre-test probability of CAD, no ECG changes and 
enzymes negative; and 
– evaluation of coronary arteries in patients with new onset heart failure to assess aetiology. 
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It should be taken into account that the imaging technology has evolved rapidly since the writing of 
these guidelines. 
 
What are the pathological findings that MSCT coronary angiography is able to 
detect? 
Results 
Coronary artery stenosis 
 
Main use of MSCT is in detecting or excluding significant coronary stenosis (>50% diameter 
reduction) in coronary arteries. Studies usually use invasive coronary angiography (ICA) as the gold 
standard for measuring stenosis. A research group led by American heart association states that a 
normal CT coronary angiogram allows the clinician to rule out the presence of haemodynamically 
relevant coronary artery stenosis with a high degree of reliability (7).  
 
Studies comparing anatomical MSCT assessment to functional imaging (perfusion scan, SPECT) 
show that only approximately 50% of significant stenoses (>50% narrowing of vessel diameter) on 
MSCT are functionally relevant; a large proportion of significant lesions in MSCT does not lead in 
perfusion abnormalities (10).  
 
Vulnerable plaques 
 
Vulnerable plaques are the ones that most likely cause thromboembolism. They are not necessarily 
big enough to cause significant stenosis and their calcium content is generally lower than in stable 
atherosclerotic plaques. The use of MSCT to identify and further characterise vulnerable plaques is 
promising but premature (7). There are a small number of studies that compare MSCT with intra-
vascular ultrasound (IVUS). Uncertainties about the treatment of vulnerable plaques may reduce the 
value of diagnostic information (1). 
 
Vessel calcification 
 
MSCT allows for accurate detection and quantification of coronary artery calcium. The radiation 
dose for a calcium scan is lower than in MSCT angiography, 1-2 mSv. 
 
Coronary calcium is a surrogate marker for the presence and amount of coronary plaques. With the 
exception of patients with renal failure, calcifications occur exclusively in the context of 
atherosclerotic lesions. On the other hand not every atherosclerotic coronary plaque is calcified, and 
calcification is a sign of neither stability nor instability of an individual plaque. Absence of 
coronary calcium has ruled out significant coronary stenosis in several studies. However, even 
pronounced coronary calcification is not necessarily associated with hemodynamically relevant 
luminal narrowing (5).   
 
Numerous prospective trials have demonstrated that coronary calcium in asymptomatic individuals 
is a strong prognostic parameter for future heart events. Patient management approaches based on 
calcium score have not been prospectively investigated (5).  
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What is the characterisation of coronary artery disease (CAD)? 
Methods 
We used some material from the corresponding issue in the Core HTA on DES: Which are the 
diagnoses or patient groups for which DES is or may be indicated? Authors: Bo Freyschuss, 
Marcial Velasco Garrido, Marjukka Mäkelä.  
Results 
Coronary artery disease (CAD) is generally caused by impaired blood flow and deficient oxygen 
supply to myocardium, mostly induced by atherosclerosis or build up of plaque in the arteries. CAD 
may be manifested by stable angina pectoris, acute coronary syndromes - including myocardial 
infarction and unstable angina, or sudden death.  
 
Stable angina pectoris is caused by the partial blockage of the artery by a plaque. Blood flow to the 
heart is still sufficient, however in physical or emotional stress or activity blood flow may be 
restricted resulting in temporary chest pain. It is traditionally accepted that the vessel narrowing has 
to be at least 50% in the internal diameter (or >75% reduction in cross sectional area) in order to 
cause ischemia and angina pectoris. 
  
Acute coronary syndromes cover a heterogeneous spectrum of ischemic heart diseases, extending 
from acute myocardial infarction, through minimal myocardial injury to unstable angina. 
In acute myocardial infarction there is, by definition, loss of myocardial tissue. It is the result of a 
complete blockage of the artery by a ruptured plaque, not necessarily involving flow limiting 
stenosis (10). Loss of myocardial tissue due to myocardial infarction can lead to heart failure and 
arrhythmias leading to sudden death.  
 
Unstable angina is a syndrome of cardiac ischemia, manifestating itself as prolonged chest pain, in 
which no myocardial necrosis can be documented. It is a syndrome that is intermediate between 
stable angina and myocardial infarction: It is characterized by chest pain that lasts longer and/or 
may be more severe than in stable angina. It may occur at rest or with less exertion than in stable 
angina. It may also be less responsive to medication. New onset angina is also included in this 
syndrome. The progression of unstable angina may lead to Non-ST-elevation myocardial infarction 
(NSTEMI) or ST-elevation myocardial infarction (STEMI). 
 
What are the symptoms of coronary artery disease (CAD) 
Methods 
We used the corresponding assessment element from the Core HTA on drug eluting stents (DES) as 
base text and made some changes and amendments. Issue name in DES: What are the most 
common or serious symptoms and consequences of the conditions that may be treated with DES? 
Authors: Bo Freyschuss, Marcial Velasco Garrido, Marjukka Mäkelä.  
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Results 
The typical symptom of CAD is chest pain, usually located on the left side or retrosternal and which 
may radiate to left arm, neck, or jaw. It may also present as breathlessness, discomfort or pressure. 
 
Stable angina 
 
Typical stable angina 
Typical angina has three characteristics:  
1. discomfort in the chest, jaw, shoulder, back or arms, that is  
2. provoked by exertion or emotional stress, and  
3. relieved by rest or nitro-glycerine.  
Angina is stable when the symptoms remain unchanged, i.e. there is no change in the usual pattern 
of pain occurrence. Unstable angina is discussed under acute coronary syndromes (10). Stable 
angina is often graded using the scale from the Canadian Cardiovascular Society (CCS) (11). 
 
CCS Angina Classification by Canadian Cardiovascular Society 
 
Class Description 
Class I Ordinary activity such as walking or climbing does not precipitate angina. 
Angina occurs with strenuous work. 
Class II Slight limitation of ordinary activity. Angina occurs on walking or 
climbing stairs rapidly, walking uphill, walking or stair climbing after 
meals, or in cold, or in wind, or under emotional stress, or only during the 
few hours after awakening. Angina occurs on walking more than 2 blocks 
on the level and climbing more than one flight of ordinary stairs at a 
normal pace and in normal condition. 
Class III Marked limitations in ordinary physical activity. Angina occurs on walking 
one to two blocks on the level and climbing one flight of stairs in normal 
conditions and at a normal pace. 
Class IV Inability to carry out any physical activity without discomfort, anginal 
symptoms may be present at rest 
 
Atypical angina 
Atypical angina has only two of the three characteristics of typical angina. Very often these patients 
have significant CAD (12). 
 
Atypical chest pain 
Atypical or non-anginal chest pain show only one or none of the characteristic symptoms of typical 
angina (13).  
 
Acute coronary syndromes 
 
Acute coronary syndromes cover a heterogeneous spectrum of ischemic heart diseases, extending 
from acute myocardial infarction, through minimal myocardial injury to unstable angina. Patients 
with acute coronary syndrome may have chest discomfort that has all the qualities of typical angina 
except that the episodes are more severe and prolonged, may occur at rest, or may be precipitated 
by less exertion than in the past (14). 
 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
33 
 
Myocardial infarction 
Chest pain is a major symptom of acute myocardial infarction, mostly occurring at rest and usually 
lasting at least 20 minutes (15). 
 
Unstable angina 
 
In unstable angina chest pain becomes more easily provoked than usual or it occurs with increased 
frequency, severity or duration (10) 
Which are the known risk factors for coronary artery disease (CAD)? 
Results 
The main risk factors for CAD development are tobacco use, high blood pressure, raised blood 
cholesterol, and diabetes mellitus (10). 
 
What is the natural course of coronary artery disease (CAD)? 
Results 
In patients with atypical chest pain, the prevalence of CAD is estimated to be between 0.8 and 
28.1%, depending on age and gender. In patients with typical angina the prevalence of CAD is 
much higher, from 25.8 to 94.3%, depending on age and gender (12). High risk CAD, defined as 
disease of the left main vessel or three vessels, is rare in men under 70 years and almost nonexistent 
in women of any age, who present atypical chest pain (16).  
 
Estimates of annual mortality of patients with stable angina in recent clinical trials range from 0.9% 
to 1.7%, with higher mortality in populations with more severe symptoms (17). Patients with 
documented CAD may have excellent prognosis. During a five year follow-up of 2000 patients with 
stable angina and median age of 65 years, it was found that 1.4/100 patient-years died (18). 
 
Patient with stable angina have been classified into risk categories according to their 5 year risk 
using a composite of death, myocardial infarction or disabling stroke. In the highest decile the risk 
of composite outcome was 35% and in the lowest 4%. Clinical variables that contributed most to 
the risk were age, left ventricular ejection fraction, and smoking (19).  
 
What is the incidence of coronary artery disease? 
Methods 
We used the corresponding assessment element from the Core HTA on DES (paragraphs marked 
with *…*), and added material. Issue name: What is the incidence of CAD? Authors: Bo 
Freyschuss, Marcial Velasco Garrido, Marjukka Mäkelä.  
Results 
At present there is no routinely updated source of Europe-wide CAD morbidity data (20). The 
WHO MONICA (monitoring trends and determinants in cardiovascular disease) examined the 
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incidence of major coronary events in 16 European countries in 1990´s (21). The project showed 
that the incidence of coronary events was higher in Northern, Central and Eastern Europe than in 
Southern and Western Europe. The geographical pattern in coronary event rates was similar to the 
pattern in death rates. The results of the MONICA project showed also that incidence of coronary 
events was decreasing rapidly in Northern and Western Europe but was not decreasing as fast in the 
rest of Europe, and even increased in some research populations (20). 
 
According to the latest available data from the MONICA Study, the incidence of coronary events in 
men varied in Europe between 835/100.000 in the Finland North Karelia population and 
210/100.000 in the Spain-Catalonia population. Similar variations were found in women, from 
777/100.000 in the UK-Glasgow population and 35/100.000 in the Spain-Catalonia population (20). 
 
The MONICA project also investigated patterns in case fatality defined as dying within 28 days of a 
coronary event.  Case fatality from CAD was higher in many populations in Central and Eastern 
Europe. Case fatality was not decreasing there as fast as in other parts of Europe*. 
 
Coronary event rates, case fatality and their annual changes in the European MONICA populations 
can be found at the European cardiovascular disease statistics, table 2.1 (20).  
 
*Sweden 
The prevalence of angina pectoris among men in Sweden is about 3% in the ages between 45-50 
years and 7% in the ages between 65-70 years of age. In a population of 9 million, the incidence of 
myocardial infarction is presently 42 000 per year and about 34 000 of these are admitted to 
hospital. About 15 000 are admitted to hospital for unspecified angina and 12 000 for instable 
angina yearly. About 5 000 bypass operations (CABG) and 18 000 revascularizations (PCI) are 
performed yearly. Coronary heart disease accounts for about 18 000 deaths each year in Sweden, 
which constitutes 22% of all deaths in men and 18% in women (22)*. 
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What is the incidence of cases presenting with angina symptoms but with low to 
moderate probability of CAD? 
Results 
In patients with atypical chest pain, the prevalence of CAD is estimated to be between 0.8 and 
28.1%, depending on age and gender. In patients with typical angina the prevalence of CAD is 
much higher, from 25.8 to 94.3%, depending on age and gender (12). High risk CAD, defined as 
left main or three vessel disease, was rare in men under 70 years and almost nonexistent in women 
of any age, who presented atypical chest pain (16).  
 
What is the mortality of coronary artery disease (CAD) and how many years of 
(healthy) life are lost due to early death or disability in Europe? 
Methods 
We used the corresponding assessment element from the Core HTA on drug eluting stents 
(paragraphs marked with *…*), and added it substantially. Issue name: What is the burden of 
coronary artery disease? Authors: Bo Freyschuss, Marcial Velasco Garrido, Marjukka Mäkelä.  
Figure 1. Hospitalizations per year for certain types of coronary artery disease 
(data from the Swedish National Board of Welfare, EPC)  
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Results 
 
Mortality 
 
Coronary artery disease (CAD) is the single most common cause of death in the Europe, accounting 
for 1.92 million deaths in Europe each year. 22% of women and 21% of men die from the disease.  
The same holds for countries that belong to European Union (EU). There are 741 000 deaths per 
year, and 15% of women and 16% men die from CHD in EU. Number of deaths in each European 
country can be found in the European cardiovascular disease statistics, table 1.1 (20).  
 
CAD is the single most common cause of death before the age of 75 in Europe, accounting for over 
900 000 deaths every year. In men 20 % of the deaths are from CAD, and in women 19%. The same 
holds for EU countries. There are 250 000 deaths per year. In men 15% of the deaths are from 
CAD, in women 10%. Number of deaths in each European country can be found in the European 
cardiovascular disease statistics, table 1.2 (20). 
 
CAD is the single most common cause of death before the age of 65 in Europe, accounting for just 
under 401 000 deaths per year. In men 17% of the deaths are from CAD, in women 12%. The same 
holds for EU countries. There are just over 104 000 deaths per year. In men 13% of the deaths are 
from CAD, in women 6%. Number of deaths in each European country can be found in the 
European cardiovascular disease statistics, table 1.3 (20). 
 
Death rates from CAD are generally higher in Central and Eastern Europe than in Northern, 
Southern and Western Europe. Western European countries generally have higher rates than 
southern European countries. Age standardized death rates from CAD (deaths per 100 000) in 
individual European countries can be found in the European cardiovascular disease statistics, table 
1.4 (20). Latest figures are from the year 2005. 
 
Death rates have been falling rapidly in most Northern and Western European countries and rising 
rapidly in some Central and Eastern European countries over the past 30 years (20). 
 
Years of life lost due to an early death 
 
The WHO Global Burden of Disease Study found that in 1990 on average 16% of years of life lost 
were due to CAD in Established Market Economies (mostly Northern, Southern and Western 
countries). This was the single most important cause of years of life lost in these countries (23). In 
Central and Eastern European countries 18% of years of life lost were due to CAD (20). 
 
Years of healthy years lost due to disability 
 
In 2002 the WHO Burden of Disease project (23) estimated the morbidity caused by different 
diseases. The main measure of the burden of the disease was DALY (Disability Adjusted Life 
Year), an aggregate of years of life lost due to premature death and years of healthy life lost due to 
disability. 
 
In developed European countries, 17% of all DALYs lost are due to cardiovascular diseases. In the 
EU, over 12 million DALYs (19% of total) and in Europe 34 million (23% of total) are lost each 
year to cardiovascular disease. There are no figures given for coronary artery disease (20). 
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*The prevalence/incidence of early retirement due to CAD depends on the severity of the condition 
but also on the social security arrangements in each country. Thus, the transferability of this kind of 
information might be very limited*. 
 
Finland 
 
In Finland (population 5.3 million) there are annually 44 000 incidents of acute coronary artery 
syndrome. Out of them 23 000 are myocardial infarctions and 21 000 unstable angina pectoris. Out 
of the 23 000 myocardial infarction cases, 5 000 die before they reach hospital. Altogether, there are 
annually 13 000 deaths due to myocardial infarction. These data are collected from Finnish hospital 
discharge register and causes of death register in 1995 (23).  
 
Sweden 
*Coronary heart disease accounts for about 18 000 deaths each year in Sweden, which constitutes 
22% of all deaths in men and 18% in women (22)*. 
 
UK 
CAD is the leading cause of mortality in the UK, with 92,289 deaths recorded in England and 
Wales in 2004. Data for England suggests a morbidity prevalence of 7.4% in men and 4.5% in 
women (2). 
 
Utilisation 
How much is MSCT coronary angiographies used in European countries? 
Methods 
Apart from information retrieved from published HTAs, investigators of the team were asked to 
find out whether there are national registers in their countries that could provide data for his issue: 
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Results 
Spain 
In Spain there is not a known register of the use of computed tomography cardiac imaging or 
invasive coronary angiographies (ICA). 
 
Finland 
In 2005 there were 10 recorded cases of imaging coronary arteries with computed tomography (24). 
More recent register data is not available. 
 
What kind of international, national or regional variation is there in the use of 
MSCT coronary angiography? 
Methods 
Investigators of the team were asked to find out whether there are national registers in their 
countries that could provide data fort his issue: 
Results 
In Spain, MSCT coronary angiography is included in the "basket of benefits". It is used more in the 
private sector than in the public sector. MSCTs have not a specific way of registration, so there is 
not a registry entry with the name MSCT. 
 
In Australia MSCT coronary angiography is predominantly used in the private sector with limited 
use in public hospitals. Many radiologists operate within both the public and private health systems 
(25).  
 
Current Management of the Condition 
How is coronary artery disease (CAD) currently diagnosed? 
Results 
Diagnosis of CAD can often be made by history taking alone, based on the pain characteristics, age, 
gender, and patients' cardiovascular risk profile (13). Physical examination can further increase the 
probability of CAD if signs of peripheral atherosclerosis or heart failure are found. 
Electrocardiogram (ECG) at rest and/or during exercise is usually performed. Laboratory testing 
can, in patients with non-acute chest pain, exclude anaemia or hyperthyroidism as a cause of angina, 
or establish other causes of chest pain (pleuritis, pneumonia etc.). In acute conditions, cardiac 
enzymes are measured from a blood sample. In patients where the resting ECG is abnormal because 
of left bundle branch block, cardiac pacing, left ventricular hypertrophy or drug effects, stress-ECG 
is of no help. In these patients, myocardial perfusion scintigraphy (SPECT) and in those who have 
contraindication to SPECT (e.g. asthma), dobutamine stress echocardiography may be used to 
further evaluate chest pain. These non-invasive tests are considered also for patients who are unable 
to exercise due to orthopaedic, pneumologic or other reasons (10). According to the diagnostic 
pathway proposed by ACC/AHA, invasive coronary angiography is only indicated when symptoms, 
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clinical findings or results from previous tests suggest high risk of CAD (13). The potential role of 
multislice computed tomography (MSCT) angiography lies before invasive coronary angiography 
(ICA) in the diagnostic pathway. It has been advocated as a technology that might prevent ICA in 
patients who turn out not to have obstructive CAD. 
 
Is there evidence for inappropriate use of MSCT coronary angiography in the 
diagnostic pathway of CAD? 
Results 
We found no information on this. 
 
What is the role of MSCT in the management of coronary artery disease (CAD) 
according to evidence based guidelines? 
Methods 
Source Search terms Date of 
inquiry 
Inve
stiga
tor 
Selected 
Evidence Based Medicine 
Guidelines (EBMG) 
http://ebmg.wiley.com/ebmg/ 
Finnish version 
sepelvaltimotauti 26.8. 
2008 
IP (25) 
SIGN 
http://www.sign.ac.uk/ 
Guidelines>by topic>CHD and 
stroke 
26.8. 
2008 
IP (26) 
NICE guidelines 
http://www.nice.org.uk/Guidanc
e/CG/Published 
browsed all 78 published 
guidelines 
26.8. 
2008 
IP found no 
relevant 
The evidence-based Finnish 
Current Care guidelines (in 
finnish) 
http://www.kaypahoito.fi/ 
 
browsed all 6 guidelines under 
subtitle "cardiology" 
26.8. 
2008 
IP (27,28) 
National Guidelines 
Clearinghouse 
http://www.guideline.gov/ 
"coronary"  yielded 310 hits 
guidelines, 16 of them were 
published 2005 or later. If full 
text of the guideline was not 
available elsewhere information 
on MSCT was sough in the NGC 
summaries. Find-function using 
the words "tomography" or "ct" 
was used to search the 
documents. 
27.8. 
2008 
IP (25,26,29-
36) 
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GIN 
http://www.g-i-n.net 
coronary, heart, cardiac 26.8. 
2008 
IP found no 
relevant 
 
Results 
Ten evidence-based guidelines on management of coronary artery disease (CAD), published in 
2005 or later, were identified. Seven of them did not mention MSCT. In three guidelines the 
statements about the use of MSCT are cautious but emphasize that it is a developing technology that 
may have potential. See more detailed expressions in the table below.  
 
Guideline Published Role of MSCT in the diagnostic pathway 
Coronary heart disease (CHD): 
symptoms, diagnosis and 
treatment. In: EBM Guidelines. 
Evidence-Based Medicine (25) 
2007 No mention 
Guidelines for the diagnosis and 
treatment of non-ST-segment 
elevation acute coronary 
syndromes.Task Force for 
Diagnosis and Treatment of Non-
ST-Segment Elevation Acute 
Coronary Syndromes of European 
Society of Cardiology (29) 
2007 At the current state of development, cardiac computed tomography (CT) cannot be recommended as the 
coronary imaging modality in non-ST-elevation acute coronary syndrome, because of suboptimal diagnostic 
accuracy. Fast technical evolution may result in improved diagnostic accuracy in the near future and lead to 
reconsideration of the use of this tool in the decision-making process. 
Diagnosis and treatment of chest 
pain and acute coronary syndrome 
(ACS). Institute for Clinical Systems 
Improvement (ICSI) (30) 
2006 CT angiogram is generally the quickest and most readily available diagnostic test in diagnosis of aortic 
dissection in clinically stable and asymptomatic patients. 
ACC/AHA 2007 guidelines for the 
management of patients with 
unstable angina/non-ST-Elevation 
myocardial infarction (31)  
2007 The detection of subclinical atherosclerosis by noninvasive imaging represents a new, evolving approach for 
refining individual risk in asymptomatic individuals beyond traditional risk factor assessment alone. A recent 
AHA scientific statement indicates that it may be reasonable to measure atherosclerosis burden using electron-
beam or multidetector computed tomography (CT) in clinically selected intermediate-CAD-risk individuals (e.g., 
those with a 10% to 20% Framingham 10-year risk estimate) to refine clinical risk prediction and to select 
patients for aggressive target values for lipid-lowering therapies (Class IIb, Level of Evidence: B).  
 
Two imaging modalities, CMR and multidetector computed tomography for coronary calcification and CCTA, 
are increasingly becoming clinically validated and applied and hold promise as alternative or supplementary 
imaging modalities for assessing patients who present with chest pain syndromes. 
 
Multislice cardiac computed tomography, which combines coronary calcium scoring with noninvasive coronary 
angiography (current resolution 0.5mm), has undergone favorable initial evaluation for assessment of the low- 
to intermediate-risk chest pain patient. The current status and appropriate application of CMR and cardiac CT 
are addressed in recent ACC/AHA documents  
Stable coronary artery disease. 
Institute for Clinical Systems 
Improvement (ICSI) (32).  
2007 no mention 
2007 Focused Update of the 
ACC/AHA 2004 Guidelines for the 
Management of Patients With ST-
Elevation Myocardial Infarction (33) 
2008 no mention 
Management of stable angina. A 
national clinical guideline. Scottish 
Intercollegiate Guidelines Network 
(26) 
2007 no mention 
Guidelines on diabetes, pre-
diabetes, and cardiovascular 
diseases. Task Force on Diabetes 
and Cardiovascular Diseases. 
European Society of Cardiology 
(ESC) (34) 
 
2007 no mention 
Acute coronary syndromes. A 
national clinical guideline. Scottish 
Intercollegiate Guidelines Network 
(SIGN) (35).  
2007 no mention 
Guidelines for the management of 
acute coronary syndromes 2006. 
2006 no mention 
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Acute Coronary Syndrome 
Guidelines Working Group (36) 
 
Which are the other evidence based diagnostic procedures for coronary artery 
disease (CAD)? 
Methods 
This research question was deemed relevant by the investigators team, but for time constraints we 
did not study it. 
 
Regulatory status 
Which approval status has MSCT coronary angiography in EU or 
internationally? 
Methods 
Source Search terms Date of inquiry Investigator 
Google "msct regulatory 
status" 
"eu regulatory status 
msct" 
 
13.7.2008 NS, LVL 
FDA "msct regulatory" 13.7.2008 NS, LVL 
 
Results 
The European Directive 97/43/Euratom provides information about Computed Tomography (CT) in 
general; but we could not find any specific data related to MSCT coronary angiography. 
 
What is the reimbursement status of MSCT cardiac angiography? 
Results 
Reimbursement of cardiac CT is currently heterogeneous between countries and often even between 
health insurance funders within a country. In most countries there is no specific reimbursement for 
cardiac CT procedures (5). The question regarding reimbursement is not relevant in some settings, 
particularly if the patient does not pay for the investigation himself. For example in Finland the cost 
is covered by the hospital that performs the investigation (applies to public hospitals only).  
 
Spain 
In Spain, MSCT coronary angiography is included in the benefit basket. Spanish benefit basket is 
not standard within the European Union (38). 
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Other 
Who manufactures MSCTs? 
Results 
The manufacturers of the technology are GE (General Electric), Philips, Siemens and Toshiba 
(www.msct.eu/MSCT_INFO/Links.htm, accessed 13.7.2008). The technical performance of their 
respective 64-scanners has been assessed recently by the ECRI institute (39). 
 
Discussion 
Coronary artery disease (CAD) is the single most common cause of death in the Europe. In 
developed European countries, 17% of all DALYs (Disability Adjusted Life Year) lost are due to 
cardiovascular diseases. The golden standard for the diagnosis of coronary artery disease (CAD) is 
invasive coronary angiography (ICA).  In past decades non-invasive imaging has been developed to 
serve as first-line diagnostic tool instead of or alongside ICA. In 2004 only early adopters were 
using the technology. Since then it has become increasingly available in many European countries.  
 
MSCT coronary angiography (MSCT) is a non-invasive technology that can be used to visualize 
stenosis of the coronary arteries and thus diagnose CAD. Several recent reviews and 
recommendations state that MSCT is best indicated in patients with intermediate risk of coronary 
artery disease. It has been suggested that using MSCT as triage for low-risk patients could reduce 
unnecessary further examinations and better target optimal preventive medication.  
 
Currently there is global consensus that MSCT should not be used for screening of CAD, both 
because of the radiation burden and lack of diagnostic accuracy in this population, but also because 
the WHO criteria for screening are not met. MSCT has been used also for assessing coronary 
calcium, which is a surrogate marker for the presence and amount of coronary plaques. According 
to current consensus repeated imaging assessment of progression of coronary calcification is not 
recommended.  Assessment of in-stent restenosis with MSCT is difficult because of metal artefacts 
caused by the stent.  
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Assessment elements table 
ID Domain Topic Issue Relevance in the 
context of MSCT 
Yes/No 
Research question(s) in the context of MSCT 
or 
Comment (if regarded as a not relevant issue in this context) 
A0001 Health Problem and Current Use of the 
Technology 
Target Condition For which disease/health problem/potential health problem will the diagnostic intervention 
used?* 
 
yes What are the potential indications (target condition and its pre-test probability) and 
aims (diagnosing, screening, monitoring, assessing prognosis) of MSCT in 
diagnostic cardiology? 
What are the pathologic findings that MSCT coronary angiography is able to detect? 
A0002 Health Problem and Current Use of the 
Technology 
Target Condition What, if any, is the precise definition/ characterization of the target disease? Which diagnosis is 
given to the condition and according to which classification system (e.g. ICD-10)?* 
yes What is the characterisation of CAD? 
A0003 Health Problem and Current Use of the 
Technology 
Target Condition What are the symptoms of the disease? yes What are the symptoms of CAD? 
A0004 Health Problem and Current Use of the 
Technology 
Target Condition What are the consequences of the condition? no Consequences will be covered in the issue no A0008 about the burden of the 
disease 
A0005 Health Problem and Current Use of the 
Technology 
Target Condition Which are the known risk factors for acquiring the condition?* yes Which are the known risk factors for CAD? 
A0006 Health Problem and Current Use of the 
Technology 
Target Condition What is the natural course of the condition?* yes What is the natural course of coronary artery disease (CAD)? 
A0007 Health Problem and Current Use of the 
Technology 
Target Condition How many people belong at the moment (will belong) to the specific target group (describe 
according to sex, age)? 
yes What is the incidence of CAD? 
What is the incidence of cases presenting with angina symptoms but with low to 
moderate probability of CAD? 
A0008 Health Problem and Current Use of the 
Technology 
Target Condition What is the burden of disease (mortality, disability, life years lost)? yes What are CAD mortality and years of (healthy) life lost due to early death or 
disability in Europe? 
A0020 Health Problem and Current Use of the 
Technology 
Target Condition What aspects of the burden of disease are targeted by the technology, i.e. are expected to be 
reduced by the technology? 
no We found it difficult to  see the relevance of this issue to MSCT( Does MSCT target 
differently the different aspects of the burden of disease : symptoms, morbidity, 
mortality, quality of life, costs 
A0009 Health Problem and Current Use of the 
Technology 
Utilisation How much is the technology being used? yes How much is MSCT coronary angiographies used in European countries? 
A0010 Health Problem and Current Use of the 
Technology 
Utilisation Describe the variations in use across countries/regions/settings, if any? yes What kind of international, national or regional variation is there in the use of MSCT 
coronary angiography? 
A0011 Health Problem and Current Use of the 
Technology 
Current Management of 
the Condition 
How is the disease/health condition currently being diagnosed? yes Is there evidence for inappropriate use of diagnostic tests in the diagnostic pathway 
of CAD? 
A0012 Health Problem and Current Use of the 
Technology 
Current Management of 
the Condition 
According to published algorithms/guidelines (if any), how should the condition be diagnosed? yes What is the current evidence based diagnostic pathway for CAD ? 
A0014 Health Problem and Current Use of the 
Technology 
Current Management of 
the condition 
What are the other evidence-based alternative diagnostic procedures, if any? yes What are the other evidence based diagnostic procedures for CAD? 
A0015 Health Problem and Current Use of the 
Technology 
Life-Cycle In which phase is the development of the technology (experimental, emerging, routine use, 
obsolete)? 
no Will be answered in Description-domain 
A0016 Health Problem and Current Use of the 
Technology 
Regulatory Status Which approval status has the technology in other countries, or international  authorities? yes Which approval status has MSCT in EU or internationally? 
A0017 Health Problem and Current Use of the 
Technology 
Regulatory Status Has the technology been included in / excluded form the benefit basket of any country? How is 
the coverage of the technology across countries? (e.g. full-coverage, co-payments, coverage 
under special circumstances/conditional coverage?) 
yes What is the reimbursement status of MSCT cardiac angiography? 
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A0019 Health Problem and Current Use of the 
Technology 
Other Who manufactures the technology? yes Who manufactures MSCTs? 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
48 
 
Appendix 1 
 
Database: CRD (= HTA, EED, DARE) 
Date of search: 4.12.2007, yield 24 references 
Search strategy: 
 
#1 MeSH Coronary Disease EXPLODE 1 2 
#2 ( coronary AND ( disease* OR arter* OR aneurysm* OR stenos* OR restenos* OR thrombos* 
OR vasospasm* OR vessel* ) ) OR "angina pectoris" OR "chest pain" OR atherosclero* 
#3 #1 OR #2 
#4 MeSH Coronary Angiography EXPLODE 1 2 3 
#5 MeSH Tomography, X-Ray Computed EXPLODE 1 2 3 4 5 6 
#6 #4 AND #5 
#7 angiograph* AND tomograph* 
#8 #6 OR #7 
#9 #3 AND #8 
#10 msct OR mdct 
#11 ( multislice OR "multi-slice" OR "multi slice" OR multirow OR multidetect* OR "multi-
detect*" OR "multi detect*" OR multiselect* ) 
#12 ( 4 OR 16 OR 32 OR 40 OR 64 ) AND ( slice* OR row* ) 
#13 #10 OR #11 OR #12 
#14 #9 AND 13  
 
Additional search in Medline 
 
pattern$.tw.         
volume  
case load" or caseload.tw.         
workload/ 
utilization  
delivery of health care/ 
volume$.tw. 
Physician's Practice Patterns/. 
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Description and technical characteristics of 
technology 
 
Iris Pasternack, Sigurður Helgason, Sami Kajander, Lorenzo Leogrande, 
Paolo Oppedisano, Heikki Ukkonen 
Introduction 
Multslice computed tomography (MSCT) coronary angiography is a relatively new non-invasive 
imaging modality with many potential indications. When policy questions about the applicability of 
the new technology are translated into research questions, we need to understand the technical and 
other features of the technology and its current status in a fast developing field.  Newer MSCT 
devices with improved software have been shown to be more accurate and sometimes safer than the 
older generations. The role of MSCT coronary angiography is an anatomic, rather than functional, 
imaging method. This is a very important difference when we consider the role of MSCT in the 
management pathway of patients with suspected coronary artery disease.  
 
In order to assess the applicability of MSCT, there are assessment elements that answer the 
questions about premises, equipment, and staff requirements needed for the use of MSCT. As it is a 
technology that uses ionizing radiation, specific staff training and performance requirements exist. 
Balanced risk communication to patients and the general public is also of great importance. 
 
Methodology  
We did not intend to conduct a systematic review of issues within this domain. Information was 
retrieved from earlier HTA reports, consensus statements, and introduction sections of guidelines, 
reviews and original articles. 
 
We used the corresponding assessment element from the Core HTA of drug eluting stents as such or 
as base text for several elements. This is mentioned and original work referred to in the methods 
section of the elements. 
 
We did a basic search for HTA-reports and systematic reviews and an additional search in Medline. 
Search strategies are in Appendix 1. Further information was sought on the internet and by 
snowballing references from relevant documents. For technical information useful information was 
sought from administrative and manufacturers' web sites. 
Methods for the topic "Investments and tools required to use the technology" 
Information was retrieved through a short literature search (1-9) and several interviews with 
radiologist, cardiologist and technical staff in a University Hospital (UCSC Policlinico Gemelli). 
Additional information sources in the Investments and tools -topic include:  
– Manufacturers web sites 
– Company brochures and data sheets  
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– Regional Law n. 4/2003:  ―Requisti minimi organizzativi strutturali, tecnologici e 
organizzativi delle strutture sanitarie e socio sanitarie‖   
– Decreto Legislativo 26 maggio 2000, n. 187: 
– Attuazione della direttiva 97/43/ EURATOM in materia di protezione sanitaria delle persone 
contro i pericoli delle radiazioni ionizzanti connesse ad esposizioni mediche. 
– Dicom Conformat statment 
– HL7 Standard Protocol  
– IHE Standard Protocol 
– US Technical Information Service  http://www.ntis.gov/ 
Methods for the Topic "Training and information needed for utilizing the technology" 
 
Information was retrieved from: 
– References to HTAs, systematic reviews, guidelines, meta-analyses and reports from 
selected medical insurance organisations. 
– Interview with clinical specialist in medical imaging (radiology & nuclear medicine) 
– Manufacturers web sites:   
o General Electric (www.gemedicalsystems.co.uk ) 
o Siemens (http://www.usa.siemens.com/en/index.htm ) 
o Philips(http://www.medical.philips.com/main/products/ct/applications/clinical/cardio
vascular.html ) 
– Company brochures, patient information and data sheets  
– European Communities (Medical Ionising Radiation Protection) Regulations, 2002. 
http://www.iir.ie/files/fileman/si_478_of_2002.pdf 
  
Text words used to search were: 
– Training / competenc$ / variation / variability / kappa / learning curve /accreditation / 
standard$ 
– Technical / inspection /maintain$ / audit 
– Patient information or leaflet / consent / patient concerns 
 
Assessment elements 
Features of the technology 
What is the technological basis of cardiac MSCT? 
Results 
Computed tomography (CT) is a radiological imaging technique that generates a three-dimensional 
volume or a set of pictures of an object from a large series of two-dimensional X-ray images. 
Cardiac motion makes conventional CT examination of the heart unsuitable. Additionally, imaging 
of small objects like coronary arteries, require high spatial resolution. Multislice CT (MSCT) with 
ECG gating has partly overcome these limitations (1). 
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Currently 64-detector row scanners are the industry standard. These systems acquire a tissue 
volume using up to 64 detectors in a single tube rotation of just 330 - 500 ms. After data 
acquisition, the images are reconstructed for further analysis.  Tube current is usually 400-950mAs 
and voltage 100 – 120 kV. On average, it causes radiation exposure comparable to 160 PA chest 
films or 3-4 times the average yearly effective dose of natural background radiation (2.5 mSv) (2). 
However, there is great variation of dose depending on the techniques used.  
 
Image quality is determined for the most part by temporal and spatial resolution. Temporal 
resolution (shutter speed) means time required to acquire data for one image. It is determined by the 
rotation time, number of X-ray beams, and the reconstruction protocol used. It needs to be high 
because of the constant motion of the heart and coronary arteries. Spatial resolution means the 
number of pixels of information that make up a digital image. It is determined by the minimal slice 
thickness. Invasive coronary angiography is the ´gold standard´ for the anatomical diagnosis of 
coronary artery disease due to its high temporal and spatial resolution (2).  
 
64-slice or detector  CT angiography uses electrocardiogram (ECG) gating or triggering techniques 
to capture data at points in the cardiac cycle when motion is minimal, usually in the mid to late 
diastolic phase. ECG is used either to prospectively trigger imaging or retrospectively reconstruct 
data from continuous acquisition. Use of ECG dependent dose modulation can decrease radiation 
dose by 30-50% and use of prospective triggering by 60-80%. Time to acquire data for one image, 
and time for the patient to hold breath, is 5-10 seconds in the new 64-slice devices (2). The newest 
scanners with 256 and 320 slices allow imaging of the coronary arteries during one or two 
heartbeats (1). 
 
Beta-blockers (or calcium channel blockers in patients with contraindications to beta-blockade)  
have been used to reduce heart rate, and lengthen the diastole to improve image quality. Iodinated 
contrast agent is administered intravenously. To ensure adequate contrast enhancement, a bolus 
tracking technique is usually used to synchronize its arrival in the coronary arteries (2).  
 
Imaging procedure 
 
Patient preparation includes informing the patient about the procedure, verifying sinus rhythm, and 
administration of beta-blockers and nitrates when needed. After patient preparation several 
exploratory scans are performed to determine accurate start and end positions. About 60-100 ml of 
highly iodinated contrast media is usually given with a flow rate of 4-5 ml/s. In some 
circumstances, especially in obese patients, using a high flow rate may be useful (3). Then, the ECG 
gated contrast enhanced scan is performed.  
 
Cardiac CT is usually based on continuous spiral scanning of the heart within a single breath hold in 
5-10 seconds.  Simultaneous ECG permits retrospective reconstruction of images at any desired 
phase of the cardiac cycle. Sequential imaging (so called "step-and-shoot" -mode) is used in some 
instances. Synchronisation of data acquisition and contrast enhancement can be achieved by 
calculating veno-atrial transit time of test bolus of contrast agent before scanning or tracking the 
arrival of the bolus by real-time monitoring. After the data is acquired, the cardiac phase with least 
motion is identified and used to reconstruct a dataset of the entire heart. For lower heart rates, the 
best time instant is usually in the mid- to end-diastolic phase. For higher heart rates end systole may 
yield better results (3). These data sets usually consist of 200-300 thin (0.5-0.75 mm) slices in 
transaxial orientation. Reconstructions are transferred to a workstation for further analysis. The 
presence of coronary artery stenosis is typically evaluated by assessing the axial images in 
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combination with processed images, including 3D volume rendered and curved multiplanar 
reconstructions or maximum intensity projections (4).  
 
What advantages does MSCT have over other modalities in cardiac imaging? 
 
MSCT versus functional imaging 
 
MSCT coronary angiography provides anatomic visualization of stenoses and does not provide 
information of the functional relevance of the lesion. Only approximately half of the significant 
stenosis prove to cause ischemia in a SPECT or PET examination (3,4). Additionally, many patients 
with a normal perfusion scan show considerable atherosclerosis on MSCT scan. There appears to be 
a discrepancy between anatomic and functional testing. They seem to produce complementary 
information, one on the atherosclerosis and the other on hemodynamically significant lesions. 
Further testing of patients with borderline stenosis or equivocal findings on MSCT with functional 
imaging could verify ischemia and lead to referral to invasive coronary angiography (ICA). Non-
ischemic patients with borderline stenosis would be saved from ICA. 
 
Ruling out coronary artery disease (CAD) in low to intermediate risk patients with chest pain 
implies that it is not complete absence of CAD which is required, but rather absence of sufficient 
stenosis to cause angina. In defining 'sufficient' stenosis the following issues arise: a stenosis 
causing angina is dependent not only on the percentage narrowing of the lumen, but also length of 
the stenosis, the difference of pressure across it, and the amount of exercise or demands set for the 
heart.  
  
MSCT versus invasive coronary angiography ( ICA) 
 
Invasive coronary angiography (ICA) offers spatial resolution of 0.1mm. In 64-slice CT the spatial 
resolution is 0.4mm or poorer. To differentiate a 10 from a 20% coronary stenosis, a resolution of 
0.3mm is required. MSCT offers thus a semi-quantitative estimate of coronary stenosis. Only 
vessels with diameter of 1.5mm or more can be reliably assessed. Studies with 64-slice CT indicate 
that quantitative estimates of stenosis severity by MSCT correlate only modestly with ICA (1).  
 
High risk plaques are lipid-rich unstable plaques which may show little or no stenosis (2). They are 
the most likely sources of coronary thrombosis. Several studies have identified differences in plaque 
composition between patients with acute coronary syndrome and stable CAD. There is some 
evidence that CT could assess the composition of plaques and identify high risk plaques better than 
ICA (2). 
 
Invasive coronary angiography (ICA) takes approximately an hour to perform but may require 
several hours of preparation beforehand and a recovery period afterwards. Therefore an overnight 
stay in hospital may be required. ICA carries a risk of heart attack or stroke. Due to the 
ineffectiveness of the pre-ICA diagnostic testing, between 25 % and 50% of diagnostic ICAs 
present a normal or minimal atherosclerosis. In England 67% of ICAs did not involve percutaneous 
coronary intervention in 2005. In 2003 in Spain 34% of ICAs led to therapeutic intervention (5). 
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MSCT versus stress electrocardiograph (ECG) 
 
In Berman's study intermediate risk patients (those who on risk scoring might have 10-20% risk of a 
cardiac event in the next ten years) CT coronary angiography was a more sensitive test than 
exercise testing for CAD. It was better in selecting patients for aggressive medical management and 
further testing (6). 
 
MSCT versus magnetic resonance angiography (MRA) 
 
Magnetic resonance angiography (MRA) is still in research and development for the evaluation of 
coronary arteries. It is non-invasive and uses no radiation. It has inferior spatial resolution and 
accuracy for CAD. Around 20% or more of clinically significant stenoses could be missed using 
MRA (7).  
 
MSCT versus electron beam computed tomography (EBCT) 
 
EBCT is also in the research and development phase. It is faster than MSCT but more expensive 
and the scanners are not widely available and not suitable for general imaging purposes. EBCT is 
non-invasive and involves some radiation exposure but at a lower level than for MSCT. It is inferior 
to MSCT in terms of power and slice thickness (7). 
Who send/select patients to MSCT coronary angiography? Who perform the 
studies? Who interpret the studies? 
Methods 
The research questions under this issue were considered relevant, but due to time constraints, we 
did not answer them in this assessment. 
 
What is the optimal patient population for cardiac MSCT? 
Results 
American College of Cardiology Foundation has produced recommendations on appropriate uses of 
cardiac computed tomography (8). The appropriate indications include: 
– evaluation of chest pain where there is intermediate pre-test probability of coronary artery 
disease (CAD) and either an uninterpretable ECG or inability exercise; or after an 
uninterpretable or equivocal stress test; 
– evaluation of suspected coronary anomalies in symptomatic CAD; 
– acute chest pain with intermediate pre-test probability of CAD, no ECG changes and 
enzymes negative; and 
– evaluation of coronary arteries in patients with new onset heart failure to assess aetiology. 
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In what kind of institutions, hospitals or clinics should MSCT coronary 
angiography be used? 
Methods 
This research questions was considered relevant, but due to time constraints, we did not answer it in 
the assessment. 
 
When was MSCT coronary angiography introduced and what is its position 
currently? 
Results 
The first (since early 1990s) CT technology that allowed ECG gated cardiac CT imaging was 
electron beam CT (EBCT). EBCT provides very high temporal resolution (100 ms per image), but 
has substantial limitations in spatial resolution and image noise (3). Previously, magnetic resonance 
imaging (MRI) and electron beam CT (EBCT) were considered as non-invasive cardiac imaging 
modalities of choice, due to their high temporal resolution. Neither has been used in routine clinical 
practice due to limited availability (2). 
 
The introduction of multidetector computed tomography in the late 1990's led to significant 
improvement of resolution in CT imaging. Small and rapidly moving structures could be visualised 
with good image quality. This permitted expansion to new imaging indications. Already the initial 
four-slice scanners demonstrated the potential of MSCT to visualize coronary arteries. This was a 
major driving force behind an ongoing, rapid evolution of scanner technology along with 
improvements in software and post processing tools (3).  
 
Four-slice machines appeared in 1998, 16-slice in 2001, and 64-slice at the end of 2004. Initially, 
four slices of five mm thickness required a 35 second breath hold from the patient. Improvements in 
hardware and software led to more advanced MSCT technology that produces more images in less 
time. Improved spatial resolution in 64-slice scanners allows better assessment of smaller coronary 
arteries such as the distal left anterior descending (LAD) and left circumflex arteries (LCX). 
Assessment of calcified or stented vessels is improved, where older machines overestimated the 
degree of stenosis (2). The number of uninterpretable segments has reduced substantially in newer 
machines: in 64-slice scanners only 4% of segments remain uninterpretable compared to 30% of 
uninterpretable segments in 4-slice scans that had to be excluded from analysis (4). This 
improvement in image quality is paralleled by an increase in the radiation dose (1).  
 
Currently 64-slice CT is considered as the industry standard for cardiac CT imaging (3). Recent 
meta-analysis demonstrated a significant improvement in the accuracy for the detection of coronary 
artery stenosis for 64-slice CT compared to the previous scanner generations (9). However, it is 
important to realize that patient selection may still heavily influence the results. Patients with higher 
heart rates or arrhythmias were generally excluded because of lowered image quality. The same 
applies to patients with severe CAD with extensive calcifications.  
 
The dominating manufacturers of the technology are GE (General Electric), Philips, Siemens and 
Toshiba (www.msct.eu/MSCT_INFO/Links.htm, accessed 13.7.2008). The technical performance 
of their respective 64-scanners has been assessed recently by the ECRI institute (10) 
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In 2007, 256- and 320-slice MSCT systems became available (1). They have large coverage along 
patient's longitudinal axis. They allow imaging of coronary arteries during one or two heartbeats 
and thus make coronary CT angiography less susceptible to arrhythmias or heart rate variability. 
This significantly lowers the scan time and reduces the amount of contrast needed (4). Although the 
spatial resolution is comparable to the older generations, the newer devices obtain more evaluable 
scans.  
 
Since motion artefacts, due to limitations in the temporal resolution, remained a problem even in 
64-scanners, dual source CT (DSCT) has been introduced. DSCT integrates two X-ray tubes into 
one scan system, increasing the temporal resolution to 83 ms. This results in improved image 
quality and less dependency on heart rate control (4). High diagnostic accuracy can be obtained 
even in patients with high heart rate. Preliminary studies using DSCT showed that up to 98% of all 
coronary segments could be visualized without motion artefacts, even without beta-blockers, or in 
people with uneven rhythm or extensive calcifications (3). Reports on radiation dose exposure when 
using DSCT are conflicting. Contrary to normal 64 MSCT, it seems likely that this technique is best 
with patients who have relatively high heart rates. 
 
A major improvement has been a reduction of the radiation dose by the development of progressive 
ECG gating. With a "step and shoot" protocol, images are taken typically in end-diastole. Because 
of intermittent data acquisition, the radiation dose can be substantially lowered down to 
approximately 1.1-3.0mSv (11,12).  
 
Although 64-slice CT is a reliable tool to rule out functionally relevant CAD in a population with 
intermediate pre-test risk of disease, an abnormal CT angiogram does not necessarily predict 
ischemia (3). Since coronary CT angiography and perfusion imaging provide different and 
complementary information, their sequential use or hybrid imaging may provide useful incremental 
information.  In a feasibility study, hybrid PET/CT was evaluated and was accurate (sensitivity 
90%, specificity 98%) in detecting hemodynamically relevant coronary lesions (13). In another 
study hybrid SPECT/MSCT had much better accuracy in detecting functionally relevant lesions 
than MSCT alone (14). 
Are major technological advantages expected with MSCT?  
Methods 
This issue was considered relevant but due to time constraints, and because this is partly answered 
in the issue B0003 "Is the MSCT technology mature?", we left this unanswered. 
 
Will current technology be outdated or phased out in near future? 
Methods 
This issue was considered relevant but due to time constraints, and because this is partly answered 
in the issue B0003 "Is the MSCT technology mature?", we left this unanswered. 
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Is there an established reference method for the assessment of coronary artery 
luminal stenosis? 
Is there an established reference method for the assessment of coronary artery 
atherosclerosis (coronary artery disease)?  
Is there an established reference method for the assessment of the cardiac 
function (myocardial perfusion and cardiac wall motion)? 
Is there an established method to evaluate the clinical consequences of the CT 
findings? 
 
Methods 
The research questions under this issue were considered relevant, but due to time constraints, and 
because these are addressed at least partly in the accuracy domain, we did not answer them in this 
assessment. 
Are there specific technological features of cardiac MSCT that are different 
from other MSCT applications? 
Results 
Imaging of the heart is technically challenging due to continuous motion during the cardiac cycle. 
Image quality depends on the patient's ability to hold his breath. Image is acquired in a single 
breath-hold to improve image quality. Currently this has been reduced to below ten seconds (2). 
 
Thinner slices have improved the resolution of three dimensional datasets and the quality of 
reformatted images. This is at the cost of increased image noise, which can significantly limit the 
use of MSCT in obese patients with a body mass index of greater than 30 (2). 
 
Heart rate significantly influences motion artefacts. Despite the use of ECG gating techniques 
motion artefacts remain a major technical problem with heart rates above 70 beats per minute (2). 
Only patients with sinus rhythm should be studied; imaging should not be performed in patients 
with severe arrhythmias (4). Low (<60 beats per minute) and regular (+/- 2 beats per minute) heart 
rates predict good image quality (3). For this reason beta blockers are frequently used. 
 
In MSCT angiography iodinated contrast agent is administered intravenously unlike conventional 
invasive coronary angiography in which contrast is administered directly into the coronary arterial 
tree. To ensure adequate contrast enhancement, a bolus tracking technique is usually used to 
synchronize its arrival in the coronary arteries. Verified and severe hypersensitivity to iodinated 
contrast agents is an absolute contraindication of the study. Relative contraindications include renal 
insufficiency, multiple myeloma and phaeochromocytoma (2).  
 
So called "blooming" artefacts occur in the presence of highly attenuating objects in coronary 
vessels, such as calcium and stents. These artefacts make objects look larger on CT image than their 
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actual size, leading to an overestimation of luminal narrowing. The problem is less severe but still 
present in 64-slice devices. Because the presence of calcium in coronary artery walls increase with 
age, this can compromise the ability to perform technically adequate MSCTs in the elderly (6). The 
quantification of coronary calcium prior to imaging may thus play a role in identifying optimal 
candidates for MSCT imaging. Some centres have adopted routine calcium scoring and a limit of 
400 IU in Agatson score, above which MSCT is not performed (1).  
 
The diagnostic performance of MSCT in detecting one or more coronary stenoses can be expressed 
on per-segment or per-patient level. Earlier studies preferred reporting per-segment level results. 
This may be misleading, because the prevalence of coronary artery disease based on per-segment 
analysis is much lower since most of the coronary segments will not be narrowed. Patient-level 
analysis is considered more clinically relevant (15). 
Investments and tools required to use the technology 
What material investments are needed to use MSCT coronary angiography? 
Results 
The use of MSCT scanner for cardiovascular applications requires considerable investments in 
adequate spacing, hardware and software. All biomedical technology described in this paragraph is 
required in order to ensure a safe and appropriate use of MSCT in hospital setting. 
  
An electrocardiogram (ECG) machine is required (usually integrated in MSCT scanner) to perform 
a specific imaging reconstruction and to implement a retrospective ECG-gated technique. It is 
necessary to have access to ventilatory support, monitoring system and an emergency trolley 
complete with cardiac defibrillator for resuscitation. A Power Injector (preferable two-way) is 
required to perform MSCT accurately.  
 
In coronary angiography MSCT it is necessary to utilize a post processing workstation compatible 
with specific software, appropriate acquisition modality and imaging processing. High performance 
centralised storage systems are often required to manage diagnostic and radiological output 
(function: storage, retrieve, send, print) in larger institutions. Information system integrated with 
RIS-PACS (Radiologic Information System – Picture Archiving and Communication System) that 
allow a safe and accurate management of data and for back-up of data/images is usually necessary. 
For power breakdowns it is very important to have a system that allows for continuing and finishing 
current examination. 
  
What kind of special premises are needed to use MSCT coronary angiography? 
Results 
Countries have different structural and safety requirements for installing radiological instruments. 
General requirements for radiological units (16) have to be checked against the instructions from 
local regulatory body.  
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General requirements: 
– There should be adequate space for proper positioning of the patient, interpretation of the 
CT examination, patient observation after testing and preparation of the reports. 
– Space permitted for storage of examination data and supplies must be sufficient for the 
volume of the unit. 
– CT room has to be property built and insulated against radiation (usually with lead). Load 
limit of the floor should be taken into account 
– Standard and auxiliary power plant, vacuum, oxygen and medical gas plants and air 
conditioning system are required 
– Direct visualization of the patient should be available through a leaded glass window.  
– Patient privacy must be assured with the use of appropriate curtains and doors. 
– A sink and antiseptic soap must be readily available and used for hand washing.  
 
What equipment and supplies are needed to use MSCT coronary angiography? 
Results 
Heart rate is monitored; only patients in sinus rhythm and who are able to hold their breath should 
be scanned. Most centres administer beta-blockers to patients with heart rates above 60-65 beats per 
minute, either with intravenous or oral beta blockers. Many centres also administer sublingual 
nitrates which dilate the coronary arteries thereby enhancing image quality (4).  
 
60-140 ml iodinated contrast agent is needed, depending on scanner type, patient size, heart rate, 
and body mass index. The contrast agent should be of high iodine concentration, followed by 40-50 
ml saline for optimal arterial enhancement.  
 
Otherwise the use of MSCT requires equipment and supplies that are frequently utilised in health 
care units i.e. syringes, needles, and bandages.  
 
What kind of data and records are needed to monitor the use of MSCT coronary 
angiography? 
Results 
Health care organizations create their records of patient and staff data and care process with HL7 
communication protocol (17). Links to national standards are available at 
http://virtual.vtt.fi/virtual/hl7/index.htm. Diagnostic imaging records are created according to 
Dicom Protocol. A record for radiation doses provided to patients is needed.  RIS – PACS system 
allows the optimization of workflow procedure.   
 
What kind of registers is needed to monitor the use of MSCT coronary 
angiography? 
Methods 
This issue was considered relevant but due to time constraints we left this unanswered. 
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Training and information needed for utilizing the technology 
What kind of qualifications, training and quality assurance are needed for the 
use and maintenance of MSCT? 
Results 
 
International Atomic Energy Agency (IAEA) has published basic safety standards in diagnostic 
radiology (18). National or regional regulatory bodies authorize practices in the form of registration 
or licence.  They provide guidelines for maintenance and periodic quality control. Regulatory 
authorities may require that the authorization be renewed periodically. Periods of renewal are based 
on safety criteria. In the view of IAEA-TECDOC-1067 a reasonable period for radiology is five 
years (19).   
 
Personal qualifications and training 
 
Cardiac MSCT requires competence on many levels. Data acquisition needs to be carefully 
performed, including necessary pre-medication. Appropriate measures are needed to keep radiation 
exposure as low as possible. Image reconstruction and post-processing require knowledge in CT 
physics, radiology, and cardiac physiology. Image interpretation must be based on knowledge in CT 
angiography, cardiac anatomy, normal and variant patterns of coronary circulation and CAD 
assessment in general. Training in radiology or cardiology alone will not provide sufficient 
background to perform and evaluate cardiac MSCT (3). 
 
There is no scientific data on the required amount of training to achieve a certain level of diagnostic 
confidence and safety in cardiac CT (3). The published recommendation described here are 
consensus-based statements. 
 
National regulations may require a personal accreditation as formal recognition of competence. 
Accreditation is usually provided by the relevant professional bodies. Some countries require a 
formal personal authorization. General requirements are described in the IAEA Report no 39, page 
4-6 (18). Some national regulatory agencies are listed in Appendix 2. 
 
Personal accreditation, continuous training and safety programmes regarding the use of MSCT for 
cardiovascular applications are important both for the safety point of view (optimal radiation safety, 
avoiding adverse effects of drugs and contrast agents), and for optimal outcome of testing 
(adequacy of image quality and proper interpretation of results with as few false negative and false 
positive results as possible). The difficulties in this rapidly changing field are the complexity of the 
imaging devices and anatomy, continually changing imaging technology, and the rapidly advancing 
uses with many new indications 
 
A licensed unit should establish a policy that encourages and provides continuing professional 
development programme, with the aim of improving staff skills, maintaining familiarity with 
current practices and fostering safety culture. Such training and development can be set up through 
informal meetings of the radiology department, seminars, accredited continuing education 
programmes or other means.  
 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
60 
 
Professional education and training to obtain the necessary qualifications need to have been 
completed before commencement of duties and continued subsequently as part of professional 
development and as required by the regulatory body. Furthermore, the instruction of personnel is 
required whenever significant changes occur in duties, regulations, the terms of licence or radiation 
safety procedures. Licensees need to maintain records with respect to the initial and periodic 
training of personnel (18).  
 
The training needs, assurance of competence and maintenance of certification of those using the 
MSCT applies primarily to radiologist although other experts (cardiologists) or specialized 
personnel (technologists, nurses, physicist) may be involved. Considerable subspecialty training 
may be required in certain areas. The appendix 2 of the IAEA safety standards report (18) contains 
requirements for training of medical practitioners, radiographers/radiological technologists, medical 
physicists, radiation protection officers (RPOs), nurses and maintenance staff. 
 
Most cardiology and radiology training programmes do not incorporate mandatory sections of 
cardiac CT at a volume that would suffice to provide competent diagnostic service. There are some 
specialty fellowship programmes in cardiac CT available. Guidelines addressing what level of 
training is required for the performance of cardiac imaging with computed tomography have been 
developed by a joint committee of the American College of Cardiology Foundation/American Heart 
Association (ACCF/AHA) (20). The guideline helps in the assessment of physicians‘ expertise in 
the ability to apply and interpret cardiovascular computed tomography (CCT) in hospital or 
outpatient settings. The minimum education, training, experience, and cognitive skills necessary for 
the evaluation and interpretation of MSCT are specified.  These guidelines that were published in 
2005, with a minor update in 2007, are used by organisations like the Intersocietal Commision for 
the Accreditation of Computed Tomography Laboratories (ICACTL, www.intersocietal.org) for 
their standards. 
 
Minimum requirements for competency in cardiac CT have been defined for three levels. Level 1 
defines a basic knowledge of cardiac CT, which is sufficient for practice in general adult cardiology 
or general radiology, but not for independent interpretation of patient data sets. Level 2 defines the 
minimum experience required in order to independently perform and interpret CT coronary 
angiography. Level 3 training would qualify an individual to direct an independent cardiac CT 
programme. 
 
In summary the committee recommends the following: 
– The minimum level of training required to be able to independently perform and interpret 
coronary CT angiography consists of at least 150 mentored CT scan examinations 
interpreted and at least 50 mentored examinations performed. 
– The minimum level required to be able to continue to independently perform and interpret 
coronary CT angiography requires at least 50 examination conducted and interpreted per 
year. 
– Candidates for competence in coronary CT angiography should have completed a formal 
residency in cardiology, nuclear medicine or radiology. 
– A CT laboratory performing coronary CTA should have a continuous quality control 
program co-ordinated by a level 3-trained physician. At this time, no definitive statements 
about the quality of  scanners has been made, although on the basis of the current literature, 
coronary CTA imaging on multidetector CT units should be performed on systems with ≥16 
detectors. 
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Similar standards have been set forward by the American College of Radiology in their Practice 
Guidelines (21) and the recently revised CT Accreditation Program (22). In their statement the 
qualifications of a radiologist who supervises and interprets cardiac CT examinations should 
include supervision and interpretation of 75 cardiac CT cases within 36 months, excluding cases 
performed exclusively for calcium scoring. 
 
Managerial commitment to safety culture and quality assurance  
 
Licensed radiology units are usually required to implement quality assurance programs that provide 
adequate assurance that the specified requirements relating to protection and safety are satisfied. 
Items for radiation protection and safety programmes are described in Appendix 1 in the IAEA´s 
report no 39 (18). 
 
Hospital senior management should be committed to an effective protection and safety policy and 
demonstrate support for those persons whose responsibility radiation protection is. The commitment 
can be demonstrated by a written policy that assigns the importance to protection and safety. This 
statement should be made known to the hospital personnel and should be followed by establishing a 
radiation protection programme (18).  
 
Managers should appoint sufficient number of medical and paramedical professionals with personal 
accreditation for imaging tasks to ensure that all activities relevant to protection and safety are 
carried out in accordance with regulations. The number of persons should be kept under review, 
especially when workload increases or new techniques and new equipment are incorporated. 
Inspection of the facilities and records by the regulatory body are possible (18). 
How does training and quality assurance affect management of MSCT 
angiography? 
Results 
It is difficult to determine to what extend training and experience translate into better patient 
outcomes. Different radiation doses are used with different imaging protocols. Careful attention to 
technique, including the employment of dose-reduction strategies, can minimize the radiation dose 
patients receive (23-25).  
 
Experience and level of training of those interpreting the results affects the accuracy and number of 
false negative and false positive readings. A high level of training and extensive experience 
increases accuracy but there is significant variation in individual performance even after training. 
This has been shown for computerised tomography of the colon (virtual colonoscopy) (26) but it is 
unclear how this applies to cardiac MSCT. 
 
Inter-rater agreement is generally slightly lower than intra-rater agreement (kappa-values from 
0.558- to 0,76 compared with 0,79 to 0,81) and slightly lower with patient-based compared to 
segment based analysis.  How this is affected by level of training or experience is unclear (27).  
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What kind of training or information about MSCT angiography is needed for 
the patients and their families and general public? 
Results 
Informing potential users, the general public, key decision- and policy-makers is increasingly 
important in the light of extensive use, variation in practice (referral for MSCT) and public interest 
and demand for MSCT. Patients advised to have MSCT should receive verbal and written 
information on the risks and benefits of the procedure.  Such information should be balanced, 
unbiased and of high quality and preferably from recognised official sources (radiological 
associations/societies and government agencies) that adhere to the Health On the Net (HON) code 
principles (http://www.hon.ch/).   
 
Suggested high quality portals for health related information:   
– Healthinsite http://www.healthinsite.gov.au/  (Australia) 
– Health On the Net Foundation  www.hon.ch/  (Switzerland)  
– NHS Direct Online http://www.nhsdirect.nhs.uk (UK) 
– MEDLINEplus  http://medlineplus.gov   (USA) 
– EQUIP http://www.equip.nhs.uk/ (UK).     
 
MSCT is safer than invasive coronary angiography (ICA) as it is less invasive and does not have the 
risks associated with arterial catheterisation. Negative consequences, in addition to the risks of the 
procedure (radiation and contrast exposure), include the downstream effects of false negative 
(delayed or missed diagnosis and potentially beneficial treatment), false positive (inappropriate 
diagnosis and labelling and even unnecessary and potentially harmful interventions) and 
inconclusive results (anxiety, further tests). The risks of ionizing radiation are perhaps best put into 
perspective by explaining the magnitude in relation to other common radiology investigation 
(comparable to 160 PA chest films or 3-4 times the average yearly effective dose of natural 
background radiation) (2). Claustrophobia is a problem for some patients and as with any procedure 
that involves radiation pregnancy is a contraindication. Allergy to contrast agents and beta-blockers 
should also be excluded. The limitation of MSCT on certain indications might need explaining in 
patients who previously had a cardiac intervention (in particular small stents) where evidence of 
effectiveness is insufficient and also the potentially harmful or beneficial incidental extra cardiac 
findings on MSCT. 
 
Discussion 
 
The use of 64-slice CT coronary angiography seems to be increasing and its indications become 
clearer. It is usually not mentioned in clinical management guidelines of coronary artery disease, 
but there are consensus statements about appropriate indications and conditions of use. The 
technology is rapidly evolving and completely new generations, with added image slices or dual X-
ray tube sources, with new features are entering market. Radiation is the major safety issue, which 
has not been resolved in a satisfactory manner. 
 
The aim of this document, the Core HTA on MSCT coronary angiography, was to test the first draft 
of the diagnostic Core Model by EUnetHTA project. The testing revealed some weaknesses in the 
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content of the assessment elements. Therefore we decided to combine the issues B0012 and B0019 
and handle the qualifications, training and quality assurance thing in a single issue, because we felt 
it was difficult to handle them separately. Instead we added an element, numbered B0020, that 
considers the effect of training and quality assurance on the management of the technology. We also 
combined the patient training and information issues B0014 and B0015 into one issue (B0014). 
 
The time-lines were strict and we ended up with a situation with not enough resources of substance 
expertise. Therefore some issues remained unanswered and some answers are not as complete as 
they should have been if it were a "real" Core HTA. A more systematic approach and a formal 
quality assessment would have been needed in some instances. 
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Assessment elements table 
 
 
Domain Topic Issue Releva
nce in 
the 
context 
of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
or 
Comment (if regarded as a not relevant issue in this context) 
B0001 Description and 
technical characteristics 
of technology 
Features of the technology What is this technology?  yes What is the technological basis of cardiac MSCT? 
B0002 Description and 
technical characteristics 
of technology 
Features of the technology Why is this technology used?  yes What advantages does MSCT have over other modalities in cardiac imaging? 
B0004 Description and 
technical characteristics 
of technology 
Features of the technology Who are the users of this technology?  yes Who send /select the patients to MSCT coronary angiography? 
Who perform the studies? 
Who interpret the studies? 
B0016 Description and 
technical characteristics 
of technology 
Features of the technology Who are the persons this technology will 
be used on? 
yes What is the optimal patient population for cardiac MSCT? 
B0005 Description and 
technical characteristics 
of technology 
Features of the technology Place and context for utilising the 
technology? 
yes In what kind of institutions, hospital or clinics should MSCT coronary angiography 
be used? 
B0003 Description and 
technical characteristics 
of technology 
Features of the technology Phase of the technology: When  was it 
developed or introduced in health care? 
yes When was MSCT coronary angiography introduced and what is its position 
currently? 
B0017 Description and 
technical characteristics 
of technology 
Features of the technology Is the technology rapidly changing / 
improving? 
yes Are major technological advantages expected?  
Will current technology be outdated or phased out in near future? 
B0018 Description and 
technical characteristics 
of technology 
Features of the technology Are the reference values or  cut-off points 
clearly established? 
yes Is there an established reference method for the assessment of coronary artery 
luminal  stenosis? 
Is there an established reference method for the assessment of coronary artery 
atherosclerosis (coronary artery disease)?  
Is there an established reference method for the assessment of the cardiac 
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function (myocardial perfusion and cardiac wall motion)? 
Is there an established method to evaluate the clinical consequences of the CT 
findings? 
B0006 Description and 
technical characteristics 
of technology 
Features of the technology Are there any special features relevant to 
this technology? 
yes Are there specific technological features of cardiac MSCT that are different from 
other MSCT applications? 
B0007 Description and 
technical characteristics 
of technology 
Investments and tools required to use 
the technology 
What material investments 
are needed to use the technology? 
yes What material investments are needed to use MSCT coronary angiography? 
B0008 Description and 
technical characteristics 
of technology 
Investments and tools required to use 
the technology 
What kind of  special premises  
are needed to use the technology? 
yes What kind of special premises are needed to use MSCT coronary angiography? 
B0009 Description and 
technical characteristics 
of technology 
Investments and tools required to use 
the technology 
What equipment and supplies are needed 
to use the technology? 
yes What equipment and supplies are needed to use MSCT coronary angiography? 
B0010 Description and 
technical characteristics 
of technology 
Investments and tools required to use 
the technology 
What kind of data and records are needed 
to monitor the use of the technology? 
yes What kind of  data and records are needed to monitor the use of MSCT coronary 
angiography? 
B0011 Description and 
technical characteristics 
of technology 
Investments and tools required to use 
the technology 
What kind of registers  
are needed to monitor the use the 
technology? 
yes What kind of registers is needed to monitor the use of MSCT coronary 
angiography? 
B0012 Description and 
technical characteristics 
of technology 
Training and information needed for 
utilizing the technology 
What kind of qualifications, training and 
quality assurance are needed for the use 
and maintenance of the technology? 
yes What kind of qualifications, training and quality assurance are needed for the use 
and maintenance of the MSCT? 
B0020 Description and 
technical characteristics 
of technology 
Training and information needed for 
utilizing the technology 
How does training and quality assurance 
affect the management of the technology? 
yes How does training and quality assurance affect management of MSCT 
angiography? 
B0014 Description and 
technical characteristics 
of technology 
Training and information needed for 
utilizing the technology 
What kind of training or information about 
the technology is needed for the patients, 
their families and general public? 
yes What kind of training or information about the MSCT angiography is needed for 
the patients, their families and general public? 
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Appendix 1 
 
Basic search 15.12.2007 
 
#1 MeSH Coronary Disease EXPLODE 1 2 
#2 ( coronary AND ( disease* OR arter* OR aneurysm* OR stenos* OR restenos* OR thrombos* 
OR vasospasm* OR vessel* ) ) OR "angina pectoris" OR "chest pain" OR atherosclero* 
#3 #1 OR #2 
#4 MeSH Coronary Angiography EXPLODE 1 2 3 
#5 MeSH Tomography, X-Ray Computed EXPLODE 1 2 3 4 5 6 
#6 #4 AND #5 
#7 angiograph* AND tomograph* 
#8 #6 OR #7 
#9 #3 AND #8 
#10 msct OR mdct 
#11 ( multislice OR "multi-slice" OR "multi slice" OR multirow OR multidetect* OR "multi-
detect*" OR "multi detect*" OR multiselect* ) 
#12 ( 4 OR 16 OR 32 OR 40 OR 64 ) AND ( slice* OR row* ) 
#13 #10 OR #11 OR #12 
#14 #9 AND 13  
 
Additional search in Medline in March 2008 
 
equipment/     
device$.tw. 
(technique$ or method$).tw. 
diagnostic tests, routine/         
diagnos$ test$.tw. 
diagnostic techniques/ 
Mass Screening/ 
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Safety 
 
 
Iris Pasternack, Nick Hicks, Cecile Camberlin, Irina Cleemput, Hans van Brabandt, Sami 
Kajander, Ritva Bly, Leonor Varela Lema, Alberto Ruano-Ravina, 
 
Introduction 
MSCT coronary angiography is a technology that may have the potential to replace a proportion of 
invasive coronary angiographies (ICA) in patients with suspected coronary artery disease. MSCT is 
non-invasive but uses more ionizing radiation than ICA and a balanced assessment of the benefits 
and risks of utilisation of the current and recent generations of MSCTscanners to other diagnostic 
modalities is necessary.  
 
Safety concerns related to cardiac MSCT can be divided into three groups: those that arise from the 
use of ionizing radiation, the use of iodinated contrast media, and the use of premedication needed 
to provide adequate image quality.  The overall risk of harms of a technology is a summation of the 
risk contribution of each component of the procedure. When weighing the overall risk of any 
medical procedure, it is important to consider how this compares to the overall risk of alternative 
procedures. In the case of MSCT coronary angiography clinical indications for cardiac CT must 
always take radiation exposure into account. All possible measures should be taken to keep the dose 
as low as possible. The statistical risk of cancer induction due to radiation exposure is difficult to 
assess at an individual level, and the harms may only manifest themselves years later. By contrast 
certain harms may appear immediately such as a decline in renal function or an allergic reaction due 
to contrast media. 
Methodology 
We did a basic search for HTA-reports and systematic reviews and an additional search in Medline. 
Search strategies are described in Appendix 1. We used the two new HTAs on MSCT coronary 
angiography published in spring 2008 (1,2). Further information was sought in internet and 
snowballing references from relevant documents and using the 'related articles' feature in PubMed.  
 
We did not intend to do a systematic review for each research question. Instead, information from 
published HTAs and systematic reviews formed the basis, and recent publications were checked. 
 
There was no formal quality assessment of the included publications. 
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Assessment elements 
Technology dependent safety risks 
What are the safety risks of MSCT coronary angiography? 
Results 
Direct harms related to cardiac MDCT studies can be divided into three groups: those that arise 
from the use of ionizing radiation, those that are due to the use of iodinated contrast media, and 
those that may occur because of the use of premedication needed to provide adequate image quality. 
In each group, the amount of harms expected or known to occur is related to different 
subpopulations subjected to the study. Morbidity figures range from 1-2% and mortality is 
estimated to be 0,1 %, but it can increase to 1 % in patients with unstable angina pectoris(3).  
 
Ionizing radiation 
 
If performed with faultless equipment according to manufacturer's instructions, the radiation doses 
due to diagnostic use of multislice CT is well below the threshold for the induction of deterministic 
effects (such as skin burns, epilation and the induction of eye cataracts). Genetic risk from CT 
studies is nowadays considered to be negligible as well. The principal concern at patient doses is the 
induction of cancer in the exposed individual.  
 
The effective radiation dose of a contrast enhanced cardiac CT scan is 5-20 mSv (4). In studies 
included in a systematic review published in 2007 (5) the estimated mean effective radiation dose 
per patient was 15 mSv for males and 20 mSv for females. With modulated protocols the 
corresponding figures were 7 and 14 mSv. This is much higher than the radiation dose of an 
invasive coronary angiography (ICA) which is about 2-7 mSv. 
 
This radiation exposure is comparable to 160 posterior-anterior chest films or three to four times the 
average yearly effective dose of natural background radiation (2.5 mSv) (2). 
 
Iodinated contrast media 
 
MSCT necessitates intravenous administration of contrast medium. This can lead to allergic 
reactions and to renal failure. In most cases renal impairment reverses within a week. Meanwhile it 
is essential to avoid further nephrotoxic agents and carefully control fluid and electrolyte balance. 
In more severe cases temporary dialysis may be necessary (1). 
 
Typically, 100 to 130 ml of non-ionic contrast media containing 300 to 350 mg of iodine per 
millilitre is injected for MSCT angiography. Extravasation (average of 18 ml) occurs in 0,3% to 
0,6% of patients when power injector is used in a peripheral vascular line (6). 
 
Allergic reactions 
 
Contrast material is generally well tolerated although approximately 1% of patients who receive 
low-osmolar non-ionic contrast material will develop anaphylaxis symptoms. Most anaphylactic 
reactions are mild and non-allergic. The risk for serious or severe reactions—anaphylaxis grade 3—
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has been estimated to be from 0.02% to 0.04% with non-ionic contrast material. In more than 90% 
of cases, the direct release of histamine and other mediators is responsible for the anaphylaxis 
symptoms after application of contrast material. However, genuine IgE-mediated allergic 
anaphylaxis is rare but may arise.  
 
Contrast induced nephropathy 
 
Contrast-induced nephropathy (CIN) is a serious complication of the use of iodinated contrast 
media. It is the third most important cause of hospital-acquired renal failure and is associated with 
increased morbidity and mortality.  
 
CIN involves an acute decline in renal function that occurs 24 to 48 hours after intravascular 
injection of contrast medium (CM). The commonest definition in use is an increase in serum 
creatinine (SCr) of >25% of baseline value occurring following the intravascular administration of 
CM without an alternative explanation. Serum creatinine usually peaks 2-3 days following CM use 
and returns to the baseline within 14 days. Some patients, however, progress to acute renal failure 
(ARF) requiring dialysis (7). 
 
Prospective studies of the incidence of CIN have produced a wide range of values, due to the 
differences in the definition of the renal failure and differences in patient comorbidity. Patients 
without risk factors had an average 3 % risk for contrast induced nephropathy (8). However, in a 
consecutive series of 1800 patient undergoing invasive cardiac procedures, the incidence of CIN 
was 14,5% (1). Contrast registry data of patients undergoing diagnostic investigations requiring 
contrast media suggest an incidence of 0.4% for subsequent dialysis (9).  
 
The occurrence of CIN has been closely identified with eight pre-existing risk factors:  hypotension, 
intra-aortic balloon pump use, congestive heart failure, age over 75 years, anaemia, diabetes, 
contrast medium volume and impaired renal function (10-17).  
 
Careful patient selection can identify those patients for whom contrast media may present an 
increased risk or be contraindicated. For some of these patients preventive pre-treatment strategies 
may reduce the risk of CIN following administration of contrast media. The physician should also 
be available to treat adverse reactions to contrast media (9,18-21). 
 
Premedication 
 
Most patients who are prepared for MSCT, will receive a beta-blocker if their heart rate is above a 
certain threshold, typically 60 or 65 b.p.m. Potential adverse effects of beta-blockade are 
hypotension, extreme bradycardia and bronchospasm. Careful clinical monitoring of blood pressure 
and heart rate during and after the procedure is usually required (1).  
 
The need for pre-test administration of beta-blocking agents is less compelling in dual-source 64-
slice CT, although this advantage may disappear when prospective ECG-gating is used (1). 
 
The use of sublingual or peroral nitrate substances is recommended in many cardiac MSCT 
protocols as a means to enhance image quality. Necessary precautions must be taken into account 
while using this premedication.  
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Comment 
 
Currently, majority of users are moving towards the use of newer dose saving protocols.   E.g 
prospective gating provides significant radiation saving without significant effects on image quality. 
The newest devices will have a dose of <1-3 mSv/patient in routine work, which is actually 
considerably less than that of an invasive angiography.  
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retrospective electrocardiogram-gated helical scan. J Am Coll Cardiol. 2008 Oct 28;52(18):1450-5. 
Kajander S, Ukkonen H, Sipilä H, Teräs M, Knuuti J. Low radiation dose imaging of myocardial perfusion and 
coronary angiography with a hybrid PET/CT scanner. Clin Physiol Funct Imaging. 2008 Nov 6. [Epub ahead of print] 
Herzog BA, Husmann L, Burkhard N, Gaemperli O, Valenta I, Tatsugami F, Wyss CA, Landmesser U, Kaufmann PA. 
Accuracy of low-dose computed tomography coronary angiography using prospective electrocardiogram-triggering: 
first clinical experience. Eur Heart J. 2008 Nov 7. [Epub ahead of print] 
Javadi M, Mahesh M, McBride G, Voicu C, Epley W, Merrill J, Bengel FM. Lowering radiation dose for integrated 
assessment of coronary morphology and physiology: first experience with step-and-shoot CT angiography in a rubidium 
82 PET-CT protocol. J Nucl Cardiol. 2008 Nov-Dec;15(6):783-90. Epub 2008 Sep 12. 
 
What are the immediate and long term consequences of the radiation exposure 
from MSCT coronary angiography? 
Results 
 
Harms due to cardiac CT may be acute or delayed. They are caused by a variety of factors both 
independent and related. If performed with faultless equipment according to manufacturer's 
instructions, the radiation doses due to diagnostic use of multislice CT is well below the threshold 
for the induction of deterministic effects (such as skin burns, epilation and the induction of eye 
cataracts). Immediate risk for genetic changes from CT studies is nowadays considered to be 
negligible. The principal concern at patient doses is the induction of cancer in the exposed 
individual. No major body that investigates radiation risks recommends the use of threshold values 
of radiation in evaluating risks of cancer induction (22-24). 
 
For any individual aged 55 years or older, lifetime risk of developing cancer after a single MSCT 
cardiac exam is low and generally considered to be below 1.0 %. In the study of Coles (25) it is 
estimated that the risk of inducing a fatal cancer is 0,07 % for MSCT and 0,02 % for invasive 
coronary angiography (ICA).  
 
The lifetime excessive risk of breast and lung cancer for girls and young women after a single 
MSCT study is much higher. Recent estimate for the relative risk of breast carcinoma incidence is 
1.004 – 1.042 from a single scan. Relative risk for lung cancer incidence, in comparison, is 1.005 – 
1.076 from a single scan. Other organs directly in the field of view (heart and oesophagus in the 
addition to the above) exhibit the highest absorbed doses. These risks, as well as risks related to 
ionizing radiation in general, are greatest in younger patient populations. 
 
In a simulation study, equivalent doses to individual organs from MSCT were determined, and life 
time cancer risk from these doses calculated using the approach of the BEIR II (National 
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Academies' Biological Effects of Ionizing radiation) 7th report (26). Life-time cancer risk estimates 
for standard MSCT varied from 1 in 143 for a 20-year-old woman to 1 in 3261 for an 80-year-old 
man. Use of simulated ECG controlled current modulation decreased these risk estimates to 1 in 
219 and 1 in 5017, respectively. The highest organ lifetime attributable risks were for lung cancer 
and, in younger women, breast cancer. 
Comment 
 
Currently, majority of users are moving towards the use of newer dose saving protocols.   E.g 
prospective gating provides significant radiation saving without significant effects on image quality. 
The newest devices will have a dose of <1-3 mSv/patient in routine work, which is actually 
considerably less than that of an invasive angiography.  
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assessability of prospective electrocardiogram-gated computed tomography coronary angiography: comparison with 
retrospective electrocardiogram-gated helical scan. J Am Coll Cardiol. 2008 Oct 28;52(18):1450-5. 
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82 PET-CT protocol. J Nucl Cardiol. 2008 Nov-Dec;15(6):783-90. Epub 2008 Sep 12. 
What is the dose relatedness of harms of ionizing radiation in MSCT coronary 
angiography? 
Results 
High doses of radiation clearly link to immediate as well as delayed harms, whereas the effects of 
long term exposure to low levels of radiation, as used in MSCT, remain highly controversial. 
Although there is no clear evidence of harm various advisory bodies use the conservative zero 
threshold assumption: only no radiation is without excess risk. To estimate the immeasurable risk 
from low-level radiation requires mathematical models. Currently, a linear relationship between 
dose and risk is used in models (6). 
 
As CT doses are much higher than those from conventional radiography, and as cardiac CT doses 
are among the highest of CT, use of the ALARA principle (―as low as reasonably achievable‖) is 
particularly important.  
 
What kind of psychological harms does coronary MSCT potentially have? 
Methods 
This issue was considered relevant for this Core HTA. Due to time constraints, and because this 
issue will be at least partly answered in the social domain, we left this unanswered. 
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Which are the means to reduce the radiation dose of MSCT coronary 
angiography? 
Results 
Using as low radiation dose as possible in cardiac patients is particularly important since the 
patients may undergo many radiographic investigations including fluoroscopically guided cardiac 
interventions that may require a high radiation dose. Use of ALARA (―as low as reasonably 
achievable‖) principle is therefore recommended. The supervising physician should be familiar with 
the technical parameters that affect radiation dosage: mAs, kVs and scan pitch. Automated X-ray-
dose shaping algorithms and X-ray tube pulsing should be applied in order to minimise the radiation 
exposure while allowing diagnostic image quality. 
 
Reduction in radiation dose can be achieved by obvious methods, such as keeping the length of the 
scan volume as short and tube current as low as possible (4). This is achieved through smaller z-axis 
scan coverage and extensive use of dose-modulating techniques, such as ECG-gated and attenuation 
based tube current modulation, use of reduced tube voltage in small patients, use of prospective 
ECG triggering (instead of retrospective gating), use of sequential (instead of spiral) imaging and 
combinations of these (27,28). 
 
Reducing tube voltage to 100 kV instead of commonly used 120 kV should be considered in 
patients with normal or low body mass (4). However this is often at the cost of image quality. 
 
Because the X-ray beam attenuation is less in the shorter postero-anterior direction than in the 
longer lateral direction, the radiation dose may be reduced when the X-ray tube is either anterior or 
posterior of the patient (6). 
 
ECG-correlated tube current modulation, in which full tube current is limited to a short time period 
in diastole, can reduce the radiation dose by 30-50% (2,4). This is particularly effective in low heart 
rates. 
 
The x-ray tube may be prospectively triggered to generate X-rays only during ventricular diastole, 
when cardiac motion artefacts are less likely. This so called "Step-and-shoot mode" could reduce 
the ionizing radiation exposure down to 2,5 mSv in non-obese patients (BMI<30) with heart rate 
less than 70 beat per minute (1,29-32). Prospective image construction enables significant reduction 
of radiation dose with the cost of diagnostic capability.  
Comment 
 
Currently, majority of users are moving towards the use of newer dose saving protocols.   E.g 
prospective gating provides significant radiation saving without significant effects on image quality. 
The newest devices will have a dose of <1-3 mSv/patient in routine work, which is actually 
considerably less than that of an invasive angiography.  
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By what means may the risk of harms from iodinated contrast medium be 
reduced? 
Results 
MSCT necessitates intravenous administration of contrast medium. This can give rise to allergic 
reactions and renal failure. In most cases renal impairment is transient and reverses within a week. 
Meanwhile it is essential to avoid further nephrotoxic agents and carefully control fluid and 
electrolyte balance. In more severe cases temporary dialysis may be necessary. 
 
A number of approaches have been used to reduce the risk of contrast induced nephropathy (CIN) 
although not all are supported by a strong evidence base (19). The issues may be considered as 
patient dependent factors and patient independent factors (9).  
Approaches include:  
– reducing the quantity of iodine medium infused 
– using low-osmolar or iso-osmolar contrast media 
– optimising the contrast media injection regime  
– optimising the dose to the physical characteristics of the individual patient 
– increasing patient hydration by oral or intravenous means before undertaking the procedure 
– using renoprotective drugs like N-acetylcysteine 
– stopping nephrotoxic drugs 
 
Undertaking an individual patient assessment in order to identify those with specific risk 
characteristics allows identification of those at highest risk of experiencing CIN (7,9).  
Are there differences in the safety profile of different MSCT devices or 
generations? 
Results 
In the original studies included in a review by Hamon 2007, the effective radiation dose in 16-slice 
CT scans ranged from 5.4 to 16.3 mSv, and from 10-21.4 mSv for 64-slice CT scans (33). Radiation 
exposure with 320-slice CTs has been reported to be around 7 mSv (1). 
 
In dual source 64-slice CT, the radiation exposure does not seem to  be different than in standard 
64-slice CT (1). 
 
The need for pre-test administration of beta-blocking agents is less compelling in dual-source 64-
slice CT, although this advantage may disappear when prospective ECG-gating is used (1). 
 
With prospective ECG-gating (the "Step-and-shoot mode") the X-ray beam is turned on only during 
late diastole, and ionizing radiation can thus be reduced. Because of intermittent data acquisition 
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radiation dose can be substantially lowered to approximately 1.1-3.0mSv (34). There are no studies 
that compare MSCT with prospective ECG-gating with invasive coronary angiography (ICA). 
 
Emerging hybrid techniques that combine MSCT with myocardial perfusion scanning will 
inevitably lead to an increase in radiation exposure (32). 
Comment 
 
Currently, majority of users are moving towards the use of newer dose saving protocols.   E.g 
prospective gating provides significant radiation saving without significant effects on image quality. 
The newest devices will have a dose of <1-3 mSv/patient in routine work, which is actually 
considerably less than that of an invasive angiography.  
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What is the safety of MSCT coronary angiography in comparison to alternative 
diagnostic technologies? 
Results 
 
MSCT versus invasive coronary angiography (ICA) 
 
Overall mortality MSCT vs ICA 
ICA is invasive and often performed with the intention to treat. Less invasive procedures are purely 
diagnostic but they may help to select patients for ICA. Contrast medium induced harms, such as 
allergic reactions and contrast nephropathy, are similar in MSCT than in ICA, while the doses of 
contrast medium are similar. MSCT appears to be safer despite its higher radiation dose (25). 
Overall mortality risk for ICA is 0.13%: radiogenic risk 0.02% and non-radiogenic risk 0.11% (25). 
In United States ICA has an adverse event rate of approximately two per cent including vascular 
complications (1,6%), arrhythmia (0.3%), stroke (0.1%), myocardial infarction (0.05%) and death 
(0.12%) (35). Most of the severe harms are a consequence of cardiac catheterization and would 
therefore be avoided with the use of MSCT.  
Overall mortality risk for MSCT is 0.07% (25). Morbidity figures in MSCT range from 1-2% and 
mortality is estimated to be 0,1 %, but it can increase to 1 % in patients with unstable angina 
pectoris (3).  
 
Radiation MSCT vs ICA 
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MSCT requires higher doses of ionising radiation than ICA when conventional spiral technique and 
retrospective image reconstruction is used. Previous studies state that MSCT exposes the patient to 
2-3 times more radiation than invasive angiography (36). Although the risk associated with the dose 
of this size is minimal, it may raise concerns about repeated doses, or in children or women of 
child-bearing age (35). 
The effective radiation dose of a contrast enhanced cardiac CT scan is 5-20 mSv (4). In studies 
included in a systematic review published in 2007 (5) the estimated mean effective radiation dose 
per patient was 15 mSv for males and 20 mSv for females. With modulated protocols the 
corresponding figures were 7 and 14 mSv. This is much higher than the radiation dose of an 
invasive coronary angiography (ICA) which is about 2-7 mSv. 
 
MSCT versus myocardial perfusion scintigraphy (MPS) 
MPS involves exposure to ionizing radiation. Its estimated dose is approximately 8 mSv if both rest 
and stress studies are performed (37). 
 
MSCT versus magnetic resonance imaging (MRI) 
MRI is non-invasive and uses no radiation. 
 
MSCT versus electron beam computed tomography (EBCT)  
EBCT is non-invasive and uses lower radiation. EBCT yielded effective doses of 1.5 and 2.0 mSv 
for male and female patients. In same study MSCT delivered effective doses of 6.7-10.9 for male 
and 8.1-13.0 for female (38). 
Comment 
 
Currently, majority of users are moving towards the use of newer dose saving protocols.   E.g 
prospective gating provides significant radiation saving without significant effects on image quality. 
The newest devices will have a dose of <1-3 mSv/patient in routine work, which is actually 
considerably less than that of an invasive angiography.  
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Accuracy problems and incidental findings 
What is the incidence and consequences of incidental extracardiac findings? 
Results 
Several extracardiac incidental findings have been described in patients that undergo MSCT 
coronary angiography. Incidental findings may lead to further and sometimes inappropriate testing 
and therapeutic acts (1). Follow-up has been considered mandatory in 5 to 56 % of patients with 
incidental findings (39).  
 
Current software programs are reasonably sensitive for pulmonary nodules, but they have limited to 
poor specificity, and a high rate of false positive findings (1). 
What are the safety consequences for patients receiving false positive test result 
in MSCT? 
Results 
Low specificity of MSCT coronary angiography in detecting significant stenosis originates from 
motion artefact and intramural coronary calcifications. The resulting high number of false positive 
test results, especially in low risk population, is a major limitation to the clinical usefulness of the 
technique (1).  
 
False positive test result may cause anxiety and lead to further unnecessary and potentially harmful 
diagnostic and therapeutic interventions. An inconclusive test result in MSCT coronary angiography 
will qualify as false positive, because it inevitably leads to invasive coronary angiography (1). 
 
Detection of an obstructive lesion by MSCT may be anatomically significant but clinically 
irrelevant if the patient's symptoms have no relation to the coronary stenosis thus detected. Studies 
comparing anatomical MSCT assessment to functional imaging (perfusion scan, SPECT) show that 
only approximately 50% of significant stenoses (>50% narrowing of vessel diameter) on MSCT are 
functionally relevant; a large proportion of significant lesions in MSCT does not lead in perfusion 
abnormalities (40).   
 
Performance of 64-slice CT coronary angiography is not yet defined in clinical practice, because no 
significant trials have been performed in real world conditions and measuring patient relevant 
outcomes (1) 
What are the safety consequences for patients receiving false negative test result 
in MSCT? 
Results 
A false negative test result in MSCT coronary angiography gives the individual false reassurance, 
which may lead to ignoring signs of early disease which would cause a delay in diagnosis and 
treatment (41). 
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Presence of luminal narrowing less than 50% may not lead to symptoms but does not exclude future 
severe events. Low grade stenosis may be prone to plaque rupture and may lead to serious clinical 
events (1). 
What are the psychological harms for families of patients with false positive test 
result in MSCT? 
Methods 
This issue was considered relevant for this Core HTA. Due to time constraints, and because this 
issue will be at least partly answered in social domain, we left this unanswered. 
Use- or user-dependent safety risks 
How does the level of training or experience of the staff affect the safety of the 
MSCT coronary angiography? 
Methods 
This issue was considered relevant for this Core HTA. Due to time constraints, we left this 
unanswered. 
What can be done to reduce user dependent risks in MSCT coronary 
angiography? 
Methods 
This issue was considered relevant for this Core HTA. Due to time constraints, we left this 
unanswered. 
Patient dependent safety risks 
What are the susceptible patient groups in MSCT coronary angiography? 
Results 
 
Young and women 
In cardiac MSCT, radiation is targeted at chest, therefore subjecting females to high organ doses of 
the breast. Recent estimate for the relative risk of breast carcinoma incidence is 1.004 – 1.042 for a 
single examination. Relative risk for lung cancer incidence, in comparison, is 1.005 – 1.076 from a 
single study. Other organs, directly in the field of view (heart and oesophagus, in the addition to the 
above), exhibit highest absorbed doses. These risks, as well as risks related to ionizing radiation in 
general, are greatest in younger patient populations.  
 
For any individual aged 55 years or older, lifetime risk of developing cancer after a single MSCT 
cardiac exam is low and generally considered to be below 1.0%. The lifetime excessive risk of 
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breast and lung cancer for girls and young women after a single MSCT study is much higher, 
recently estimated at 1.7% - 5.5 % after a single scan (42, 43, 44). 
 
To conclude, young patients, especially young women and girls, are particularly prone to the 
induction of cancer due to radiation from CT. Therefore, these subpopulations should be imaged 
with cardiac MSCT only with caution and in special situations.  
 
Previous anaphylaxis to contrast media 
Contrast material is generally well-tolerated although approximately 1% of patients who receive 
low-osmolar non-ionic contrast material will develop anaphylaxis symptoms. Genuine IgE-
mediated allergic anaphylaxis is rare but may arise. Therefore, for patients with undiagnosed 
previous anaphylaxis to contrast material (i.e., allergologic testing not performed), imaging 
procedures that do not require the administration of iodinated contrast material should be 
considered (13). 
 
Impaired renal function 
The occurrence of contrast-induced nephropathy (CIN) has been directly related to the number of 
eight pre-existing risk factors:  hypotension, intra-aortic balloon pump use, congestive heart failure, 
age over 75 years, anaemia, diabetes, contrast medium volume and impaired renal function. 
Impaired renal function, in turn, is more likely to occur in patients with proteinuria, previous kidney 
surgery, hypertension, gout, diabetes and recent intake of nephrotoxic drugs. Although measures 
such as evaluation of the renal function and hydration before and after the study decrease the risks 
for CIN, all studies involving the use of iodinated contrast must be carefully considered within these 
patient groups. (10-12,18). 
 
What can be done to improve the safety of the management of susceptible 
patient groups in MSCT coronary angiography? 
Results 
Although many risks are deterministic in nature, in a number of instances, the patient subpopulation 
at particular risk may be identified before the examination. Individual patient assessment at time of 
referral for investigation enables identifying those with those at highest risk of experiencing e.g. 
contrast induced nephropathy (CIN) (7). Thus appropriate measures can be considered either to 
perform the examination with least possible harm, or to use an alternative diagnostic method or test.  
 
A survey in 2005 of knowledge and attitudes of 509 European radiologists to contrast induced 
nephropathy (CIN) showed that many did not have a systematic approach to the identification of 
patients and underestimated the importance of certain risk factors and the incidence of CIN (45).   
 
Occupational safety 
What is the occupational radiation exposure in staff performing MSCT 
coronary angiography? 
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Methods 
Source 
 
  
Search terms Date of 
inquiry 
Investi
gator 
Selected 
Medline (PubMed) "occupational" AND 
"exposure" AND "radiation". 
Limits: published in the last 5 
years, humans. 
3.9.2008 IP (48,49) 
STUK - Radiation and 
Nuclear Safety 
Authority, Finland web 
pages 
http://www.stuk.fi/en_GB/  
 3.9.2008 IP (43,44) 
International Commission 
on Radiological Protection 
(ICRP) 
http://www.icrp.org/ 
 3.9.2008 IP (50) 
Results 
Clinical staff involved in fluoroscopically guided interventional procedures, like invasive coronary 
angiography, receive significant doses of ionizing radiation; 45 mSv annual dose above lead aprons 
and 1.6 mSv under lead aprons. There are differences in the radiation doses received by radiologists 
and cardiologists, which may reflect the differences in the way they perform the procedures (48). A 
systematic review presented the published range of effective doses to operators: for diagnostic ICAs 
0.02-38.0 μSv per examination, and 0.17-31.2 μSv for percutaneous coronary interventions. The 
doses vary by 2 to 3 orders of magnitude, and it was related to the patient dose. However, there was 
much grater variation in operator than in patient doses. This could be due to the varied use of 
personal and movable protective devises. This might imply that radiation dose to the operator might 
be reduced by improving radiation protection practices (49). 
What are the staff safety requirements in MSCT coronary angiography? 
Results 
Principles of radiation protection  
The aim of radiation protection is to ensure that radiation is used safely. The principles of radiation 
protection are based on the recommendations of the International Commission on Radiological 
Protection (ICRP) (50). The ICRP recommendations are widely accepted internationally and have 
also been taken into account in national radiation acts (46). 
 
Acceptable radiation use must fulfil the following basic principles: 
– Principle of justification 
o The benefits of using radiation must outweigh the drawbacks. 
– Principle of optimisation (ALARA principle, As Low As Reasonably Achievable) 
o Radiation exposure caused by the use of radiation must be kept as low as reasonably 
achievable. 
– Principle of limitation 
o Radiation exposure must not exceed dose limits. 
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Only persons whose presence is essential for the examination or for the safety of the patient may be 
present in the examination room during an X-ray examination. The persons should be appropriately 
protected using suitable protective devices, and no part of them may be exposed to primary 
radiation. Unnecessary presence in the vicinity of the patient and of the X-ray tube should be 
avoided during an X-ray examination.  
 
A systematic review presented the published range of effective doses to operators for diagnostic 
invasive coronary angiographies (ICA) and noticed that the doses vary by 2 to 3 orders of 
magnitude, and relate to the patient dose. However, there was much grater variation in operator than 
in patient doses. This could be due to the varied use of personal and movable protective devises. 
This might imply that radiation dose to the operator might be reduced by improving radiation 
protection practices (49). 
 
Radiation shielding that forms part of the appliance or portable radiation shielding should be used 
when working in the immediate vicinity of the radiation beam in the course of examinations causing 
high levels of exposure to radiation. Use of safety goggles and a thyroid protective device or 
radiation shields for the head and upper body are also recommended. Monitoring of the radiation 
exposure of workers and medical surveillance shall be arranged in accordance with national 
guidelines. Work of pregnant women in duties causing exposure to radiation is usually governed by 
specific sections of national guidelines and decrees (47). 
 
Monitoring of radiation exposure in the European Union 
Individual monitoring is necessary when an employee regularly or repeatedly stays in the premises 
where diagnostic radiological procedures are performed or monitored. Dose monitoring also 
concerns employees who install, fix or maintain radiation equipment. Continual monitoring is not 
required when X-ray equipment is operated from a shielded control room. 
 
Exposure to radiation is monitored using personal dosimeters. Radiation doses are recorded in the 
statutory dose register. The dose register is maintained by national regulatory body which also 
ensures that dose control is organised appropriately. When abroad or outside dosimetric service, the 
employee records the level of exposure, duration of work, and possible medical surveillance results 
in the individual radiological monitoring document. Upon returning, he returns the document to 
local national regulatory body, which enters the data in the dose register. On the basis of data 
recorded in the dose register, it is possible to determine the total exposure of every radiation worker 
and ensure that prescribed maximum values, so-called dose limits, are not exceeded. 
  
Radiation work is classified as either A or B. Class A includes all employees who receive over 6 
mSv effective dose per year. Employees in class A must use dosimeter and doses must be 
determinated by an approved dosimetric service. Employees in class B should be monitored the 
same way if exposure exceeds 1mSv per year.  
 
An employee who is going to carry out class A radiation work in another European Union member 
state will require a radiation passbook. A radiation passbook consists of an individual radiological 
monitoring document and a medical certificate. The individual radiological monitoring document 
contains information about the holder‘s previous exposure to radiation and is issued by a national 
regulatory body. A medical certificate which details the employee‘s suitability for radiation work is 
issued by a doctor who is responsible for medical surveillance of people who do class A radiation 
work (46). 
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Medical surveillance 
 
There are national modifications of the principles presented by International Commission on 
Radiological Protection (ICRP) (50) regarding medical surveillance of radiation workers. Here we 
present the Finnish custom:  
A national safety guide by Finnish radiation and nuclear safety authority exists that describes the 
medical surveillance necessary for an employee involved with radiation work (46). The Finnish 
Radiation Act (592/1991, revised 1142/1998) requires that employees classified as Class A 
radiation worker must have a registered physician responsible for medical surveillance. The 
competence requirements of the surveying physician are determined in the Radiation Decree 
(1512/1991, revised 1598/1998). Physicians apply for a certificate from the safety authority, when 
following requirements are met: 
 
– The physician has specialised in occupational health care or has completed the advanced 
course offered by the Finnish Institute of Occupational Health. 
– He has completed the ‗use of radiation and its effects‘ course offered by the Finnish Institute 
of Occupational Health or equivalent. 
 
Environmental safety 
Is there evidence of environmental harms when using MSCT? 
What kind of environment protection is needed when using MSCT? 
Methods 
This question was deemed relevant but due to time constraints we left it unanswered. 
Discussion 
Radioactivity and the use of iodinated contrast media are the major safety issues in the use of 
MSCT. Induction of cancer especially in the young and women, and contrast induced nephropathy 
in patients with impaired renal function are the principal concerns. There are technical means to 
reduce the radiation dose received, but this is usually with the cost of image quality. The risk of 
contrast induced nephropathy may be reduced with careful patient assessment prior to MSCT.  
 
We had difficulties in using the assessment elements listed in the July 2008 version of the HTA 
Core Model for diagnostic technologies. Therefore we made a lot of changes in the element 
hierarchy, renamed issues, deleted and created new assessment elements. The next version of the 
Safety domain of the diagnostic HTA Core Model will thus change substantially. 
 
We wanted to categorize the safety issues as either technology-dependent, user-dependent, or 
patient-dependent, and named the topics accordingly. Under the new topic "Use- or user-dependent 
safety risks" we created two new issues C0041 and C0042 about the safety problems that occur 
when using (applying/interpreting/maintaining) the technology and the means of reducing their 
incidence. 
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We renamed some assessment elements: The assessment element C0027 "What kind of patient 
protection is needed?" was given a name "Which are the means to reduce the risk of harms?" In 
C0022 we changed the name "Does this technology have more harms than alternative technology?" 
into "What is the safety of the technology in comparison to alternative diagnostic technologies?" 
We changed also the element C0026 "Where does the harms originate and are there differences in 
devices or generations?" into the form "How does the safety profile of the technology vary between 
different devices or generations of devices?" We also left out the element C0032 about learning 
curve because we thought these issues will be covered in the element C0041 "What are the special 
features in using (applying/interpreting/maintaining) the technology that may increase the risk of 
patient safety?" 
 
Under the topic "Patient dependent safety risks" we combined and renamed the issues C0028 and 
C0029 about susceptible patient groups and optimal patient population into an issue C0028 "Are 
there patient related (individual or disease specific) factors that modify the safety of the diagnostic 
technology?" and added another new issue C0043 called "Which are the means to reduce the patient 
dependent safety risks?" 
 
The Topic called "Consequences of false positive and false negative test results" was changed into 
"Accuracy problems and incidental findings". Under that topic we created a single new assessment 
element C0040 named "Consequences of false positive, false negative and incidental findings".  
 
We created a new assessment element C0039 "What kind of psychological harms can the 
technology cause to the patient?" although we recognize that this is an issue which probably will be 
answered in the Social domain. At the same time we left out the element C0034 "Are there harms 
that are especially important for patients, their quality of life?" because these were largely 
overlapping. 
 
We left out the elements C0001 and C0005 about the need for licence or authorization and restricted 
use, and the elements C0030 and C0031 about staff quality requirements, because these issues are 
covered in the Health problem and current use domain, as well as the Description and technical 
characteristics domain.  
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Assessment elements table 
ID Domain Topic Issue Relevance 
in the 
context of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
or 
Comment (if regarded as a not relevant issue in this context) 
C0008 Safety Technology dependent safety risks What is the spectrum of technology dependent harms: their 
incidence, severity and duration? 
yes What are the safety risks of MSCT coronary angiography? 
C0010 Safety Technology dependent safety risks What is the timing of onset of harms: immediate, early or late? yes What are the immediate and long term consequences of the radiation exposure from MSCT 
coronary angiography? 
C0033 Safety Technology dependent safety risks What is the dose relatedness of the harms? yes What is the dose relatedness of harms of ionizing radiation in MSCT coronary angiography? 
C0039 Safety Technology dependent safety risks What kind of phychological harms can the technology cause 
to the patient? 
yes What kind of phychological harms does coronary MSCT potentially have? 
C0027 Safety Technology dependent safety risks Which are the means to reduce the risk of harms? yes Which are the means to reduce the radiation dose of MSCT coronary angiography? 
By what means may the risk of harms from iodinated contrast medium be reduced? 
C0026 Safety Technology dependent safety risks How does the safety profile of the technology vary between 
different devices or generations of devices? 
yes Are there differences in the safety profile of different MSCT devices or generations? 
C0022 Safety Technology dependent safety risks What is the safety of the technology in comparison to 
alternative diagnostic technologies? 
yes What is the safety of MSCT coronary angiography in comparison to alternative diagnostic 
technologies? 
C0040 Safety Accuracy problems and incidental 
findings 
Consequences of false positive, false negative and incidental 
findings 
yes What is the incidence and consequences of incidental extracardiac findings? 
What are the safety consequences for patients receiving false positive test result? 
What are the safety consequences for patients receiving false negative test result? 
What are the psychological harms for families of patients with false positive test result?  
C0041 Safety Use or user dependent safety risks What are the special features in using 
(applying/interpreting/maintaining) the technology that may 
increase the risk of patient safety? 
yes How does the level of training or experience of the staff affect the safety of the MSCT 
coronary angiography? 
C0042 Safety Use or user dependent safety risks Which are the means to reduce the user dependent safety 
risks? 
yes What can be done to reduce user dependent risks in MSCT coronary angiography? 
C0028 Safety Patient dependent safety risks Are there patient related (individual or disease specific) 
factors that modify the safety of the diagnostic technology? 
yes What are the susceptible patient groups in MSCT coronary angiography? 
C0043 Safety Patient dependent safety risks Which are the means to reduce the patient dependent safety 
risks? 
yes What can be done to improve the safety of the management of susceptible patient groups in 
MSCT coronary angiography? 
C0035 Safety Occupational safety Is there evidence of occupational harms? yes What is the occupational radiation exposure in staff performing MSCT coronary 
angiography? 
C0036 Safety Occupational safety What kind of employee protection is needed? yes What are the staff safety requirements in MSCT coronary angiography? 
C0037 Safety Environmental safety Is there evidence of environmental harms? yes What kind of environmental protection is needed when using MSCT coronary angiography? 
C0038 Safety Environmental safety What kind of environment protection is needed? no  
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Appendix 1 
 
Database: CRD (= HTA, EED, DARE) 
Date of search: 4.12.2007, yield 24 references 
Search strategy: 
 
#1 MeSH Coronary Disease EXPLODE 1 2 
#2 ( coronary AND ( disease* OR arter* OR aneurysm* OR stenos* OR restenos* OR thrombos* 
OR vasospasm* OR vessel* ) ) OR "angina pectoris" OR "chest pain" OR atherosclero* 
#3 #1 OR #2 
#4 MeSH Coronary Angiography EXPLODE 1 2 3 
#5 MeSH Tomography, X-Ray Computed EXPLODE 1 2 3 4 5 6 
#6 #4 AND #5 
#7 angiograph* AND tomograph* 
#8 #6 OR #7 
#9 #3 AND #8 
#10 msct OR mdct 
#11 ( multislice OR "multi-slice" OR "multi slice" OR multirow OR multidetect* OR "multi-
detect*" OR "multi detect*" OR multiselect* ) 
#12 ( 4 OR 16 OR 32 OR 40 OR 64 ) AND ( slice* OR row* ) 
#13 #10 OR #11 OR #12 
#14 #9 AND 13  
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Accuracy 
 
 
Tuija Ikonen, Sigurdur Helgason, Heikki Ukkonen, Iris Pasternack, Marjukka Mäkelä 
 
 
Introduction 
Based on current practice, one major indication for the use of multislice computed tomography 
(MSCT) is its use as a diagnostic test for ruling out significant coronary artery disease (CAD) in 
patients with specific or unspecific symptoms and low or intermediate risk for CAD. There is no 
other diagnostic method up to date for this purpose in the diagnostic pathway that could totally 
replace it or could as such be nominated as the reference test for accuracy assessment. 
 
In the literature, the majority of studies of accuracy of MSCT have been designed to compare it 
with invasive coronary angiography (ICA) due to the similarity of information obtained by these 
two methods (anatomical or structural imaging of the vessel patency). A typical research setting is 
to assess the presence of significant (usually over 50 %) coronary stenosis by MSCT from patients 
who have been scheduled to undergo ICA due to known or suspected CAD, not infrequently in high 
risk patients. Consequently, the proportion of positive findings is high, varying between 60 % and 
80 % (1). High frequency of positive findings refers to appropriate use of ICA, a method associated 
with a low but not insignificant rate of complications (2). 
 
In its use as a rule-out test for CAD in low or intermediate risk patients, the comparison of MSCT 
with ICA is not without controversies with the clinical decision making, since ICA is seldom 
justified solely as a rule-out test for CAD in these patients. Other less invasive diagnostic tests for 
CAD, on the other hand, measure other aspects of the coronary disease: stress tests (ergometry, 
dobutamine or stress ECHO, SPECT, PET etc) look at ischemia as a sign of functional performance 
of the myocardium, whereas currently the information obtained from MSCT is purely 
morphological. In addition to clinical relevance, the choice of different diagnostic methods depends 
on physician's and patient's preferences, the health care system, local facilities, reimbursement and 
insurance systems, making the definition of optimal study setting even more complex.  
 
Selection of the reference test and the cut-off level for a positive test depends on the indications of 
testing. The definition of significant stenosis as ≥ 50% narrowing of a coronary artery segment on 
ICA has been established to select patients for consideration of myocardial revascularisation, 
though it does not necessarily correlate with the degree of myocardial ischemia (3). A higher 
percentage of lumen obstruction might provide a more specific measure for ischemia. For other 
indications, such as confirming or ruling out coronary atherosclerosis or plaques, even lesser 
degrees of atherosclerosis and stenoses might be relevant (4).  
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In this Core HTA of 64-slice CT, we have chosen to use ICA as a reference standard for the 
assessment of accuracy, being fully aware of its limitations mentioned above. Our aim is to describe 
the process of acquiring information and to test the set of assessment elements in the context of 64-
slice CT rather than to produce an exhaustive review of the topic. Therefore some answers to the 
research questions might be incomplete.   
Methodology 
Literature review 
For the review of the literature on MSCT angiography, we searched Medline (936 references), 
Premedline (50 references) and CRD (= HTA, EED, DARE). The searches were performed between 
the December 5th and 7th, 2007. Search strategies for each database are presented in Appendix 1. A 
complementary search was performed from Premedline (84 references) and a specific search for 
accuracy on the 21st of May, 2008 (Appendix 1). 
 
The search strategy resulted in over 1000 references across all databases. The specific search for 
accuracy gained 104 references. Two researchers independently selected relevant titles and 
abstracts. For references selected by only one researcher a consensus was sought by discussion and 
opinion of a third researcher. HTAs on 64-slice MSCT were accepted as background documents. 
Letters and editorials were excluded, and studies published only as abstracts were not used for this 
analysis. 
 
The inclusion criteria for original studies to be accepted for full text retrieval were:  
– Suspected coronary artery disease (CAD) with typical or atypical non-acute chest pain in 
patients with low or intermediate risk for CAD.  
– Assessment of the quality/severity/location of the CAD-lesions in patients with stable 
chronic CAD 
– MSCT using 64-slice technology, or a subgroup analysis of 64-slice technology included in 
the study. 
 
Exclusion criteria were: 
– Monitoring treatment effect after PTCA, stent or CABG 
– Diagnosis of acute chest pain, myocardial infarction/acute coronary syndrome 
– Assessment of the culprit lesion or a specific anatomical location in patients with known 
CAD 
– Assessment of coronary arteries in adjunction with other diseases of the myocardium, heart 
valves or ascending aorta 
– Assessment of coronary anomalies 
– Screening of asymptomatic high-risk or low-risk population 
– Assessment of high risk population with known CAD or patients with high pre-test 
probability for CAD only 
– Techniques lower than 64 slices. 
 
Initially, 8 HTA reports or reviews with meta-analyses and 60 abstracts were selected for full-text 
retrieval. A recent HTA report from the NIHR Programme of NCCHTA was selected as a basic 
background document (5). Of the selected full text articles 12 studies were included in the Mowatt's 
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HTA. While working on this assessment, another HTA was published on the 7th of July 2008 (4). 
In addition, 9 full text articles matched with the inclusion and exclusion criteria for accuracy 
assessment (6-14), and 3 for effectiveness assessment (15,16,17). For specific answers in the 
accuracy domain, another 3 studies were considered useful (3,18,19). Scanning the full text articles 
led to exclusion of 33 papers. 
Quality assessment of diagnostic accuracy studies 
Two assessors (SH and TSI) performed quality assessment on the selected HTA (5) by using a 
quality assessment tool (SIGN - Methodology: Critical appraisal: Notes and checklists. 
Methodology Checklist 1: Systematic Reviews and Meta-analyses  
http://www.sign.ac.uk/guidelines/fulltext/50/checklist1.rtf   and   
http://www.sign.ac.uk/guidelines/fulltext/50/notes1.html). See Appendix 2. 
 
The QUADAS tool (Appendix 3) was used in a modified form (39). Eleven questions (1, 3, 4, 7, 8, 
10 and 11, 12, 14, 17 and 19 of the original QUADAS tool) were used. One reviewer (SH) assessed 
the quality of all included studies answering these eleven questions with either ‗Yes‘ (+), ‗No‘ (-) or 
‗Unclear‘ (?). Due to time limitation a second review was not performed but will be added in the 
final version of this document. The results of the quality assessment are presented in Appendix 4.   
 
Assessment elements 
Accuracy measures 
What is the accuracy of 64-slice CT against invasive coronary angiography 
(ICA) as reference standard? 
Methods 
The analysis in Mowatt's HTA (5) is presented as background data and is quoted in this report for 
overall assessment of accuracy for patient-level and segment-level results. From the studies 
published after studies included in Mowatt's HTA, 8 studies with 50 % stenosis as the cut-off level 
for CAD were included in the data extraction on a data sheet for accuracy including sensitivity and 
specificity, likelihood ratios and pre-test probabilities (6-10,12,13,20). In addition, one study is 
referred, where the cut-off level for CAD was 70 % (14). Of these 8 studies five are used in the 
HTA of van Brabant 2008 (7-11). In this analysis we will present data for patient-level and 
segment-level assessment of MSCT. Some studies also presented results from per-vessel analysis 
(6,8,10-13). See also Appendices 4 and 5.      
Results 
Background HTA (Mowatt) 
In Mowatt's HTA there were two studies (21,22)  that looked at the use of MSCT specifically in the 
low or intermediate risk population without previous CAD diagnosis, which was the first inclusion 
criteria in this assessment. In a third study the patient population consisted of suspected CAD 
because of left branch bundle bock (LBBB) (23). In other six studies there were heterogeneous 
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patient populations with the proportion of known CAD varying between 9 % and 57 %, typically 
including patients with a previous percutaneous intervention (PCI) (24-28)(29). In two studies 
(30,31) there were patients with unstable angina pectoris (UAP) included (6 %  of the patient in the 
other study and 36 % in the other). Other studies out of the scope of our analysis, but analysed in 
Mowatt's HTA, were studies on acute coronary syndrome (ACS) (32), patients referred for valve 
surgery patients assessed for coronary artery bypass graft (CABG) (33), or after CABG (22) , and 
the use of MSCT together with calcium screening. Suspected ACS, with or without known CAD, 
was reported only in abstracts (17,34). 
 
Patient-level analysis 
Segmental analysis is useful when assessing the accuracy of the test against reference, whereas 
patient level data are more useful in determining management and effectiveness. In Mowatt's HTA 
eighteen studies (13 full text and five abstracts) enrolling 1313 people, with 1286 included in the 
analysis, provided sufficient information to allow their inclusion in the pooled estimates for patient 
level analysis. The median post-test prevalence of CAD was 58 % (range 23 to 96 %). Figure 1 
presents the over-all patient-level analysis for sensitivity, specificity, SROC-curve and pooled 
estimates when 50 % stenosis is used as a cut-off level for significant CAD (5). Overall there was 
no substantial statistical heterogeneity in terms of sensitivity (I2 = 0.1 %) or specificity (I2 = 31.7 
%). In Mowatt's analysis, 11 (2 %) of 718 patients had unevaluable CT scans (median across studies 
0 %, range 0 to 6 %), most often because of heavy vessel calcification. 
 
Segment-level analysis 
Figure 2 presents the over-all segment-level analysis of sensitivity and specificity with respective 
measures. In Mowatt's HTA, there were seventeen studies (14 full text and three abstracts) enrolling 
1102 people, with 1078 included in the analysis, that provided sufficient information to allow their 
inclusion in the pooled estimates for segment-level analysis (n=14,199). There was substantial 
statistical heterogeneity across the studies in terms of both sensitivity (I2=80.1%) and specificity 
(I2=95.1%).  The heterogeneity in terms of specificity was most noticeable in a study including 
participants who had previously undergone CABG surgery (22). One reason suggested by the 
authors for the low specificity and consequently a high level of false positive results, was the 
prevalence of severe calcifications which led to an overestimation of the extent of stenosis (5). 
Around 8 % (997) of 12,476 segment scans could not be evaluated (median across studies 9%, 
range 0 to 18%). The reasons for poor image quality were caused by irregular heart rhythm, sinus 
tachycardia > 90/min, calcification, vessel motion, inadequate breath hold, low contrast 
opacification and anomaly (35).  
 
Accuracy for patients with suspected CAD    
In Mowatt's HTA the accuracy measures for patients with suspected and known CAD were assessed 
separately. They are presented in Table 1. In patient-level analysis, better sensitivity, positive 
predictive value (PPV) and negative predictive value (NPV), but worse specificity, were reported 
for those with known CAD. The lowest NPV (93%) was reported by Nikolaou and colleagues in a 
sub-group analysis of 39 patients with suspected CAD, but no explanation of the reasons for the 
false negative results in this group was provided.  For segment-level analysis, better sensitivity was 
reported for those with suspected CAD, better PPV for those with known CAD, while specificity 
and NPV were similar for both groups (5).  
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Figure 1 Patient-level analysis: sensitivity, specificity, SROC curve and pooled estimates (5). 
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Pooled estimates 
Number of studies 18 
Sensitivity % (95% CrI) 99 (97 to 99) 
Specificity % (95% CrI) 89 (83 to 94) 
Positive likelihood ratio (95% CrI) 622.5 (278.2 to 1579) 
Negative likelihood ratio (95% CrI) 0.02 (0.01 to 0.03) 
DOR (95% CrI) 9.3 (5.9 to 15.3) 
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Figure 2 Segment-level analysis: sensitivity, specificity, SROC curve and pooled estimates (5). 
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Pooled estimates 
Number of studies 17 
Sensitivity % (95% CrI) 90 (85 to 94) 
Specificity % (95% CrI)   97 (95 to 
98) 
Positive likelihood ratio (95% CrI) 26.1 (17.0 to 40.2) 
Negative likelihood ratio (95% CrI) 0.10 (0.06 to 0.15) 
DOR (95% CrI) 260.3 (147.7 to 474.5) 
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Table 1 Studies reporting data separately for those with suspected and known CAD (5). 
 
 No of 
studies 
Median  % 
(range) 
sensitivity  
Median % 
(range) 
specificity  
Median % 
(range) 
PPV 
Median  % 
(range) 
NPV 
Suspected CAD 
Patients (n=283) 4 96 (95-100) 87 (82-91) 86 (76-93) 96 (93-100) 
Segments 
(n=>5606) 
6 92 (82-100) 97 (95-99) 68 (55-95) 99 (98-100) 
Known CAD 
Patients (n=64) 2 100 (both) 83 (75-90) 91 (85-96) 100 (both) 
Segments 
(n=2623) 
3 85 (79-99) 96 (96-97) 78 (72-80) 98 (97-100) 
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Accuracy studies of patients with high risk or without specification of the risk category 
Two studies were identified that were published after Mowatt´s HTA and which included 
symptomatic patients with suspected CAD (12,14) with a high or not specified pre-test probability 
of CAD.  
 
In the Oncel´s study significant (over 50 % stenosis) CAD was present in 77 % of patients. In this 
prospective analysis of 80 patients sensitivity, specificity, PPV, and NPV of positive CAD 
diagnosis (patient level analysis) were 100 % against ICA. The respective values for per-segment 
analysis were 96 %, 98 %, 91 %, and 99 %. The ĸ-index for the agreement between segments on 
MSCT and ICA was 0.923 (12).  
 
In the other study by Muhlenbruch that assessed high-risk population, the cut-off level for a 
significant stenosis was 70 %, wherefore the results are not comparable with other studies quoted in 
this report. Sensitivity, specificity, PPV and NPV reported on patient-level and segment-level were 
97.8 %, 50 %, 93.6 %, 75 % and 86.7 %, 95.2 %, 75.2 % and 97.7 %, respectively. 
 
Accuracy studies for assessment of symptomatic patients with low or intermediate pre-test 
likelihood for CAD 
 
Patient-level analysis 
 Accuracy measures for patients with low or intermediate pre-test probability for CAD could be 
obtained from four studies (6,8,9,10). Altogether 364 patients were analysed per patient level. Out 
of these 364 patients there were 121 patients with low risk for CAD (55 patients in Herzog's study 
and a subgroup of 66 patients in Mejboom's study) and  171 with intermediate risk 88 in Leber's 
study and a subgroup of 83 patients in Mejboom's study). For the 72 patients of Cademartiri's study 
the risk definition was low or intermediate.  
 
Accuracy data for patient-level analysis are presented in Table 2. For the population with a mean of 
28.5 % of patients having at least one significant (over 50 %) stenosis on MSCT, high sensitivity 
and negative predictive value were obtained in all studies, whereas specificity varied between 84 % 
and 98.1 % and positive predictive value between 74 % and 95.2 %. Overall the lowest accuracy 
measures were obtained by Leber. In his study a dual-source CT was used to generate faster 
reconstruction of the images and no pulse lowering premedication was used. 
 
In two studies the correlation with ICA was analysed on patient-level (10). The ĸ-values for 
intermediate and low risk groups were 0.81 and 0.82, respectively in Mejboom's study, and 0.88 for 
the low-risk patients analyzed by Herzog. 
 
Likelihood ratios were given in one study (10). For patient-level analysis the positive LR was 6.38 
in the intermediate and 13.50 in the low risk group, and negative LR was 0.00 for both groups. 
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Table 2 Patient-level accuracy in studies of low to intermediate risk for CAD 
 
 N of patients 
analysed / total n 
of patients 
Risk category Patients (%) with 
stenosis 
> 50 % 
on ICA 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV 
(%) 
Cademartiri 
2007 
72 / 72 low to 
intermediate 
28 % 100  98.1 95.2 100 
Herzog 2007 55 / 151 
consecutive 
low 35 % 100 83.3 76.0 100 
Leber 2007 88 / 90 intermediate 24 % 95 90 74 99 
Mejboom 
2007 
(105) 
83 
66 
(high) 
intermediate 
low 
(78 %) 
39 % 
18 % 
(98) 
100 
100 
(74) 
84 
93 
(93) 
80 
75 
(89) 
100 
100 
Total  364       
 
 
In addition to the four studies of patient-level analysis that also included segment-level analyses, 
two studies were identified with segment-level analysis of the low or intermediate risk patients 
(7,13). Hausleiter et al reported per segment analysis of a subgroup assessed with 64-slice MSCT 
from 114 patients with intermediate pre-test probability and Schlosser reported an analysis of 915 
segments from 61 patients. Altogether 7499 segments were analysed in these six studies. Image 
quality was considered good or excellent in 92.4 - 98.5 % of segments in the three studies that 
assessed image quality. Results from these six studies and the segment based analysis from the 
study of Oncel (12) are in the table 3. The observed incidence of significant stenosis in ICA was 77 
%.  
 
In the patients with low or intermediate pre-test likelihood for CAD, accuracy measures for per 
segment analysis were inferior to per patient analysis. Sensitivity varied between 81.9 % and 100 
%, and NPV was nearly 100 % (98.5-100 %). Specificity was 96 % and PPV was low 62 %. All 
these figures are in the range of the results from patients with known or suspected CAD analysed in 
Mowatt's HTA.  
 
Per segment correlation with ICA was analysed in four studies. The ĸ-values varied from 0.58 to 
0.98 (6,8,10,12) . In one study the proportion of segments with overestimation and underestimation 
were reported as 38.8 % and 17.2 %, respectively (8).  
 
Likelihood ratios were given in one study (10). For segment-based analysis the positive LR was 
18.74 in the intermediate and 52.50 in the low risk group, and negative LR was 0.14 and 0.27, 
respectively.  
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Table 3. Segment-level analysis of accuracy  
 
Study id N of 
patients 
analysed / 
total n of 
patients 
 
N of segments 
analysed (/ 
total n of 
segments) / 
% of good 
quality 
Sensitiv
ity (%) 
Specif
icity 
(%) 
PPV 
(%) 
NPV 
(%) 
Correlation 
with CA 
N of segments 
and minimum 
segment 
diameter 
analysed 
Cademartiri 
2007 
72 / 72 1098 / 98,5 % 100 98,6 71,1 100 ĸ 0,98 17 segments, 
regardless of 
diameter 
Hausleiter 
2007 
114 /243 
64 subgr 
1266 /92,4 % 92 92 54 99 not assessed 
 
2 mm diameter 
of CA 
Herzog 2006 55 / 151 
consecutive 
825 / 92,4 % 81,9 97,1 69,4 98,5 0,65 
MSCT 
underest 39% 
overest 17%  
<1,5 mm 
regarded as 
evaluation 
compromised 
Leber 2007 88/90 1216 (/ 1232) 90 98 81 99 not assessed 
 
AHA segment 
model 
Mejboom 
2007 
105 (high) 
83 
66 
1468 
1219 
960 
 
90 
87 
73 
90 
95 
99 
56 
46 
59 
98 
99 
99 
 
0,64 
0,58 
0,65 
ĸ*per segm 
17 segment 
AHA model, all 
included 
Oncel 2007 80 1200 / 91 % 96 98 91 99 0,923 
ĸ*per segm 
15 segment 
AHA model, all 
included 
Schlosser 
2007 
61 / 63 915 / 
99 % 
100 96,8 54,8 100 not assessed 
 
15 segment 
AHA model, all 
included 
 
 
A subgroup analysis of accuracy for male and female patients 
 
One study without pre-test risk definition reported accuracy figures separately for female and male 
patients (11). Among 402 included symptomatic patients there were 123 women and 279 men with 
CAD prevalence of 51 % and 68 %, respectively. Of the study population 12 % of patients had 
unstable angina pectoris (UAP) and 13 % non-ST-segment elevation acute myocardial infarction 
(AMI). Accuracy was lower in females. Sensitivity, specificity, PPV and NPV for patient level 
analysis were 100 %, 75 %, 81 %, and 100 % for women, and the respective values for men were 99 
%, 90 %, 95 %, and 98 %. For segment level analysis the figures for women and men were 82 %, 
94 %, 53 %, 98 % and 93 %, 92 %, 59 %, 99 %, respectively. Positive and negative likelihood 
ratios on patient level for females and males were 7.24 vs. 6.25 and 0 vs. 0.01, respectively. The 
respective figures on segment level were 13.87 vs. 12.02 and 0.20 vs. 0.07. Background data for 
studies referred in this element are presented in Appendix 5.  
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Comment 
This element concentrates on the analysis for per-patient and per-segment level. Per-vessel level 
analysis was not regarded to be in the focus of this study. Publication bias was not assessed. The 
studies quoted might include repeated patients in consecutive publications from same centres. 
 
How does 64-slice  CT compare to other optional diagnostic technologies 
(SPECT, stress ergometry, stress ECHO, IVUS, 4-slice or 16-slice MSCT) in 
terms of accuracy measures? 
Methods 
Studies comparing MSCT to other diagnostic methods were retrieved from the initial literature 
search, without considering the PICO of the overall Core HTA or homogeneity of the population in 
terms of low or intermediate risk. In addition to the studies included in Mowatt's analysis 
(25,36,37,38) three relevant studies were identified (3,18,19). 
Results 
Sixty-four-slice CT angiography has the potential to replace some perfusion scanning tests. 
According to Mowatt et al, the sensitivity of single photon emission computed tomography 
(SPECT) against invasive coronary angiography (ICA) for detecting  a significant stenosis was 
either 81%, 87% or 88%, depending on the type of analysis undertaken, while specificity was 64%, 
65% or 69% from two reviews and in a study re-analysing the results of one of the reviews (37,38).  
The pooled estimates for MSCT accuracy against ICA in a patient-level analysis are for 
comparison: sensitivity 99% and specificity 89% (5). 
 
Schuijf et al compared 64-slice MSCT and Stress-rest myocardial perfusion imaging (MPI, 
technetium 99m) in a subset of 86 of 114 patients with an intermediate likelihood of coronary artery 
disease (CAD) and without previous CAD diagnosis. In addition, 28 patients were evaluated by 16-
slice MSCT. 58 patients were further analysed by ICA. Sensitivity of MSCT and SPECT in 
detecting a significant stenosis against ICA as reference standard were 100 % and 81% respectively, 
and specificities were 59 % vs 48 %. There was no difference in the ability to obtain correct 
diagnosis between 16- and 64-slice CT, 90 % vs. 89 %, respectively (3). 
 
Intravascular ultrasound (IVUS) was compared with 64-slice MSCT in two studies. The study of 
Leber et al., also included in Mowatt's report, compares all three methods, 64-slice MSCT, ICA, 
and IVUS in a subset of 18 out of 59 patients. 46 of the 55 lesions (84 %) were identified correctly 
by 64-slice MSCT compared to IVUS as reference standard. Both plaque areas and vessel 
obstruction were higher when measured by IVUS compared to CT (25).  
 
In the study of Caussin et al., 40 patients with 54 intermediate lesions of coronary arteries defined 
as 30 % - 70 % luminal narrowing on MSCT were analysed by IVUS (40 MHz). 23 % of the 
included patients had had a previous percutaneous coronary intervention (PCI) and 56 % presented 
with myocardial infarction (MI) or unstable angina pectoris (UAP). Four patients were excluded 
from the analysis because of inadequate image quality. The correlation of minimal lumen area 
between the two methods was r = 0.88 (Pearson's correlations coefficient). Sensitivity, specificity, 
accuracy, and Cohen's ĸ coefficient for inter-observer variability were 87 %, 72 %, 80 %, 0.6, 
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respectively (18). The authors concluded that there was a good correlation and that MSCT was able 
to determine the lesion severity in patients with intermediate lesions.   
 
When 64-slice technology has been compared with earlier generations of MSCT e.g. 4-slice or 16-
slice scans, the performance of newer generations have shown progressive improvement (19). In 
detecting CAD of native vessels, the improvement between 16-sice and 64-slice scanners is not as 
obvious as between 4-slice and 16-slice scanners.     
Comment 
The methods compared in this element measure coronary artery stenosis from different aspects, 
from functional and anatomical, wherefore the results are not straightforward comparable with each 
other.  
How likely does invasive coronary angiography (ICA) classify the morphological 
coronary artery disease (CAD) lesions correctly compared to intravascular 
ultrasound (IVUS) or pathology? 
Methods 
Studies comparing invasive coronary angiography (ICA) to other morphological diagnostic methods 
were retrieved from the initial literature search, without considering the PICO of the overall Core 
HTA or homogeneity of the population in terms of low or intermediate risk. In addition to the 
studies included in Mowatt's HTA one study was identified (18). 
Results 
In the analysis of Mowatt et al. (5) a subset of 18 patients in one study (25) were assessed with 
MSCT, ICA and intravascular ultrasound (IVUS). There were 19 coronary segments that were 
graded stenotic by MSCT but had no detected stenosis on ICA. Out of these 19 segments five were 
graded as stenotic by IVUS. 
  
Caussin et al assessed accuracy of 64-slice CT and ICA compared to IVUS. The sensitivity, 
specificity, and accuracy for ICA detecting mean luminal area compared to IVUS were 79 %, 68 %, 
and 77 %, respectively (18). All figures were lower than the respective values for 64-slice CT.  
Comment 
 
There are more studies that compare ICA with IVUS. We did not cover this area systematically. 
How does invasive coronary angiography (ICA) perform in detecting 
functionally relevant coronary artery disease (CAD) lesions compared to 
physiological test (e.g. stress tests or radionuclide imaging)? 
Methods 
Studies comparing invasive coronary angiography (ICA) to physiological stress tests were retrieved 
from the initial literature search, without considering the PICO of the overall Core HTA or 
homogeneity of the population in terms of low or intermediate risk. In addition to the studies 
included in Mowatt's analysis one study was identified (3,5). 
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Results 
In Mowatt's HTA the reference standard was considered likely to correctly classify CAD in all 
studies (5).   
 
In the study of Schuijf et al., there is a relatively high disagreement between positive and negative 
myocardial perfusion imaging (MPI) studies and significant stenosis on ICA. Of the 32 patients 
with an abnormal SPECT finding, only 16 had a stenosis of 50 % or over. On the other hand, of the 
26 patients with a normal SPECT finding, 11 were diagnosed to have CAD on ICA (3).  
Comment 
There are situations where ICA might not be the ideal gold standard. Comparison between the three 
methods as in Schuijf et al 2006 might be worth a separate analysis. 
Context related requirements for accuracy 
What are the requirements for accuracy (sensitivity, specificity, PPV, NPV) for 
ruling in or ruling out CAD in patients with low or intermediate likelihood of 
CAD?  
Results 
There are no specific studies to answer this element. A baseline assumption might be to set a 
requirement to accuracy measures to be comparable or better than existing imaging modalities, such 
as isotope stress tests, dobutamine stress test or MRI. 
Comment  
Answering this element might require an extensive literature review. 
What is the optimal threshold value of significant coronary artery disease (CAD) 
in patients with low or intermediate likelihood of CAD? 
Results 
The cut-off level used to describe significant CAD is typically 50 %. In one study of this analysis 
70 % stenosis was used to define significant CAD (14). The figures are based on the degrees of 
stenosis at which lesions are thought to be of potential functional significance and where 
revascularisation may be indicated (5). Since the cut-off level depends on two outcomes, relief of 
anginal symptoms and reduction in mortality in patients with a severe prognosis such as left main 
stem disease, the relevance of 50 % cut-off level in patients with low or intermediate risk for CAD 
has not been widely evaluated. In the study of Shuijf 50 % stenosis on MSCT and invasive coronary 
angiography (ICA) is associated with a positive SPECT result in 50 % of patients (3).    
Comment 
Threshold value of 50 % has been traditionally used in different studies comparing ICA. Wide use 
of this threshold value supports its further use for a reference value, especially when different 
methods are compared.  
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Does 64-slice CT have the potential to reliably rule in or rule out significant (≥ 
50 %) stenosis as a sign of coronary artery disease (CAD)? 
Results 
According to the accuracy figures, the high sensitivity in the pooled estimates and high negative 
value (NPV) across studies, it seems like 64-slice CT is able to reliably rule out significant CAD in 
patients with low or intermediate likelihood for CAD. According to Mowatt et al 64-slice CT is 
only very marginally worse than invasive coronary angiography (ICA) in terms of detecting true 
positives. However it is somewhat worse in its rate of false positives. Consequently, diagnostic 
strategies involving 64-slice CT angiography will result in a number of false positives. In Mowatt's 
analysis it was considered likely that diagnostic strategies involving 64-slice CT will still require 
ICA as the final gold standard among MSCT test positives in order to eliminate the incorrect 
treatment of MSCT false positives (5). 
 
In the low and intermediate risk group, especially with unspecific symptoms, functional imaging 
(SPECT, ECHO-stress tests) might be more appropriate next step in the diagnostic strategy than 
ICA. See also effectiveness domain. 
 
Reliability and transferability of reported accuracy 
How does the analysis per segment / per vessel / per patient impact the accuracy 
of 64-slice CT? 
Results 
In the Mowatt's HTA pooled estimates of 64-slice CT angiography were highly sensitive (99%, 
95% CI 97 to 99%) for patient-based detection of significant coronary artery disease (CAD) 
(defined as > 50% or ≥ 50% stenosis). Across studies the negative predictive value (NPV) was very 
high (median 100%, range 86 to 100%).  In segment-level analysis compared with patient-based 
detection, sensitivity was lower (90% versus 99%) and specificity higher (97% versus 89%), while 
across studies the median NPV was similar (99% versus 100%) (5).  
 
How does learning curve and the experience and volume of diagnostic unit affect 
the accuracy of 64-slice  CT? 
Results 
Not assessed in the studies included. 
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What is known about the intra- and inter-observer variation in 64-slice CT test 
interpretation for per segment / per vessel / per patient analysis?  
Results 
In Mowatt's HTA ten full text studies reported the results of kappa analysis for inter-observer 
variation in assessing 64-slice CT scans (Table 4).  The median kappa score across these studies 
was 0.74 (range 0.53 to 0.95). In conclusion, there was good overall inter-observer agreement for 
64-slice CT for assessing coronary artery disease (CAD) in native vessels but poor for stents (5). 
 
Table 4.  64-slice CT inter-observer variation in detecting significant stenosis by Mowatt 2008. 
 
Study  Unit of analysis  Kappa 
Ehara 2006a  Segment   0.95  
Hoffmann 2006 Patient   0.82  
Johnson 2007 Patient   0.81  
Leschka 2005 Unclear whether patient or segment 0.95  
Meijboom 2006 Segment   0.71  
Mollet 2005  Unclear whether patient or segment 0.73  
Nikolaou 2006 Patient   0.81  
Plass 2006  Unclear whether patient or segment 0.93  
Pugliese 2006a Unclear whether patient or segment 0.73  
Rist 2006  Stent   0.53 
 
In the studies of low or intermediate risk for CAD, Leber describes the interobserver variation as 
5.2 % for the quantification of stenosis within three categories of < 50%, from 50 % to 75 % and > 
75 % (9). In Mejboom's study the interobserver and intraobserver variability for segment-based 
analysis were 0.70 and 0.72, respectively (11).  
Discussion 
 
In the per-patient analysis sensitivity of 64-slice CT is excellent, specificity is good and these 
figures do not seem to be affected by the pre-test likelihood of coronary artery disease (CAD) in 
low to intermediate risk group when compared to the analysis of Mowatt where the population 
studied included patients from all risk categories.  
 
Results support the current use of 64-slice MSCT for exclusion of CAD in low and intermediate 
risk group: the negative predictive value (NPV) is excellent. In classifying the patients for CAD the 
positive predictive value (PPV) per-patient level analysis is varying between studies, being modest 
to good. From these studies the results are inconclusive regarding correlation between PPV and pre-
test risk. The diagnostic assessment of accuracy is preferably performed on per-segment analysis. 
For low and intermediate risk group the NPV is excellent in all studies and PPV is mainly modest.  
 
One source of bias is the possible cumulative publication of the material. Included studies are from 
a limited number of centres. Each publication has been included as independent study, but it does 
not exclude the possibility that same patients might have been included in the analysis repeatedly.  
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Some important issues remain unanswered. From the clinical point of view it would be of major 
interest to know the risk threshold for using MSCT as a rule out test for CAD. None of the included 
studies looked at this specific question. This might be an aim of further studies.  
 
Answers to the elements were obtained from an HTA and consequent studies selected for accuracy 
assessment. Some issues would require a separate literature search to be answered explicitly. Due to 
the scope of this analysis and the character of being a test HTA, further effort was not considered 
necessary. Since EUnetHTA format is flexible and enables further amendments, some issues might 
be completed later. 
 
Combining Accuracy and Effectiveness domains has been suggested by some validation reviewers. 
However, the decision to combine the domains is beyond the scope of this assessment.  
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Assessment elements table 
Elemen
t 
Identifi-
cation 
Code 
(ID) 
Domain Topic Issue Relevance in the 
context of MSCT 
Yes/No 
Research question(s) in the context of MSCT 
or 
Comment (if regarded as a not relevant issue in this context) 
      
J0001 Accuracy Accuracy measures What is the accuracy of the test against reference standard? Yes What is the accuracy of 64-slice  CT in terms of sensitivity and specificity, 
likelihood ratios, pre-test probabilities, SDORs, AUC or Q* against CA as 
reference standard? 
J0002 Accuracy Accuracy measures How does the technology compare to other optional diagnostic technologies 
or other development stages of the same technology in terms of accuracy 
measures? 
Yes How does 64-slice  CT compare to other optional diagnostic technologies 
(SPECT, stress ergometry, stress ECHO, IVUS, 4-slice or 16-slice MSCT) 
in terms of accuracy measures? 
J0003 Accuracy Accuracy measures What is the reference standard and how likely does it classify the target 
condition correctly? 
Yes How likely does CA classify the morphological CAD lesions correctly 
compared to IVUS or pathology? 
How does CA perform in detecting ischemia inducing CAD lesions 
compared to physiological test (e.g. stress tests or radionuclide imaging)? 
J0004 Accuracy Context related requirements for 
accuracy 
What are the requirements for accuracy in the context the technology will be 
used? 
Yes What are the requirements for accuracy (sensitivity, specificity, PPV, NPV) 
for ruling in or ruling out CAD in patients with low or intermediate likelihood 
of CAD?  
J0005 Accuracy Context related requirements for 
accuracy 
What is the optimal threshold value in this context? Yes What is the optimal threshold value of significant CAD in patients with low or 
intermediate likelihood of CAD? 
J0006 Accuracy Context related requirements for 
accuracy 
Does the technology have the potential to reliably rule in or rule out the 
target condition? 
Yes Does 64-slice CT have the potential to reliably rule in or rule out significant 
(≥ 50 %) stenosis as a sign of CAD? 
J0007 Accuracy Reliability and transferability of 
reported accuracy 
How does test accuracy vary in different settings? Yes How does the use of 64-slice CT in patients with low or intermediate risk for 
CAD affect the accuracy of 64-slice CT? 
How does the analysis per segment / per vessel / per patient impact the 
accuracy of 64-slice  CT? 
J0009 Accuracy Reliability and transferability of 
reported accuracy 
How does learning curve and volume of tests affect accuracy? Yes How do learning curve and the experience and volume of diagnostic unit 
affect the accuracy of 64-slice  CT? 
J0008 Accuracy Reliability and transferability of 
reported accuracy 
What is known about the intra- and inter-observer variation in test 
interpretation? 
Yes What is known about the intra- and inter-observer variation in 64-slice  CT 
test interpretation for per segment / per vessel / per patient analysis? 
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Appendix 1 Search Strategies 
 
Multislice CT, Basic search for EUnetHTA  
Database: Ovid MEDLINE(R) <1950 to November Week 2 2007> 
Search date: 7.12.2007 
Search strategy: 
-------------------------------------------------------------------------------- 
1    exp Coronary Disease/di, ra [Diagnosis, Radiography]  
2      (coronary adj2 (disease$ or occlus$ or vessel$ or arter$ or stenos$ or restenos$ or aneurysm$ 
or thrombos$ or vasospasm$ or obstruct$)).tw.  
3      calcinosis/di, ra or myocardial ischemia/di, ra  
4      1 or 2 or 3  
5      exp Coronary Angiography/  
6      exp Tomography, X-Ray Computed/ 
7      5 and 6  
8      (angiograph$ and tomograph$).tw.  
9      7 or 8  
10     4 and 9  
11      (msct or mdct).tw.  
12      (("8" or "16" or "32" or "40" or "64") adj2 (slice$ or row$)).tw.  
13      (multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or "multi-detect$" or 
"multi detect$" or multisect$ or "multi-sect$" or "multi sect$").tw.  
14      11 or 12 or 13  
15      10 and 14  
16      animals/  
17      humans/  
18      16 not (16 and 17)  
19      15 not 18  
20      limit 19 to yr="1990 - 2008"  
  
Multislice CT, Accuracy 
Database: Ovid MEDLINE(R) <1950 to May Week 2 2008> 
Search date: 23.5.2008 
Search strategy: 
-------------------------------------------------------------------------------- 
1      exp Coronary Disease/di, ra [Diagnosis, Radiography]  
2      (coronary adj2 (disease$ or occlus$ or vessel$ or arter$ or stenos$ or restenos$ or aneurysm$ 
or thrombos$ or vasospasm$ or obstruct$)).tw.  
3      calcinosis/di, ra or myocardial ischemia/di, ra  
4      1 or 2 or 3  
5      exp Coronary Angiography/  
6      exp Tomography, X-Ray Computed/  
7      5 and 6  
8      (angiograph$ and tomograph$).tw.  
9      7 or 8  
10    4 and 9  
11      (("64" or sixty-four or sixtyfour) adj2 (slice$ or row$)).tw.  
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12   (msct or mdct or multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or 
"multi-detect$" or "multi detect$" or multisect$ or "multi-sect$" or "multi sect$").tw.  
13      11 or 12  
14      10 and 11  
15      animals/  
16      humans/  
17      15 not (15 and 16)  
18      14 not 17  
19      18 not (news or letter or comment or editorial).pt.  
20      exp "Sensitivity and Specificity"/  
21      sensitivity.tw.  
22      specificity.tw.  
23      ((pre-test or pretest) adj probability).tw.  
24      ((post-test or posttest) adj probability).tw.  
25      predictive value$.tw.  
26      likelihood ratio$.tw.  
27      diagnostic accuracy.tw.  
28      diagnostic performance.tw.  
29      false positive$.tw.  
30      false negative$.tw.  
31      inter-observer variation$.tw.  
32      intra-observer variation$.tw.  
33      learning curve$.tw.  
34     or/20-33  
35      19 and 34  
36      limit 35 to yr="2002-2008" (127) 
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Appendix 2 Quality assessment: SIGN 
Quality assessement of Mowatt et al 2008 (by SH and TSI) 
 
 
S I G N 
Methodology Checklist 1: Systematic Reviews and Meta-
analyses 
Study identification  (Include author, title, year of publication, journal title, pages) 
Mowatt G, Cummins E, Waugh N, Walker S, Cook J, Jia X, et al. Systematic review of the clinical 
effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an 
alternative to invasive coronary angiography in the investigation of coronary artery disease. Health Technol 
Assess 2008;12(17) 
Guideline topic:  Key Question No: 
Checklist completed by:  Sigurður Helgason (SH) and Tuija S Ikonen (TSI).  
Section 1:  Internal validity 
In a well conducted systematic review In this study this criterion is:: 
1.1 The study addresses an appropriate and clearly 
focused question. 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.2 A description of the methodology used is 
included. 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.3 The literature search is sufficiently rigorous to 
identify all the relevant studies. 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.4 Study quality is assessed and taken into account. Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.5 There are enough similarities between the 
studies selected to make combining them 
reasonable. 
Well covered SH 
Adequately addressed TSI 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
SECTION 2:   OVERALL ASSESSMENT OF THE STUDY 
2.1 
How well was the study done to minimise 
bias?  
Code ++, +, or  
++ SH / ++ TSI 
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2.2 If coded as +, or  what is the likely direction in 
which bias might affect the study results? 
 
 
 
SECTION 3:   DESCRIPTION OF THE STUDY Please print answers clearly 
3.1 What types of study are included in the review? 
(Highlight all that apply) 
RCT 
Case-control 
CCT 
Other 
Cohort SH 
/TSI 
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Appendix 3 QUADAS tool 
 
QUADAS quality assessment tool (39) 
 
Mandatory items (as in the Cochrane handbook): 
1. Was the spectrum of patients representative of the patients who will receive the test in 
practice? 
2. Is the reference test likely to correctly classify the target condition? 
3. Is the time period between reference test and index test short enough to be reasonably sure 
that the target condition did not change between the two tests? 
4. Did the whole sample, or random selection of the sample, receive verification using a 
reference standard of diagnosis (reference test)? 
5. Did patients receive the same reference test regardless of the index test result? 
6. Was the reference test independent of the index test i.e. the index test did not form part of 
the reference test? 
7. Were the index test results interpreted without knowledge of the results of the reference test? 
8. Were the reference test results interpreted without knowledge of the results of the index test? 
9. Were the same clinical data available when the test results were interpreted as would be 
available when the test is used in practice? 
10. Were uninterpretable / intermediate test results reported? 
11. Were withdrawals from the study explained? 
 
Additional items 
12. If a cut-off value has been used, was it established before the study was started (pre-
specified cut-off value)? 
13. Is the technology of the index test likely to have changed since the study was carried out? 
14. Did the study provide a clear definition of what was considered to be a "positive" test result? 
15. Was treatment started after the index test was carried out but before the reference test was 
performed? 
16. Was treatment started after the reference test was carried out but before the index test was 
performed? 
17. Were data on observer variation reported? 
18. Were data on instrument variation reported? 
19. Were data presented for appropriate patient sub-groups? 
20. Was an appropriate sample size included? 
21. Were objectives pre-specified? 
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Appendix 4 Quality assessment of original studies 
 
The QUADAS tool was used in a modified form where eleven questions (1, 3, 4, 7, 8, 10 and 11, 
12, 14, 17 and 19) of the original QUADAS tool (Appendix 3) were used.  
 
1. Was the spectrum of patients representative of the patients who will receive the test in practice? 
3.  Is the time period between reference test and index test short enough to be reasonably sure that 
the target condition did not change between the two tests? 
4.  Did the whole sample, or random selection of the sample, receive verification using a reference 
standard of diagnosis (reference test)? 
7.  Were the index test results interpreted without knowledge of the results of the reference test? 
8.  Were the reference test results interpreted without knowledge of the results of the index test? 
10.  Were uninterpretable / intermediate test results reported? 
11.  Were withdrawals from the study explained? 
12.  If a cut-off value has been used, was it established before the study was started (pre-specified 
cut-off value)? 
14.  Did the study provide a clear definition of what was considered to be a "positive" test result? 
17.  Were data on observer variation reported? 
18.  Were data on instrument variation reported? 
19.  Were data presented for appropriate patient sub-groups? 
 
Select from  
QUADAS 
items* 
1  3  4 7 8 10 11 12 14 17 19 
Cademartiri 2007 + + + + + + + + + + + 
Hausleiter 2007 + ? + + + + + + + + + 
Herzog 2007 + + + + + + + + + - + 
Leber 2007 + + + + ? + + + + + + 
Mejboom 2007 a + + + + + + + + + + + 
Mejboom 2007 b + + + + + + + + + + + 
Muhlenbruch 
2007 
+ ? + + + + + + + + - 
Oncel 2007 + + + + + + + + + + + 
Schlosser 2007 + + + + ? + + + + - - 
 
Comments:  
 
Cademartiri 2007 
Item 10 and 11. No withdrawals or uninterpretable results? Selection into the study? 
 
Hausleiter 2007 
Item 1. The authors state that the patients have an intermediate pre-test probability for having CAD.  
The description of the study population is not very detailed but they included both patients with 
chest pain, dyspnea or intermittent arrhythmias with an equivocal stress test or in the absence of a 
positive stress test as well as asymptomatic patients with a positive stress test. The last group might 
account for 18.9% of the patients.   
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Item 3. The only statement on the time period between MSCT and ICA is "invasive coronary 
angiography was performed after MSCT angiography, usually on the same or next day after MSCT 
angiography". 
 
Leber 2007 
Item 7 and 8. Blinding is not described but MSCT performed and likely analysed the day before 
ICA.  
Item 19. Sub-groups 50-74% stenosis and >75%. 
 
Mejboom 2007a.  
Item 1. Not consecutive.  Patients referred over 24 months for ICA.  Is this same material as 
Mejboom 2007b? 
 
Mejboom 2007b.  
Item 1. Not consecutive.  Patients referred over 24 months for ICA. Is this same material as 
Mejboom 2007a? 
 
Muhlenbruch 2007  
Item 1. Significant stenosis defined as ≥ 70%.  
Item 3. All patients underwent CTA and CCA within a short timeframe (mean 2.4±3.2 days).  
Item 19. Not separate subanalysis for known CAD patients. 
 
Schlosser 2007 
Item 8.  No information is given on this issue but in the text the following answers Item 7. "MDCT 
images were read by a radiologist and a cardiologist in consensus blinded to the clinical data and 
the results of ICA".  
Item 19. Not separate subanalysis for low risk patients. 
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Appendix 5 Demographic data  
 
Demographic data of the selected studies for accuracy analysis.  
 
Study id Homogenou
s population 
of low or 
inter-
mediate risk 
N of 
patients 
analysed / 
total 
Mean age Symptoms 
 
Risk 
category 
 
Patients with 
CAD > 50 % 
present on 
ICA 
Cademartir
i 2007 
yes 72 53.9 ± 8.0 atypical or 
typical chest 
pain 
low to 
intermediate 
28 % 
Hausleiter 
2007 
yes 
16-slice (53 
%) 
64-slice (47 
%) 
243 62.0 ± 9.9 chest pain, 
dyspnea, 
arrhythmia, 
positive stress 
test 
intermediate 42 % 
Herzog 
2007 
yes 55 67 (49 - 73) atypical chest 
pain 
low 35 % 
Leber 2007 yes 88 / 90 58 ± 8 typical or 
atypical chest 
pain, dyspnea 
intermediate 24 % 
Mejboom 
2007 
subgroup 
analysis of 
all risk 
groups  
254 
105 
83 
66 
 
63 ± 9 
61 ± 8 
50 ± 12 
typical or 
atypical chest 
pain 
 
high 
intermediate 
low 
 
78 % 
39 % 
18 % 
Mejboom 
2007 
UAP and 
non-ST-AMI 
11 % vs. 13 
% both, 
known CAD 
12 % vs. 10 
% 
402 
F 123 
M 279 
 
F 62 ± 11 
M 58 ± 11 
acute or stable 
AP 
not reported F 51 % 
M 68 % 
Muhlenbru
ch 2007 
high risk  
cut-off 70% 
51 58.5 ± 7,9 positive stress 
test 
symptomatic  
high 88 % 
Oncel 2007 risk not 
mentioned 
80 56 (63 - 72) chest pain or 
positive stress 
test 
not reported 77 % 
Schlosser 
2007 
yes 61 / 63 62.4 (33 - 
78) 
atypical chest 
pain 
ambiguous 
stress test 
not defined not reported 
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Effectiveness 
 
  
Tuija Ikonen, Heikki Ukkonen, Sigurdur Helgason, Iris Pasternack, Marjukka Mäkelä 
Introduction 
For the assessment of effectiveness of multislice computed tomography (MSCT) coronary 
angiography, it would be optimal to compare two management pathways: one with MSCT as a rule 
out diagnostic test for coronary artery disease (CAD), and one without. A complete management 
path includes also the selection of treatment options. Pre-assumptions for this path are  
1) patients have low or moderate likelihood of CAD, related to factors such as age, gender, 
symptoms, and risk factors for CAD,  
2) there is a clinical need to rule out CAD because previous testing has not confirmed the presence 
or absence of the disease, and  
3) the established diagnosis of CAD is esteemed to be useful for making decisions concerning the 
treatment options. 
 
Information obtained from MSCT should always have clinical impact, either in the sense of ruling 
out CAD and consequent ex-juvantibus (diagnosis made on basis of the treatment outcome) 
unnecessary medical treatment, or verifying the diagnosis of CAD with optimal treatment protocol 
and possibility to avoid coronary disease end-points such as acute myocardial infarction (AMI), 
invasive treatment or death. 
 
In the current medical literature there are only few, if any, studies that look into the effectiveness of 
MSCT as a part of management path. For the effectiveness assessment, however, it is of importance 
to formulate the relevant questions based on the process e.g. the diagnostic path rather than on the 
existing studies of accuracy, where MSCT is compared with invasive coronary angiography (ICA) 
and where effectiveness of MSCT is derived from the studies of effectiveness of ICA. Further work 
is needed to fill in the missing pieces of information. 
Methodology 
Literature review 
For the review of the literature on MSCT angiography, we searched Medline (936), Premedline (50) 
and CRD (= HTA, EED, DARE). The search was performed between the December 5th and 7th, 
2007. A completion search was performed from Premedline (84) and a specific search strategy for 
effectiveness on the 21st of May, 2008. Search strategies for each database are presented in 
Appendix 1.  
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The search strategy resulted in over 1000 references across all databases. Specific search for 
effectiveness gained 6 references. Two researchers independently selected relevant titles and 
abstract. In disagreement a consensus was sought.  
 
Inclusion criteria were:  
– Suspected coronary artery disease (CAD) in patients with typical or atypical non-acute chest 
pain, or a subgroup analysis of patients without known CAD, preferably in the group of low 
or intermediate pre-test likelihood of CAD.  
– MSCT using 64-slice technology, or a subgroup analysis of 64-slice technology. 
– Selecting proper treatment, e.g. risk factor reduction, medical treatment, invasive treatment 
for the patients who have undergone MSCT.  
– Consequences of using MSCT, including incidental findings of the image area. 
– At least 6 months follow-up for assessing clinical effectiveness of MSCT. 
 
Exclusion criteria were: 
– Assessment of high risk population or known CAD (e.g. invasive treatment), only. 
– CAD diagnosed in adjunction with other diseases of the myocardium, heart valves or 
ascending aorta. 
– Techniques lower than 64-slices, only. 
– Diagnosis and treatment of acute chest pain, myocardial infarction/acute coronary 
syndrome. 
– Screening and follow-up of asymptomatic high-risk or low-risk population. 
– Monitoring treatment effect after coronary balloon dilatation (PTCA), stenting, or bypass 
operation (CABG). 
 
In addition to Mowatt's HTA report (4), three studies looking at 64-slice MSCT as a part of 
diagnostic chain were obtained with follow-up over 6 months (1-3). In the retrospective study of 
Rubinshtein there were 100 patients with no previous invasive angiograms or treatments for CAD. 
In the study of Pundziute the proportion of patients with previous myocardial infarction was 33 %, 
and majority of them had a previous revascularisation (PCI). Suspected CAD was the indication for 
MSCT in 65 % of the patients (n=65). Pundziute et al. combined data from both 16 and 64-slice 
technologies. The third study reported a 15 ± 3 months follow-up of 421 symptomatic patients with 
intermediate risk after abnormal myocardial perfusion stress imaging and a consequent 64-slice CT 
angiography (1). Of the patients, 34 % had a positive history of CAD based on a previous 
angiogram or known acute myocardial infarction (AMI).   
Quality Assessment 
There is no straightforward way to assess the quality of the varying study types of diagnostic 
effectiveness studies. Therefore we had no formal quality assessment of these three studies 
included. The quality of the HTA of Mowatt et al. has been assessed by two assessors (SH and 
TSI), who performed quality assessment by using a quality assessment tool (SIGN - Methodology: 
Critical appraisal: Notes and checklists. Methodology Checklist 1: Systematic Reviews and Meta-
analyses http://www.sign.ac.uk/guidelines/fulltext/50/checklist1.rtf   and   
http://www.sign.ac.uk/guidelines/fulltext/50/notes1.html). See Appendix 2. 
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Assessment elements 
Comparative accuracy of a replacement technology 
Based on the accuracy and safety data, is there evidence that MSCT is more 
specific in ruling out coronary artery disease (CAD) and need for invasive 
procedure, compared to another test? 
Results 
 
What is the accuracy of MSCT against invasive coronary angiography (ICA)? 
 
MSCT has usually lower specificity (approximately 87%) than sensitivity (appr 96%) when 
compared to ICA as reference standard for the diagnosis of coronary artery disease (CAD), both in 
patient level and in segment level analysis. If MSCT would have similar sensitivity but better 
specificity (against ICA) than another test that aims at diagnosing CAD, it could be seen a more 
effective diagnostic modality, because effective treatments exist. It would then find the CAD 
patients as well as the comparative technology (if similar sensitivity), and there are less false 
positive among those with positive test results (if better specificity). Increased sensitivity does not 
automatically imply improved effectiveness while the extra cases found with the more sensitive test 
could react differently to the treatment, so the results of treatment trials are not directly applicable. 
See more in issues J0001 and J0003 in the accuracy domain. 
 
Is MSCT more specific than stress radionuclide imaging against ICA 
  
According to Mowatt et al (4), the sensitivity of single photon emission computed tomography 
(SPECT) against invasive coronary angiography (ICA) for detecting a significant stenosis was 
either 81%, 87% or 88%, depending on the type of analysis undertaken, while specificity was 64%, 
65% or 69% from two reviews and in a study re-analysing the results of one of the reviews (37,38).  
The pooled estimates for MSCT accuracy against ICA in a patient-level analysis are for 
comparison: sensitivity 99% and specificity 89% (5). 
 
Schuijf et al compared 64-slice MSCT and Stress-rest myocardial perfusion imaging (MPI, 
technetium 99m) in a subset of 86 of 114 patients with an intermediate likelihood of coronary artery 
disease (CAD) and without previous CAD diagnosis. 58 patients were further analysed by ICA. 
Sensitivity of MSCT and SPECT in detecting a significant stenosis against ICA as reference 
standard were 100 % and 81% respectively, and specificities were 59 % vs 48 % (11). 
 
The study of Danciu et al (1) compared MSCT directly to radionuclide stress imaging. From the 
population of 421 intermediate risk patients, majority (81.5 %) was considered not to have a 
significant CAD on 64-slice MSCT after unspecific or abnormal stress myocardial perfusion 
imaging (MPI). The group was heterogeneous including patients with no or mild coronary artery 
disease (CAD) on MSCT, mismatch between myocardial perfusion stress imaging (MPSI) and 
MSCT findings or occluded by-pass graft. During the follow-up of 15 months 6 patients required 
ICA and one of them underwent revascularisation. In this patient group classified as intermediate 
risk after stress MPI, and low-risk after MSCT, patients had a 0.3 % rate of the combined end-point 
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of death, acute myocardial infarction and revascularisation. The authors concluded that the use of 
MSCT improved specificity of the diagnostic path after stress MPI by ruling out significant CAD in 
46 % of the patients in who the ruling out was not possible by radionuclide imaging (1). See also 
issue J0002 in the accuracy domain. 
 
In conclusion: MSCT appears to be more sensitive and more specific than stress radionuclide 
imaging against common reference standard ICA. 
Comment 
It has to be remembered that MSCT is a tool to assess the coronary anatomy and plaques of CAD, 
whereas the functional studies define the extent of ischemia as functional consequences of the 
plaques. Therefore these methods are not completely comparable in the diagnostic path. 
Safety 
What is the mortality related to MSCT compared to invasive coronary 
angiography(ICA)? 
Results 
None of the included studies reported any mortality from MSCT or invasive coronary angiography 
(ICA). It is generally accepted that there is a small risk of fatal complications associated with ICA, 
whereas MSCT being less invasive does not have the same risk profile. Mortality of ICA is in order 
of 0.1 %. (5). See also safety domain. 
Comment 
There are studies regarding 64-slice MSCT mortality that have been presented as abstracts. 
What is the incidence of radiation induced morbidity?  
Results 
In the HTA of Mowatt et al. (4) the radiation risk was reported in 12 full text studies. Technical 
factors that enhance image quality in 64-slice also result in a higher radiation dose compared with 
invasive CA.  Both Hausleiter et al (6) and the Technology Evaluation Center estimated the 
effective dose for 64-slice CT to be around 11.0 mSv compared with 2.1 mSv or 4 to 8 mSv for 
invasive coronary angiography (ICA). Using ECG-dependent dose modulation the CT radiation 
dose can be reduced further by 30 to 50% during systole. The International Commission on 
Radiological Protection quote typical effective dose values of 5 to 12 mSv for CT angiography, 5 to 
10 mSv for ICA, 13 to 16 mSv for sestamibi myocardial perfusion imaging and 35 to 40 mSv for 
thallium myocardial perfusion imaging.  Across the studies reporting this information for the patient 
group as a whole, the CT radiation dose ranged from 6 to 11 mSv to 10 to 14 mSv (7,8). Women 
tended to receive a higher radiation dose than men.  Across the studies reporting CT radiation dose 
separately for men and women, for men this ranged from 7.45 mSv to 15.2 mSv and for women 
from 12.2 mS to 21.4 mSv (9). 
Comment 
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None of the included studies answered these questions directly. These questions are answered more 
profoundly in the Safety domain. Radiation dose depends on the devices and used programmes. The 
level of the multimodal technology itself does not provide enough information to assess actual dose 
and consequent potential radiation harms of the used method. More specific details about the 
technology for calculations are required. 
Change-in management 
Does 64-slice CT improve the physician's ability to make correct diagnosis of 
CAD in patients with low or intermediate risk for CAD? 
Methods 
The answers were obtained from the three full text studies included for obtaining effectiveness data 
(1,2,10) 
Results 
Rubinshtein et al. assessed 100 patients by MSCT, who were suspected to have coronary artery 
disease (CAD) because of chest pain but who only had a negative or non-diagnostic exercise 
treadmill test (ETT). The ETT results were negative in 59 patients and non-diagnostic in 41. 
Obstructive CAD was present on MSCT in 22 % of patients with negative and 39 % of patients with 
non-diagnostic ETT examination, and 26 of 29 positive findings were confirmed by invasive 
coronary angiography (ICA). Two patients were false positive on MSCT. In one patient there was a 
2-vessel disease instead of 1-vessel disease suggested by MSCT (10) Of the 71 patients diagnosed 
not to have obstructive lesions on MSCT, ICA was performed in 15 due to continuing symptoms 
within 2 weeks. Of these significant CAD (70 % stenosis) was found in one patient. In patients with 
unequivocal or negative stress test, CAD was correctly diagnosed in 26 of 29 patients by using 
MSCT, with a positive predictive value (PPV) of 90 %, and among the 71 patients who were 
condemned not to have CAD, there was only one positive diagnosis that was failed within a short 
term follow-up. Thus, MSCT led to improved detection of the diagnosis of CAD in majority of the 
patients with suspected CAD. 
 
Furthermore, calculated from the figures given in Rubinshtein's study, in the group of negative ETT 
in 73 % of patients CAD was correctly ruled out by MSCT and in 76 % by ETT. MSCT excluded 
CAD in 61 % of patients with non-diagnostic ETT, thus in this group, MSCT was more specific 
than ETT in ruling out CAD. 
 
In the study of Pundziute et al. 100 patients with known or suspected CAD were assessed with 
MSCT. 20 patients did not have any signs of CAD, and 32 were diagnosed to have a significant 
CAD (>50 % stenosis) on MSCT. During 16 months follow-up there were 33 events in 26 patients 
including one death of myocardial infarction (MI). All events occurred in patients with abnormal 
coronary arteries. Based on clinical judgement and stress test, a total of 24 patients underwent 
revascularisation, of which 7 had cardiac surgery. Patients with events had more extensive 
atherosclerosis on MSCT. In a multivariate analysis, the findings on MSCT predictive for CAD 
were the presence of plaques, obstructive CAD, left main/ left anterior descending artery 
(LM/LAD) disease, number of coronary segments with plaques and number of coronary segments 
with mixed plaques (2). Based on the study results MSCT was able to rule out 20 patients from the 
suspicion of CAD, of which patients none had cardiac events during the follow-up. 
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In the study of Danciu et al. from the population of 421 intermediate risk patients where the 
majority (81.5 %) was medically managed, 78 patients (18.5 %) were sent for ICA and when 
required for revascularisation after stress myocardial perfusion imaging (MPI) and MSCT-
examination. The medically managed group was heterogeneous including patients with no or mild 
CAD, mismatch between myocardial perfusion stress imaging (MPSI) and MSCT, or occluded by-
pass graft. During the follow-up of 15 months 6 patients required ICA, and one of them underwent 
revascularisation. In this patient group classified as low-risk after MSCT, the rate of the combined 
end-point of death, acute myocardial infarction (AMI) and revascularisation was 0.3%. Thus, the 
use of MSCT was able to rule out clinically significant CAD in the majority of patients (1). 
  
Of the patients referred to ICA based on over 70 % stenosis (34 patients) or over 50 % stenosis and 
matching MPI stress defect (42 patients), revascularisation rates were 23/42 and 27/30. 
The positive predictive value of severe stenosis on ICA was 88 % (30/34 patients).     
Comment 
This element is beyond specific study questions in the assessed studies.  
Does the use of 64-slice CT modify the use of invasive treatment for CAD? 
Results 
Mowatt's HTA reported two studies which dealt the usefulness of MSCT in decision making. 
Auseon and colleagues reported that, in the year following the introduction of 64-slice CT 
compared to the previous four years, the yearly rates of increase in diagnostic catheterisation 
volume and percutaneous interventions had not been significantly affected. Danciu and colleagues 
reported that in the first six months following the introduction of 64-slice CT, invasive coronary 
angiography (ICA) had been avoided in 82% of 486 patients (4). 
 
Rubinshtein et al. (10) assessed 100 patients by MSCT, who were suspected to have coronary artery 
disease (CAD) because of chest pain but who only had a negative (n=59) or non-diagnostic (n=41) 
exercise treadmill test (ETT). Obstructive CAD was present on 64-slice CT in 29 patients, all of 
whom underwent ICA. Among them 26 patients were confirmed to have significant CAD. 18 
patients underwent revascularisation. During the follow-up of one year, none of the 71 patients who 
were not primarily catheterized died or had myocardial infarctions (MI). Another 15 patients 
underwent ICA within two weeks and one of the ICAs led to CAD diagnosis. The information 
about consequent revascularisation is missing. Later, five patients underwent ICA, with 
percutaneous intervention in two of them. The authors considered at least one of these lesions to 
have been a missed diagnosis and the other one might have represented disease progression. By 
using 64-slice CT in the clinical pathway of this low or intermediate risk population, 51 ICAs were 
avoided, but at least one patient who later required invasive treatment was missed initially.  
 
In the study of Pundziute et al, among 100 patients with suspected or known CAD, MSCT was able 
to rule out CAD in 20 patients and of these none had a cardiac event during the follow-up (2). In the 
study setting MSCT was not used as a part of diagnostic/therapeutic workup, wherefore it was not 
designed to answer the study question. 
 
In the study of Danciu et al. from the population of 421 intermediate risk patients who were initially 
referred for ICA after stress myocardial perfusion imaging (MPI), the use of 64-slice MSCT-
examination led to the decision of medical management in 343 patients (81.5 %), and only 78 
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patients (18.5 %) were sent for ICA, of whom 50 underwent revascularisation (1). However, 6 
patients required late ICA due to continuing symptoms, of which one required late (over 1 month 
after MSCT) revascularisation. 
Comment 
There are no specific answers to these elements in included studies.  
Does MSCT detect other disease conditions causing chest pain which have 
impact on the CAD treatment decisions? 
Does MSCT detect other disease conditions (e.g. pulmonary nodules, vascular 
aneurysms) that lead to new diagnostic pathways or other treatments than 
CAD?  
How does this impact the use of health technologies and resources, and the 
quality of life and mortality of patients? 
Results 
Not answered in the included studies. 
Comment 
Case studies might have been described, but they are beyond this analysis. Different risk groups 
might have different likelihoods of incidental findings. It would be important to assess the clinical 
relevance of the incidental findings.  
How does the use of 64-slice CT modify the need for Emergency Room 
visits/contacts, unscheduled hospitalization or outpatient visits or modify the 
need of intensive care? 
Results 
Not answered in the analysed studies. 
Health outcomes 
Is there effective treatment for non-obstructive (<50% stenosis)/ obstructive 
CAD in patients with stable symptoms of angina pectoris? 
Results 
Concerning non-obstructive coronary artery disease (CAD), in Mowatt's HTA review there was a 
conclusion that 64-slice CT would also show lesser degrees of stenosis, and could therefore 
influence management other than revascularisation.  For example, a patient with 30% stenosis 
might receive lifestyle advice, a statin, and perhaps intensified control of blood pressure or blood 
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glucose.  Several studies have reported regression of coronary artery disease (CAD) after statin 
treatment, though usually modest (4). 
 
Obstructive CAD is treated by medication, percutaneous coronary intervention (PCI) or by-pass 
surgery. The contemporary medical treatment has been shown to improve the prognosis in patients 
with CAD. PCI and by-pass surgery, although useful at controlling symptoms in symptomatic 
patients, have only limited prognostic benefit if any.   
 
In patients with low or intermediate risk for CAD, what is the effect of 64-slice 
CT - invasive / non-invasive treatment on mortality? 
Results 
In Rubinshtein's study of 100 patients with negative or non-diagnostic treadmill examination, 
positive MSCT led to invasive coronary angiography (ICA) in 29 patients, and MSCT result 
suggested rule-out significant coronary artery disease (CAD) in 71 patients, of whom 15 were 
assessed with ICA within 2 weeks due to on-going symptoms, and one of patients was diagnosed to 
have CAD on ICA. During the follow-up of one year, none of the 71 patients died or had 
myocardial infarctions (MI). Later, five patients underwent ICA, with percutaneous intervention in 
two of them (10) 
 
In the study of Danciu et al. from the population of 421 intermediate risk patients where the 
majority (81.5 %) was medically managed (N=343), 78 patients (18.5 %) were sent for ICA and 
when required for revascularisation after stress myocardial perfusion imaging (MPI) and MSCT-
examination. The medically managed group was heterogeneous including patients with no or mild 
CAD, mismatch between myocardial perfusion stress imaging (MPSI) and CT-findings or occluded 
by-pass graft. During the follow-up of 15 months 6 patients required ICA, and one of them 
underwent revascularisation. In this patient group classified as low-risk after MSCT, the rate of the 
combined end-point of death, acute myocardial infarction (AMI) and revascularisation was 0.3%. 
There was no mortality in 343 patients on medical treatment considered to have low risk of CAD 
within 15 months after MSCT (1).  
In patients with low or intermediate risk for CAD, how does the 64-slice CT - 
treatment modify the clinical end points of CAD (AMI, UAP, revascularisation) 
or symptoms of chest pain and need for health care compared to a comparator 
treatment path without use of 64-slice CT? 
In patients with low or intermediate risk for CAD, how does the use of 64-slice 
CT - treatment modify the number of patients receiving effective treatment? 
Results 
With 64-slice CT it is possible to detect stenosis of lesser degree. Therefore its results could lead to 
secondary prophylaxis of coronary artery disease (CAD), such as lifestyle advice or a drug to lower 
lipids, blood pressure or blood glucose that otherwise would not have been initiated. However, the 
identified studies did not look specifically to this question.   
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In the study of Rubinshtein et al. none of the 71 patients treated conservatively based on MSCT-
finding died or had acute myocardial infarction (AMI) during the follow-up of one year. Within the 
first two weeks 15 with continuous symptoms or clinical signs underwent invasive coronary 
angiography (ICA) and one patient with a significant CAD was found. It is not reported if 
revascularisation (PCI) was required. Later, five of the patients underwent I CA, with PCI in two of 
them. The authors considered at least one of these lesions to have been a missed diagnosis and the 
other one might have represented disease progression (10). 
 
In the study of Danciu et al. during the follow-up of 15 months 6 patients from the medically treated 
group (343 patients) required ICA and one of them underwent revascularisation. In this patient 
group classified as low-risk after MSCT, the rate of the combined end-point of death, AMI and 
revascularisation was 0.3%. The use of MSCT instead of ICA possibly led to delayed diagnosis in 
one case (1).  
 
The conclusion from these two patient series is that correct diagnosis might have been missed in 
few patients compared to use of ICA, but the consequences in terms of clinical events are rare. 
Comment  
Imaging modalities are tools to be used in proper context of the clinical path. All results need to be 
judged in the clinical context. 
In patients with low or intermediate risk for CAD, how does the use of 64-slice 
CT - treatment modify the effectiveness of invasive or non-invasive treatment? 
Results 
When MSCT is used for add-on information to the clinical diagnosis, it might give possibility to 
enhance medical treatment. There are several studies about primary and secondary prevention at 
population level. However, in this specific context no studies have been found to improve the 
effectiveness of treatment path. 
What is the effect of 64-slice CT on health-related quality of life in patients who 
are diagnosed to have obstructive CAD / non-obstructive CAD / no CAD? 
Results 
This element was not answered in the included studies. 
What are the negative consequences of further testing and delayed treatment in 
patients with false negative test result on 64-slice CT? 
Results 
There were only few comments on this in analysed studies. In the study of Rubinshtein, among 71 
patients without evidence of obstructive coronary artery disease (CAD), 15 patients with on-going 
symptoms had invasive coronary angiography (ICA), of which one showed a significant stenosis in 
the left anterior descending artery (LAD). No clinical consequences were described. Another five 
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patients underwent clinically driven ICA during the follow-up of one year. Among them were two 
with percutaneous angioplasty for LAD. No hard cardiac events were described.  
What are the negative consequences of further testing and treatments in patients 
with false positive test result on 64-slice CT? 
Results 
Rubinshtein (10) assessed 100 patients by MSCT, who were suspected to have coronary artery 
disease (CAD) because of chest pain but who only had a negative or non-diagnostic exercise 
treadmill test (ETT).  Obstructive CAD was present on 64-slice CT in 29 patients, all of whom 
underwent  invasive coronary angiography (ICA). Among them 26 patients were confirmed to have 
significant CAD. Three were diagnosed as not significant CAD on invasive coronary angiography 
(ICA). No other negative consequences are described except that the ICA procedure might have 
been avoided with a proper diagnosis on MSCT.   
What are the overall benefits and harms in health outcomes considering the 
amount of false positive and false negative? 
Results 
Answer was not found in the literature. 
What is the effect of knowledge of test results in patients who are diagnosed to 
have obstructive CAD / non-obstructive CAD / no CAD? 
Results 
This element was not answered in the included studies. 
Would the patient be willing to use MSCT for the diagnosis of CAD again? 
Results 
This element was not answered in the included studies.  
Comment 
Answer to this element might be found from studies using other that 64-slice MSCT, or from the 
studies included in the Social Domain. 
Discussion 
 
Very few studies were identified that dealt with the usefulness of 64-slice CT in the diagnostic path 
of patients with stabile chest pain and low to intermediate risk of coronary artery disease (CAD). 
Based on accuracy data and what is known from large population studies of CAD prevention, 64-
slice CT helps to indentify and classify the patients between groups of primary and secondary 
prevention and patients between obstructive and non-obstructive disease. Further studies are needed 
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to find more specific and direct evidence to the questions asked in the elements of EUnetHTA 
effectiveness domain.   
 
Form the methodological point of view the questions from generic EUnetHTA diagnostic format 
were initially translated into the specific context of MSCT by two authors (TSI and HU). From the 
literature, only three studies were identified that looked at the diagnostic path and clinical follow-up 
of the patients after 64-slice CT examination. The answers were extracted from the studies with a 
specific interest to the target group of low and intermediate risk for CAD in patients with non-acute 
symptoms. Because of lack of appropriate studies, specific answers for majority of the issues were 
lean. On the other hand, some elements would have required a specific literature search with a 
wider or completely different focus, e.g. questions about mortality, or the reference standard, and 
the effective treatment for CAD. 
 
Assessment of effectiveness for a diagnostic test requires different approach from the basic 
accuracy assessment and leads to a more complex setting. However, these questions are of major 
interest and they are essential requirements in the core of clinical work: does the effort paid for 
diagnostic work-up really benefit the patients?   
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Assessment elements table 
Element 
Identifi-
cation 
Code (ID) 
Domain Topic Issue Relevance in 
the context of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
Or Comment (if regarded as a not relevant issue in this context) 
      
D0019 Effectiveness Comparative 
accuracy of  a 
replacement 
technology 
Based on the accuracy and safety data is there evidence that the 
replacing technology is more specific or safer than the gold standard or 
comparator test? 
Yes In patients with low or intermediate risk for CAD, is 64-slice CT more specific or safer than CA / 
radionuclide imaging /stress ECHO / the best medical treatment and clinical follow-up? 
D0001 Effectiveness Safety What is the mortality related to the diagnostic technology? Yes What is the mortality related to MSCT compared to CA? 
D0008 Effectiveness Safety What is the morbidity related to the diagnostic technology? Yes What is the morbidity related to MSCT? What is the incidence of radiation induced morbidity? What is 
the impact of MSCT on renal function? 
D0020 Effectiveness Change-in 
management 
Does the use of the technology lead to improved detection of the 
disease?  
Yes In patients with low or intermediate risk for CAD, does 64-slice CT improve the pysician´s ability to 
make correct diagnosis of CAD? 
D0021 Effectiveness Change-in 
management 
Does the use of the technology lead to a change in the physicians' 
management decisions?  
Yes Does the use of 64-slice CT change the physicians' prescription of primary or secondary prevention 
medication to the patients with low or intermediate risk for CAD? 
Does the use of 64-slice CT modify the use of invasive treatment for CAD?  
D0022 Effectiveness Change-in 
management 
Does the use of technology detect other health conditions (e.g. 
incidental findings) which have impact on the treatment decisions 
concerning the target condition? 
Yes Does MSCT detect other disease conditions causing chest pain which have impact on the CAD 
treatment decisions? 
Does MSCT detect other disease conditions (e.g. pulmonary nodules, vascular aneurysms) that lead 
to new diagnostic pathways or other treatments than for CAD? How does this impact the use of 
health technologies and resources, and the quality of life and mortality of patients? 
D0023 Effectiveness Change-in 
management 
How does the technology modify the need for other tests and use of 
resources? 
Yes How does the use of 64-slice CT modify the use of stress ergometry, stress ECHO, SPECT or CA in 
patients with low or intermediate risk for CAD, and what is the impact on resources? 
D0010 Effectiveness Change-in 
management 
How does the technology modify the need for hospitalization? Yes How does the use of 64-slice CT modify the need for Emergency Room visits/contacts, unscheduled 
hospitalization or outpatient visits or modify the need of intensive care?  
D0024 Effectiveness Health outcomes Is there an effective treatment for the condition the technology is 
detecting? 
Yes Is there effective treatment for non-obstructive (<50% stenosis)/ obstructive CAD in patients with 
stable symptoms of AP? 
D0025 Effectiveness Health outcomes What is the effect of the test-treatment intervention on mortality? Yes In patients with low or intermediate risk for CAD, what is the effect of 64-slice CT - invasive / non-
invasive treatment on mortality? 
D0005 Effectiveness Health outcomes How does the test-treatment intervention influence the magnitude and 
frequency of morbidity? 
Yes In patients with low or intermediate risk for CAD, how does the 64-slice CT - treatment modify the 
clinical end points of CAD (AMI, UAP, revascularisation) or symptoms of chest pain and need for 
health care compared to a comparator test - tratment or a treatment path without use of 64-slice CT? 
In patients with low or intermediate risk for CAD, how does the use of MSCT - treatment modify the 
number of adverse outcomes from MSCT versus other diagnostic tests?  
In patients with low or intermediate risk for CAD, how does the use of 64-slice CT - treatment modify 
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the number of patients receiving effective treatment? 
D0026 Effectiveness Health outcomes How does the technology modify the effectiveness of subsequent 
interventions? 
Yes In patients with low or intermediate risk for CAD, how does the use of 64-slice CT - treatment modify 
the effectiveness of invasive / non-invasive treatment?  
D0013 Effectiveness Health outcomes What is the effect of the technology on health-related quality of life?  Yes What is the effect of 64-slice CT on health-related quality of life in patients who are diagnosed to 
have obstructive CAD / non-obstructive CAD / no CAD?  
D0027 Effectiveness Health outcomes What are the negative consequences of further testing and delayed 
treatment in patients with false negative test result? 
Yes What are the negative consequences of further testing and delayed treatment in patients with false 
negative test result on 64-slice CT? 
D0028 Effectiveness Health outcomes What are the negative consequences of further testing and treatments 
in patients with false positive test result? 
Yes What are the negative consequences of further testing and treatments in patients with false positive 
test result on 64-slice CT? 
D0029 Effectiveness Health outcomes What are the overall benefits and harms in health outcomes 
considering the amount of false positive and false negative? 
Yes What are the overall benefits and harms in health outcomes considering the amount of false positive 
and false negative? 
What are the impacts of risks of radiation and kidney failure?  
D0030 Effectiveness Patient satisfaction Does the knowledge of the test result improve the patient's quality of 
life? 
Yes What is the effect of knowledge of test results in patients who are diagnosed to have obstructive CAD 
/ non-obstructive CAD / no CAD?  
D0018 Effectiveness Patient satisfaction Would the patient be willing to use the technology again? Yes Would the patient be willing to use MSCT for the diagnosis of CAD again? 
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Appendix 1 Search Strategies 
 
Multislice CT, Basic search for EUnetHTA  
Database: Ovid MEDLINE(R) <1950 to November Week 2 2007> 
Search date: 7.12.2007 
Search strategy: 
-------------------------------------------------------------------------------- 
1     exp Coronary Disease/di, ra [Diagnosis, Radiography]  
2     (coronary adj2 (disease$ or occlus$ or vessel$ or arter$ or stenos$ or restenos$ or aneurysm$ or 
thrombos$ or vasospasm$ or obstruct$)).tw.  
3     calcinosis/di, ra or myocardial ischemia/di, ra  
4     1 or 2 or 3  
5     exp Coronary Angiography/  
6     exp Tomography, X-Ray Computed/ 
7     5 and 6  
8     (angiograph$ and tomograph$).tw.  
9     7 or 8  
10     4 and 9  
11     (msct or mdct).tw.  
12     (("8" or "16" or "32" or "40" or "64") adj2 (slice$ or row$)).tw.  
13     (multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or "multi-detect$" or 
"multi detect$" or multisect$ or "multi-sect$" or "multi sect$").tw.  
14     11 or 12 or 13  
15     10 and 14  
16     animals/  
17     humans/  
18     16 not (16 and 17)  
19     15 not 18  
20     limit 19 to yr="1990 - 2008"  
 
Multislice CT, Effectiveness 
 
Database: Ovid MEDLINE(R) <1950 to May Week 2 2008> 
Search date: 23.5.2008 
Search strategy: 
-------------------------------------------------------------------------------- 
1     exp Coronary Disease/di, ra [Diagnosis, Radiography]  
2     (coronary adj2 (disease$ or occlus$ or vessel$ or arter$ or stenos$ or restenos$ or aneurysm$ or 
thrombos$ or vasospasm$ or obstruct$)).tw.  
3     calcinosis/di, ra or myocardial ischemia/di, ra  
4     1 or 2 or 3  
5     exp Coronary Angiography/  
6     exp Tomography, X-Ray Computed/  
7     5 and 6  
8     (angiograph$ and tomograph$).tw.  
9     7 or 8  
10     4 and 9  
11     (("64" or sixty-four or sixtyfour) adj2 (section$ or slice$ or row$)).tw.  
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12     (msct or mdct or multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or 
"multi-detect$" or "multi detect$" or multisect$ or "multi-sect$" or "multi sect$").tw.  
13     11 or 12  
14     10 and 11  
15     animals/  
16     humans/  
17     15 not (15 and 16)  
18     14 not 17  
19     18 not (news or letter or comment or editorial).pt.  
20     ("change-in manage$" or "change-in patient manage$").tw.  
21     "diagnostic before and after".tw.  
22     test-treatment path$.tw.  
23     clinical path$.tw.  
24     ((pre-test or pretest) adj2 manage$).tw.  
25     ((post-test or posttest) adj2 manage$).tw.  
26     diagnostic triag$.tw.  
27     ((clinical or therapeutic) adj2 decision$).tw.  
28     decision analy$.tw.  
29     Decision Making/  
30     Triage/  
31     or/20-30  
32     19 and 31 (9) 
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Appendix 2 Quality assessment 
Quality assessement of Mowatt et al 2008 (by SH and TSI) 
 
 
S I G N 
Methodology Checklist 1: Systematic Reviews and Meta-
analyses 
Study identification  (Include author, title, year of publication, journal title, pages) 
Mowatt G, Cummins E, Waugh N, Walker S, Cook J, Jia X, et al. Systematic review of the clinical 
effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an 
alternative to invasive coronary angiography in the investigation of coronary artery disease. Health 
Technol Assess 2008;12(17) 
Guideline topic:  Key Question No: 
Checklist completed by:  Sigurður Helgason (SH) and Tuija S Ikonen (TSI).  
Section 1:  Internal validity 
In a well conducted systematic review In this study this criterion is:: 
1.1 The study addresses an appropriate and 
clearly focused question. 
 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.2 A description of the methodology used is 
included. 
 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.3 The literature search is sufficiently rigorous 
to identify all the relevant studies. 
 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.4 Study quality is assessed and taken into 
account. 
 
Well covered SH/TSI 
Adequately addressed 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.5 There are enough similarities between the 
studies selected to make combining them 
reasonable. 
Well covered SH 
Adequately addressed TSI 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
SECTION 2:   OVERALL ASSESSMENT OF THE STUDY 
2.1 
How well was the study done to minimise 
bias?  
Code ++, +, or  
++ SH / ++ TSI 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
133 
 
2.2 If coded as +, or  what is the likely direction 
in which bias might affect the study results? 
 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
134 
 
Costs and economic evaluation 
Irina Cleemput ,Cécile Camberlin , Pirjo Räsänen , Victor Sarmiento Gonzàlez-Nieto, Belén 
Corbacho, Torbjørn Wisløff , Kersti Meiesaar 
Introduction  
The interest in the costs and cost-effectiveness of multi-slice computed tomography (MSCT) 
coronary angiography comes from the possible savings from avoiding unnecessary invasive 
coronary angiographies (ICA). If MSCT is used for screening purposes, its aim is to detect 
subclinical atherosclerosis; the idea being that if you can treat such manifestations in an early phase, 
future costs of expensive interventions may be avoided or delayed and the quality and length of life 
may increase. However, these beneficial effects on costs and health effects remain to be proven 
while limitations and potential harms have to be considered. Concerns are the exposure to high-dose 
radiation, the potential of misdiagnosis (false positives), the administration of beta-blockers and the 
injection of iodinated contrast.  
 
Research in this domain aims at finding out the following: ‖Is MSCT angiography a cost-effective 
alternative to standard work-up for the diagnosis and treatment of coronary artery disease in patients 
at low to intermediate risk for cardiovascular events?‖ The comparator in this economic evaluation 
of MSCT is the standard work-up as defined in the clinical trial (5) upon which the economic 
evaluation is based. This trial is frequently cited to demonstrate MSCT‘s cost-effectiveness. There 
is only very little literature on the economics of MSCT in the patient group examined in this HTA. 
This is actually not so surprising given the lack of evidence for the impact of diagnostic procedures 
on patient outcomes in the patient population with low to intermediate risk for cardiovascular 
events. In view of this lack of evidence, one could question the usefulness of a cost-effectiveness 
analysis.  
Methodology  
Literature review 
For the review of the economic literature on MSCT angiography, we searched MEDLINE, Pre-
MEDLINE, EMBASE, EconLit, HTA database and NHSEED. The search was performed between 
November 30th and December 6th, 2007. Search strategies for each database are presented in the 
appendix 2.  
 
The search strategy resulted in 290 unique references across all databases. Two researchers 
independently selected relevant titles and abstract. For references selected by one researcher, but 
not the other, a consensus was sought.  
Inclusion criteria were:  
– population: low to medium risk, non-acute chest pain 
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– intervention: MSCT  
– outcome: avoided invasive procedures (intermediary outcome), quality-adjusted life years 
(QALYs) or simply life years gained (LYG) (final outcome) 
– design: full or partial economic evaluation, cost-outcome description 
Exclusion criteria were  
– focus on EBCT (electron beam computed tomography) or MSCT of less than 64 slices 
– absence of economic information 
– MSCT in high-risk population  
– MSCT in patients with acute chest pain at the emergency department  
– letters, editorials and papers that were not in English  
 
After the first selection round, 53 titles and abstracts were selected for full text retrieval. Scanning 
the full text led to the 50 exclusions. Three studies were retained: Dewey et al. 2007 (3), Otero et al. 
2007 (9) and Goldstein et al. 2007 (5). Three additional studies were identified by handsearching: 
Rubinshtein et al. 2006 (10), Cole et al. 2007 (2) and a primary economic evaluation as part of an 
HTA on MSCT from AETSA 2008 (7). 
 
None of the three studies that were retained for the literature review used final outcome parameters 
in the analysis. Moreover, no single full economic evaluations, including an incremental cost-
effectiveness analysis, were found in literature. Nevertheless, some of these studies are frequently 
cited to demonstrate cost-effectiveness of MSCT. One of these is the RCT of Goldstein et al. (5), 
alongside which economic data were collected. The study provides interesting information on both 
the therapeutic impact of MSCT and outcomes on 6 months follow-up. Unfortunately, however, the 
data have not been fully explored to assess the technology‘s cost-effectiveness relative to standard 
diagnostic care. Because we aim to fully explore the data provided by this work for our economic 
evaluation of MSCT relative to standard of care, we briefly discuss the study of Goldstein et al. (5). 
Economic evaluation 
The economic evaluation was performed according to the methodological guidelines for 
pharmacoeconomic evaluations in Belgium (1). 
 
Design 
For the evaluation of the incremental costs and effects of a diagnostic strategy with MSCT and a 
standard diagnostic strategy in low-risk patients with chest pain, we used the data presented in the 
report of the RCT and economic evaluation of Goldstein et al. (5). Although we are well aware that 
it might be too early to examine the intervention‘s cost-effectiveness given the lack of evidence on 
the utility of diagnostic techniques in the target population, we performed this rudimentary 
economic evaluation mainly for the sake of testing the core HTA model for diagnostic procedures. 
Goldstein et al. (5) performed a RCT of MSCT for the evaluation of acute chest pain.  One hundred 
ninety-seven (197) patients aged 25 years or older, at low risk for coronary events, with no history 
of coronary artery disease (CAD) and presenting at the emergency department with acute chest pain 
were randomized to ―Standard of Care‖ or MSCT. Their ECG at time=0 and time=4 hours were 
normal as well as their serum biomarkers. The standard of care diagnostic protocol to rule out 
myocardial infarction included serial ECG and cardiac enzymes, followed by rest-stress myocardial 
perfusion SPECT imaging before referring home or to catheterization laboratory. The MSCT 
strategy included calcium scoring and angiography, followed by conventional ICA when positive, 
discharge home when normal and by nuclear stress testing when MSCT results are intermediate or 
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inconclusive. Outcomes included number of tests complications, major adverse cardiovascular 
events (death, acute myocardial infarction (AMI), unstable angina), number of correctly diagnosed 
patients and time to diagnosis. A diagnosis was judged correct based on the results of a 
catheterization or the presence or absence of major adverse cardiovascular events during the index 
admission or the 6-month follow-up period. Among the 99 patients following the MSCT arm, 96 
(95%) were correctly diagnosed: 88 without CAD (including 1 readmission for a negative ICA) and 
8 with a positive ICA. Twenty-four (24.2%) had to have a nuclear stress imaging due to non-
diagnostic MSCT and 4 patients had an ICA that turned to be negative. In the emergency 
department setting, MSCT was able to immediately identify or exclude CAD in 75% of cases. No 
test complications or major cardiovascular events were noticed in either arm in the 6-month follow-
up period. Eight patients in each group required a late office or emergency department visit for 
recurrent chest pain. Fewer patients required additional non-invasive evaluations (the protocol was 
not described) in the MSCT than in the ‖Standard of Care‖ arm (2% versus 7%; p=0.10). The 
median time to diagnosis was 3.4 hours in the MSCT arm (25th percentile: 2.3 hours, 75th 
percentile 14.8 hours) versus 15 hours in the ―Standard of Care‖-arm (25th percentile 7.3 hours; 
75th percentile 20.2 hours). As a result from reduced time in the emergency department, costs were 
significantly lower for MSCT patients amounting to $1 586 (25th percentile $1 413; 75th percentile 
to $2 059) against $1 872 for the standard of care arm (25th percentile $1 727; 75th percentile $2 
069).  
 
The authors conclude that MSCT is safe and highly effective to give a correct diagnosis over a 6-
months period. However, MSCT still has limitations in determining the physiological significance 
of intermediate coronary lesions. They warn against a possible oculostenotic reflex, caused by the 
inability of MSCT to provide coronary blood flow data. Further studies are recommended to 
determine the optimal use of MSCT. 
 
Although this study is frequently cited to demonstrate the cost-effectiveness of MSCT, it does not 
strictly satisfy the criteria of a full economic evaluation. No incremental calculations were made, no 
incremental cost-effectiveness ratio (ICER) was calculated and costs were incompletely taken into 
account, e.g. costs of ICA, percutaneous coronary intervention (PCI), coronary artery bypass 
grafting (CABG), or repeated evaluations during follow-up. Costs were calculated based on data 
from the hospital billing department and based on the emergency department‘s cost-to-charge ratio. 
Although not clearly stated in the methods section of the article, the cost-to-charge ratio seems to be 
a cost per hour of use of the emergency department. The authors were contacted to obtain more 
details about the ratio used, but no response to the email was received. Costs of the procedure were 
included (MSCT $507 and nuclear imaging $538). 
  
While the authors are very enthusiastic about MSCT for the evaluation of acute chest pain, it should 
be noted that the number of invasive procedures (ICA, PCI and CABG) is higher in the MSCT-arm 
than in the ―Standard of Care‖-arm, while the outcomes in terms of mortality and morbidity up to 6 
months are not any different between the arms. 
 
Moreover, despite the apparent safety of both strategies (absence of adverse complications), 10% of 
the patients in the MSCT arm had to be radiated twice (MSCT+nuclear testing) and 4% even three 
times (MSCT+nuclear testing+ICA). Iodinated contrast also presents a potential harm in MSCT 
evaluation. Although 8 ICAs out of 12 were positive in the MSCT-arm and only 1 out of 7 in the 
‖Standard of Care‖-arm, this does not necessarily mean anything for the prognosis of the patients 
with a positive ICA.  
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The numbers of patients were too small to evaluate the true incidence of false positive cases and 
false negative cases, especially in a population with a low prevalence. 
 
Although the data from this RCT were directly used for the economic evaluation, we did not use the 
same approach as the authors for the economic analysis. We decided to extrapolate the economic 
results of the study by Goldstein et al. (5) to include the costs of invasive angiography, 
revascularisations and complications up to six months after initial admission to the emergency 
department for acute chest pain. The basic idea is that the cost-effectiveness of MSCT depends not 
only on the costs and effects of the diagnostic strategy, but also the costs and effects of its sequelae, 
i.e. the changes in therapeutic behaviour and the consequent impact on patient outcomes. Therefore, 
it is insufficient to consider only the technique‘s diagnostic accuracy (sensitivity and specificity) in 
an economic evaluation. An economic evaluation should also incorporate the technique‘s effect on 
patients‘ final outcomes (LYG or QALYs gained).   
 
The design of our economic evaluation can be considered as a kind of retrospective piggy-back 
economic evaluation based on a data from one RCT. More specifically, the economic evaluation is 
based on the clinical results and the description of procedures performed in the patients in both 
diagnostic arms of one RCT. Based on these results and descriptions, costs and effects as relevant 
for the economic evaluation were estimated. The construct of the decision tree is entirely based on 
the movements of patients observed in that RCT. In that sense, the decision tree is a limited 
representation of the expected reality, as the number of patients in the RCT was limited and not all 
branches of a more realistic model could be filled with data from the trial. However, with the 
limited data available in literature, it was unfortunately unrealistic to fill a decision tree that 
includes all possible real-life scenarios. 
 
A simple decision tree was constructed in Excel, where the numbers of patients moving from one 
intervention to another were derived directly from the RCT. The structure of the decision tree is 
presented in Appendix 2. 
 
Analytic technique 
Because outcomes in terms of mortality or major cardiovascular events are not different between 
the two diagnostic arms in the study, an analysis of the ―cost-per-LYG‖ based on these data would 
ultimately boil down to a cost-minimisation analysis. However, invasive coronary angiography has 
a demonstrated impact on the quality of life of patients undergoing this procedure (12,13). 
Therefore, it is worth looking at the QALY gains or losses of the two diagnostic work-up paths 
being compared. A cost-utility approach is therefore performed, calculating the incremental cost-
per-QALY gained associated with MSCT as compared to ―Standard of Care‖. 
 
Perspective 
The perspective taken is that of the Belgian health care payer, including both the National Institute 
for Health and Disability Insurance (RIZIV/INAMI) and the patients. For the calculation of the 
costs of the two diagnostic work-up arms, we calculate the total reimbursement by the 
RIZIV/INAMI and add, if applicable, the patients‘ out-of-pocket expenses.  
 
Target population 
The target population of our model is as in the RCT: adult patients with acute chest pain who are 
deemed at low risk for coronary events after an initial work-up in the emergency department (ECG, 
biomarkers). Population characteristics in both groups are presented in Table 1. 
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Table 1: Characteristics of patients included in the economic model 
 
 MSCT  
N=99 
“Standard of Care”  
N=98 
P-value 
Age, mean in yrs 47 50 0.08 
Male, % 43 57 0.05 
Body Mass Index 28 28 0.78 
Hypertension, % 39 38 0.88 
Diabetes, % 8.2 12.2 0.35 
Family history of early coronary 
disease, % 
40 44 0.56 
Current smoker, % 15 20 0.35 
Goldman Riley criteria, % 
0- very low risk 
1- low risk 
2- moderate risk 
 
100 
0 
0 
 
99 
1 
0 
 
1 
 
Comparator 
The comparator to MSCT angiography is the ‖Standard of Care‖ as defined by Goldstein et al.  (5). 
This includes non-invasive coronary tests, i.e. serial ECG and cardiac biomarkers at 0, at 4 and at 8 
hours and rest-stress myocardial perfusion single-photon emission computed tomography imaging. 
Common procedures to both diagnostic arms were the electrocardiograms and cardiac biomarkers at 
0 and at 4 hours. Patients were randomised if both of these were normal. Therefore, the difference 
in primary diagnostic protocol between the ‖intervention‖, i.e. MSCT, and the comparator, i.e. 
‖Standard of Care‖, is one cardiac biomarker and SPECT as part of the initial diagnostic strategy in 
the ‖Standard of Care‖ group. 
 
Costs 
 
Initial diagnostic strategy 
 
The costs of the initial diagnostic strategy were calculated on the basis of the prevailing 
reimbursement tariffs and out-of-pocket expenses of the procedures associated with the strategy. 
 
For MSCT angiography no reimbursement tariff exists (yet). Therefore, we used the reimbursement 
and patients‘ out-of-pocket expenses for ―chest CT― as a proxy for the costs of MSCT angiography 
from the perspective of the Belgian health care payer. Usually other costs are associated with 
procedures than the costs of the procedure itself. For example, when a patient enters an emergency 
department and gets a MSCT angiography after which he is immediately discharged, the hospital 
can charge other costs to the RIZIV/INAMI such as a physician‘s fee.  
 
To identify the resource use, and especially the lump sums a hospital can charge if a patient is either 
discharged the same day after MSCT or ―Standard of Care‖ or is hospitalised for ICA that is 
eventually not followed by an invasive procedure, we presented different scenarios to the 
accounting service of a hospital who then retrieved the actual bill of a patient fitting into the 
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respective scenarios to identify what can be charged in each of the cases. The scenarios presented to 
the hospitals were the following: 
 
– a patient enters the emergency department for chest pain, undergoes a standard diagnostic 
work-up and subsequently a conventional ICA which turns out to be negative  
– a patient enters the emergency department for chest pain, undergoes a diagnostic work-up 
including a chest CT (used as a proxy for MSCT) and a nuclear stress test and is then 
discharged home 
– a patient enters the emergency department for chest pain, undergoes a chest CT and is 
immediately discharged home 
– a patient enters the emergency department for chest pain, undergoes the standard of care, 
including nuclear stress test and is then discharged home 
 
If no bill could be retrieved for an actual patient fitting in one of these scenarios, medical experts 
and accounting services simulated what would be charged in these cases. This was the case for the 
scenarios where a nuclear stress test is performed at the emergency department, on the basis of 
which it would be decided to send the patient home. According to the medical administration, no 
single patient fitted in this scenario according to their register. This would mean that the scenario 
presented in the study by Goldstein et al. (5) might not be realistic in Belgium. Because we 
nevertheless had to calculate a cost for this scenario, as we had to adhere to the diagnostic protocols 
suggested in the trial, we simply added the procedure cost of a radionuclide myocardial perfusion 
scintigraphy (MPS) to the cost of a patient satisfying the other criteria of the scenario where MPS 
was included. 
 
For ICA that is not followed by revascularisation, we obtained a patient bill from one hospital, on 
the basis of which we identified the procedures that are charged in such a case.  
 
Revascularisation: PCI and CABG 
 
The costs of PCI and CABG were derived from a Belgian HTA on drug eluting stents (DES) (8). 
These cost data were based on actually observed cost data of all patients having received a bare 
metal stent (BMS) or DES in 2004 in Belgium. A distinction was made between the costs 
associated with PCI with BMS and PCI with DES and between treatment with one or another stent-
type in diabetic and non-diabetic patients. The distribution of the costs for a hospitalisation episode 
due to PCI and CABG was taken into account in the sensitivity analysis. 
 
Point estimates, along with their distribution used in the sensitivity analysis, are presented in table 
2. 
 
Table 2. Average cost and parameters of the distributions of PCI and CABG in diabetic and non-
diabetic patients 
 
Costs Mean S.E.M. distribution
lower 
bound
upper 
bound source
PCI with stent (BMS) in non-diabetic patients 6298 255 normal 3018 24221 KCE report 66A; www.kce.fgov.be
PCI with stent (DES) in non-diabetic patients 7000 1541 normal 3371 68450 KCE report 66A; www.kce.fgov.be
PCI with stent (BMS) in diabetic patients 7190 773 normal 2118 17444 KCE report 66A; www.kce.fgov.be
PCI with stent (DES) in diabetic patients 7732 770 normal 1836 51591 KCE report 66A; www.kce.fgov.be
CABG in non-diabetic patients 15319 804 normal 7650 56287 KCE report 66A; www.kce.fgov.be
CABG in diabetic patients 17439 2459 normal 8742 52521 KCE report 66A; www.kce.fgov.be  
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From the same HTA, we derived the distribution of BMS and DES across diabetic patients and non-
diabetic patients respectively. The data are as follows: 
 
 
 
 
Outcomes 
The outcomes are valued based on data from literature about the quality of life impairment 
associated with PCI, CABG and ICA. SPECT and MSCT are assumed to have no impact on health-
related quality of life (HRQoL). 
 
Serruys et al. (13) studied HRQoL in 600 patients who had undergone PCI with stenting and 605 
patients having undergone CABG. The instrument was the EuroQol (EQ-5D). EQ-5D health states 
were translated into an index value on a scale from 0 (dead) to 1 (perfect health) based on the UK 
off-the shelf utility values for EQ-5D health states (4). This study found that healthy, on average 60-
year old, patients have a quality of life index of 0.86 (s.d. 0.16). At the time of intervention, patients 
had an index of 0.69 (s.d. 0.20) in case of PCI and 0.68 (s.d. 0.20) in case of CABG. One month 
after the intervention, quality of life values were 0.84 (s.d. 0.16) and 0.78 (s.d. 0.17) for PCI and 
CABG respectively. At six months after the intervention, there was no longer a significant 
difference between the quality of life of patients who had undergone PCI and patients who had 
undergone CABG and both patient groups had already reached the quality of life index of 0.86, 
which is equivalent to baseline values in healthy patients of the same age. 
 
Scuffham and Chaplin (11,12) used these values to calculate the quality of life loss due to PCI and 
CABG in an economic model. They assumed a quality of life loss due to PCI of 0.17 for 1 month, 
which boils down to 5 quality- adjusted life days lost. For CABG, they assumed a quality of life 
loss of 0.18 for one month and 0.08 for the subsequent 2.5 months. This is equivalent to 11.4 
quality adjusted life days lost due to CABG. Other authors have used similar QALY decrements. 
Kuntz et al. (6), for instance, estimated the number of quality-adjusted life days lost due to PCI and 
CABG at 2 and 10 days respectively.  
 
We used the quality of life values and their observed distribution as reported by Serruys et al.  (13) 
to define the number of quality adjusted life days lost. Assumptions had to be made about the 
duration of quality of life impairment due to these procedures as for obvious reasons no continuous 
data are available for quality of life. Similarly to Scuffham and Chaplin (11,12) we assume that the 
baseline values at time of intervention as reported by Serruys et al. (13) hold for one month in case 
of PCI and CABG and that in addition CABG patients suffer from a quality of life reduction of 0.08 
compared to healthy individuals at that age during 2.5 months following the intervention. Unlike 
Scuffham et al. (11,12), however, we take the distributions in observed quality of life values into 
account in our estimates of the variability in quality of life impairment. For angiography without 
PCI we did not find specific utility values. We therefore assumed the same quality of life 
impairment as for PCI, albeit for a shorter period of time, i.e. 0.5 months instead of 1 month. 
 
Diabetic  
patients 
Non-diabetic  
patients 
BMS 21,7% 88,2% 
DES 78,3% 11,8% 
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The quality of life values and their distributions for each of the states, on the basis of which the 
QALY decrements are calculated, are presented in Table 3. 
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Table 3. Distributions of quality of life index values used to calculate the number of quality-
adjusted life days lost 
 
Health 
state 
Duration 
of state 
Quality of 
life index 
values, 
mean 
Standard 
deviation 
Distribution Lower 
bound 
Upper 
bound 
Baseline  0,86 0,16 Normal 0.2 1 
PCI 
procedure 
1 month 0,69 0,2 Normal 0.25 1 
CABG 
procedure 
1 month 0,68 0,2 Normal 0.25 1 
CABG 
follow-up 
2.5 
months 
0,78 0,17 Normal 0.5 1 
 
The impact of symptom relief from revascularisation on HRQoL was not taken into account in our 
economic evaluation because the RCT gave no information on this aspect. 
 
Time horizon 
The time horizon used in the economic model is the one for which data are available from the RCT, 
i.e. from admission to the emergency department up to 6 months follow-up. We assume that longer 
time horizons would not change the results of the economic analysis, because there is insufficient 
proof that early diagnosis of CAD or early revascularisation of CAD in patients with no 
documented ischemia would change lifetime outcomes. 
 
As for the outcomes, we assume that only invasive coronary procedures (ICA, PCI and CABG) 
have an impact on the number QALYs. The absolute difference between the numbers of QALYs in 
both procedures remains therefore de facto the same in extended time periods if the difference in the 
number of invasive procedures remains the same. Obviously, the relative impact of the quality of 
life loss due to the procedures decreases if the time horizon increases. 
 
If the observed trend in the RCT of more revascularisations in the MSCT arm continues in longer 
follow-up periods, the difference between the costs and outcomes of both diagnostic strategies will 
only increase. The RCT is, however, underpowered to allow such hypothesis.  
 
Sensitivity analysis 
Bootstrapping was performed to obtain confidence intervals around the cost and outcome estimates 
in the economic evaluation. 1000 bootstrap samples were drawn from the defined distributions. The 
distributions used in the bootstrapping for cost and outcome variables are presented in the 
paragraphs where the sources and assumptions with respect to the cost and outcome variables are 
discussed. Bootstrapping was performed in @RISK. 
 
We verified the conclusions of Goldstein et al. by calculating the costs of both diagnostic strategies 
up to the point where the decision to perform CCA is taken. Costs of CCA or revascularisation were 
not included. On the basis of this analysis; Goldstein et al. concluded that the MSCT procedure is 
less costly than the ―Standard of Care‖ procedure. Outcomes, however, were not measured in terms 
of QALYs but in terms of ‖time to diagnosis‖, which is, as explained earlier, not relevant for 
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resource allocation decisions in health care. Health care decision makers are interested in obtaining 
the highest improvement in health with a given amount of resources. 
 
Discounting 
Because the time horizon of the evaluation is less than one year, there is no need to discount costs 
and outcomes. 
Assessment elements  
Resource utilization 
What types of resources are used when delivering MSCT and its comparators? 
What amounts of resources are used when delivering MSCT and its 
comparators? 
Results  
Types of resources and volumes of resource use for which no real observational data were available 
are presented in Table 4.  
 
Table 4. Resource for MSCT, standard of care and conventional coronarography  
 
 Both strategies* MSCT diagnostic path Standard diagnostic path 
(standard tests+MPS) 
Conventional 
coronarography 
Procedure fees 2 blood tests 
(cardiac 
biomarkers) 
MSCT procedure  1 additional blood test 
(cardiac biomarkers) 
Coronarography  
 2 ECG  MPS procedure fee  Additional blood tests 
Products  Iodinated contrast  Radio-isotope (1/6 kit 
sestamibi)  
Iodinated contrast  
Physician fees  Radiologist‘s fee  Radiologist‘s fee Radiologist‘s fee 
  Cardiologist‘s fee in ED  Cardiologist‘s fee in ED  Cardiologist‘s fee  
    Surveillance fee per 
hospitalisation day  
Lump sums  1 ―mini lump sum‖ (if 
MSCT scan is not 
followed by 
hospitalisation) 
1 ―mini lump sum‖ (if MPS 
is not followed by 
hospitalisation) 
2 hospitalisation days – per 
diem price 
  Lump sum medical 
imaging  
 Lump sum clinical biology 
per day 
    Lump sum medical imaging 
    Lump sum for hospital 
admission  
* these costs are not taken into account as they are equal between the two strategies. Only incremental 
costs are calculated.  
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The corresponding cost figures for these items are presented in Table 5. The distributions 
mentioned are the ones used for the sensitivity analysis. Distributions are only defined for cost 
items that are variable across hospitals. Other amounts, e.g. those defined in the Belgian 
―nomenclature‖, are deterministic and have hence no distribution. 
 
Table 5. Cost items included in the analyses  
 
 Cost item Mean (RIZIV + Patient) Standard 
deviation 
Distribu
tion 
Lower 
limit  
Upper 
limit 
Procedures Cardiac biomarkers 10.33 (7.75+2.58) -    
 MSCT procedure fee 121.35 (118.87+2.48) -    
 SPECT procedure fee 318.11 (280.93+37.18) -    
 Coronarography 
procedure fee 
484.56 (484.56+0) -    
 Additional blood tests in 
case of ICA 
25.69 
(25.69+0) 
-    
Products Contrast agent MSCT 44.68 (44.68+0) -    
 Radio-isotope SPECT  37.18 (37.18+0) -    
Physician’s 
fees 
Radiologist’s fee  25.96 
(18.52+7.44) 
-    
 Radiologist’s fee (sum 
for all procedures in case 
of ICA) 
39.87 
(33.33+6.54) 
-    
 Cardiologist’s fee in ED 35.25 
(31.18+4.07) 
-    
 Surveillance honorarium 
per hospitalisation day 
24.84 (19.88+4.96) -    
Lump sums Hospital per diem price 20.83 3.61 normal 15.77 42.67 
 “Mini” lump sum 56.39 12.798 normal 41.27 124 
 Lump sum clinical 
biology (per hospital 
admission) 143.92 30.88 normal 94.03 233.17 
 Lump sum clinical 
biology (per day) 
21.89 5.82 normal 11.84 
45.48 
 Lump sum medical 
imaging (per day) 
50.72 12.07 normal 22.13 88.74 
 
For the calculation of the costs of PCI and CABG, there was no need to first identify all resources 
and secondly measure them, as all resources used and their costs were included in the cost figures of 
the national database.    
Unit costs 
What are the unit costs of the resources used when following a diagnostic 
protocol with MSCT and a standard diagnostic protocol? 
Results 
The results of the base-case analysis are presented in Table 6. 
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Table 6. Results of the base-case economic analysis    
 
Diagnostic path Cost per patient, mean 
(95% C.I.) 
QALYs lost per patient, 
mean (95% C.I.) 
MSCT, index 
hospitalisation 
914.92 (875;955) 0.0014 (0;0.004) 
MSCT follow-up 88.55 (83.15;94.49) 0.00014 (0;0.0046) 
Total 1003.48 (959;1047) 0.0016 (0;0.0045) 
Standard of care, 
index hospitalisation 
461.38 (444;484) 0.0003 (0;0.0009) 
Standard of care, 
follow-up 
62.53 (58.63;66.49) 0.00028 (0;0.0009) 
Total 523.91 (505.12;548.03) 0.00056 (0;0.0018) 
 
According to these results the MSCT diagnostic strategy is on average €479.56 more expensive 
than the standard of care strategy.  
Indirect costs 
What is the impact of a diagnostic strategy with MSCT on indirect costs? 
Results 
In the RCT used as a basis for the economic evaluation, more patients in the MSCT arm underwent 
revascularisation than in the ―Standard of Care‖ arm. Revascularisation requires hospitalisation for, 
on average, 3 to 7 (dilatation/stenting, PCI) or 13 to 18 (bypass operation, CABG) days in Belgium 
(https://tct.fgov.be/etct/anonymous?lang=nl; visited on April 10, 2008).  This would imply higher 
indirect costs associated with MSCT. 
 
We have not calculated this impact in monetary terms, as indirect costs are not part of the reference 
case analysis according to the Belgian guidelines for pharmacoeconomic evaluations, which were 
followed in this study (1). Moreover, as it was already clear from the direct cost calculation that 
MSCT is more expensive than ―Standard of Care‖, indirect costs would only add to the cost 
difference between MSCT and ―Standard of Care‖. This is a qualitative conclusion that can be 
drawn, without having to quantify the precise impact on productivity. 
Outcomes/consequences 
What are the incremental effects of a diagnostic protocol with MSCT relative to 
a standard diagnostic procedure? 
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Results 
The economic model based on one RCT and data from literature about HRQoL after invasive 
procedures, showed that MSCT leads to a higher loss in QALYs: 0.0016 QALYs are lost in the 
MSCT as compared to 0.00056 QALYs in the ―Standard of Care‖. This is equivalent to about 6 
hours of life in perfect health more lost in the MSCT arm than in the ICA arm.  
Is the technology cost-effective compared to current procedures? 
What is the incremental cost-effectiveness ratio for MSCT versus standard 
diagnostic procedure? 
Results 
Base-case results 
The costs of MSCT were found to be higher than the costs of the ‖Standard of Care‖. In addition, 
more QALYs were lost with MSCT than with the ‖Standard of Care‖, although this difference (6 
hours) can be considered negligible. Therefore, we conclude that for this patient population, the 
diagnostic strategy with MSCT is dominated by the ―Standard of Care‖. 
  
Sensitivity analysis 
We tested the primary results of Goldstein et al. (5) and found that both the costs of the MSCT and 
the ―Standard of Care― diagnostic strategy are lower if the costs of ICA during the index 
hospitalization and the costs of late diagnostic testing and revascularizations are not included in the 
cost estimates. The corresponding costs per patient for both diagnostic arms in Belgium are 
presented in Table 7. 
 
Table 7. Average cost of MSCT and “Standard of Care” when cost of invasive interventions is 
not included  
 
 Cost per patient (€) QALYs per patient 
MSCT 347.71 (331;370) 0 
Standard of care  383.26 (366;406) 0 
 
In this case, costs of the strategy with MSCT are indeed lower than the costs of the standard of care 
strategy. Because in this scenario the model stops right before the decision to do an ICA is made 
and because no quality of life loss is assumed due to nuclear stress testing or MSCT, the number of 
QALYs is the same in both diagnostic arms.  
Discussion 
Our economic model, based on observed data from one RCT, showed that the total costs of MSCT 
angiography in patients at low or intermediate risk for coronary events and no documented ischemia 
are higher than the ―Standard of Care‖, defined as 3 cardiac biomarker tests (at 0, 4 and 8 hours), 2 
ECGs and nuclear stress testing. The outcomes of the diagnostic strategy with MSCT as a filter for 
nuclear stress testing, i.e. only patients with intermediate or inconclusive MSCT test results undergo 
a nuclear stress test, are worse than the outcomes of the standard of care strategy. Because more 
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patients in the MSCT arm undergo revascularisation, and revascularisation impacts on HRQoL, this 
result is not surprising.   
 
Goldstein et al. (5), however, did not reach the same conclusion, mainly because they stopped their 
costing procedure when the decision to do an invasive angiography was taken. Their endpoint, 
therefore, was an intermediate one. The relevance of it can be questioned in general but especially 
in this patient population. The general argument against the use of intermediate endpoints in 
economic evaluation is that they are not relevant for the policy maker or the patient. The policy 
maker is interested in how he can obtain the highest health benefit at a given cost. The patient is 
interested in how he can obtain the highest health benefit. The fact of reaching more or less quickly 
a decision to do an ICA is not relevant if eventually this has no impact on final outcomes such as 
LYG or QALYs gained. 
 
The results of our economic evaluation only pertain to the diagnostic and treatment path followed 
by actual patients observed in the trial and to the period of observation in the trial. The advantage of 
this approach is that no assumptions have to be made about the future events and interventions, 
thereby reducing the uncertainty of the results. The disadvantage of the approach, however, is that it 
also introduces a level of uncertainty in the sense that it is uncertain to what extent the results would 
hold if larger patient populations were treated. The patient numbers in each health state were too 
small to reliably estimate transition probabilities and make the model more generic. For instance, 
none of the patients in the ―Standard of Care‖-arm who underwent a late ICA were revascularised. 
This might be a coincidence due to the small number of patients undergoing a late ICA. The RCT 
was not powered to detect such potential relevant differences. In real life, with very large patient 
numbers, the situation might be different, and some patients might undergo revascularisation if late 
ICA is positive.  To increase the generalisability of the results, more data on the long-term 
consequences of both diagnostic interventions would be needed (need for revascularisation, AMI, 
death). Data from larger data sets would allow us to define transition probabilities and hence build a 
more generic model. 
 
As far as the limited duration of the trial, and consequently the economic model is concerned, we 
know from the clinical literature review that the prognosis of patients who present with atypical 
chest pain is generally good. Early intervention in patients with CAD but no documented ischemia 
diagnosed by MSCT angiography does not necessarily improve long-term outcomes in these 
patients.  
 
We conclude that there is no economic rational for using MSCT angiography in low-risk patients 
with atypical chest pain.  
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Assessment elements table 
ID Domain Topic Issue Relevance in 
the context of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
Or Comment (if regarded as a not relevant issue in this context) 
      
      
E0001 Costs and 
economic 
evaluation 
Resource utilization  What types of resources are used when delivering the assessed 
technology and its comparators?  
 
Yes What types of resources are used when following a diagnostic strategy that includes 
MSCT as a filter for nuclear stress testing and what types of resources are used when 
following a standard diagnostic protocol?  
 
E0002 Costs and 
economic 
evaluation 
Resource utilization What amounts of resources are used when delivering the assessed 
technology and its comparators? 
Yes What amounts of resources are used when following a diagnostic strategy that 
includes MSCT as a filter for nuclear stress testing versus a standard diagnostic 
protocol?  
 
E0003 Costs and 
economic 
evaluation 
Unit costs What are the unit costs of the resources used when delivering the 
assessed technology and its comparators? 
Yes What are the unit costs of the resources used when following a diagnostic protocol 
with MSCT and a standard diagnostic protocol? 
E0004 Costs and 
economic 
evaluation 
Indirect Costs What is the impact of the technology on indirect costs? 
 
Yes What is the impact of a diagnostic strategy with MSCT on indirect costs? 
E0005 Costs and 
economic 
evaluation 
Outcomes/consequences What are the incremental effects of the technology relative to its 
comparator(s)? 
Yes What are the incremental effects of a diagnostic protocol with MSCT relative to a 
standard diagnostic protocol? 
E0006 Costs and 
economic 
evaluation 
Is the technology cost-effective 
when compared to current 
procedures? 
What is the incremental cost-effectiveness ratio? Yes What is the incremental cost-effectiveness ratio of MSCT angiography compared to a 
”standard of care” diagnostic procedure that includes nuclear stress testing and 3 
cardiac biomaker assays? 
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Appendix 1: Search strategy for literature review 
Embase  
 
Date of search: 06.12.2007 
Number of hits: 51 (for entire strategy) 
No.  Query Results                                          Results  Date 
#1.  'computer assisted tomography'/exp                     278,698  06 Dec 2007 
#2.  'multidetector computed tomography'/exp                  2,507  06 Dec 2007 
#3.  'angiocardiography'/exp                                 48,033  06 Dec 2007 
#4.  coronary AND ('angiography'/exp OR 'angiography')       52,937  06 Dec 2007 
#5.  'computed tomographic angiography'/exp                   3,011  06 Dec 2007 
#6.  computed AND tomographic AND ('angiography'/exp OR       5,125  06 Dec 2007 
      'angiography')                                    
#7.  coronary AND ('artery'/exp OR arter*)                  249,531  06 Dec 2007 
#8.  coronary AND ('vessel'/exp OR vessel*)                  47,812  06 Dec 2007 
#9.  mdct* OR msct* OR multi*row* OR multi*detect* OR m       7,439  06 Dec 2007 
     ulti*spiral* OR multi*slice*                       
#10. ((#3 AND (#7 OR #8)) OR #4)                             52,937  06 Dec 2007 
#11. (#2 OR ((#1 OR #5 OR #6) AND #9))                        5,779  06 Dec 2007 
#12. #10 AND #11                                              1,111  06 Dec 2007 
#13. 'coronary artery bypass graft'/exp OR cabg OR (cor      56,110  06 Dec 2007 
     on* AND by*pass)                                   
#14. 'calcium'/exp OR 'artery calcification'/exp OR 'ca     556,705  06 Dec 2007 
     lcinosis'/exp OR calci*                            
#15. 'coronary stent'/exp OR 'drug eluting stent'/exp O      50,257  06 Dec 2007 
     R stent*                                           
#17. 'ischemic heart disease'/exp OR (ischemi* OR myoca     859,250  06 Dec 2007 
     rd* OR arteriosclero* OR ('angina'/exp AND pectori 
     s) OR ((('chest'/exp OR thora*) AND 'pain'/exp) OR 
      'thorax pain'/exp) OR atherom* OR coronar* OR ste 
     no*) OR 'coronary artery disease'/exp              
#18. #13 OR #14 OR #15 OR #17                             1,383,870  06 Dec 2007 
#19. #12 AND #18                                              1,111  06 Dec 2007 
#22. 'clinical trial'/exp OR 'clinical trial' OR random   1,052,965  06 Dec 2007 
     * OR rct* OR cohort* OR 'cohort analysis'/exp      
#23. 'diagnostic accuracy'/exp OR 'sensitivity and spec     185,276  06 Dec 2007 
     ificity'/exp                                       
#24. #22 AND #23                                             26,805  06 Dec 2007 
#25. #19 AND #24                                                 86  06 Dec 2007 
#26. #25 AND [humans]/lim AND [2000-2007]/py                     85  06 Dec 2007 
#27. (((fiscal:ab,ti,de OR financial:ab,ti,de OR financ     608,245  06 Dec 2007 
     e:ab,ti,de OR funding:ab,ti,de) OR ((variable*:ab, 
     ti,de OR unit*:ab,ti,de OR estimate*:ab,ti,de) AND 
      cost*:ab,ti,de) OR ('socioeconomics'/ OR 'cost be 
     nefit analysis'/ OR 'cost effectiveness analysis'/ 
      OR 'cost of illness'/ OR 'cost control'/ OR 'econ 
     omic aspect'/ OR 'financial management'/ OR 'healt 
     h care cost'/ OR 'health care financing'/ OR 'heal 
     th economics'/ OR 'hospital cost'/ OR 'cost minimi 
     zation analysis'/)) OR ('economic evaluation'/ OR  
     'cost'/ OR 'reimbursement'/ OR 'cost utility analy 
     sis'/ OR 'drug cost'/ OR 'energy cost'/ OR 'hospit 
     al cost'/ OR 'hospital running cost'/ OR 'biomedic 
     al technology assessment'/))                       
#28. #26 AND #27                                                  8  06 Dec 2007 
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#29. #28 AND [embase]/lim AND [2000-2007]/py AND [2000-           8  06 Dec 2007 
     2007]/py                                           
#30. #19 AND #27                                                 59  06 Dec 2007 
#31. #30 AND [humans]/lim AND [embase]/lim AND [2000-20          51  06 Dec 2007 
     07]/py                                             
 
CRD: HTA(13), NHS-EED(7), DARE (6) 
Date of search: 06.12.2007 
Number of hits: 26 (for entire strategy) HTA(13), NHS-EED(7), DARE (6) 
 
Search history 
 
   Search Matching records  
 
# 1 MSCTA OR MSCT OR MDCT OR MDCTA      14  
# 2 CT OR "compute tomograph*" OR CTA      843  
# 3 multi*detector* OR multi*row* OR multi*slice* OR multi*spiral*   24  
# 4 #2 AND #3       24  
# 5 #4 OR #1       31  
# 6 #4 OR #1 RESTRICT YR 2000 2007     26  
 
Econlit(Ovid) 
Date of search: 06.12.2007 
Coverage period database: 1969 to November 2007 
Number of hits: 15 (for entire strategy)  
 
# Search History Results 
1 
(MSCT$ or MDCT$ or CTA or multi$slice$ or multi$detector$ or multi$row$ 
or multi$spiral$).mp. [mp=heading words, abstract, title, country as subject] 
15  
 
Ovid MEDLINE(R)  
Date of search: 30.11.2007 
Coverage period database: 1950-November, week 2, 2007.  
Number of hits: 215 (for entire strategy) 
 
 
1     exp tomography, x-ray computed/ or multi-slice computed tomography.mp. (191800) 
2     (mdct or msct or ((multi$row$ or multi$detect$ or multi$spiral$ or multi$slice$) and 
((compute$ and tomograph) or ct))).mp. (3695) 
3     1 or 2 (192051) 
4     exp coronary angiography/ (32102) 
5     (coronar$ and angiograp$).mp. (49714) 
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6     exp coronary vessels/ (38297) 
7     (coronar$ and (vessel$ or arter$)).mp. (173752) 
8     exp myocardial ischemia/ (273633) 
9     (myocard$ or ischemi$ or arteriosclero$ or angina pectoris or chest pain or atherom$).mp. 
(579065) 
10     (calcium or calcinos$ or calcification$).mp. (412807) 
11     exp stents/ or stent$.mp. (37840) 
12     exp coronary artery bypass/ or cabg.mp. or by$pass.mp.  (86191) 
13     exp coronary stenosis/ or stenos$.mp.  (115427) 
14     or/3-6 (269182) 
15     or/7-12 (1109590) 
16     3 and 14 and 15 (20105) 
17     limit 16 to humans (19529) 
18     limit 17 to yr="2000 - 2007" (9908) 
19     clinical trial$.mp. or clinical trial.pt. or random$.mp. or RCT.mp. or exp *cohort studies/  
(858660) 
20     exp *"sensitivity and specificity"/ (1496) 
21     18 and 19 and 20 (0) 
22     (price$ or pricing$).mp. (14212) 
23     ec.fs. (235528) 
24     cost$.tw. (200524) 
25     exp "Costs and Cost Analysis"/ (133793) 
26     22 or 23 or 24 or 25 (396432) 
27     21 and 26 (0) 
28     18 and 26 (215) 
 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations  
 
Date of search: 3.12.2007  
Coverage period database: November 30, 2007 
Number of hits: 0/4/59 
 
 
1     (MDCT or MSCT or ((multi$row$ or multi$detect$ or multi$spiral$ or multi$slice$) and 
((compute$ and tomograph$) or CT))).tw. (416) 
2     (coronar$ and angiograp$).tw. (758) 
3     (coronar$ and (vessel$ or arter$)).tw. (3097) 
4     2 or 3 (3246) 
5     (myocard$ or ischemi$ or arteriosclero$ or angina pectoris or chest pain or atherom$).tw. 
(7296) 
6     (calcium or calcinos$ or calcification$).tw. (5231) 
7     stent$.tw. (1453) 
8     (CABG or by$pass).tw. (1923) 
9     stenos$.tw. (1728) 
10     5 or 6 or 7 or 8 or 9 (15777) 
11     1 and 4 and 10 (59) 
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12     (clinical trial$ or random$ or RCT or cohort).tw. (25267) 
13     11 and 12 (4) 
14     (price$ or pricing).tw. (543) 
15     econom$.tw. (3696) 
16     cost$.tw. (7752) 
17     14 or 15 or 16 (10872) 
18     11 and 17 (4) 
 
 
 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
154 
 
Appendix 2: Structure of the decision tree for the economic model 
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Ethics 
Pietro Refolo, Dario Sacchini, Marco Marchetti,  Ilona Autti-Rämö, Samuli Saarni, 
Dagmar Lühmann, Bjørn Hofmann, Marcial Velasco Garrido 
Introduction 
Ethical analysis within an HTA aims at analyzing the moral questions raised by the technology 
itself and by the implications of implementing or not implementing a health technology, as well as 
ethical issues that are inherent in the HTA process. In principle, this may be accomplished by 
systematically eliciting the values which are placed on a technology and its implementation by 
different stakeholders. This can be done either through conducting own primary research or through 
literature and document analysis. These different values are then analyzed for congruency and 
compatibility with each other as well as with prevalent morals in the respective societies. The 
results of the analyses should be integrated into the overall conclusions of the HTA report in such a 
way that they are helpful for decision-making. 
 
Ideally, ethical analysis should not consider only the use or non-use of one technology in a specific 
setting from the ethical viewpoint, but rather accompany and advise the whole HTA process from 
prioritizing topics, defining research questions, choosing the methodology to summarizing results 
and drawing conclusions. 
 
Once the importance of ethical analyses is admitted, the question of how to integrate ethics in HTA 
reports raises. In fact, ethical evaluations can be conducted very differently depending on the 
resources in the HTA organization, the technology in question and, above all, the research 
methodology.  
 
Ethical analysis is built into the HTA Core Model on two levels. The more general inclusion of 
ethical considerations in the whole HTA process is presented in the chapter "Introduction". It 
emphasizes the somewhat different nature of ethics as a domain within HTA. The results of more 
practical reflection on the consequences and implications of the use of a technology are recorded in 
the assessment elements.  
In the ethical analysis domain of the Core Model the assessment elements represent a standard set 
of questions, based primarily on the work of Hofmann (2005). This set – that has been also used for 
the MSCT coronary angiography – is suggested to guide value analysis referring to the technology 
and its implementation as well as discussing compatibility and congruency with prevalent societal 
moral values. 
Methodology 
The description of the stakeholder perspectives and the completion of the assessment elements are 
performed by using information from the ongoing assessment as well as data from the published 
literature. Primary sources, e.g. information from patients and patient organizations, is vital for 
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assessments, but for time and resource reasons there was no opportunity to elicit primary 
information (e.g. patients perspectives on outcomes used in clinical trials) for this assessment. 
Literature searches 
A three-part literature search was applied: 
1. Database searches for articles relating to multi-slice computed tomography (MSCT) coronary 
angiography. The searches were performed in three well known databases: PubMed, EMBASE and 
Euroethics. A search strategy constructed combing the words ―ethics‖ (AND) ―MSCT coronary 
angiography‖ yielded not a single paper. Consequently the present ethical analysis has been carried 
out relying on information provided in „general― articles on MSCT coronary angiography. 
2. Additional references were taken from reference lists of retrieved publications as well as from 
recently published journal articles. 
3. Additional searches combining the general search terminology for ―multislice CT‖ supplied by 
Finohta with terms derived from the ethical issues were performed in the unfiltered PubMed 
database as well as the PubMed ―bioethics subset‖. The additional searches are documented in 
Appendix 1. 
Information selection 
The studies that have been considered eligible are those published in English language from January 
2002 to December 2007, in which there was an empirical assessment of MSCT coronary 
angiography with at least 16 slices in patients presenting mild and stable symptoms of chest pain 
with low or moderate risk for coronary artery disease.  
Assessment of study / publication quality 
No assessment of methodological study quality was undertaken. 
Assessment elements 
Principal questions about the ethical aspects of technology 
Is MSCT coronary angiography a new, innovative mode of care, an "add on" to 
a standard mode of care, intended as a triage to other tests or a replacement of a 
standard? 
Results 
MSCT coronary angiography is emerging as a non-invasive clinically reliable diagnostic tool to 
detect coronary stenosis. It is an imaging method that generates a three-dimensional image of the 
coronary vessels from a series of two-dimensional computerized tomography images. The scan, 
equipped with 8-, 10-, 16-, 32-, or 64-slices, consists of a CT angiography of the thorax 
characterized by a retrospective synchronization technique based on the ECG, that is recorded 
simultaneously with the MSCT scan. The vascular enhancement is obtained by means of 
administration of a bolus of iodinated contrast material (CM), through an antecubital vein (100-140 
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ml of CM 300-400 mgI/ml at 4 ml/s). The development of MSCT is still in progress. It started with 
4-slice CT. Currently 320-slice CT is being introduced. Imaging of cardiac vessels is clinically 
challenging due to continuous motion during cardiac cycle.  
 
The anatomical visualization provided by MSCT differs from the one of conventional coronary 
angiography because it is not a simple ―lumenology― but it is capable to provide information on the 
vessel wall and on neighbouring structures, which until now can only be achieved by invasive 
techniques such as intravascular ultrasound or optical coherence tomography. 
 
A preliminary note with regard to its clinical applications is that patients who have risk factors for 
coronary artery disease (CAD), stable symptoms of chest pain, no previous history of myocardial 
infarction, and ECG not pointing at acute ischemia are usually referred to exercise ECG. Positive 
finding in exercise ECG is usually sufficient to determine the diagnosis of coronary artery disease 
and initiation of medication. If the diagnosis remains open, MSCT is proposed as a non-invasive 
alternative to invasive coronary angiography. Negative findings on MSCT obviate invasive 
angiography, but those with positive MSCT findings (i.e., significant stenosis) would still need to 
be confirmed by invasive coronary angiography. 
 
Further, with regard to patients where exercise ECG is not feasible e.g. patients unable to move 
their legs, MSCT can be a replacement test to determine the diagnosis of and treatment for CAD.  
Finally, MSCT has also been proposed as an additional non-invasive cardiac test that may be 
complementary to other non-invasive tests currently available (e.g., stress tests) (Hoffmann et al. 
2006). 
 
Can MSCT coronary angiography challenge religious, cultural or moral 
convictions or beliefs of some groups or change current social arrangements? 
Results 
MSCT coronary angiography seems not to impose challenges to religious, cultural or moral 
convictions, or to the beliefs of some groups, or to changes of current social arrangements. 
 
What can be the hidden or unintended consequences of MSCT coronary 
angiography and its applications for different stakeholders? 
Results 
The intended use (in whom, how, with what benefits / harms to expect) of MSCT coronary 
angiography is specified by manufacturers and through documents (safety data, trial results) 
required and accepted as prerequisite for market approval by regulatory bodies (see technology 
description). Nevertheless, MSCT requires a higher exposure of the patient to ionizing radiation 
than with other radiological techniques. Although the long-term risks associated with radiation 
exposure from single examinations are relatively low, it raises a concern about repetitive and 
unnecessary use on patients and risks for radiologists and other staff. Unnecessary exposure of 
tissue (as part of a necessary examination) can also be a consequence of widespread use of the 
method. So far the optimal candidates are not yet determined. It may even be regarded as a 
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possibility to rule out cardiac disease in people with no clinical symptoms as has occurred with the 
marketing of whole body MRI. 
 
The information provided by MSCT is not limited to the coronary vessels. Anomalies in other 
structures (e.g. pulmonary nodules, aortic anomalies, etc) can be incidentally discovered in an 
MSCT. These findings may prompt a diagnostic chain including more invasive manoeuvres. This is 
especially problematic for patients as well as for the treating physicians since the clinical relevance 
of such incidental findings without clinical manifestations can be unclear. 
  
The use of MSCT for triple rule-out of myocardial infarction, pulmonary embolism and aortic 
dissection in patients with chest pain at the emergency department has also been suggested, which 
would widen the use of MSCT and place it close to emergency units. 
 
Questions about effectiveness and accuracy 
What are the proper end-points for assessment of MSCT coronary angiography 
and how should they be investigated? 
Results 
The ultimate end-point for diagnostic tests is patient outcome and societal efficacy (Fryback and 
Thornbury 1990). If there are no studies showing results on this area, assessment of therapeutic 
efficacy in combination with results on diagnostic thinking efficacy and diagnostic accuracy 
efficacy may be acceptable. The latter are especially suitable in situations where the technology is 
intended to completely replace an existing one taking its place in a well established diagnostic 
chain. In contrary, in such situations where the technology adds to an existing diagnostic chain, its 
value should be assessed relying on patient outcomes. It is also important to notice that ―even high-
quality diagnostic imaging may be non-contributory in certain instances, and radiology of lesser 
quality may be of great value in others.‖ Therefore it is important that if such lower level efficacy is 
accepted as end-points, further study has to be promoted in order to find evidence on the ―hard 
endpoints‖  (Fryback and Thornbury 1990:89). 
 
Are the accuracy measures of MSCT coronary angiography decided and 
balanced on a transparent and acceptable way? 
Results 
See accuracy domain. 
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Autonomy 
Does the implementation or use of MSCT coronary angiography challenge 
patient autonomy? 
Results 
It is important to highlight that MSCT adds to diagnostic imaging technologies as ECG, invasive 
coronary angiography (ICA), etc. Typical patients present mild and stable symptoms of chest pain 
and are not suffering from an acute pathology – therefore, their decision making capabilities should 
not be (severely) compromised. Still, some characteristics of MSCT in comparison to other 
investigative technologies may be difficult to understand. Consequently, patients must be 
thoroughly informed of them in order to make an informed decision for or against the use of MSCT. 
 
The main points to consider are: 
1. MSCT is a non-invasive procedure but compared to ICA, it does not offer the possibility to treat 
the discovered pathologies in the same session (interventions of myocardial revascularization). 
2. The effective radiation dose of a contrast enhanced cardiac CT scan is 5-20 mSv. In comparison, 
diagnostic ICA has a mean effective radiation dose of 2–7 mSv . Consequently, patients must be 
informed that – even if still extremely low – the risk of inducing cancer is higher for MSCT 
coronary angiography than that for ICA. See more details in the safety domain. 
3. The vascular enhancement is obtained by means of administration of a bolus of iodinated contrast 
material, through an antecubital vein. Iodinated contrast media are generally safe. Nevertheless, 
they can occasionally cause allergic reactions and renal failure. Allergic reactions are usually mild 
but may progress to life-threatening situations (0,02-0,04%) (See safety domain). Contrast-induced 
nephropathy (CIN) is a serious complication of the use of iodinated contrast media and it is 
especially related to some pre-existing risk factors. 
4. Drugs are used in many procedures in order to achieve better image quality: ß-blockers to lower 
the heart rate and short-acting nitro-glycerine preparations to improve the visualisation of coronary 
artery lumen. Special attention must be given to patients for which ß-blockers and nitrates are 
contraindicated. It is to be evaluated whether the potential serious adverse effects caused by these 
drugs could interfere with their decision making capabilities. 
5. Besides the injection of iodinated contrast material, the breath hold is also necessary to visualize 
the coronary artery lumen. Therefore, it is important to prepare the patient for the sensations 
experienced from the injection of the contrast agent and to perform repeated test breath holds. This 
is an element that could interfere with their autonomy. 
6. MSCT may produce incidental findings from adjacent structures, which still do not explain the 
symptoms which lead to the diagnostic work-up of coronary artery disease (CAD), e.g. a pulmonary 
or a lymph node. Such an incidental finding may put the patient and the clinician in the need of 
clarifying its clinical relevancy. Diagnostic work-up of incidental findings may require invasive 
investigations. This is problematic since incidental findings do not relate to the original motive of 
consultation but often force the patient into an additional diagnostic work-up with all its 
consequences. In such situations, there is a risk of ―labelling‖ the patient with an additional 
condition until the incidental finding have been clarified (e.g. if a node is incidentally found a 
patient may get a ―cancer‖ label until it has been ruled-out, with all its implications for the patient 
such as anxiety, etc.). When something truly pathological is found, (e.g. in fact malignant cells), the 
patient would be referred to aggressive treatments. The problem is that the true meaning of 
incidental findings is not known. In the worst case, someone would have been treated for something 
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which in his/her lifetime would have not had any clinical relevancy had it been not incidentally 
discovered. This is a problem that has been discussed e.g. in the context of prostate cancer 
screening. 
7. Finally, it should be considered that even if patients are provided with sufficient information on 
procedures, possible benefits and risks, they may not be able to understand the information in the 
situation they are in. On the other hand, informed consent can be used in radiology, not only to 
respect and promote patients autonomy, but also for other less patient oriented purposes, such as 
judicial, economic and responsibility-reduction (Hofmann et al 2008).  
 
Is MSCT coronary angiography used for patients/people that are especially 
vulnerable?  
Results 
In this context ―vulnerability‖ means that patients in the situation of treatment have not the full 
capabilities of decision-making, due to critical illness, age (children) or mental disturbances.  
In this assessment we concentrate on the use of the MSCT angiography in patients presenting mild 
and stable symptoms of chest pain with low or moderate risk for coronary artery disease, so there is 
no direct issue on decision-making capabilities concerning consenting to this treatment. In cardiac 
MSCT, radiation is targeted at chest, therefore subjecting females to high organ doses of the breast, 
The lifetime excessive risk of breast and lung cancer for girls and young women after single MSCT 
is much higher than for individuals aged 55 years or older, recently estimated at 1.75-5.5% after a 
single scan (see Safety domain).  
 
Can MSCT coronary angiography entail special challenges/risk that the 
patient/person needs to be informed of?  
Results 
For a description of formal requirements of an ―informed consent‖ procedure see legal domain. 
Risk assessment is particularly complex because certain negative outcomes are apparent 
immediately whereas others are manifest only years later (such as the statistical risk of cancer 
induction). With regard to immediate risks, MSCT is absolutely contraindicated in subjects who 
have hypersensitivity to iodinated contrast agent. Relative contraindications exist with respect to 
conditions that are known to limit diagnostic image quality: history of allergies or allergic reactions 
to other medications; renal insufficiency (serum creatinine level of  > 1.5 mg/dL), congestive heart 
failure, history of thromboembolic disorders, multiple myeloma, hyperthyroidism, 
pheochromocytoma, atrial fibrillation, inability to perform breath hold for 15 s (Hoffmann et al. 
2006). 
 
Further, sublingual administration of short-acting nitro-glycerine (2 tablets, equal to 0.8 mg) 
immediately before a scan has been used sometime to improve the visualization of the coronary 
artery lumen. Current data on the effects of nitro-glycerine in MSCT coronary angiography are not 
available. Case-control studies are warranted to establish the benefits of the use of nitro-glycerine, 
which include improved visualization of the coronary arteries, especially in women, subjects with 
diabetes, and subjects with hypertension. Nitro-glycerine is contraindicated in subjects taking 
phosphodiesterase inhibitors, such as sildenafil or vardenafil, and in subjects with hypersensitivity 
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to organic nitrates, increased intracranial pressure, symptomatic hypotension, and severe anaemia 
(Hoffmann et al., 2006).  
 
Risks that manifest only later are very difficult to assess. To estimate the practically immeasurable 
risk of cancer from low-level radiation, various mathematical models are required to extrapolate 
dose-risk data from highly exposed populations. Currently, a linear relationship between dose and 
risk is used in the risk model for low-level exposures. For example, for any individual aged 55 years 
or older, lifetime risk of developing cancer after a single MSCT cardiac exam is low and ,generally, is 
considered to be below 1.0 %. In the study of Coles it is estimated that the risk of inducing a fatal cancer 
is 0,07 % for MSCT and 0,02 % for invasive coronary angiography (ICA) (See safety domain). 
Recently published data (Abdulla et al. 2007, Dewey et al., 2008) suggest that the effective 
radiation dose of MSCT coronary angiography is higher in the examination of women than of men, 
mainly as a result of the fact that the radiosensitive female breast is in the x-ray path. Therefore, it 
can be observed that the radiation risk of MSCT coronary angiography would need to be weighed 
especially in female patient (See safety domain). 
 
Finally, there are some risks related to diagnostic accuracy of MSCT coronary angiography. In 
general, the studies have demonstrated the high degree of  accuracy of 64-slice MSCT in the 
detection of significant stenosis in smaller coronary artery segments and side branches. A high 
negative predictive value suggests that there is a good probability that 64-slice MDCT rules out the 
presence of hemodynamically significant CAD. The probability is high, but it is not complete. 
Consequently, there may be risks in terms of delay of diagnostic decisions making. See more details 
in the safety domain. 
Does the implementation of MSCT challenge or change professional values, 
ethics or traditional roles? 
Results 
The anatomy of the heart and coronary arteries does not constitute a main backbone of the 
knowledge and daily clinical practice of the radiologist. Cardiac imaging has been until now 
remitted to cardiologists, and it is still not a daily radiology practice. So, radiologists and 
cardiologists must try working together in order to ensure safe and effective care. Furthermore, 
there is potential for conflicts derived from the expansion of one of the professions and reduction of 
the other. This can be for example problematic in fee-for-service systems, where the two 
professions would compete for the same patients. In the worst case, this can lead to unnecessary 
duplication of investigations. 
 
Another challenge is posed by the problem of ―self-referral‖, when the referring physician has a 
financial interest in the health care institution he or she is referring to. In the context of MSCT the 
problem of self-referral is especially of concern within the cardiologist profession, when the 
cardiologist is at the same time the owner of the CT equipment. A few approaches have been 
suggested to safe-guard against unethical self-referral: a) the use of evidence-based guidelines; b) 
physician and laboratory credentialing; c) periodic case conferences; d) oversight/reviews 
processes; e) consultation with other providers; f) full disclosure/ transparency and discussions with 
patients regarding alternatives, including an option for a second opinion (Wann et al., 2007) 
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Human dignity 
Does the implementation or use of MSCT coronary angiography affect human 
dignity? 
Results 
Human dignity is affected if a certain technology exposes patients to unbalanced risks. MSCT 
coronary angiography seems not to impose such challenges.  
 
Human integrity 
Does the implementation or use of MSCT coronary angiography affect human 
integrity? 
Results 
MSCT coronary angiography seems not to impose such challenges.  
 
Beneficence/ nonmaleficence 
What are the benefits and harms for patients, and what is the balance between 
the benefits and harms when implementing and when not implementing MSCT 
coronary angiography?  Who will balance the risks and benefits in practice and 
how? 
Results 
Harms of MSCT have been discussed in more detail in other assessment elements within this 
domain. On the other hand, MSCT has several benefits for patients over conventional angiography, 
including: volumetric acquisition, which permits visualization of the anatomy from multiple angles 
and in multiple planes after a single acquisition; improved visualization of soft tissues and other 
adjacent anatomic structures; less invasiveness and thus fewer complications. Benefits of CT 
angiography over magnetic resonance imaging (MRI) include wider availability of scanners, higher 
spatial resolution, absence of flow-related phenomena that may distort MRI images, and the 
capability to visualize calcification and metallic implants such as endovascular stents or stent grafts. 
In summary, there is currently no other diagnostic method that could totally replace it in the 
diagnostic chain or could as such be nominated as the reference test (see accuracy domain). 
Nevertheless, not everyone agree that the net health outcome is favourable. For example, the 
Technology Evaluation Center (2005) – an American center that has pioneered the development of 
scientific criteria for assessing medical technologies through comprehensive reviews of clinical 
evidence – thinks that ―The evidence is insufficient to determine whether the use of MSCT 
improves net health outcome or whether it is as beneficial as any established alternatives‖. In 
general, major doubts are related to the fact that all potential clinical applications are uncertain and 
data on cost-effectiveness are scarce.  
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Can MSCT coronary angiography harm any other stakeholders? What are the 
potential benefits and harms for other stakeholders, what is the balance between 
them? Who will balance the risks and benefits in practice and how? 
Results 
Besides patients, the relevant stakeholder groups that may directly or indirectly be affected from the 
use of MSCT coronary angiography are care providers, the professionals, payers, and 
manufacturers. Due to time limitations, in this assessment we concentrate on the benefits of some 
relevant stakeholder groups. 
 
Providers (hospitals etc.) 
Implementing MSCT coronary angiography requires extra financial resources. How high these extra 
costs are, and by whom they are borne, depends on the regulation of the hospital financing systems 
in the respective countries. In fee-for-service systems MSCT might offer the chance for extra profits 
for care providers, whereas in systems with flat rate hospital financing the provision of MSCT 
might impose extra costs on health care providers (e. g. Kearney et al., 2006). Taking into 
consideration the high value that is put on technically advanced, ―cutting edge‖ medical technology 
by patients as well as by society it is attractive for providers to advertise that patients receive the 
most innovative care in their facilities. 
 
Professionals 
MSCT coronary angiography is a very recent technique, so it is difficult to know if MSCT is 
accepted by physicians. We report here the opinions of professionals' associations. 
According to American College of Cardiology Foundation (ACCF) (Hendel et al., 2006) MSCT is 
appropriate  
– for the detection of coronary artery disease (CAD) in symptomatic patients and evaluation 
of chest pain syndrome in intermediate pre-test probability of CAD and if ECG is 
uninterpretable or the patient is unable to exercise; 
– for the evaluation of intracardiac structures, if there is a suspicion of coronary anomalies; 
– for assessing cardiac morphology in complex congenital heart diseases, including anomalies 
of coronary circulation, great vessels, and cardiac chambers and valves; and in patients with 
new onset heart failure to assess aetiology. 
The American Heart Association (AHA) published a scientific statement on assessment of CAD by 
cardiac computed tomography in October 2006 (Budoff et al., 2006). The recommendations specific 
to MSCT include: 
– CT coronary angiography is appropriate for the assessment of obstructive disease in 
symptomatic patients; 
– Imaging of patients for monitoring stent placement cannot be recommended; 
– There is no data on the prognostic implications of MSCT for non-calcified plaque (NCP) 
assessment; therefore, its use for this purpose is not recommended. 
 
Manufacturers 
MSCT scanners were introduced in 1998 with the release of 4-slice CT scanners. In 2004, 64-slice 
CT scanners were introduced. All major CT manufacturers offer 64-slice CT scanners, such as: 
AADCO Medical Inc, Analogic Corp, Anexa Corp, Beekley Corp, Composites Horizons Inc, 
Covidien (formerly Tyco Healthcare Mallinckrodt), DeJarnette Research Systems Inc, Eizo Nanao, 
Technologies Inc, Gamma Medica-Ideas, GE Healthcare, Hitachi Medical Systems America Inc, 
Imaging3 Inc, MEDRAD Inc, Mercury Computer Systems Inc, NeuroLogica Corp, Philips Medical 
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Systems, R2 Technology Inc, a Hologic Co, Siemens Medical Solutions USA Inc, Thinking 
Systems Corp, Toshiba America Medical Systems, Unfors. MSCT has revived CT technology that 
was on the edge of being out-phased. 
Justice and Equity 
What are the consequences of implementing / not implementing MSCT coronary 
angiography on justice in the health care system? (Are principles of fairness, 
justness and solidarity respected?) 
Results 
This question warrants at least two types of considerations: 
The medical one is concerned with the principle that technologies should be supplied to those who 
are in need of them in order to improve health. This concept of „need for a technology― implies that 
there is evidence, that use of the technology offers a net benefit (meaning that benefit outweighs 
harms), also in comparison to other available modes of care. Taken into consideration current 
knowledge, it is unclear whether benefits outweigh harms in the context of MSCT coronary 
angiography. Up to now, an evidence-based decision whether a particular patient or a group of 
patients „need― or does not need MSCT coronary angiography can not be made. Taking into 
consideration the widespread development of MSCT coronary angiography the question arises 
whether for the implementation of MSCT fairness, justness and solidarity could also mean to 
efficiently protect patients in whom harm might outweigh possible benefits from receiving the 
technology. 
 
If future evidence will be able to determine a patient group that is clearly in need of MSCT, 
economic considerations might impair the principles of fairness, justness and solidarity. The price 
of MSCT is generally high (see also costs and economic evaluation domain). Who carries these 
extra costs depends on the reimbursement regulation of the respective countries. Taking into 
consideration the limited availability of resources for the health care sector it will be mandatory to 
implement transparent and fair allocation procedures for the technology. 
How are technologies presenting with similar (ethical) problems as MSCT 
coronary angiography treated in the health care sector? 
Results 
The main moral problems around MSCT result from two types of considerations: the first is that it 
is unclear whether net harm or net benefit will result from its implementation. For new technologies 
in some health care systems (e. g. Interventional Procedures Program, NICE, UK; Switzerland) it is 
an established procedure that: 
1. the technology may only be applied under ―monitoring conditions‖, which could involve a 
clinical trial or establishment of a registry. It seems worthwhile to note here that the monitoring 
condition should preferably be set up independent of funding from manufacturers in order to avoid 
conflicts of interests should unfavourable results arise. 
2. implementation of an innovative technology requires thorough explanation of its developmental 
status as well as the scope of possible benefits and harms to the patients.  
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The second consideration is that MSCT involves risks related to radiation exposure. To assess 
technologies with this type of risks in some countries, practical guidelines have been published.  
Rights 
Does the implementation or use of MSCT coronary angiography affect the 
realisation of basic human rights?  
Results 
In the context of health care mainly the following human rights issues apply: 
– The human right to the highest attainable standard of physical and mental health, including 
reproductive and sexual health.  
– The human right to equal access to adequate health care and health-related services, 
regardless of sex, race, or other status. 
(The People's Movement for Human Rights Education; http://www.pdhre.org/rights/health.html) 
 
The ―adequacy‖ of applying MSCT in different patient groups has been discussed in other 
assessment elements (benefits and harms for patients) as well as aspects of distributive justice. 
Using MSCT coronary angiography seems not to affect the realisation of basic human rights.  
Nevertheless, recently published data (Dewey et al., 2008) suggest that the effective radiation dose 
of MSCT coronary angiography is higher in the examination of women than men, mainly as a result 
of the fact that the radiosensitive female breast is in the x-ray path. This aspect should also be taken 
into consideration when establishing criteria/guidelines for the implementation of MSCT (to avoid 
favouring men, since they are less exposed to this specific risk and to avoid unnecessary risks for 
women).  
Legislation 
Is legislation and regulation to use MSCT coronary angiography fair and 
adequate?  
Results 
European Union directions do not include specific instructions for issues directly linked to MSCT 
technology, such as authorisation, patents/licenses, price and reimbursement regulations, product 
safety, guarantee and liability. They regulate the market of health technologies in a more general 
fashion (i.e. through CE certification for new technologies). See also legal domain.  
  
The use of ionising radiation in medical imaging procedures is regulated by European law. There 
are quality criteria for operation, exposure, radiation protection and image quality (Bongartz, et Al. 
2004). In many countries though, the fulfilment of the European law is lacking.  From ethical point 
of view, the legislation seems not to be fully efficient to protect the best interest of the patients at 
the moment.  
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Assessment elements table 
 
ID Domain Topic  Issue  Relevance 
in the 
context of 
MSCT 
Yes/No 
Research Question in the context of DES 
      
F0001 Ethical aspects Principal questions 
about the ethical 
aspects of technology  
Is the technology a new, innovative mode of care, an "add on" to a 
standard mode of care or a replacement of a standard? 
Yes Is MSCT coronary angiography a new, innovative mode of 
care, an "add on" to a standard mode of care or a replacement 
of a standard? 
F0002 Ethical aspects Principal questions 
about the ethical 
aspects of technology  
Can the technology challenge religious, cultural or moral convictions 
or beliefs of some groups or change current social arrangements? 
No Can MSCT coronary angiography challenge religious, 
cultural or moral convictions or beliefs of some groups or 
change current social arrangements? 
F0003 Ethical aspects Principal questions 
about the ethical 
aspects of technology 
What can be the hidden or unintended consequences of the technology 
and its applications for different stakeholders? 
Yes What can be the hidden or unintended consequences of 
MSCT coronary angiography and its applications for 
different stakeholders? 
F0017 Ethical aspects Questions about 
effectiveness and 
accuracy 
What are the proper end-points for assessment and how should they 
be investigated? 
Yes What are the proper end-points for assessment of MSCT 
coronary angiography and how should they be investigated? 
F0018 Ethical aspects Questions about 
effectiveness and 
accuracy 
Are the accuracy measures decided and balanced on a transparent and 
acceptable way? 
Yes Are the accuracy measures of MSCT coronary angiography 
decided and balanced on a transparent and acceptable way? 
F0004 Ethical aspects Autonomy Does the implementation or use of the technology challenge patient 
autonomy? 
(Yes) Does the implementation or use of MSCT coronary 
angiography challenge patient autonomy? 
F0005 Ethical aspects Autonomy Is the technology used for patients/people that are especially 
vulnerable? 
No Is MSCT coronary angiography used for patients/people that 
are especially vulnerable?  
F0006 Ethical aspects Autonomy Can the technology entail special challenges/risk that the 
patient/person needs to be informed of? 
Yes Can MSCT coronary angiography entail special 
challenges/risk that the patient/person needs to be informed 
of?  
F0007 Ethical aspects Autonomy Does the implementation challenge or change professional values, 
ethics or traditional roles? 
Yes Does the implementation of MSCT challenge or change 
professional values, ethics or traditional roles? 
F0008 Ethical aspects Human Dignity Does the implementation or use of the technology affect human No Does the implementation or use of MSCT coronary 
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dignity? angiography affect human dignity? 
F0009 Ethical aspects Human integrity Does the implementation or use of the technology affect human 
integrity? 
No Does the implementation or use of MSCT coronary 
angiography affect human integrity? 
F0010 Ethical aspects Beneficence/ 
nonmaleficence 
What are the benefits and harms for patients, and what is the balance 
between the benefits and harms when implementing and when not 
implementing the technology?  Who will balance the risks and benefits 
in practice and how? 
Yes What are the benefits and harms for patients, and what is the 
balance between the benefits and harms when implementing 
and when not implementing MSCT coronary angiography?  
Who will balance the risks and benefits in practice and how? 
F0011 Ethical aspects Beneficence/ 
nonmaleficence 
Can the technology harm any of the other stakeholders? What are the 
potential benefits and harms for other stakeholders, what is the balance 
between them? Who will balance the risks and benefits in practice and 
how? 
Yes Can MSCT coronary angiography harm any other 
stakeholders? What are the potential benefits and harms for 
other stakeholders, what is the balance between them? Who 
will balance the risks and benefits in practice and how? 
F0012 Ethical aspects Justice and Equity What are the consequences of implementing / not implementing the 
technology on justice in the health care system? Are principles of 
fairness, justness and solidarity respected? 
Yes What are the consequences of implementing / not 
implementing MSCT coronary angiography on justice in the 
health care system? (Are principles of fairness, justness and 
solidarity respected?) 
F0013 Ethical aspects Justice and Equity How are technologies presenting with similar (ethical) problems 
treated in health care system? 
Yes How are technologies presenting with similar (ethical) 
problems as MSCT coronary angiography treated in the 
health care sector? 
F0014 Ethical aspects  Rights Does the implementation or use of the technology affect the realisation 
of basic human rights? 
No Does the implementation or use of MSCT coronary 
angiography affect the realisation of basic human rights?  
F0016 Ethical aspects Legislation Is legislation and regulation to use the technology fair and adequate?  Is legislation and regulation to use MSCT coronary 
angiography fair and adequate?  
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Appendix 1: Additional search strategies 
 
Search within 1250 Hits from Pubmed, using the basic search on MSCT: 
 
Connector Field  Terminology Results 
 Keywords Informed Consent 21 
OR Keywords Jurisprudence 22 
OR All non-indexed text fields ethic\* OR moral\* OR justice OR autonomy OR 
beneficience OR beneficence 
22 
OR All non-indexed text fields {burden\*benefit ratio } OR {burden benefit ratio} 
OR {fact value distinction\*} OR {facts and 
values} OR {patient preference\*} OR {valule 
based} OR {value judgement\*} OR {norm\*} OR 
{normative} OR {non-malfeasance} OR 
{nonmalfeasance} 
180 
OR All non-indexed text fields {benefit AND harm} OR {technology-driven} OR 
{technology driven} OR {normative effective\*} 
180 
OR All non-indexed text fields {fairness} OR {equity} OR {access AND care} 180 
OR All non-indexed text fields {innovation\*} OR {triage\*} 211 
OR All non-indexed text fields {cultural} OR {conviction\*} OR {religion\*} OR 
{belief} OR {ideology} OR {philosophy} 
211 
OR All non-indexed text fields {family} OR {famili\*} OR {relatives} OR 
{stigma} OR {label} OR {adverse event\*} OR 
{adverse effect\*} 
237 
OR All non-indexed text fields {autonomy} OR {informed consent} OR {false 
positiv\*} OR {false negativ\*} OR {counseling} 
259 
OR All non-indexed text fields {dignity } OR {human integrity} OR {human 
right\*} 
259 
OR All non-indexed text fields {resource allocation} OR {solidar\*} OR 
{fairness} OR {justness} OR {equity} OR 
{availability} OR {access} 
283 
OR All non-indexed text fields {legislation } OR {regulation} OR {legal*} 289 
 
Search within the bioethics subset of PubMed: 
 
Number Query Results 
1 ((((("Coronary Angiography"[Mesh])) AND (("Tomography, X-Ray 
Computed"[Mesh])))) OR ((angiograph* AND tomograph*))) AND 
((bioethics[sb]) ) 
36 
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Organisational Domain 
Marco Marchetti, Mirella Corio, Carmen Furno, Marco Oradei, Matteo Ruggeri, 
Ulla Saalasti-Koskinen, Tuija Ikonen, Camilla Palmhøj Nielsen, Americo Cicchetti 
Introduction  
The research within the organisational domain aims at finding out what types of resources (material 
things, human skills and knowledge, money, etc) must be mobilised and organised when 
implementing a new technology, and what kinds of changes or consequences the use can cause in 
an organisation. In this Core HTA the new technology is multi-slice computed tomography (MSCT) 
and the objective is to assess the organizational effects of the introduction of a 64-slice-MSCT in 
coronary angiography compared to the conventional invasive coronary angiography as a golden 
standard for coronary artery disease (CAD).  
 
MSCT can have the potential to reduce the number of invasive coronary angiographies. It can also 
have other possible consequences in the management pathway of CAD. Still, from an 
organizational point of view, the introduction of  MSCT does not induce major new changes in 
management.  
Methodology  
Organisational aspects are rarely analyzed within clinical studies and HTA reports, so the analysis 
required several activities. A systematic review of the literature was crucial but not enough to 
answer the research questions of this domain. In an initial search no relevant scientific evidence was 
found. To complement our search, we reviewed also grey literature using a commonly used web 
search engine (Google) and consulted websites of manufacturers, regulatory agencies, and health 
technology assessment agencies. Since organisational aspects are strictly linked to their own 
contexts, it is useful to integrate results with the experience of local experts in this area. 
 
Strict PICO-framing (Patient, Intervention, Control, Outcome) is often not pertinent in the issues of 
organisational domain, neither from the view point of data retrieval nor reporting. Organisational 
features of an imaging modality are not strictly linked to a particular technology or patient 
population. Rather, they are similar over a wider range of similar technologies (here imaging 
technologies using radiation) and across indications and patient populations. Rarely a device like 
MSCT is purchased only for the management of cardiac patients. If MSCT is available, it is used 
for all possible patient groups and indications. Therefore, evidence of organisational features of 
imaging other anatomical areas, or another cardiac conditions than coronary artery disease, may be 
equally relevant for this assessment. In this Core HTA we recognise the framing used in other 
domains. The PICO framing for organisational domain would be thus: P=patients with a suspicion 
of CAD and low to moderate risk for CAD; I=management pathway with MSCT; C=management 
pathway without MSCT; O= correctly treated patient. In some issues we use broader scope and 
include other issues than strictly in the PICO.   
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Literature search: 
Published literature was obtained by searching Ovid MEDLINE, CINAHL (Cumulative Index to 
Nursing & Allied Health Literature), and CRD Database (DARE, NHS, EED, HTA).  
 
Basic searches for the Core HTA on coronary MSCT have been done by information specialist 
Jaana Isojärvi in Finohta by utilising general terms to define the technology and disease. The search 
strategy is available as an appendix in the General design chapter. Additional literature searches 
were performed by adding domain-specific key words in the search strategy.  
Selection criteria and method: 
A study was eligible for inclusion if it met each of the following inclusion criteria: 
 
– Included patients with coronary artery disease; 
– Analyzed and reported results of any of the following organizational topics: utilization, 
work processes, (de)centralization, staff, cooperation and communication, finances, 
management and controlling, stakeholders. 
 
A total of 115 studies were identified. Two reviewers independently selected the relevant studies by 
reading the abstracts. A study was included if it provided useful information to answer the research 
questions. We identified 41 papers. Figure 1 shows a QUORUM flowchart1 of study selection.  
 
Figure 1: Selection of studies for inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality assessment 
Quality assessment criteria for clinical studies are not pertinent in the investigation of 
organizational aspects. We are currently not aware of suitable quality criteria for articles looking at 
health care organisation.  
Potential studies 
identified from search 
 
115 
Excluded:  
 
74 not relevant for topics investigated 
in the organizational domain 
Selected studies 
 
41 
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Assessment elements  
Process 
What kind of work flow and patient flow processes is needed when 
implementing MSCT? 
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. Semi-structured interviews to a clinician in staff at an Italian 
university hospital were performed. 
Results 
MSCT could have a crucial role as a diagnostic tool where findings of preliminary conventional 
tests (ECG, exercise ECG, stress test) show an intermediate probability of coronary artery disease 
(CAD) or are uninterpretable or the tests are not possible to perform. These patients could be 
referred to MSCT instead of directly undergoing to coronary angiography. Introduction of MSCT 
means an additional step in the diagnostic part of the management chain. The potential of MSCT to 
reliably rule out CAD could reduce the number of invasive coronary angiographies (ICA). If MSCT 
will replace a significant percentage of them, the ICAs will be performed only as interventional 
procedure and not more as a diagnostic test (5). Evidence shows that MSCT allows a faster 
diagnosis for CAD compared to conventional ICA. This may have a significant impact on the work 
flows because of the possibility to reduce length of stay, costs and work charges (2). 
 
MSCT coronary angiography could be used also for those low risk patients in whom invasive 
coronary angiography is not indicated. In that group MSCT could affect the treatment or prognosis 
if it resulted in improved allocation of preventive medications and life style changes.  
 
It has been also pointed out that MSCT-CA (MSCT coronary angiography) could have a potential 
role in the management of patients with severe CAD (Acute Coronary Syndrome - ACS). Patients 
with ACS and STEMI (ST-segment elevation myocardial infarction) are referred for primary PCI 
(percutaneous coronary intervention). If referred for thrombolysis, and this is successful, MSCT-CA 
could be performed to assess extent and severity of CAD which may be useful for further patient-
management or prognosis. In patients with UA/NSTEMI (unstable angina/non-ST-segment 
elevation myocardial infarction) MSCT-CA could be used to assess the extent and severity of CAD 
which may be useful for clinical decision making for medical treatment, PCI or CABG (coronary 
artery bypass grafting) (3).  
 
The introduction of MSCT changes hospitals work flows as new departments are involved in the 
patients‘ management path. The MSCT scan must be analyzed by a radiologists; this implies new 
procedures which involve a close collaboration between cardiologist and radiologist. The resulting 
interdisciplinary cooperation will likely affect current practice patterns.  
 
MSCT coronary angiography practices require a more customized examination with more 
cooperation between referring clinician and reading physician than in traditional CT practices and 
in angiography laboratories where a smaller number of examinations are performed by a physician 
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who is directly involved in clinical decision making. It will also impact on current models of 
training (4).  
Comment 
MSCT has the potential to change the organization of treatment of several diseases, including CAD 
which is the focus of this Core HTA. The rapid technical development of CT requires constant 
adaptation of acquisition protocols. 
What kind of patient and relative involvement in treatment or care has to be 
mobilized when implementing MSCT? 
Methods 
Analysis of selected studies extracted from the literature review. We found additional information 
by internet search of grey literature. 
Results 
A study (6) shows that performing MSCT scan requires a collaborative behaviour and cooperation 
with the patient. Before the scanning process, the patients should perform multiple breath-holding 
exercises. They improve the capability of the patients to hold breath for longer times and make 
them familiar with the scanning procedure resulting in decreased anxiety.  
 
The patients should refrain from eating four hours before the procedure; otherwise, they may have 
nausea after the contrast material administration. In addition, they must void their bladder before the 
examination to prevent increased heart rates associated with anxiety over a full bladder. 
 
Compliance of the patients is best achieved when all information about the procedure, the risks and 
advantages of the test is given to them. A clear explanation of the technology and brief clinical 
information is essential. Possible heat sensation caused by the injection of the contrast medium is 
worth to be explained, as well as the side effects caused by the premedication be used. The patient 
should know how important it is for the image quality to stay still throughout the image acquisition. 
What kind of changes can the implementation of MSCT generate in the quality 
of care? 
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. 
Results 
The available data support the notion that MSCT coronary angiography may be an alternative to 
invasive coronary angiography in symptomatic patients with a low to intermediate likelihood of 
having coronary artery disease. The introduction of MSCT can have the potential to reduce the 
number of invasive coronary angiography. This could improve the health care process in terms of 
quality.  
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We have considered the Joint Commission's, an organization committed in improving quality and 
safety in heath care, definition for quality (7). Performing MSCT scan doesn‘t affect all the 
dimensions of quality. The Appropriateness and effectiveness dimensions could be most likely 
affected by the introduction of MSCT, because it allows avoiding unnecessary examination.  
Moreover, MSCT can affect the Efficiency dimension because it allows a decrease of hospital stay, 
procedure time and costs. Finally, performing MSCT scan may improve the safety: the contrast 
complications and radiation exposure related to MSCT (8) seem to be smaller than the rare but 
severe risks from an invasive procedure (death, stroke, bleeding, infection).  See Table 1 
 
Table 1 
 
 CT coronary angiography Invasive coronary angiography 
Hospital stay 1 hour Usually at least 4 to 5 hours, 
including the time before the 
procedure and bed rest after 
procedure 
Procedure time <5 minutes Roughly 1 hour including patient 
preparation time but not including 
recovery area stay 
Cost Around $2,000 Around $10,000 or more 
Risk of procedure Very small: related to contrast 
medium and radiation exposure 
Small: anyway there is a 
probability of death, stroke, 
bleeding, infection and contrast 
related complications 
  
Table adapted from Schussler J.M. et al. Computed tomographic coronary angiography: experience 
at Baylor University Medical Center/Baylor Jack and Jane Hamilton Heart and Vascular Hospital. 
BUMC PROCEEDINGS 2005;18:228-233. 
What kind of staff, training and other human resources is required when using 
MSCT?  
Methods 
Analysis of selected studies extracted from the literature review. Systematic review using Pubmed 
with the following keywords: ―Ct angiography‖ and ―training‖. Additional information was found 
by internet search of grey literature. 
Results 
Computed tomography (CT) is one of the most rapidly evolving techniques for assessing 
cardiovascular anatomy. Multidisciplinary teams of specialists from radiology, cardiovascular 
medicine, and cardiothoracic surgery are best suited to lead the clinical and scientific evaluation of 
non-invasive coronary imaging with MSCT. The complex nature of the imaging devices and 
anatomy as well as the rapidly advancing uses of these modalities requires the trainee to be 
introduced to this modality (9).  
 
Since MSCT coronary angiography is a multidisciplinary procedure it may best 
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be interpreted jointly by cardiologists and radiologists. Some radiologists may lack the clinical 
experience to interpret the findings in the setting of a specific clinical scenario. Conversely, 
cardiologists may be unfamiliar with the interpretation of CT images, especially if extra-cardiac 
structures are included despite a field of view limited to the heart (10).  The appropriate approach to 
MSCT coronary angiography would be a team that includes multiple skills of individuals trained in 
radiology and in cardiology (11). 
 
Table 1 General training needs and strengths of cardiologists and radiologists 
 CARDIOLOGIST RADIOLOGIST 
N
E
E
D
S
 
 Increased knowledge of CT operations, 
CT components, CT physics, and image 
formation 
 Concepts of gating CT cardiovascular 
studies and retrospective reconstruction 
 Radiation safety review  Review of 3D cardiac anatomy 
 Understanding of contrast kinetics, 
administration and safety 
 Understanding of clinical implications of 
technology (i.e. where it fits in) 
S
T
R
E
N
G
H
T
S
  Understanding of cardiovascular testing 
modalities in clinical practice 
 Understanding of CT operation, image 
formation, and radiation safety  
 Detailed knowledge of how cardiac 
findings will impact care 
 Comfort with review of CT images and 
workstations 
 Understanding 3D cardiac structure  Understanding of contrast administration 
and dynamics 
  
Table adapted from Tony De France, Cardiac CT angiography training picks up steam. Diagnostic 
Imaging, 2006 (12) .  
 
The American College of Cardiology (ACC)/AHA developed recommendations for attaining and 
maintaining the minimum experience, cognitive and technical skills necessary for the competent 
performance of cardiovascular CT (13). They are: 
 
– General                                                                                              
o Physics of CT and radiation generation and exposure 
o Scanning principles and scanning modes for noncontrast- and contrast-enhanced 
vascular imaging 
o Principles of intravenous iodinated contrast administration for safe and optimal 
vascular imaging 
o Prevention, recognition, and treatment of adverse reactions to iodinated contrast 
o Prevention, recognition, and treatment of adverse reactions to ß-blockers‘ 
administration  
o Principles of image post-processing and appropriate applications 
 
– Cardiovascular anatomy, physiology and pathophysiology 
– Cardiovascular pathology 
– Symptoms and signs of diseases related to cardiovascular pathology 
 
 
For appropriate use of this technology, it is possible to define three levels of expertise (9). All 
cardiology fellows must attain at least the first level of expertise.  
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– Level 1: This entails understanding the basic principles, indications, applications, and 
technical limitations of CT and the interrelation of this technique with other diagnostic 
methods. During cumulative 4-week training, a trainee should be actively involved in 
Cardiovascular Computed Tomography (CCT) interpretation under the direction of a 
qualified (preferably Level 3-trained) physician-mentor. There should be a mentored 
interpretative experience of at least 50 cases.  This level will not qualify a trainee to perform 
CT or to interpret CT independently. 
– Level 2 is defined as the minimum recommended training for a person to independently 
perform and interpret CCT. To accomplish this, he/she should devote an additional 1 month, 
interpreting a minimum of 150 contrast studies. The non-contrast and contrast studies may 
be evaluated in the same patients. Of these, at least 35 cases should be performed under 
appropriate supervision. Competence at this level implies that the person is sufficiently 
experienced to interpret the CT examination accurately and independently. Continued 
exposure to special CT procedures such as hybrid studies with nuclear imaging and 
integration of images into electrophysiologic procedures is appropriate during Level 2 
training. 
– Level 3 of expertise would enable the trainee to direct a CT laboratory. A total of 6 months 
of training is required, with an additional 6 months experience that can be obtained 
concurrently with training in other imaging modalities. To attain Level 3, candidates should 
be involved with interpretation of at least 100 non-contrast and 300 contrast CCT 
examinations. For at least 100 of these cases, the candidate must be physically present and 
be involved in the acquisition and interpretation of the case. 
 
As is true for many other procedures, a minimum number of cases are necessary to ensure 
continued proficiency in quality of care. Maintenance of vascular CT expertise requires both 
ongoing Continuing Medical Education (CME) and regular performance and interpretation of 
cardiovascular CT examinations. Physicians should periodically attend postgraduate courses and 
workshops that focus on cardiovascular CT, especially those that emphasize new and evolving 
techniques and developments. In addition, physicians should seek to compare the quality, 
completeness, and results of their own examinations with those presented at scientific meetings and 
in professional publications. A minimum of 50 examinations per year is recommended in order to 
maintain the physician‘s skills (13).  
 
The British Cardiovascular Society working group highlighted that there is undoubtedly a need for 
consultants to be trained in non-invasive cardiac imaging (5). Professional groups need to develop 
new training curricula that might be open to trainees from both cardiology and radiology 
backgrounds. Since the complementary expertise cardiology and radiology teams bring to 
Cardiovascular magnetic resonance (CMR) and Multi detector computed tomography (MDCT), it 
was recommended, wherever possible and depending on local circumstances, that there should be 
training available to both cardiology and radiology physicians who aim to become experts in the 
field, and this should be organised through close collaboration between cardiology and radiology 
consultants who have specialist expertise in these modalities. The training curriculum for specialist 
registrars (SpRs) is being revised to increase the profile of non-invasive imaging. Regional training 
schemes are clearly defined and focused imaging modules throughout SpR training. A final module 
in cardiac imaging is recommended for all those who have decided this is their career path and 
should be offered in all units training SpRs. A curriculum for such a final year is considered 
essential, but should be flexible and regularly reviewed in what is likely to be an area of rapid 
change (5).  
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What kind of co-ordination and communication of activities does MSCT 
require?  
Methods 
Analysis of selected studies extracted from the literature review. We found additional information 
by internet search of grey literature. 
Results 
Performing and evaluating coronary MSCT will need the implementation of an integrated process 
involving different units of the organization, clinical actors and stakeholders. An integrated process 
of care presumes the standardization of coordination and communication mechanisms among the 
different actors. MSCT involves different medical specialties, imaging scientists, and manufacturers 
of MSCT systems. Multidisciplinary teams of specialists from radiology, cardiovascular medicine, 
and cardiothoracic surgery are best suited to lead the clinical and scientific evaluation of non-
invasive coronary imaging with MSCT. Interdisciplinary cooperation will likely affect current 
practice patterns. Modern practices require a more customized examination with more cooperation 
between referring clinician and reading physician than in traditional CT practices and in 
angiography laboratories (4).  
 
It is also important taking into account the communication with patients. There is the clinical 
priority to provide patients (and often their relatives) with adequate information about the proposed 
procedure, in order to let them appropriately decide whether to be submitted the procedure or not. It 
is crucial that they understand the whole procedure and the risks involved, as well as all the other 
options available to be cured. Patient should be provided with a full information set; the entire 
clinical path should be explained as well as the single procedure of MSCT diagnosis.  
 
According to the Council Directive 97/43/Euratom, 30 June 1997, informed consent needs to be 
received for performing MSCT (14). The format designed by several institutions from different 
countries entitles that the doctor explains to the patient his/her medical conditions and the procedure 
to follow, in order to make the patient aware of the risks involved (linked to the contrast agent 
administration, radiation exposure and ß-blocker administration) and also the possible other 
diagnostic options and their risks. Radiologists should cooperate with cardiologists in order to avoid 
any possible lack of information as well as any possible replication or conflicting information. The 
referring physician should also inform the patients about the test procedure in order to increase the 
patients‘ comfort and reduce anxiety. 
 
The manufactures of MSCT have developed a protocol regarding patient preparation. The protocol 
is available on the Internet (15).  
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Structure 
What consequences will MSCT have for decentralisation or centralisation? 
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. 
Results 
Literature search did not allow to focus the analysis on patients with suspected CAD and low to 
moderate risk of the disease. Rather, information on organizational impact of the introduction of 
MSCT is referred generally. The choice between centralization or decentralization is dependent on 
the specific uses of MSCT. 
 
According to Loewinger and Budoff (16),  MSCT could be utilized in emergency department 
setting as a possible 'triple rule-out' for myocardial infarction, pulmonary embolus, and aortic 
dissection, improving efficiency and efficacy. In terms of centralization/decentralization decision it 
could mean that MSCT facilities are suitable for hospitals with emergency department. Also 
Hoffman et al 2006 (17) underlined that MSCT-based detection of significant coronary stenoses, in 
emergency department setting, has the potential to decrease the number of unnecessary hospital 
admissions, without reducing appropriate admission rates. Another study (18) suggests the use of 
MSCT also in risk assessment of CAD, so that primary preventive strategies could be performed 
more selectively and cost-effectively. 
 
Probably, at the moment, there is no clear trade-off between centralization and decentralization,  
Clinical (epidemiological and medical) reasons could suggest a wider extension of the use of 
MSCT. According to Gani et al (19), there has been increasing interest in MSCT recently, 
especially with the advent of 64-slice CT. On the other hand, costs constraint has prevenedt a wide 
distribution of MSCT in hospitals, even if Gaylord  asserts that the costs would be affordable even 
to smaller hospitals (20). However there is still no quantitative evidence on the amount and on the 
value of these potential savings that decentralization could bring (21). 
What kinds of investments are needed (materials or premises) when introducing 
MSCT?  
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. A semi-structured interview with purchase managers was 
performed. 
Results 
The standard technological equipment to perform coronary CTA (Computed Tomography 
Angiography) should comprise (22):  
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Specification 64-Slice scanner 
Tube current (mAs) 500–950 
Tube voltage (kV)  120–140 
Tube rotation time (ms)  375–500 
Temporal resolution (ms)  165–210 
Slice collimation (mm) 0.5–0.6 
Scan length (s)  6–13 
Contrast dose (mL)  50–80 
 
Table adapted from 23 Udo Hoffmann et al. Coronary CT Angiography. J Nucl Med 2006; 47:797–
806. 
 
Some authors have stated that the equipment standards required for MSCT coronary angiography 
comprise a multi-detector CT scanner capable of creating a minimum of 64 slices per gantry 
rotation (24) include:  
– ECG: Interface with CT system for the acquisition - prospective and retrospective 
reconstruction   
– Angiographic automatic injector for contrast media  
o Dual-syringe  
o Automatic, programmable  
o Interface with CT system for the synchronisation between  bolus injection and scan 
o High pressure infusion line, 18-20G cannula 
o Maximum flow ≥ 5ml/sec 
– Workstation for reconstruction (6,23,8,25,26,27,28,29,30,31,32,33,34,35,36)    
o The type of software depends on the kind of analysis needed to perform: MIP, MPR, 
VR (Volume Rendering), CPR (Curve Planar reformation), advanced tools of 
vascular tests, calcium scoring, etc. 
o DICOM 
 
– Availability of the RIS-PACS system for the electronic recording of the test scans and image 
reconstruction. The system is strongly advised although it does not  determine the 
performance of the technology.   
 
Introduction of MSCT coronary angiography in a health care organization involves high costs 
related to the purchasing investment and to the utilization in the routinely clinical practice. 
Decisions have differed by organizations, depending on their clinical goals, business strategy, local 
market conditions, PACS readiness and progressiveness of their cardiac programs. In the table 
below, a list of costs have been reported in order to measure the economic impact of MSCT 
introduction.   
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Item Cost (€) 
Purchase of the MSCT scanner* 1,100,000 
Construction and installation** 40,000 
Radiation screen* 200,000 
Electricity requirements per month** 1,200 
Maintenance and service per year** 100,000 
  
* Information collected through semi structured interview with purchase managers 
**Data from 
30
 (Marc Dewey et al. Noninvasive Detection of Coronary Artery Stenoses 
with Multislice Computed Tomography or Magnetic Resonance Imaging. Ann Intern 
Med. 2006;145:407-415).  
 
 
The cost of personnel varies in different countries according to the national labour market 
regulations. It is very unlikely that any centre could justify the installation of a dedicated cardiac CT 
scanner. The provision of MSCT would be best achieved through shared cardiac time on scanners 
being used for current (albeit expanding) radiological indications. It is essential though that all new 
CT scanner installations have a cardiac capability (5).  
 
In conclusion, introducing MSCT into clinical practice means significant investment that only few 
centres can afford. The costs of the investment will influence the diffusion of the technology in the 
health care system. The decision on acquisition of MSCT means not only costs and resource 
utilization but also cost savings connected to the avoidable coronary angiographies. The invasive 
coronary angiographies could be performed only as an interventional procedures and not anymore 
as a diagnostic test. Moreover, the health benefits of patients have to be considered, in terms of 
infarctions and other heart diseases avoided, which could lead into indirect cost savings.  
 
What is the likely budget impact of MSCT for the payers (e.g. government)  
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. 
Results 
The introduction of a new technology raises the question about whether and how the service 
provided with the new technology will be reimbursed. The decisions in terms of reimbursement 
rates have a direct effect on the choices of the providers, in particular on the composition (kinds and 
amount) of the provided services. 
 
In the United States Medicare‘s national coverage policy for computed tomography (CT) does not 
specifically address coverage of coronary CT angiography. The policy states that CT scans may be 
covered as diagnostic services if reasonable and necessary, and if performed on an FDA-approved 
model of CT equipment. The local Medicare contractors have discretion to determine the specific 
circumstances under which a CT scan is covered. In March 12, 2008 the Centers for Medicare and 
Medicaid Services (CMS) has decided to make no change to section 220.1 of the National Coverage 
Determination Manual titled ―Computed Tomography‖ (Pub. 100-3, 220.1). It has been decided that 
no national coverage determination on the use of cardiac computed tomography angiography for 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
183 
 
coronary artery disease is appropriate at this time and that coverage should be determined by local 
contractors through the local coverage determination process or case-by-case adjudication (37).  
 
A group of radiologists and lab directors, the American College of Radiology (ACR), vendors, and 
contrast developers are lobbying CMS to change the CPT codes, arguing that such low 
reimbursement doesn‘t reflect the reality of expense and time in using the technology. CT 
angiographies have largely replaced catheter angiography so it is not only cost-effective in time and 
materials, it also exposes patients to less risk. But as Medicare rates do not reflect the work 
involved, hospitals are losing money. A traditional catheterized angiogram costs $5,000 (38), while 
a CTA costs $299  plus Carrier Priced (in Hospital Outpatient Department) (39).  
 
Similarly the Italian system does not have a specific fee for MSCT angiography utilization. These 
examinations are covered in an outpatient basis. In Lazio region the fee linked to Thorax TC with or 
without ―contrast‖ is applied. Below there are the ICD 9 CM codes reported for the service and the 
related fees for three Italian regions.  
 
Code ICD 9 
CM 
Service  
87.41.1 
Computed axial tomography of thorax  with or without 
contrast. [lung, thorax aorta, airtube, oesophagus, sternum] 
88.42.1 
Aortography (digital angiography of aorta and of aortic 
arch) 
 
Region Fee 
 87.41.1 88.42.1 
Lazio € 137,89 € 283.28 
Emilia Romagna  € 137,90 € 283.30 
Veneto   € 210.75 € 288.95 
 
A German study has shown that in a high-referral centre (30 coronary MSCT examinations per 
day), already with the present reimbursement rate (€ 124,43 – reimbursement minus contrast agent 
costs) the break-even point could be reached after a short period of 23 months. However, since such 
high referral rates are rather unlikely, MSCT coronary angiography would only be profitable in a 
reasonable time frame after investment if reimbursement were three-times higher than with the 
present outpatient reimbursement system in Germany40.  
Management 
What management problems and opportunities are attached to the new technology? 
What management problems and opportunities are attached to MSCT? 
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. 
Results 
The use of MSCT requires multidisciplinary clinical skill to manage MSCT use in clinical practice 
and multidisciplinary competences for assessment activities (clinical, economical and 
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organizational. Close collaboration of multiple disciplines can be challenging to implement, but on 
the other hand it may lead to important synergies. 
Who decides which patients are to undergo MSCT coronary angiography and 
on what basis? 
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature. 
Results 
Decision about testing with MSCT requires the competence of different professionals in different 
situations: 
– Patient could be admitted from emergency department (ED) by the ED physician who needs 
MSCT to rapidly evaluate patients for life-threatening illnesses. MSCT may allow safer and 
earlier discharges of patients with chest pain compared t traditional rule-out protocol (41).  
– Patient could undergo a MSCT exam because the GP asks it for him. In that case the exam 
will be scheduled.   
– Patient could undergo a MSCT in a pre-operative phase because the cardiologist needs more 
information for surgery.  MSCT may provide useful information for the selection of 
potential candidates for percutaneous mitral annuloplasty (29).  
Culture 
How is MSCT accepted?  
Methods 
Analysis of selected studies extracted from the literature review and a search in Google.  
Results 
Recently, multislice computed tomography (MSCT) has gained increasing acceptance within the 
cardiology and radiology communities as a valuable, diagnostic imaging tool (43).  Technological 
advances have facilitated its rapid expansion. MSCT and other noninvasive coronary artery imaging 
procedures are becoming important gatekeepers, helping to select patients for invasive cardiac 
catheterization. 
 
Traditional stress-test approach is time-consuming, expensive, and is often not feasible or 
equivocal.  MSCT coronary angiography has been shown to be helpful in patient management: it 
has reduced the time to make the diagnosis by about 75% and also reduced the costs (46). A cultural 
resistance by practitioners is possible as the new technology requires new and more specialized 
skills. Anthony N. DeMaria, MD, MACC, editor-in-chief of the Journal of the American College of 
Cardiology, also sees "a blurring of the boundaries between disciplines, and perhaps the emergence 
of new types of cardiologists, a cardiovascular imaging specialist.‖.  
 
While mean direct costs of MSCT are lower than in the alternative modalities, administrators often, 
incorrectly, predict decreasing revenues. This could lead to a resistance from the management to the 
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introduction of MSCT. Although the mean payment for MSCT coronary angiography was 
substantially lower than other tests, the experience of South Carolina Heart Center, Columbia, SC 
shows an increase in revenue, considering direct and indirect costs including physician time, 
ancillary labor, and equipment costs. 
 
Additionally, unlike traditional angiography, MSCT does not require any procedural time for the 
cardiologist. The available work units from the shift of angiography modalities result in increased 
capacities for interventional time, making additional revenues (43) possible. A study of Goldstein et 
al. outlined that, compared with patients treated according to the standard of care, diagnoses were 
significantly shorter and cheaper in the MSCT coronary angiography group. 
 
Outcomes: Multislice CTA vs standard of care (43) 
 
 
Outcome 
Multislice 
CTA 
Standard of 
care 
p 
Diagnostic time (h) 3.4 15.0 <0.001 
Cost ($) 1586 1872 <0.001 
Reevaluations over  
6 months (%) 
2 7 0.10 
 
Schonenberger et al. have prospectively compared patient acceptance of the two new non-invasive 
tests (MSCT and MRI) with that of the invasive reference standard – conventional invasive 
coronary angiography (ICA) – in a consecutive cohort of 111 patients with suspected coronary 
artery disease. MSCT was considered significantly more comfortable than MRI (p<0.001), and the 
patients indicated a significantly lower degree of helplessness during MSCT than during 
angiography (p<0.001). Patients were significantly more concerned prior to the tests about 
conventional coronary angiography than about either of the two non-invasive tests (p<0.001). 
Overall satisfaction was higher for MSCT than for MRI and ICA. From the patients‘ perspective the 
main reasons for the high acceptance of MSCT are: it is uncomplicated, non-invasive, painless, and 
fast. This subjective assessment is corroborated by the comparison of the total duration of the 
different tests, which shows that MSCT was significantly faster (17.4 min) than both MRI (58.4 
min, p<0.001) and ICA (58.0 min, excluding time necessary for interventions, p<0.001) (47).  
How will the other interest groups of MSCT be taken into account in the 
planning / implementation of MSCT? 
Methods 
Analysis of selected studies extracted from the literature review. Additional information was found 
by internet search of grey literature.  
Results 
Government agencies are important drivers in the development of biomedical imaging through 
support of biomedical research and through policy guidance on the ethical responsibilities of 
investigators, especially those using animals and human participants in research. Government 
support of research in biomedical imaging is critical to the growth of new knowledge and to new 
applications of this knowledge in the clinical arena. 
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 Scientific and professional societies are also essential partners in the expansion of biomedical 
imaging and in developing and delivering imaging innovations. The education of members, 
scientists, and health care providers from other disciplines, as well as patients and the public, about 
new imaging technologies and their benefits for biomedical research and clinical medicine is a 
responsibility best shouldered by scientific and professional societies.  
 
Academic institutions are the home of most basic and translational research in biomedical imaging. 
They are also the training ground for the next generation of basic and clinical imaging scientists. 
 
Corporations are also important stakeholders and innovators in the area of biomedical imaging. 
Companies developing imaging probes—radiopharmaceuticals, optical agents, and magnetic 
resonance (MR), ultrasound (US), and CT contrast agents—and imaging device companies have 
invested millions of dollars in a research infrastructure to support the development process.  
 
Foundations and voluntary health agencies also play important roles in the development of new 
technologies and therapies to benefit patients and the public. They can help facilitate two-way 
communication between researchers and those who use the products and services created through 
research, including clinicians and patients. 
 
The ultimate stakeholders in biomedical imaging are, of course, patients and the public. Because of 
rapidly emerging advances in molecular biology, genetics, and proteomics, it is likely that health 
care as we know it today will be transformed tomorrow into a more effective and efficient process 
that benefits patients and all of society. Biomedical imaging will play a major role in bringing this 
potential to fruition (48).  
Discussion 
The objective of organizational domain was to assess what kinds of resources (material things, 
human skills and knowledge, money, etc) need to be mobilised and organised when implementing 
Multi Slices Computed Tomography (MSCT) (64 slices) procedures, and what kind of changes or 
consequences can their use cause in the organisation. The investigation of MSCT's impact on 
management and structure of organization was very complex, because organisational aspects are 
rarely analysed within clinical studies and HTA reports and hence little evidence is available in the 
scientific literature. The traditional systematic literature review was not completely suitable to 
obtain full information on organisational aspects, and it was necessary to complement the search 
with analysis of other sources.  
 
The impact of MSCT-64 on clinical pathways of patients could lead into reducing length of stay and 
avoiding repeated evaluations for recurrent chest pain. Introducing MSCT-64 into practice does not 
lead into completely novel organisational challenges. Comparative imaging systems have been 
introduced before. The incremental features of MSCT require some changes though, mainly in the 
co-operation across disciplines.  
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Assessment elements table 
 
ID Domain Topic Issue Relevance 
in the 
context of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
Or Comment (if regarded as a not relevant issue 
in this context) 
      
G0001 Organisational 
aspects 
Process What kind of work flow and patient 
flow processes are needed?  
 
yes What kind of work flow and patient flow processes 
is needed when implementing MSCT? 
G0002 Organisational 
aspects 
Process What kind of changes can the 
implementation of a new technology 
generate in the quality of care?  
yes What kind of changes can the implementation of 
MSCT generate in the quality of care? 
 
G0003 Organisational 
aspects 
Process What kind of patient and relative 
involvement in treatment or care has 
to be mobilized? 
yes What kind of patient and relative involvement in 
treatment or care has to be mobilized when 
implementing MSCT? 
G0004 Organisational  Process What kind of staff, training and other 
human resources is required? 
 
yes What kind of staff, training and other human 
resources is required when using MSCT?  
G0005 Organisational 
aspects 
Process What kind of co-operation and 
communication of activities have to be 
mobilised? 
 
yes What kind of co-ordination and communication of 
activities does MSCT require?  
G0006 Organisational 
aspects 
Structure What consequences the 
implementation of the new technology 
will have in respect of decentralisation 
or centralisation? 
 
yes What consequences MSCT will have in respect of 
decentralisation or centralisation? 
G0007 Organisational 
aspects 
Structure What kinds of investments are 
needed (material or premises)?  
 
 
yes What kinds of investments are needed (materials or 
premises) when introducing MSCT?  
G0008 Organisational 
aspects 
Structure  What is the likely budget impact of the 
implementation of the technology for 
the payers (e.g. government)? 
 
yes What is the likely budget impact of MSCT for the 
payers (e.g. government)  
G0009 Organisational 
aspects 
Management What management problems and 
opportunities are attached to the new 
technology? 
yes What management problems and opportunities are 
attached to MSCT? 
G0010 Organisational 
aspects 
Management Who decides which patients are to 
undergo a treatment and on what 
basis?  
 
yes Who decides which patients are to undergo MSCT 
coronary angiography and on what basis? 
G0011 Organisational 
aspects 
Culture How is the new technology accepted? yes How is MSCT accepted?  
G0012 Organisational 
aspects 
Culture How will the other interest groups of 
the new technology be taken into 
account in the planning / 
implementation of the new 
technology? 
yes How will the other interest groups of MSCT be 
taken into account in the planning / implementation 
of MSCT? 
 
 
Appendix 1 Search strategy 
 
Database: Ovid MEDLINE(R) <1950 to October Week 4 2007> 
Search date: 1.11.2007 
Search strategy: 
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-------------------------------------------------------------------------------- 
1     Tomography, X-Ray Computed/ (186962) 
2     ("64-slice$" or "multislice$" or MSCT or "multi-detect$" or "multidetect$" or 
MDCT).tw. (5665) 
3     1 or 2 (189092) 
4     exp delivery of health care/ (531676) 
5     work process$.tw. (483) 
6     4 or 5 (532064) 
7     3 and 6 (1230) 
8     (centraliz$ or centralis$ or decentralis$ or decentraliz$).tw. or centralized hospital 
services/ (9607) 
9     3 and 8 (50) 
10     health manpower/ or exp health personnel/ (282682) 
11     (staff$ or personnel$).tw. (100334) 
12     (competenc$ or skill or skills).tw. (81951) 
13     Staff Development/ (4742) 
14     10 or 11 or 12 or 13 (423765) 
15     3 and 14 (827) 
16     exp communication/ (249186) 
17     cooperative behavior/ (12335) 
18     (collaborat$ or cooperat$).tw. (103369) 
19     16 or 17 or 18 (354762) 
20     3 and 19 (1435) 
21     Investments/ (6084) 
22     exp Health Care Costs/ (29701) 
23     (cost or costs or fees or fee or finance or finances or financial).tw. (200579) 
24     Resource Allocation/ (5795) 
25     21 or 23 or 24 (210775) 
26     3 and 25 (2364) 
27     Leadership/ (17810) 
28     (leadership$ or management$).tw. (413474) 
29     27 or 28 (424183) 
30     3 and 29 (12558) 
31     2 and 6 (65) 
32     2 and 8 (2) 
33     2 and 14 (26) 
34     2 and 19 (34) 
35     2 and 25 (125) 
36     2 and 29 (257) 
37     31 or 32 or 33 or 34 or 35 or 36 (449) 
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Social aspects 
Dagmar Lühmann, Juha Koivisto, Tuija Ikonen, Päivi Reiman-Möttönen, Heidi Anttila 
Introduction  
The social domain takes the patient as a point of departure in its analysis of the manifold 
social implications of health technology. The focus of the domain is on the diverse social 
arenas where the patient lives and acts during the period of sickness and treatment. 
Application of diagnostic technologies possibly interacts with peoples social arenas in two 
ways: first, directly by application of the technology and second, by generating a diagnosis 
and the patient having to face its consequences. 
 
In the context with MSCT, direct social interactions may concern the way and circumstances 
of accessing an examination, preparatory procedures, perceptions (such as pain, discomfort, 
anxiety) during the procedure, aftercare and cost related aspects. Social interactions related to 
the diagnosis of Coronary Heart Disease (CHD) could involve communication and support 
needs before and after the examination, self perception and future life planning as a patient 
with a chronic disease. While the direct interactions are specific for MSCT the diagnosis 
related aspects also refer to other diagnostic modalities for CHD. Therefore, the emphasis in 
the following chapter is laid more on the direct interactions. 
 
This study analyzed views of patients and professionals on social aspects utilizing and 
adapting assessment elements defined in the Social aspects of the EUnetHTA Core Model. 
Data were taken from a systematic overview of the (very limited amount) of published 
literature as well as from interviews conducted with patients and professionals concerning 
their views on the implementation of 64-slice computerized tomography coronary 
angiography also called as multi-slice computer tomography (MSCT) in the diagnostics of 
coronary artery disease. 
Methodology 
Literature overview 
Literature searches concerning social aspects of MSCT coronary angiography were performed 
in Medline, Premedline (via the PubMed system), the CRD databases (HTA, EED, DARE) 
and the ISI Social Sciences Citation Index (SSCI). In the first step the basic search for 
literature on MSCT supplied by Finohta (see Appendix 1 in General design chapter) was 
adapted for the use in PubMed. A search run on June 4th 2008 yielded 1275 hits. These hits 
were transferred to a Reference Manager database and in the second step combined with 
search terms for articles dealing with social aspects of MSCT. Search terms were deducted 
from the issues formulated in the core model (both models developed during the project were 
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used). The combination yielded 376 potentially relevant citations in the Pubmed, 1 in the 
SSCI and 22 in the CRD databases. The abstracts of these 399 citations were in the third step 
further screened using the following inclusion criteria: 
– Abstracts mentioning patients reception/ perceptions/ reactions of MSCT 
– Abstracts mentioning outcomes of MSCT, other than accuracy parameters 
– Abstracts mentioning information and communication issues concerning MSCT 
– Abstracts mentioning the integration of MSCT in processes of care from the 
perspective of patients, relatives or clinicians 
Exclusion criteria were: 
– Indications for MSCT use other than coronary artery disease (CAD) 
– Studies and reviews reporting accuracy results only 
 
After elimination of duplicates the abstract screening left 34 potentially relevant publications 
(Appendix 2). These were ordered in full-text. Full-text screening of the 34 abstracts led to 
exclusion of 32 publications. A table with excluded studies and reasons for exclusion can be 
found in the Appendix 3. 
 
Two studies, one prospective case series (Schroeder et al., 2004) and one comparative patient 
survey (Schoenenberger et al., 2007) fulfilled the inclusion criteria. Relevant information on 
study design and results were extracted. (Tables are found in Appendix 4). 
Interview studies 
Individual semi-structured interviews on patients and professionals were conducted. The 
interview themes were prepared on the basis of the pre-defined social and psychological 
topics and issues in the Core Model. The issues included questions such as the following: 
– what kind of changes can the use of the technology produce to patients' social 
relations? 
– what kind of reactions can the use of the technology give rise to in patients? 
– what kind of consequences can the use of the technology produce to patients' self-
perception? 
– how does the information gained from the diagnostic study influence patient's 
psychological and social well being? 
 
The patients were asked to describe their views for three different timeframes: before the 
intervention, during the intervention and after the intervention.  
 
Patients that had been examined by MSCT during February-March 2008 in the Turku 
University Central Hospital (TUCH) were asked for informed consent by their physician. 
Eleven patients consented, and seven of them were finally available for interviews (patient 
characteristics see table 1). In addition, we interviewed three cardiologists who refer patients 
to MSCT coronary angiography in Turku, two from TUCH and one from a private clinic 
Pulssi.  
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Table 1: Patient characteristics in the interview study 
 
Patient Number Gender, occupational status, age 
1 Male, pensioner, 68  
2 Male, pensioner, 68 
3 Male, pensioner, age not given 
4 Male, pensioner, 72 
5 Male, in working life, 37 
6 Female, in working life, 52 
7 Female, unemployed, working parttime, age not given 
 
One researcher (JK) interviewed all patients at their homes and two researchers (TI and JK) 
the professionals, one guiding the discussions and the other taking notes during the sessions. 
All interviews were recorded, then transcribed to written texts and summarized into English 
(Appendices 5 and 7).  
 
The study was financed by the Finnish Office for Health Technology Assessment (Finohta) 
within the National Development Centre for Welfare and Health (STAKES). 
Assessment elements 
Major life areas 
In which social areas of the patients may the use of the MSCT generate 
change? 
Results 
Interview studies: Patient expressed concern over the influence of the diagnosis (results from 
the MSCT examination) and its consequences (e.g. bypass surgery) on everyday life (patients 
2 and 6) and on the ability to work and thereby the economical situation (patients 6,7,8). This 
perception was shared also by the experts, who state that a diagnosis of CAD will have 
multiple consequences (e.g. need for treatment, rehabilitation) for the future life of the 
patients (experts 1,2,3). 
 
Literature review: no information. 
 
Who are the significant others that are involved in the use of MSCT 
coronary angiography in addition to the patient? 
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Results 
Interview studies: Other persons than the patient, namely spouses and/or friends are involved 
in the use of the technology in that way that patients seek their mental support (calm down 
fear, insecurity and uneasiness) before the examination, awaiting the diagnosis (patients 
1,2,3,4,5,7).  
 
Literature review: no information. 
 
What kind of support and resources are needed or might be released as 
MSCT is put to use? 
Methods 
Questions asked in the interview studies: 
– Did you have to make some special arrangements in your daily life because of the 
upcoming diagnosis?  
– Did you need to mobilize some special resources (e.g. money, time) for the diagnosis? 
How long did it take? 
– Did you need any kind of psychological, social or practical support before the 
diagnosis? 
– Did you need any support during your stay at the hospital, when the diagnostic testing 
was done? 
– Have you needed to make some special rearrangements in your daily life after the 
diagnosis?  
– Have you needed any kind of support?  
– Have you needed to mobilize some special resources as a consequence of the 
diagnosis? 
Results 
Interview studies: Before MSCT the patients did not need any support (patient 6) or they had 
talked about the upcoming MSCT examination with their spouse or the nearest ones (patients 
1,2,3,4,5,7). The financial resources needed were 493 € at the private clinic (patient 1), or 
normal health care costs (22 € - patients 2,3,4,5,6,7) at the city hospital. The patients also 
needed to spend some time (range 30 minutes to 2 hours) for the investigation and stay at the 
hospital. The patients needed no support during the MSCT. 
 
After the intervention the patients had various paths depending on the result of the MSCT. 
Some patients had another consultation with their doctor and changes in medication (patient 
1) or were sent to further investigations (patients 2,3,4). One patient will have bypass surgery, 
and would need support after the operation (patient 2). Some patients returned to their regular 
life, because nothing serious was found (patients 5,6,7).  The waiting time for the results was 
mentioned by three patients (5,6,7) as a period of uneasiness , although these waiting times 
seem to differ in length. This point is also mentioned by one of the experts (1) as an aspect 
that patients have to be prepared for.  
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While the patients did not report needing social support after the MSCT, experts mention that 
the diagnosis of coronary artery disease (CAD) triggers the need for support by e.g. support 
groups (expert 2) or rehabilitation measures (expert 3). 
 
Literature review: In the comparative study of patient acceptance of MSCT, MRI or 
angiography for the diagnosis of suspected CAD (with every patient undergoing all three 
examinations) patient-perceived degree of concern before the examination was measured on a 
1-5 point Likert-Scale (1=none to 5=very high). Before MSCT and MRI the measured degree 
of concern was 1,51 ± 0,85 or 1,64 ±0,93 (mean ± SD), which was significantly lower than 
before angiography (2,75±1,23) (Schoenenberger et al., 2007). In the same study, 63 out of 
111 patients pointed out the ―fastness‖ of the examination as an advantage of MSCT over 
MRI or angiography. 
 
What kinds of changes does the use of MSCT coronary angiography 
generate in the patient's role? 
Results 
Literature review: no information. 
Interview studies: Nothing special or discussions with spouse or friends. Experts (2,3) pointed 
out that after the MSCT diagnosis (which either confirms or excludes coronary artery disease, 
CAD) it will be possible for most patients to keep up or resume his or her normal activities. 
CAD is considered a treatable disease, which still allows the patients to continue in their 
working life. On the other hand they mentioned that in a minority of cases a CAD diagnosis 
as a result of MSCT lead to the perception that retirement would be adequate – although stress 
tests are normal and the disease is adequately treated (expert 3). 
What kind of changes does the implementation and use of MSCT coronary 
angiography mean for the patients physical and psychological functioning? 
Methods 
Questions asked in interview studies: 
– Did the diagnosis produce any harm for you? 
– Was the diagnosis necessary for you? Benefits? Adverse effects? 
Results 
Interview studies: During the MSCT the patients reported pain (patients 2, 3), and a hot wave 
(patients 3,5,7). After the examination two patients (4,6) felt exhausted or not well. One 
patient reported no adverse effects. All patients reported that the MCST was necessary for 
them, because the results changed their care or medication (patients 1,2,3,4,6), or because 
nothing was found and it released them from their worries (5,7). 
 
Literature review: In the comparative study of MSCT, MRI and angiography patients reported 
very little pain during the MSCT examination (maximum experienced pain 0,9 ± 4,5 (mean ± 
SD) on 1-100 VAS). The respective values for MRI (5,2 ±1,6) and angiography (24,6 ±23,4) 
were much higher (p<0,001). 11% of all patients pointed out ―painlessness‖ as one advantage 
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of MSCT over MRI and angiography. Also, comfort during the test (measured on a 1-5 point 
Likert-Scale 1=best, 5=worst) was perceived better for MSCT (1,49 ±0,64) compared to MRI 
(1,75 ±0,81) (p>0,001). The perceived degree of helplessness was lower during MSCT (1,19 
±0,48) than during MRI (1,39±0,89) or angiography (1,52±0,86) (p< 0,001 for comparison 
MSCT – angiography). 
Overall satisfaction on a five-point Likert-Scale was also highest for MSCT (1,32±0,51) 
compared to MRI (1,58±0,89) and angiography (1,46±0,61), although the differences were 
not statistically significant (Schoenenberger, 2007). 
 
In a consecutive case series with 455 ±  166 days of follow-up between 92% and 98% of 
patients with low or intermediate probability of coronary artery disease (CAD) examined with 
MSCT as the first-line investigation were satisfied or very satisfied with the procedure in the 
Cardiac imaging outpatient clinic. Slightly better values (98% and 96% satisfaction) were 
found in the groups of patients, where CAD was excluded or no severe stenoses were 
detected. Clinical condition and quality of life were also improved or equal in all patients of 
these groups. In the groups with pathological findings or uninterpretable images the clinical 
condition at follow-up was deteriorated in 4% and 10% of patients and the quality of life was 
reported worse by 2% and 10% of patients at follow-up. Statements on the patient‘s social 
roles were not given in the publication (Schroeder, 2005). 
Individual  
How do patients and important others react and act upon MSCT coronary 
angiography?  
Methods 
Questions asked in interview studies: 
– What kind of consequences did the upcoming diagnosis have on your psyche and on 
your different social arenas?  
– How did you react on the upcoming diagnosis? 
– How did you react during the diagnosis? 
– What did the waiting time of the results of the MSCT mean for your psyche and social 
life? 
– How did you react as a consequence of the diagnosis? 
Results 
Interview studies: Some patients indicated not being afraid, having discussed the coming 
examination with their spouse (patients 1,2,5), family (patient 4) or friends (patients 4,5,6,7), 
some felt a little exited (patients 3,6), some did not even remember the coming MSCT 
(patient 2). Some told that they were a little unsure or afraid of what consequences a possible 
disease would generate in their economic situation and working life (patients 6,7). The tube 
used in the examination and possible allergy raised also some concerns (patient 7). During the 
MSCT the patients had no special reaction, except the pain (see above). The patients 
commented that the waiting time was short, but at the same time most difficult for some of 
them. Some patients were excited to hear the results. After hearing the results of the MSCT 
the patients' reactions were variable: positive, surprise, released or no special reactions. 
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In the expert interviews the opinion was expressed (expert 2) that patients have to be prepared 
to live with the ―label‖ CAD for the rest of their lives. Doctors have to realize how important 
it is to prepare patients for the oncoming diagnosis. 
 
Literature review: no information 
Communication  
What is patients' and significant others’ knowledge and understanding of 
MSCT coronary angiography? 
Methods 
Questions asked in interview studies: 
– What kind of route did follow to you come to the diagnosis? 
– Was your opinion asked when choosing the CTCA for the diagnostic method?  
– What kind of instructions did you get for preparing to the diagnosis? 
– Did you get enough information before the diagnosis? 
– How did the diagnosis work from your opinion?  
– What kind of activities did you have to perform during the diagnosis? 
Results 
Interview studies: All patients have had several previous consultations (tolerance test) in 
health care about their chest pain, some for several years. Their physician sent them to the 
investigation, except one patient, who himself had to put pressure on and convince the doctors 
for the MSCT in the private clinic. The patients were instructed that they should not eat that 
morning before the MSCT, or they did not remember anything special. One patient did not get 
any instructions and searched for them on the Internet. 
 
The patients felt that they got enough information during the MSCT. The patients told that 
they could have been informed better about a feeling of a hot wave or possible strong pain 
during the MSCT. Everything worked very well during the examination. The MSCT required 
no activities of the patients. The patients just needed to lie down, and hold their breath for 
some ten seconds. 
 
During expert interviews it turned out that the indications for MSCT are not handled 
uniquely. Two experts agreed though, that MSCT should not be used for screening purposes. 
There is agreement in the expert‘s answers that the patient pathway usually starts in the health 
centre or district hospital, continues to a cardiologist who then may or may not refer to 
MSCT. Depending on the patient‘s condition, waiting times to see a cardiologist can stretch 
from 1 to 4 months.  
 
Literature review: Patients in the comparative study rated the preparation and information 
prior to the test on a five-point Likert-Scale (1=very good; 5=poor). The average values were 
1,27± 0,52 (mean +/- SD) for MSCT, 1,35 ± 0,64 for MRI and 1,48 ± 0,72 for angiography. 
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How is the information regarding the use of MSCT processed and 
exchanged? 
Results 
Interview studies: By discussion between the doctor, nurses and the patient. 
Literature review: no information. 
What are the consequences of using MSCT coronary angiography for 
decision making? 
Results 
Interview studies: According to the patients, MSCT provided information to the doctors and 
patients that led to changes in care or medication (patients 1,2,3,4) or exclusion of diagnosis 
(patients 5,6,7). 
 
Literature review: In the follow-up study of 142 consecutive patients, in 77 patients CAD was 
ruled out or clinically irrelevant stenoses were detected by MSCT. These patients were given 
a recommendation against angiography. The recommendation was followed in 73 patients, 4 
patients had an angiography against recommendation, two of them with positive results 
(which leads to a false negative rate of 2,6 % (2 out of 77)). 59 patients with relevant stenoses 
or uninterpretable images were given a recommendation for angiography, 26 of which were 
performed. Seven angiographies yielded negative results which leads to a false positive rate of 
11,8% (7 out of 59)) (Schroeder, 2005). 
Discussion 
MSCT can still be considered a ―technology under development‖ (e.g. from 4-slice to the 
currently available 256-slice technology). Without clear indications it is not surprising, that 
the scientific literature mostly deals with its clinical efficacy (in the sense of ―accuracy‖ for 
the diagnosis of different cardiac and extra-cardiac conditions). Only very few publications 
report social aspects and patient perceptions of the technology as specified for this report. 
Against this background, semi-structured interviews with patients and experts were conducted 
complementing the literature analysis to at least outline possible social and patient-related 
aspects of MSCT for the diagnosis of coronary artery disease. 
 
Major life areas: Major life areas that may be somehow changed by the use of MSCT are 
patient‘s everyday life at home as well as working life. Relating to the technology use itself, it 
seems that changes are just minor – since the technology maybe applied in an ambulatory 
setting, requires no time-consuming preparation, is fast and requires no special aftercare. For 
the patients the availability of a partner (spouse, family, friends) with whom the upcoming 
examination and its potential results may be discussed, seemed sufficient psychological 
preparation. The consequences seem to be larger, when related to the possible diagnosis. 
Some patients perceive the diagnosis ―CAD‖ (and to some extent its therapeutic 
consequences) as a threat to their ability to lead an independent life or to continue with their 
working life –although there is the general view that a properly treated CAD must not limit a 
patients ability to work. In this context, also economic losses are feared. This view is shared 
EUnetHTA WP4 - Core HTA on MSCT Coronary Angiography 
31 Dec 2008 
Pilot assessment to test the HTA Core Model. Not for decision-making. 
 
 
 
200 
 
by experts, who state that a diagnosis of CAD ―may change the whole life of the individual‖. 
The meaning of CAD diagnosed by MSCT may be of particular relevance if the technology is 
used in populations with high numbers of false positive results (low risk populations, 
screening). 
 
Individual: Patients in the interviews reported some minor physical limitations that were 
directly related to the MSCT examination, especially experience of pain, heat sensations and 
to some degree exhaustion after the examination. These results are somewhat contradictory to 
the data reported in the literature, where patients undergoing MSCT as well as MRI and 
angiography for the diagnosis of CAD only reported very low values for pain and discomfort 
during MSCT. Overall, very high rates of satisfaction with the examination were reported. It 
must be noted though, that the literature data are derived from two studies only. Psychological 
consequences (in the sense of uneasiness, insecurity) were again more related to the 
expectation of the diagnosis rather than to the technology itself. Both patients and clinicians 
pointed out that especially the waiting time before final results are communicated is a critical 
period that patients have to be prepared for. Although patients expressed no need for special 
aftercare, experts pointed out that a diagnosis of CAD may trigger the need for support groups 
or comprehensive rehabilitation measures. 
 
Communication: In the interviews as well as in the literature review patients were mostly 
satisfied with the information supplied before the examination. This again may have to do 
with the fact that the examination itself generates only minor physical, psychological and 
organisational consequences. Furthermore, all patients in the interviews expressed that they 
considered the examination ―necessary‖, regardless whether the findings were positive or 
negative. Indirectly this supports the view that communication did not raise any unrealistic 
hopes or expectations. 
 
It has to be noted, that these results have to be regarded as preliminary. There were only two 
studies so far analysing patient perceptions of MSCT, both with certain methodological 
limitations. The patients' and experts' interviews were conducted in Finland and it remains to 
be discussed, whether other aspects (e.g. financial aspects) may be of major importance in 
other health care systems. Ideally, patient related outcomes such as quality of life, 
psychological and physical wellbeing and impact of diagnosis on patients‘ major life areas 
and interpersonal relations should be investigated in future (controlled) implementation 
studies. 
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Assessment elements table 
 
 ID Domain Topic Issue Relevance in the 
context of MSCT 
Yes/No 
Research question(s) in the context of MSCT 
Or Comment (if regarded as a not relevant issue in this context) 
      
H0001 Social 
aspects 
Major life areas Which social areas does the use of the technology influence? yes In which social areas of the patients may the use of the MSCT generate change? 
H0002 Social 
aspects 
Major life areas Who are the important others that the use of the technology may affect in 
addition to the patient? 
yes Who are the important others that are involved in the use of MSCT coronary 
angiography in addition to the patient? 
H0003 Social 
aspects 
Major life areas What kind of support and resources are needed or might be released as 
the technology is put to use? 
yes What kind of support and resources are needed or might be released as MSCT is 
put to use? 
H0004 Social 
aspects 
Major life areas What kinds of changes does the use of the technology generate in the 
patient's role in the major life areas? 
yes What kinds of changes does the use of MSCT coronary angiography generate in the 
patient's role? 
H0005 Social 
aspects 
Major life areas What kind of changes does the implementation and use of the technology 
mean for the patients physical and psychological functioning in his or her 
major life areas? 
yes What kind of changes does the implementation and use of MSCT coronary 
angiography mean for the patients physical and psychological functioning? 
H0006 Social 
aspects 
Individual How do patients and important others react and act upon the technology?  yes How do patients and important others react and act upon MSCT coronary 
angiography?  
H0007 Social 
aspects 
Communication What is patients' and important others’ knowledge and understanding of 
the technology? 
 What is patients' and important others’ knowledge and understanding of MSCT 
coronary angiography? 
H0008 Social 
aspects 
Communication How is the information regarding the use of the technology processed and 
exchanged? 
yes How is the information regarding the use of MSCT processed and exchanged? 
H0009 Social 
aspects 
Communication What are the consequences in decision making? yes What are the consequences of using MSCTcoronary angiography in decision 
making? 
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Appendix 1: Search strategies 
 
PubMed 
 
Search terms Hits potentially  
relevant 
{support} OR {ressource} 208 13 
{employment } OR {return to work} OR {length of stay} OR {hospital stay} OR 
{discharge} 
17 4 
{leisure} OR {activities} OR {ADL} 2 0 
{family } OR {relations} OR {relatives} OR {carer} 73 1 
{social} OR {psychologic\*} 2 0 
{wellbeing} OR {well-being} OR {recovery} 5 1 
{information} OR {understanding} OR {informed consent} 166 13 
{attitude} OR {perception} OR {preference} OR {self conception} OR {self-conception} 
OR {satisf*} OR {expectation} 
15 1 
{insecurity} OR {worr\*} OR {hope} OR {anxiety} OR {stigmat\*} 3 0 
{leisure} OR {lifestyle} OR {life-style} OR {life style} OR {daily activities} OR {ADL} 2 0 
{quality of life} OR {QoL} 2 0 
{Care\*} OR {rehabilitation} 47 7 
Sum 376 40 
After duplicate elimination  31 
 
Social Science Citation Index 
An abbreviated search in the Social Science Citation Index ® yielded one hit, which was of no 
relevance for the Core Topic Assessment. 
 
Step Search terms (2003-2008) Hits 
#1 TS=(coronary AND (disease* OR occlus* OR vessel* OR arter* OR stenos* OR restenos* 
OR aneurysm* OR thrombos* OR vasospasm* OR obstruct*)) OR TS=(angina pector* OR 
calcinos* OR myocardial ischem*) 
4.378 
#2 TS=(multi row OR multislice OR multi-slice OR multi slice OR multidetect* OR multi-
detect* OR multi detect* OR multisect* OR multi-sect* OR multi sect*) OR TS=(msct OR 
mdct) 
1.048 
#3 TS=(angiograph* AND tomograph*) OR TS=("coronary angiograph*" OR "computer 
tomograph*" OR "computed tomograph*" OR "computerized tomograph*") 
667 
#4 #1 AND #2 AND #3 1 
 
The one publication retrieved turned out to be not relevant after abstract screening. 
 
CRD databases 
References retrieved from the DARE/HTA/EED searches were supplied by FINOHTA (n=22). 
Abstract screening (using the same in- and exclusion criteria as noted above) left 4 (one included in 
the PubMed searches as well) possibly relevant publications which were also ordered in fulltext. 
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Appendix 2: Potentially relevant citations (n=34) 
 
PubMed 
(1) Bax JJ, Schuijf JD, van der Wall EE. [Non-invasive imaging for the detection of coronary artery disease]. Ned Tijdschr Geneeskd 2007 Apr 
7;151(14):799-804. 
(2) Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on 
advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic 
angiography in the diagnosis and evaluation of ischemic heart disease--executive summary. Can J Cardiol 2007 Feb;23(2):107-19. 
(3) Cademartiri F, Schuijf JD, Mollet NR, Malagutti P, Runza G, Bax JJ, et al. Multislice CT coronary angiography: how to do it and what is the 
current clinical performance? Eur J Nucl Med Mol Imaging 2005 Nov;32(11):1337-47. 
(4) Dewey M, Richter WS, Lembcke A, Hamm B, Borges AC. [Noninvasive diagnosis of coronary artery disease]. Med Klin (Munich) 2004 Feb 
15;99(2):57-64. 
(5) Gallagher MJ, Raff GL. Use of multislice CT for the evaluation of emergency room patients with chest pain: the so-called "triple rule-out". 
Catheter Cardiovasc Interv 2008 Jan 1;71(1):92-9. 
(6) Gani F, Jain D, Lahiri A. The role of cardiovascular imaging techniques in the assessment of patients with acute chest pain. Nucl Med Commun 
2007 Jun;28(6):441-9. 
(7) Goldstein JA, Gallagher MJ, O'Neill WW, Ross MA, O'Neil BJ, Raff GL. A randomized controlled trial of multi-slice coronary computed 
tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007 Feb 27;49(8):863-71. 
(8) Hecht HS. Applications of multislice coronary computed tomographic angiography to percutaneous coronary intervention: how did we ever do 
without it? Catheter Cardiovasc Interv 2008 Mar 1;71(4):490-503. (2008a) 
(9) Hecht HS, Jelnin V, Roubin GS. Indications for multidetector computed tomographic coronary angiography after catheter-based coronary 
angiography. J Invasive Cardiol 2008 Jan;20(1):1-6. (2008b) 
(10) Hoffmann U, Pena AJ, Cury RC, Abbara S, Ferencik M, Moselewski F, et al. Cardiac CT in emergency department patients with acute chest 
pain. Radiographics 2006 Jul;26(4):963-78. 
(11) Johnson PT, Eng J, Pannu HK, Fishman EK. 64-MDCT angiography of the coronary arteries: nationwide survey of patient preparation practice. 
AJR Am J Roentgenol 2008 Mar;190(3):743-7. 
(12) Kolnes K, Velle OH, Hareide S, Hegbom K, Wiseth R. Multislice computed tomography coronary angiography at a local hospital: Pitfalls and 
potential. Acta Radiol 2006 Sep;47(7):680-6. 
(13) Lesser JR, Flygenring B, Knickelbine T, Hara H, Henry J, Kalil A, et al. Clinical utility of coronary CT angiography: coronary stenosis detection 
and prognosis in ambulatory patients. Catheter Cardiovasc Interv 2007 Jan;69(1):64-72. 
(14) Loewinger L, Budoff MJ. New advances in cardiac computed tomography. Curr Opin Cardiol 2007 Sep;22(5):408-12. 
(15) Philippe F. [Invasive angiography, computed tomography or magnetic resonance imaging for coronary imaging and cardiovascular risk 
stratification? Regulatory and practical considerations]. Ann Cardiol Angiol (Paris) 2004 Mar;53(2):79-90. 
(16) Picano E, Lombardi M, Neglia D, Lazzeri M. [Sustainability of medical imaging in cardiology]. Recenti Prog Med 2006 Nov;97(11):652-62. 
(17) Poon M. Technology insight: Cardiac CT angiography. Nat Clin Pract Cardiovasc Med 2006 May;3(5):265-75. 
(18) Raman SV, Winner MW, III. Clinical decision making with contemporary cardiovascular imaging: ischemic heart disease. J Cardiovasc Med 
(Hagerstown ) 2007 Nov;8(11):959-64. 
(19) Roberts WT, Bax JJ, Davies LC. Cardiac CT and CT coronary angiography: technology and application. Heart 2008 Jun;94(6):781-92. 
(20) Rubinshtein R, Halon DA, Gaspar T, Jaffe R, Goldstein J, Karkabi B, et al. Impact of 64-slice cardiac computed tomographic angiography on 
clinical decision-making in emergency department patients with chest pain of possible myocardial ischemic origin. Am J Cardiol 2007 Nov 
15;100(10):1522-6. (2007b) 
(21) Rubinshtein R, Halon DA, Kogan A, Jaffe R, Karkabi B, Gaspar T, et al. Initial experience with a cardiologist-based chest pain unit in an 
emergency department in Israel. Isr Med Assoc J 2006 May;8(5):329-32. 
(22) Rubinshtein R, Halon DA, Gaspar T, Jaffe R, Karkabi B, Flugelman MY, et al. Usefulness of 64-slice cardiac computed tomographic 
angiography for diagnosing acute coronary syndromes and predicting clinical outcome in emergency department patients with chest pain of uncertain 
origin. Circulation 2007 Apr 3;115(13):1762-8. (2007a) 
(23) Schoenhagen P, Stillman AE, Garcia MJ, Halliburton SS, Tuzcu EM, Nissen SE, et al. Coronary artery imaging with multidetector computed 
tomography: a call for an evidence-based, multidisciplinary approach. Am Heart J 2006 May;151(5):945-8. 
(24) Schoepf UJ, Zwerner PL, Savino G, Herzog C, Kerl JM, Costello P. Coronary CT angiography. Radiology 2007 Jul;244(1):48-63. 
(25) Schoepf UJ, Becker CR, Hofmann LK, Das M, Flohr T, Ohnesorge BM, et al. Multislice CT angiography. Eur Radiol 2003 Aug;13(8):1946-61. 
(26) Schoenenberger E, Schnapauff D, Teige F, Laule M, Hamm B, Dewey M. Patient acceptance of noninvasive and invasive coronary angiography. 
PLoS ONE 2007;2(2):e246. 
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(27) Schroeder S, Kuettner A, Beck T, Kopp AF, Herdeg C, Heuschmid M, et al. Usefulness of noninvasive MSCT coronary angiography as first-line 
imaging technique in patients with chest pain: initial clinical experience. Int J Cardiol 2005 Jul 20;102(3):469-75. 
(28) Schuijf JD, Bax JJ, van der Wall EE. Non-invasive visualization of the coronary arteries with multi-detector row computed tomography; 
influence of technical advances on clinical applicability. Int J Cardiovasc Imaging 2005 Apr;21(2-3):343-5. 
(29) Schuijf JD, Jukema JW, van der Wall EE, Bax JJ. The current status of multislice computed tomography in the diagnosis and prognosis of 
coronary artery disease. J Nucl Cardiol 2007 Jul;14(4):604-12. 
(30) White CS, Kuo D. Chest pain in the emergency department: role of multidetector CT. Radiology 2007 Dec;245(3):672-81. 
(31) Zimmet JM, Miller JM. Coronary artery CTA: imaging of atherosclerosis in the coronary arteries and reporting of coronary artery CTA findings. 
Tech Vasc Interv Radiol 2006 Dec;9(4):218-26. 
 
CRD-Databases 
(1) NHS Quality Improvement Scotland: The use of multislice computed tomography angiography (CTA) for the diagnosis of coronary artery disease. 
Glasgow: NHS Quality Improvement Scotland (NHS QIS).  Evidence Note 9. NHS Quality Improvement Scotland (NHS QIS), 2005 
(2) Ontario Ministry of Health and Long-Term Care: Multi-detector computed tomography angiography for coronary artery disease.Toronto: Medical 
Advisory Secretariat, Ontario Ministry of Health and Long-Term Care (MAS), 2005 
(3) Medical Services Advisory Committee: Diagnostic and therapeutic modalities for coronary artery disease. Horizon Scanning 003. Medical 
Services Advisory Committee.  2003 
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Appendix 3: Publications excluded after fulltext screening 
 
Reference Study type Social aspects mentioned Remarks 
PubMed 
Bax, 2007 Narrative review on multiple imaging technologies none  
Beanlands, 2007 Systematic review on accuracy and prognosis data none  
Cardematriri, 2005 Narrative review of (technical) patient preparation to achieve optimal 
image quality 
none  
Dewey, 2004 Narrative comparison of different non-invasive diagnostic modalities 
for CAD 
none  
Gallagher, 2008 Narrative review on the "Triple rule out" strategy none  
Gani, 2007 Narrative comparison of different non-invasive diagnostic modalities 
for CAD 
none  
Goldstein, 2007 RCT MSCT versus standard care time to definite diagnosis given in hours; no patient perspective 
Hamon, 2006 Meta-Analysis of diagnostic studies none Also contained in CRD-Database search 
Hecht, 2008a   publication not accessible 
Hecht, 2008b retrospective Case series of MSCT after invasive angiography none  
Hoffmann, 2006 Educational paper on Utility of MSCT none  
Johnson, 2008 Survey on patient preparation practice, practical aspects only none  
Kolnes, 2006 Diagnostic accuracy study in a local hospital none  
Lesser, 2007 Accuracy and prognosis study none  
Loewinger, 2007 Narrative Review on Utility of MSCT none  
Philippe, 2004 Narrative Review on Utility of MSCT, MRI  and invasive angiography none  
Picano, 2006 Narrative review on the radiation exposure by different radiological 
examination 
not specifically for MSCT  
Poon, 2006 Narrative Review on Utility of MSCT none  
Raman, 2007 Vignette, illustrating clinical decisionmaking none  
Roberts, 2008 Narrative Review on Utility of MSCT none  
Rubinshtein, 2006 Evaluation of a chest pain unit including MSCT proportion of hospitalised 
patients 
not clear, how CPU care differed from routine ER 
care 
Rubinshtein, 2007a Proof-of-Concept study to establish the role of MSCT in ED triage none  
Rubinshtein, 2007b Double publication of the data from Rubinshtein 2007a   
Schoenhagen, 2006 Editorial – Need for evidence on diagnostic accuracy; need for 
multidisciplinary collaboration 
not data based 
(multidisciplinary 
cooperation) 
 
Schoepf, 2003 Narrative Review on possible clinicial utility none  
Schoepf, 2007 Review of practical aspects of MSCT none  
Schuif, 2005 Editiorial Comment on Technical advances none  
Schuif, 2007 Narrative Review on possible clinicial utility none  
White, 2007 Narrative Review on Utility of MSCT none  
Zimmet, 2006 Narrative Review of result interpetation none  
CRD Databases 
NHS QIS, 2005 Quality Improvement Issues none  
MAS, 2005 Effectiveness and economic review not data based (one 
statement on patients fear 
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Reference Study type Social aspects mentioned Remarks 
of complications) 
MSAC, 2003   Publication not publicly available anymore 
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Appendix 4: Results of the literature review, included studies (n=2) 
 
Study characteristics 
Reference Study type Setting Patients Radiologic Examinations Follow-Up-Investigations Completeness of 
Follow-Up 
Limitatations/ Remarks 
Schoepf, 2003 Prospective case series Cardiac Imaging Outpatient 
Clinic of University hospital; 
routine care 
n=142 consecutive patients of the 
department 
gender: 
Age 
Inclusion criteria: 
Clinical suspicion of CAD or 
progression of CAD after PTCA or 
CABG because of chest pain 
and/or positive stress test. 
Exclusion criteria: Acute coronary 
syndrome, stented lesions, 
chronic congestive heart failure, 
renal insufficiency, 
hyperthyeoridism, allergic 
reaction against contrast media, 
COPD 
MSCT 
Somatom Volume Zoom 4-slice 
scanner (Siemens) or Somatom 
Sensation 16 (Siemens) 
Result reporting: 
Group I: No coronary 
angiography recommended 
Ia: no severe stenosis detected 
IIb: CAD excluded 
Group II: Coronary angiography 
recommended 
IIa: detection of stenosis 
IIb: insufficient image quality or 
calcifications prohibiting 
determination of lesion severity 
Telephone interview after 455 ± 
155 days: 
a) Compliance of treating 
physicians with MSCT results 
b) Results of angiography if 
performed 
c) Correspondence of 
angiography results with MSCT 
d) Patients clinical symptoms 
(better – equal – worse) 
e) Patients satisfaction with care 
in Cardiac Imaging Outpatient 
Clinic (very satisfied – satisfied – 
not satisfied) 
f) Quality of life (better – equal – 
worse) 
136 of 142 
Drop Outs: 
2 deaths (carcinoma, 
unknown reason) 
4 moved away (1 
consent withdrawn) 
one-arm study, no control 
group 
Instruments for follow-up 
investigation not specified 
Schönenberger, 
2007 
Cross-sectional 
comparative study; 
survey of patient 
acceptance of invasive 
and non-invasive 
coronary angiography 
MSCT, MRI, 
Angiography 
University Hospital (part of an 
investigator initiated study to 
determine accuracy of MSCT 
and MRI) 
n=111 consecutive patients 
n=28 (26%) female 
mean age: 63 ± 8 years 
Inclusion criteria: suspected CAD 
Exclusion criteria: contraindication 
against MSCT, MRI or 
angiography 
MSCT 
Aquilion 16 (Toshiba) 
MRI 
1,5T MRI Scanner (Siemens) 
Angiography (Integris 2000, 
Philips) 
Written questionnaires to be filled 
one day after completion of all 
tests 
patient acceptance of: 
a) preparation and information 
prior to tests 
b) degree of concern prior to test 
c) comfort through the test 
d) degree of helplessness during 
the tests 
e) overall satisfaction 
all: 5-point Likert scale 
f) maximum subjective pain level 
(VAS 0-100) 
g) preference for future 
examinations 
h) free text comments on 
advantages / disadvantages of 
examinations 
111 of 111 (100%) 
 
patients were blinded to 
diagnostic test results upon 
completion of the 
questionnnaire 
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Results 
Reference MSCT results Compliance with MSCT results Follow-Up Diagnostic accuracy Clinical symptoms Quality of life Patient satisfaction Remarks 
Schoepf, 2003 Group I 
Ia: n= 51 
IIb: n=26 
Group II 
IIa: n=38 
IIb: n=21 
Group I 
Ia: n= 47 (92%) 
IIb: n= 26 (100%) 
Group II 
IIa: n=16 (42%) 
IIb: n=7 (33%) 
Group I: 4 angiographies 
performed against 
recommendations in 77 patients, 
2 with positive results 
(by recommendation: false 
negative rate of MSCT: 2,6%) 
Group II: 23 out of 59 
recommended angiographies 
performed, 7 with negative 
results 
(by recommendation: false 
positive rate of MSCT: 11,8%) 
Group Ia: 
better 18 (35%) 
equal 33 (65%) 
worse 0 (0%) 
Group Ib: 
better 13 (50%) 
equal 13 (50%) 
worse 0 (0%) 
Group IIa 
better 12 (32%) 
equal 24 (64%) 
worse 2 (4%) 
Group IIb: 
better 5 (24%) 
equal 14 (66%) 
worse 2 (10%) 
Group Ia: 
better 16 (32%) 
equal 35 (68%) 
worse 0 (0%) 
Group Ib: 
better 10 (38%) 
equal 16 (62%) 
worse 0 (0%) 
Group IIa 
better 12 (32%) 
equal 25 (66%) 
worse 1 (2%) 
Group IIb: 
better 4 (19%) 
equal 15 (71%) 
worse 2 (10%) 
Group Ia: 
very satisfied 18 (35%) 
satisfied 32 (63%) 
not satisfied 1 (2%) 
Group Ib: 
very satisfied 11 (42%) 
satisfied 14 (54%) 
not satisfied 1 (4%) 
Group IIa 
very satisfied 7 (18%) 
satisfied 28 (74%) 
not satisfied 3 (8%) 
Group IIb: 
very satisfied 6 (29%) 
satisfied 14 (66%) 
not satisfied 1 (5%) 
 
Schönenberger, 
2007 
not given not given not given Pain on VAS (mean  SD) 
MSCT 0.9  4,5 
MRI 5,2  16,6 
Angio 24,6  23,4 
 
Comfort during test 
5-point Likert-Scale 
(mean  SD) 
MSCT 1,49  0,64 
MRI 1,75  0,81 
Angio 1,54  0,68 
 
Patient acceptance of  
Preparation and Information 
5-point Likert-Scale 
(mean  SD) 
MSCT 1,27  0,52 
MRI 1,35  0,64 
Angio 1,48  0,72 
Degree of concern prior to 
test 
5-point Likert-Scale 
(mean  SD) 
MSCT 1,51  0,85 
MRI 1,64  0,93 
Angio 2,75  1,23 
Degree of helplessness 
5-point Likert-Scale 
(mean  SD) 
MSCT 1,19  0,48 
MRI 1,39  0,89 
Angio 1,52  0,86 
 
 
Overall satisfaction 
5-point Likert-Scale 
(mean  SD) 
MSCT 1,32  0,51 
MRI 1,58  0,89 
Angio 1,46  0,61 
Preferred test 
MSCT 80 (75%) 
MRI 18 (16%) 
Angio 13 (12%) 
Not preferrred test 
MSCT 31 (28%) 
MRI 93 (84%) 
Angio (98 (88%) 
Open commentaries 
Advantages (n; %*): 
MSCT 
104 comments by 79 patients 
Fast 63; 61% 
uncomplicated 13; 13% 
painless 11; 11% 
noninvasive 7;7% 
non confinement 4; 4% 
noncardiac findings, low risk, outpatient 
setting, silent, no fear, comfortable each 
1; 1% 
MRI 
42 comments by 38 patients 
no radiation 13; 31 
nonvasive 11; 26% 
painless 7; 17% 
uncomplicated 3; 7% 
fast 2; 5% 
noncardiac findings, low risk, outpatient 
setting, no contrast agent, images 
immediately available, active 
cooperation of patient each: 1; 2% 
Angio 
65 comments given by 59 patients 
therapy possible 33; 51% 
highest accuracy 16; 25% 
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Reference MSCT results Compliance with MSCT results Follow-Up Diagnostic accuracy Clinical symptoms Quality of life Patient satisfaction Remarks 
images during examination 8;12% 
faster information regarding findings 3; 
5% 
fast 2;3% 
painless 2; 3% 
Disadvantages (n; %): 
MSCT 
37 comments by 34 patients 
radiation 23; 62% 
contrast agent 7;19% 
no therapy 3;8% 
long breathhold 3; 8% 
no online images 1;3% 
MRI 
105 comments by 73 patients 
long examination 43;41% 
confinement 34;32% 
noise 9;9% 
long and frequent breathholds 7;7% 
strenuous 3;3% 
great strain 3;3% 
being alone 2;2% 
no therapy, active cooperation, fan, felt 
cold each: 1;1% 
Angio 
112 comments given by 75 patients 
long lying flat after procedure 35; 31% 
invasive 17; 15% 
pressure dressing 15; 13% 
pain 14; 13% 
time consuming 8; 7% 
possible adverse effects 8;7% 
inpatient setting 3; 3% 
radiation 2;2% 
groin hematoma 2;2% 
not possible to use restroom 2; 2% 
constrast agent, duration, more 
expensive, narrow table, sensation of 
catheter in the heart, psychological 
stress each 1;1% 
* percentages relate to total number of commentaries given to the respective test 
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Legal Aspects 
Marco Marchetti, Marco Oradei, Mirella Corio, Carmen Furno, Matteo Ruggeri, Laura Walin 
Introduction  
Multi(64)-slice computed tomography (MSCT) was recently introduced into the market. It is 
proposed to be a substantial improvement in the diagnostics of cardiac diseases, when compared 
with traditional, invasive alternatives. Legal issues related to MSCT technology are discussed in 
this domain. Some are directly related to the patient and his/her basic rights, such as autonomy, 
informed consent, privacy and confidentiality. Introduction of MSCT in coronary angiography does 
not represent a major change in legal issues compared to existing computed tomography protocols; 
there are no specific regulations, principles or guidelines dedicated to MSCT. Therefore some 
issues in this domain were considered not relevant and they were not translated into research 
questions. 
 
The issues that are directly linked to MSCT technology, such as authorisations, patents/licenses, 
price and reimbursement regulations, product safety, guarantee and liability, and European 
directions, do not include specific instructions for MSCT. Rather, they follow the general 
regulations of similar imaging technologies. Also the acquisition processes are similar to those 
previously applied in acquiring imaging technologies using ionizing radiation (i.e. CE certification 
for new technologies). 
Methodology  
The authors performed a comprehensive search on several issues. All sources of relevant, topic 
related information, from both legal and patient autonomy perspectives, were considered. The 
methodology of this Core HTA is based on several steps that are reported below. Each issue 
contains a specific methods section. 
 
1. According to the guidelines provided by the Corel Model, legal sources related to MSCT 
were analysed at the different levels requested.   
– European Council Level (i.e. Convention on Human Rights and Biomedicine and 
European Human Rights Convention) 
– EU level (medical devices guidelines) 
– National level  
– Documentation provided by MSCT producers. 
 
2. Subsequently the authors performed a search in legal databases such as EURlex and DOGIS 
using specific key words for each specific topic: ―market‖, ―guarantee‖, ―property‖, 
―ownership‖, ―liability‖, ―safety‖, ―tourism‖, ―privacy‖, ―advance directive‖, ―medical file‖, 
―medical data‖, ―consent‖, ―autonomy‖, ―information‖, ―equality‖, and variations of these 
roots. Articles on medical-legal aspects were searched in Medline with Pubmed search 
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engine, using a specific search strategy (see appendix 1). The results were limited to articles 
published in the last five years. In total 171 articles were selected from Pubmed. 
 
3. An analogous search strategy was used in Cinahl and Emerald databases. The results of 
these strategies are reported in Appendices 2 and 3 respectively. 
 
4. Finally, articles were searched also in grey literature using generic search engines (e.g. 
Google). 
Assessment elements  
Autonomy of the patient  
Can future patients understand the implications of using/not using the MSCT? 
Methods  
Search on Eur-lex internet database was performed in order to find EC legislation on informed 
consent. Analysis of guidelines on appropriateness criteria for cardiac computed tomography. 
Examination of patient information sheets about radiological procedures with contrast injection 
obtained by internet search on hospitals‘ websites.  
Results  
Patient‘s capacity to understand the health implication of being submitted to CT scan is connected 
to the type of information received from the physician and the way it is transferred. The potentially 
harmful effects of radiation exposure should be explained to the patient. The Practice Guidelines on 
informed consent for image-guided procedures elaborated by American College of Radiology 
state:―Because of the documented low incidence of adverse events in intravenous injection of 
contrast media, this may be exempted from the need for informed consent, but this decision should 
be based on state law, institutional policy, and departmental policy‖(1). 
 
Consensus on the use of CT in the assessment of coronary artery disease is still developing. The 
first major document dealing with the clinical indication for a range of clinical scenarios for MSCT 
was recently published by American College of Cardiology (ACC) and AHA. It is clear from these 
reports that there are a larger number of situations were appropriates of MSCT is uncertain. A list of 
appropriate indications for cardiac CT is reported below (2):  
 
CT Coronary Angiography is appropriate in the 
– Evaluation of chest pain syndrome when there is 
o intermediate pre-test probability of coronary artery disease (CAD), uninterpretable 
ECG and the patient is unable to exercise 
o uninterpretable or equivocal stress test (exercise, perfusion or stress echo) 
– Evaluation of acute chest pain when there is 
o Intermediate pre-test probability of CAD, no ECG changes and serial enzymes 
negative 
– Assessment of complex congenital heart disease, including anomalies of coronary 
circulation, great vessels and cardiac chambers and valves 
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– Evaluation of coronary arteries in patients with new-onset heart failure to assess aetiology  
– Non-invasive coronary arterial mapping, including internal mammary artery before repeated 
cardiac surgical revascularisation 
 
In emergency situations (not just in the emergency department), when immediate treatment is 
required to prevent more serious harm, the patient lacks decision making capacity, and no substitute 
decision maker (surrogate) is always available. In these circumstances law allows emergency 
medical treatment to be administered without consent. MSCT procedures are usually elective. 
Therefore, when patients are legally competent an informed consent needs to be obtained. Informed 
consent is a communicative process of sharing information with patients, ascertaining their 
understanding of the information, and asking for their cooperation and their permission to proceed. 
Patients legally competent to give their own consent are usually able to understand the procedure of 
MSCT coronary angiography and its clinical implications, if correctly explained. 
 
Three essential elements in obtaining informed consent (3,4): 
1. Determining whether the patient has decision making capacity (can understand the options, 
understand the risks and benefits to them of the options, and make decisions based on a 
stable set of values and goals). If the patient lacks decision making capacity, the surrogate 
decision makers should be given the same information. 
2. Providing patients with sufficient information to allow them to make an informed choice. 
3. Allowing patients to make their decision voluntarily and without coercion. 
 
Are there relevant optional technologies for MSCT that future patients should 
be allowed to consider? 
Methods  
Search on Eur-lex internet database in order to find EC legislation on informed consent. 
Analysis of guidelines on appropriateness criteria for cardiac computed tomography.  
Examination of patient information sheets about radiological procedure with contrast injection 
obtained by internet search on hospitals‘ websites.  
Results  
The concept of informed consent also comprises the possibility to consider other diagnostic and 
therapeutic choices. The available alternatives to MSCT are invasive coronary angiography and 
cardiac magnetic resonance imaging. Invasive coronary angiography is currently the gold standard 
for assessing coronary artery stenoses. The patients' informed consent forms (found by internet 
search on world wide hospitals‘ websites) usually also inform patients on risks with injection of 
radiographic intravenous contrast media (3).  
Is it possible to give future patients enough time to consider their MSCT related 
decisions? 
Methods  
Semi-structured interviews to a radiologist and a medico-legal clinician in staff at an Italian 
university hospital were performed. 
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Results  
In an elective MSCT scan procedure it is possible to have advance meetings with the patients, so 
that they can receive all of the necessary information to make informed decisions on their health. If 
MSCT scan is performed in emergency situation the patient may not have enough time to decide 
whether to submit to the diagnostic procedure. Moreover, it is possible that the patient temporarily 
lacks decision making capacity. 
 
Is it possible to obtain an advance directive on the use of MSCT? 
Methods  
Search on Eur-lex internet database in order to found EC legislation on advance directive.  
Internet research has been performed in order to find advance directives related to the MSCT scan 
procedure.  
Results  
An advance directive is a legal document that helps to ensure that patient's wishes will be respected 
if he becomes unable to speak or otherwise communicate. In the absence of a written document, an 
advance directive may sometimes be an oral communication, where patient express his wishes for 
care verbally to his family members or health care professional. An advance directive may become 
important if patient are severely injured or develop a serious illness that prevents him from actively 
participating in decisions about his medical care. 
 
Living wills and medical powers of attorney are types of advance directives. 
– A living will documents personal wishes about end-of-life medical treatment in case 
decision-making or communication abilities are lost due to e.g. ventilation or feeding tubes 
or in the event the patient is in a terminal condition or persistent vegetative state.  
– A medical power of attorney is a legal document that lets a person appoint someone (usually 
called a health care agent or health care proxy) to make medical treatment decisions for 
him/herself not only at the end of life but at any time one is unable to speak for oneself.  
 
Convention On Human Rights And Biomedicine (art. 9 ) establishes that ‖The previously expressed 
wishes relating to a medical intervention by a patient who is not, at the time of the intervention, in a 
state to express his or her wishes shall be taken into account‖ (4). Each Country has proper Laws 
for assigning individuals their rights to decide on their own life, depending on the legal value they 
assign to ―life‖ as a good. As a consequence, different rights to decide on one's own life, could 
affect, in case of life danger, advance directives‘ relevance. 
 
The performed research produced no meaningful results that link advance directives with MSCT 
scan procedures; it has been thought that it is not necessary to obtain an advance directive on the 
use of this specific technology.  
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Privacy of the patient 
Does the use of MSCT produce such information on the patient that is not 
directly relevant to the disease/condition that is being diagnosed or tested? 
Methods 
Literature review on clinical use of MSCT and semi-structured interview to a radiologist and a 
medico-legal clinician in staff at an Italian university hospital were performed. 
Results 
No evidence was found that MSCT would produce such additional information on patients that 
would violate their privacy. Incidental findings (e.g. pulmonary nodules) are described in the in the 
safety domain.  
 
Does the use of MSCT produce information that would be relevant for relatives 
of the patient? 
Methods 
Literature review on clinical use of MSCT and semi structured interview to a radiologist and a 
medico legal clinician in staff at an Italian university hospital were performed. 
Results 
The MSCT does not produce additional information on patients relevant for their relatives. 
 
Can the access to the patient database be secured properly? 
Methods  
An analysis of the sources of legislation at European level was carried out. The search was done 
using specific search engines. The keywords used were 'Privacy in health care', 'Patient privacy, 
MSCT.' 
Results 
The systems of data handling, regardless of nationality or residence of individuals, have to respect 
the freedoms and fundamental rights of people, in particular their privacy as announced by 
Directive 95/46/EC, October 24 1995 of the European Parliament and European Union Council (5), 
on the protection of individuals with regard to the processing of personal data, in Section III, Article 
8, Member States prohibit the processing of personal data concerning health. This principle shall 
not apply where:  
 
(Citation from art 8 point 2) 
– the data subject has given his explicit consent to the processing of those data or 
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– processing is necessary for the purposes of carrying out the obligations and specific rights of 
the controller in the field of employment law in so far as it is authorized by national law 
providing for adequate safeguards; or 
– processing is necessary to protect the vital interests of the data subject or of another person 
where the data subject is physically or legally incapable of giving his consent; or 
– processing is carried out in the course of its legitimate activities with appropriate guarantees 
by a foundation, association or any other non-profit-seeking body with a political, 
philosophical, religious or trade-union aim and on condition that the processing relates 
solely to the members of the body or to persons who have regular contact with it in 
connection with its purposes and that the data are not disclosed to a third party without the 
consent of the data subjects; or 
– the processing relates to data which are manifestly made public by the data subject or is 
necessary for the establishment, exercise or defence of legal claims 
 
In addition, the point 3 in Article 8 states that the general principle shall not apply: ―where 
processing of the data is required for the purposes of preventive medicine, medical diagnosis, the 
provision of care or treatment or the management of health-care services, and where those data are 
processed by a health professional subject under national law or rules established by national 
competent bodies to the obligation of professional secrecy or by another person also subject to an 
equivalent obligation of secrecy‖ 
 
In the sequent section VIII, article 17, the Directive foresees that:  ―Member States shall provide 
that the controller must implement appropriate technical and organizational measures to protect 
personal data against accidental or unlawful destruction or accidental loss, alteration, unauthorized 
disclosure or access, in particular where the processing involves the transmission of data over a 
network, and against all other unlawful forms of processing. Having regard to the state of the art 
and the cost of their implementation, such measures shall ensure a level of security appropriate to 
the risks represented by the processing and the nature of the data to be protected‖. 
 
What levels of access to which kind of patient information exist in the chain of 
care? 
Methods  
An analysis of regulatory sources was carried out on specific search engines by using a specific 
keyword like ―privacy of patient‖. 
Results 
Using MSCT does not imply a specific management of patients‘ clinical data in order to guarantee 
the privacy of patients. Access to the patients‘ data must be allowed to all clinical professionals 
involved in the health care process (referral clinicians, nurses, residents, etc). In the European 
context EuroSOCAP Commission, has produced a document containing standard on confidentiality 
and privacy in health care. The document states that: ―All patients have the right to privacy and the 
reasonable expectation that the confidentiality of their personal information will be rigorously 
maintained by all healthcare professionals. Each patient‘s right to privacy and the professional‘s 
duty of confidentiality apply regardless of the form (for example, electronic, photographic, 
biological) in which the information is held or communicated. Not all healthcare professionals are 
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bound by the same legal obligations of confidence, but all are under the same ethical obligations to 
maintain confidentiality. Particular care is needed on the part of healthcare professionals to ensure 
that the right to privacy of vulnerable patients is respected and that their duty of confidentiality 
toward them is fulfilled‖(6). 
 
Another European committee, Cittadinanzattiva-Active Citizenship Network group, has elaborated 
the ―European Charter of Patients' rights‖ identifying fourteen rights; the sixth states: ―Every 
individual has the right to the confidentiality of personal information, including information 
regarding his or her state of health and potential diagnostic or therapeutic procedures, as well as the 
protection of his or her privacy during the performance of diagnostic exams, specialist visits, and 
medical/surgical treatments in general. 
 
All the data and information relative to an individual‘s state of health, and to the medical/surgical 
treatments to which he or she is subjected, must be considered private, and as such, adequately 
protected. Personal privacy must be respected, even in the course of medical/surgical treatments 
(diagnostic exams, specialist visits, medications, etc.), which must take place in an appropriate 
environment and in the presence of only those who absolutely need to be there (unless the patient 
has explicitly given consent or made a request)‖ (7). 
 
Equality in health care 
Is MSCT equally accessible to all needing members in a given society? 
Methods  
An analysis of regulatory sources was carried out on search engines by using specific keywords like 
―equality care‖, ―accessibility‖. 
Results  
As provided in Article 35 of the Charter of Fundamental Rights of the European Union, every 
individual has the right of access to preventive health care and to obtain medical care, surgical 
procedures and diagnostic performance under the conditions established by national laws and 
practices (8). The definition and implementation of all policies and activities shall ensure a high 
level of protection of human health. The equality in health care is a main topic in the Convention 
for the Protection of the Rights and Dignity of the Human Being with regard to biology and 
medicine: Convention on the Rights and Biomedicine.  
 
The introduction of MSCT may reduce the time needed to diagnose coronary artery disease It may 
shorten the waiting lists for elective examinations, and give a more immediate answer to the 
patients more equally. However it is necessary to highlight the balance between improved access 
and the available resources managing the highly complex technology of MSCT, which may cause 
problems especially in rural areas and further away from large urban centres (9). 
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Is MSCT subsidized by the society? 
Methods  
An analysis of legal sources at International level was performed. Articles were searched from 
scientific journals and ad hoc searches from both generic search engines (e.g. Google) and 
specialized databases (e.g. Pubmed). 
Results 
From the legal point of view no evidence of specific subsidizing principles of MSCT was found.  
Cost of purchasing and maintenance of MSCT or fee for service delivered have been subsidized by 
health care systems.  
 
Is there a wide variation in the acceptability of MSCT across Europe? 
Methods  
An analysis of legal sources at National level was performed. Articles were searched from scientific 
journals and ad hoc searches from both generic search engines (e.g. Google) and specialized 
databases (e.g. Pubmed). 
Results  
The performed search produced no meaningful results in terms of wide variation in the acceptability 
of the technology across Europe. As a consequence, since it is difficult to find differences in the 
comparison of the legal issues concerning the acceptability, we should deduce that the technology 
issues are not controversial. 
 
Is health-care tourism expected from/to other European countries? 
Methods  
Sources of legal information at European level were searched. Specific search engines, using 
keywords such as: ―Cross-border health care‖, ―Mobility, MSCT‖ and ―Health care tourism, 
MSCT‖. 
 Results:  
The coordination of care and diagnostic services that are provided across borders is increasingly 
becoming in the field of European legislation. In particular, the border areas are developing more 
flexible procedures for access to treatment. An analysis of these developments from the institutional 
/ constitutional (economic) point of view suggests that a great legislative flexibility could lead to 
paretian improvements and, as a consequence, to an improvement in equity for migrants. This 
theory could be applied also to the international mobility based on access to MSCT. In this case 
mobility should follow the migratory flows from Eastern European nations, recently joined the 
European Union (Romania, Poland, Bulgaria), to countries like Italy, Spain and France (10).  The 
bilateral agreements and the flexible procedures in the frontier areas should be encouraged to adapt 
the institutional arrangements to the request for "cross-border" care. This can be made possible by 
the judgement of the Court of Justice of the European Community that enforce to reimburse the cost 
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of treatment delivered in a hospital in another member state that applies to a national health service 
which provides such treatment free of charge. In the case of MSCT the regulations governing 
international mobility may be applied and these should consequently cover the problems and 
dynamics in general (11) . 
 
End-users 
Who is the intended end-user of MSCT? 
Methods 
Scientific articles on this issue were not found, therefore a semi structured interview to a radiologist 
and a medico legal staff clinicians was performed at an Italian university hospital. 
Results 
MSCT end users are: 
1. Patients who need: 
– A clear, understandable and complete information on the MSCT and options in order to 
make a conscious decision assuming that the technology meets the safety standards 
established by EC or national laws. 
2. Medical professionals who need: 
– Easiness of use. 
– On-going training. 
– Protection from radiation exposure. 
3. Regulatory institutions who require: 
– CE marks 
– Conditions that are in line with EU's and national laws. 
 
Is the use of MSCT limited in legislation? 
Methods 
Search on Eur-lex internet database in order to find EC legislation.  
Results 
Radiation in large doses can cause injury and death or induce cancer. Chronic exposure to lower 
levels of radiation may cause an increased risk of certain kinds of disease, such as cancer. The 
major source of radiation exposure to the public is medical and environmental. Medical exposure 
involves radiation-producing machine such as computed tomography. The Directive 97/43/Euratom 
(―Health protection of individuals against the dangers of ionizing radiation in relation to medical 
exposure, and repealing Directive 84/466/Euratom‖) (12) states the general principles of the 
radiation protection of individuals in relation to medical exposure. The use of MSCT is allowed 
when it guarantees two principles: 
1. Justification principle; 
2. Optimization principle. 
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The first principle means that medical exposure to MSCT shall show a sufficient net benefit, 
weighing the total potential diagnostic or therapeutic benefits it produces, against the individual 
detriment that the exposure might cause, taking into account the efficacy, benefits and risks of 
available alternative techniques having the same objective but involving no or less exposure to 
ionizing radiation. So a medical exposition through MSCT is forbidden when it is unjustified. The 
second principle means that radiation doses should be kept as low as reasonably achievable, still 
obtaining the required diagnostic information. 
 
EU member states shall promote the establishment and the use of diagnostic reference levels for 
ionizing radiation. The optimization process shall include the selection of equipment, the consistent 
production of adequate diagnostic information or therapeutic outcome as well as the practical 
aspects. It includes also quality assurance and quality control, and the assessment and evaluation of 
patient doses, or administered activities, taking into account economic and social factors. Written 
protocols shall be established for each equipment and for every type of standard radiological 
practice.  Member states shall ensure that recommendations concerning referral criteria for medical 
exposure, including radiation doses, are available to the prescribers of medical exposure. The 
Directive has been implemented in each single EU nation trough national implementing measures. 
 
Is the health care personnel using MSCT according to the professional 
standards? 
Methods 
Searches on Eur-lex internet database in order to find EC legislation, and on―Pubmed‖ with the 
following keywords: ―Ct angiography‖ and ―training‖ was carried out. 
Results 
―Council Directive 97/43/Euratom of 30 June 1997 (12) on health protection of individuals against 
the dangers of ionizing radiation in relation to medical exposure, and repealing Directive 
84/466/Euratom‖ states that (art.5) Member States shall ensure that any medical exposure is 
effected under the clinical responsibility of a practitioner. Clinical responsibility comprises (art.2 ): 
justification; optimization; clinical evaluation of the outcome; cooperation with other specialists and 
the staff, as appropriate, regarding practical aspects; obtaining information, if appropriate, of 
previous examinations; providing existing radiological information and/or records to other 
practitioners and/or prescribers, as required; giving information on the risk of ionizing radiations to 
patients and other individuals involved, as appropriate. In order to ensure that patients, personnel 
and the environment are protected, Members States shall ensure that the operators are properly 
trained (art. 7), and radiation equipment and facilities meet current protection standards (art. 8).  
 
Art. 7 establishes that Member States shall ensure that practitioners and other clinical operators 
have adequate theoretical and practical training for the purpose of radiological practices, as well as 
relevant competence in radiation protection. For this purpose Member States shall ensure that 
appropriate curricula are established and shall recognize the corresponding diplomas, certificates or 
formal qualifications. Member States shall ensure that continuing education and training after 
qualification is provided and, in the special case of the clinical use of new techniques, they shall 
assure the organization of training related to these techniques and the relevant radiation protection 
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requirements. Member States shall encourage the introduction of a course on radiation protection in 
the basic curriculum of medical and dental schools. 
 
The complex nature of imaging devices, as well as the rapidly advancing practices require the 
trainee to be introduced to MSCT. Scientific societies (i.e. ACC/AHA, British cardiovascular 
Society) have developed recommendations for attaining and maintaining the minimum experience, 
cognitive and technical skills necessary for competent performance of MSCT (13,14,15). A more 
detailed explanation is given in the organisational domain. 
 
Authorisation & safety 
Has MSCT national/EU level authorisation? 
Methods  
Scientific articles on this issue were not found, therefore an analysis of the database of European 
Lex and Directive (http://eur-lex.europa.eu)at European level was made. The search of the sources 
was conducted with the help of specific search engines and using keywords like ―level 
authorisation‖ and ―product safety‖. 
Results 
At the moment there are four models of MSCT 64-slice available in the market. All the products 
satisfy the authorisation requirements. 
 
Patient safety, as expressed in product safety, is one domain of health care technology assessment 
which clearly falls under the mandate of the European Union. It is important to consider all the 
various permission levels, starting with the European directive on eco-compatibility RoHS  
(2002/95/CE) and to identify in our case the potential exemptions, consulting Attachment 5 of the 
Decree, which provides exemptions for electro-medical technologies, such as the CT.  
 
There are national regulations for the characteristic of the premises where MSCT procedures are 
performed: a proper room, adequate energy sources and walls designed to protect from X-ray beams 
are needed. Crucial is also the radiation protection equipment both for the patient and operator. For 
example, in Italy, the Italian National Institute of Health ensures proper management of 
interventional and diagnostic imaging involving ionizing radiation, and issues appropriate 
guidelines to guarantee the imaging units' quality control (National Assembly) (16). The guidelines 
emphasize the technical management and quality control equipment and optimizing examinations 
and dosimetry of the patient, with particular reference to the evaluation of diagnostic reference 
levels and the provisions of the D.Lgs. 187/2000 (17,18). Similar guidelines exist in other countries 
as well (19,20). 
Comments 
MSCT is classified, according to Directive 2007/43/CE of European Council, as a device. This 
directive demands an approval defined as ―CE mark‖. It allows marketing the device in all 
European countries. 
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Does MSCT need to be listed in a national/EU register?  
Methods 
Consultation of the directive on ionizing radiations as available on Eurolex search engine (eur-
lex.europa.eu) 
Results 
―Council Directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the 
dangers of ionizing radiation in relation to medical exposure, and repealing Directive 
84/466/Euratom‖ establishes that each Member States shall ensure that (art.8) an up-to-date 
inventory of radiological equipment for each radiological installation must be available to the 
competent authorities. So, each Member State must organize its own register. 
 
Does MSCT fulfil product/tissue safety requirements?  
Methods 
Consultation of the directive on ionizing radiations as available on Eurolex search engine (eur-
lex.europa.eu) 
Results 
Many novel health technologies may utilize human cells or tissue. These products must fulfil the 
safety requirements issued by EC Directive 2004/23/EC; MSCT does not utilize those organic 
samples. So the above mentioned Directive is not applicable to MSCT. 
 
Nevertheless MSCT must fulfil other requirements for protection against ionizing radiation as it is 
stated by the ―Council Directive 97/43/Euratom of 30 June 1997 on health protection of individuals 
against the dangers of ionizing radiation in relation to medical exposure, and by the repealed 
Directive 84/466/Euratom‖. This directive is not referring specifically to MSCT but to any kind of 
radiological equipment. 
 
Ownership & liability 
Does MSCT infringe some intellectual property right? 
Methods 
Medline was searched using keywords such as ―computed tomography‖ and ―patent‖ or ―property 
right‖ in title. Also the following databases were consulted: CINAHL Plus with Full Text, NHS 
Economic Evaluation Database (Trial), Health Technology Assessments (Trial), Cochrane Central 
Register of Controlled Trials (Trial), Cochrane Database of Systematic Reviews (Trial), Database of 
Abstracts of Reviews of Effects (Trial). Keywords were ―msct‖ or ―mdct‖ and ―patent‖.  
EPO and World Intellectual Property Organization websites were also searched.  
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Results 
Articles from Medline were not pertinent to this issue. The search performed in CINAHL and others 
databases resulted in no article on the topic. We found many patents related to CT equipment, 
software and linked services. They did not reveal that CT would infringe any intellectual property 
rights. 
Does the introduction of MSCT presume some additional licensing fees to be 
paid?  
Methods 
Medline was searched using keywords such as ―computed tomography‖ and ―licensing fee‖. Also 
the following databases were consulted: CINAHL Plus with Full Text, NHS Economic Evaluation 
Database (Trial), Health Technology Assessments (Trial), Cochrane Central Register of Controlled 
Trials (Trial), Cochrane Database of Systematic Reviews (Trial), Database of Abstracts of Reviews 
of Effects (Trial). Keywords were ―msct‖ or ―mdct‖ and ―licensing fee‖.  
Results 
Articles from Medline were not pertinent to this issue. The search performed in CINAHL and others 
databases resulted in no articles on the topic. It is not apparent that the introduction of MSCT would 
presume additional fees to be paid. 
What are the width, depth and length of the manufacturers guarantee? 
Methods 
We have performed a search of the MSCT manufacturers‘ websites. 
Results 
We focused the analysis on the 64-slice MSCT. The table below shows the features of each MSCT 
system and manufacturers‘ guarantee. Data have been collected from rt-image website (21).  
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GE Healthcare 
 
GE Healthcare GE Healthcare Philips Medical Systems 
Siemens Medical 
Solutions 
Toshiba America 
Medical Systems 
Toshiba America 
Medical Systems 
Toshiba America 
Medical Systems 
Product Name LightSpeed VCT  LightSpeed VCT XT  LightSpeed VCT standard  Brilliance CT, 64-channel 
configuration  
SOMATOM Sensation  Aquilion 32  Aquilion 64  Aquilion 64 CFX  
Web Site www.gehealthcare.com  www.gehealthcare.com  www.gehealthcare.com  www.medical.philips.com  www.medical.siemens.co
m  
www.medical.toshiba.com
  
www.medical.toshiba.com
  
www.medical.toshiba.com
  
FDA-Approved Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  
DICOM-Compliant Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  
Images 
Slice Acquisition per 
Rotation 
64  64  64  N/A  24, 40, 64 depending on 
the version  
32 slices, upgradeable to 
64  
64 slices  64 slices  
Image Storage 
Capabilities 
146 GB for 250,000 
images ; 2.3 GB MOD and 
9.4 DVD-R DICOM  
146 GB for 250,000 
images ; 2.3 GB MOD and 
9.4 DVD-R DICOM  
146 GB for 250,000 
images ; 2.3 GB MOD and 
9.4 DVD-R DICOM  
292 GB  146 GB image disk 
(260,000 images) + 5.2GB 
MOD (7500 images) + 700 
MB CD-R (1100 images) 
+ 300 GB raw data disk  
180 GB hard drive; 9.4 GB 
DVD-RAM / CD-R; 
additional storage 
available  
180 GB hard drive; 9.4 GB 
DVD-RAM / CD-R; 
additional storage 
available  
180 hard drive; 9.4 GB 
DVD-RAM / CD-R 
Additional storage 
available  
Services 
Service/Support InSite remote support 
center is available 
24/7/365. Service offering 
can be customize to meet 
your unique needs, 
including: after-hour and 
weekend service, uptime 
performance guarantees, 
24/7 remote support, 
expedited part delivery, 
asset management  
After-hour and weekend 
service, uptime 
performance guarantees, 
24/7 remote support, 
expedited part delivery, 
asset management tools 
and much more  
InSite remote support 
center is available 
24/7/365. Service offering 
can be customize to meet 
your unique needs, 
including: after-hour and 
weekend service, uptime 
performance guarantees, 
24/7 remote support, 
expedited part delivery, 
asset management  
Customer Care Center 
offering tier 1 (24/7) and 
tier 2 support for 
applications and/or service 
assistance. Remote service 
network (with "Look-
Over-the-Shoulder" 
feature.)  
Available  National service support, 
InnerVision Plus, 
minimize system 
interruptions and optimize 
system utilization, 
monitors functionality and 
room conditions to identify 
and resolve problems 
before your system is 
compromised, allows 
transfer of clinical images  
National service support, 
InnerVision Plus, 
minimize system 
interruptions and optimize 
system utilization, 
monitors functionality and 
room conditions to identify 
and resolve problems 
before your system is 
compromised, allows 
transfer of clinical images  
National service support, 
InnerVision Plus, 
minimize system 
interruptions and optimize 
system utilization, 
monitors functionality and 
room conditions to identify 
and resolve problems 
before your system is 
compromised, allows 
transfer of clinical images  
Training University style 
curriculum, TVA, remote 
training with live 
interactive observation and 
two-way interaction, 
classroom training with 
hands-on lab work, CE 
credits for completion of 
TiP programs  
University-style 
curriculum, TVA, remote 
training with live 
interactive observation and 
two-way interaction, 
classroom training with 
hands-on lab work, CE 
credits for completion of 
TiP programs  
University-style 
curriculum, TVA, remote 
training with live 
interactive observation and 
two way interaction, 
classroom training with 
hands-on lab work, CE 
credits for completion of 
TiP programs  
Yes, on-site, off-site, 
computer-based CD, 
online  
Available  1 week at International 
Training Academy in 
California 1 week onsite, 1 
week follow-up onsite. A 
full complement of 
classrooms and labs, the 
most advanced training 
products, technologist 
training, physician 
training, practical hands-
on training*  
1 week at International 
Training Academy in 
California 1 week onsite, 1 
week follow-up onsite; a 
full complement of 
classrooms and labs, the 
most advanced training 
products, technologist 
training, physician 
training, practical hands-
on training*  
1 week at International 
Training Academy in 
California 1 week onsite, 1 
week follow-up onsite; a 
full complement of 
classrooms and labs, the 
most advanced training 
products, technologist 
training, physician 
training, practical hands-
on training*  
Warranty 1 year  1 year  1 year  1-year parts and labor  1 year  1 year  1 year  1 year  
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Is the user guide of MSCT comprehensive enough? 
Methods 
We have performed a search of the MSCT manufacturers‘ websites. 
Results 
Substantial changes in computed tomography (CT) protocols are essential as radiologists move 
from 4-slice to 16-slice and more recently towards 64-slice MSCT systems. As the number of CT 
applications expands with newer generations of CT systems, practicing radiologists face significant 
challenges. Not only must they develop and implement new protocols such as cardiac CT or 
peripheral angiography, but they need to revise established protocols in view of CT technical 
refinements (22). Given the abbreviated scan times associated with 16-slice and even more with 64-
slice CT, accurately timed contrast delivery becomes critical. GE, Philips, Siemens, Toshiba 
Manufacturers have developed Protocols for Multidetector CT.  
 
In particular protocols describe three features: 
1. Technical Considerations‖; 
2. Preparing Patients for Contrast-Enhanced Exams; 
3. Contrast medium Safety. 
 
Technical Considerations refer to: 
– Temporal resolution; 
– Spatial resolution; 
– Radiation dose; 
– CM administration; 
– Scan timing. 
Preparing Patient refers to: 
– Scheduling the exam; 
– Preparing the exam; 
– Planning the scan. 
Contrast Medium Safety refers to: 
– Patients at risk for contrast-induced nephropathy; 
– Patients with immediate-type hypersensitivity to contrast; 
– Other reactions to IV contrast administration; 
– Treatment of reactions to IV contrast; 
– Considerations when using gastrointestinal (GI) contrast. 
Regulation of the market 
Is MSCT subject to price control? 
Methods 
The European Court of Justice Database, Eurlex database was searched by using the keyword 
―MSCT‖ and ―price control‖. Medline, Cinhal, and Emerald were also searched using keywords 
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such as ―MSCT‖ and ―price control‖. In addition, a grey literature search on Italian system has been 
performed. 
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Results 
Search in European Court of Justice Database and Eurlex did not indentify any relevant information 
on MSCT linked to price control. Medline, Cinhal and Emerald searches did not either indentify 
any useful information. There seems not to be an explicit price control of the MSCT market.  
 
Is MSCT subject to acquisition regulation? 
Methods 
―Directive 2004/18/Ec‖ was consulted to verify if it contains prescriptions that may influence 
MSCT acquisition 
Results 
―Directive 2004/18/Ec‖ does not contain prescriptions on MSCT acquisition. This is a general law 
that regulates public works, supply, and service contracts, without explicit reference to medical 
devices sector. 
 
Is the marketing of MSCT to the patients restricted? 
Methods 
The European Court of Justice Database and Eurlex database were searched by using the keyword 
―MSCT‖ and ―market$‖ and ―marketing‖. Medline, Cinhal, and Emerald were also searched by 
using keywords such as ―MSCT‖ and ―market$‖ and ―marketing‖. In addition, a grey literature 
research on Italian system has been performed. 
Results 
CE marking is a legal requirement for medical devices intended for sale in Europe. MSCT CE 
marking is regulated by Council Directive 2007/47/EC of 5 September 2007 concerning medical 
devices. 
 
Legal regulation of novel/experimental techniques 
Is MSCT so novel that existing legislation has not been designed to cover its 
regulation? 
Methods 
Semi-structured interview to a radiologist and a medico legal clinician in staff at an Italian 
university hospital 
Results 
MSCT is not a new technology from this point of view. General regulation on CT is most likely 
suitable also for MSCT. 
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How are the liability issues solved according to existing legislation? 
Methods 
Semi structured interview to a radiologist and a medico legal clinician in staff at an Italian 
university hospital 
Results 
There are no specific liability questions about the use of MSCT. The liability is linked to an 
appropriate use of medical devices and diagnostic instruments. From this point of view the question 
is not pertinent to MSCT. 
 
Are new legislative measures needed? 
Methods 
Semi-structured interview to a radiologist and a medico-legal clinician in the staff of an Italian 
university hospital. 
Results 
MSCT does not require new specific legislation for its use. 
 
Is the voluntary participation of patients guaranteed properly? 
Methods 
Semi-structured interview to a radiologist and a medico-legal clinician in the staff of an Italian 
university hospital 
Results 
The technology cannot be considered experimental, and as a consequence this question is not 
pertinent to MSCT. In general the use of MSCT as medical diagnostic tool go under general laws on 
informed consent, see the topic ―Autonomy of patient‖. 
Discussion 
The objective of legal domain was to point out questions on basic rights of patients (autonomy, 
informed consent, privacy and confidentiality) and legal requirements of the new technology 
(authorisation, guarantee, regulation of market). It was very difficult to find specific information on 
MSCT on legal issues, because usually the literature and the laws use the general concept of CT. As 
a consequence, the MSCT, from this point of view is not a completely new technology, because its 
use, as far as legal issues are concerned, is similar to traditional CT. The main issues are about legal 
requirement to guarantee the safety (health protection of individuals against the dangers of ionizing 
radiation). 
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Assessment elements table 
 
ID Domain Topic Issue Relevance in 
the context of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
Or Comment (if regarded as a not relevant issue in this context) 
      
I0030  
Legal aspects 
 
End-user 
 
Who is the intended end-user of the technology? 
yes Who is the intended end-user of MSCT? 
I0031 Legal aspects End-user Is the use of the diagnostic technology limited in legislation? yes Is the use of MSCT limited in legislation? 
I0032 Legal aspects End-user Is the health care personnel using the technology according the 
professional standards 
 
yes Is the health care personnel using MSCT according to the professional 
standards? 
I0002 Legal aspects Autonomy of the patient Can future patients understand the implications of using/not using the 
technology? 
yes Can future patients understand the implications of using/not using the MSCT? 
I0003 Legal aspects Autonomy of the patient Are there relevant optional technologies that future patients should be 
allowed to consider? 
yes Are there relevant optional technologies for MSCT that future patients should be 
allowed to consider? 
I0004 Legal aspects Autonomy of the patient Is it possible to give future patients enough time to consider their decisions? yes Is it possible to give future patients enough time to consider their  MSCT related 
decisions? 
I0005 Legal aspects Autonomy of the patient Is it possible to obtain an advance directive on the use of the technology? yes Is it possible to obtain an advance directive on the use of MSCT coronary 
angiography? 
I0007 Legal aspects Privacy of the patient Does the use of the technology produce some additional (i.e. diagnostically 
or therapeutically irrelevant) information on the patient? 
  
I0008 Legal aspects Privacy of the patient Does the use of the technology produce such information on the patient that 
is not directly relevant to the disease/condition that is being diagnosed or 
tested 
yes Does the use of MSCT produce such information on the patient that is not directly 
relevant to the disease/condition that is being diagnosed or tested? 
I0033 Legal aspects Privacy of the patient Does the use of the technology produce information that would be relevant 
for the relatives of the patient  
yes Does the use of MSCT produce information that would be relevant for relatives of 
the patient? 
I0009 Legal aspects Privacy of the patient Can the access to the patient data be secured properly? yes Can the access to the patient data be secured properly? 
I0010 Legal aspects Privacy of the patient What levels of access to which kind of patient information exist in the chain 
of care? 
yes What levels of access to which kind of patient information exist in the chain of 
care? 
I0011 Legal aspects Equality in health care Is the technology equally accessible to all needing members in a given 
society? 
yes Is MSCT equally accessible to all needing members in a given society? 
I0012 Legal aspects Equality in health care Is the technology subsidized by the society? yes Is MSCT subsidized by the society? 
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ID Domain Topic Issue Relevance in 
the context of 
MSCT 
Yes/No 
Research question(s) in the context of MSCT 
Or Comment (if regarded as a not relevant issue in this context) 
I0013 Legal aspects Equality in health care Is there a wide variation in the acceptability of the technology across 
Europe? 
yes Is there a wide variation in the acceptability of MSCT across Europe? 
I0014 Legal aspects Equality in health care Is health-care tourism expected from/to other European countries? yes Is health-care tourism expected from/to other European countries? 
I0015 Legal aspects Authorisation & safety Has the technology national/EU level authorisation? yes Has MSCT national/EU level authorisation? 
I0016 Legal aspects Authorisation & safety Does the technology need to be listed in a national/EU register? yes Does MSCT need to be listed in a national/EU register?  
I0017 Legal aspects Authorisation & safety Does the technology fulfil product safety requirements? yes Does MSCT fulfil product/tissue safety requirements?  
I0018 Legal aspects Authorisation & safety Does the technology fulfil tissue safety requirements? no  
I0019 Legal aspects Ownership & liability Does the technology infringe some intellectual property right? yes Does MSCT infringe some intellectual property right? 
I0020 Legal aspects Ownership & liability Does the introduction of the technology presume some additional licensing 
fees to be paid? 
yes Does the introduction of MSCT presume some additional licensing fees to be 
paid?  
I0021 Legal aspects Ownership & liability What are the width, depth and length of the manufacturers guarantee? yes What are the width, depth and length of the manufacturers guarantee? 
I0022 Legal aspects Ownership & liability Is the user guide of the technology comprehensive enough? yes Is the user guide of MSCT comprehensive enough? 
I0023 Legal aspects Regulation of the market Is the technology subject to price control? yes Is MSCT subject to price control? 
I0024 Legal aspects Regulation of the market Is the technology subject to acquisition regulation? yes Is MSCT subject to acquisition regulation? 
I0025 Legal aspects Regulation of the market Is the marketing of the technology to the patients restricted? yes Is the marketing of MSCT to the patients restricted? 
I0026 Legal aspects Legal regulation of 
novel/experimental techniques 
Is the technology so novel existing legislation was not designed to cover its 
regulation? 
yes Is MSCT so novel existing legislation was not designed to cover its regulation? 
I0027 Legal aspects Legal regulation of 
novel/experimental techniques 
How are the liability issues solved according to existing legislation? yes How are the liability issues solved according to existing legislation? 
I0028 Legal aspects Legal regulation of 
novel/experimental techniques 
Are new legislative measures needed? yes Are new legislative measures needed? 
I0029 Legal aspects Legal regulation of 
novel/experimental techniques 
Is the voluntary participation of patients guaranteed properly? yes Is the voluntary participation of patients guaranteed properly? 
Appendix 1  Search Strategy: Pubmed 
(Day of search: 16.06.2008) 
  
Search strategy: 
  
#1 
Search coronary disease (195355) 
#2 
Search coronary AND disease* (392185) 
#3 
Search coronary AND (disease* OR vessel*) (437372) 
#4 
Search coronary AND (disease* OR vessel* OR arter* OR aneurysm* OR stenos* OR 
restenos* OR thrombos* OR vasospasm) (520363) 
#5 
Search #4 (520363) 
#6 
Search coronary AND vasospasm* (3815) 
#7 
Search (#4) OR (#6) (520366) 
#8 
Search angiograph* AND tomograph* (30630) 
#9 
Search coronary (1007000) 
#10 
Search (#7) AND (#8) (5778) 
#11 
Search (#7) AND (#8) Limits: published in the last 5 years (2722) 
#12 
Search msct OR mdct Limits: published in the last 5 years (2478) 
#13 
Search msct OR mdct (2730) 
#14 
Search slice OR row (23628) 
#15 
Search multislice OR multirow (2749) 
#16 
Search multi-slice (804) 
#17 
Search ((#16) OR (#15)) OR (#14) (25594) 
#18 
Search (#11) AND (#17) (938) 
#19 
Search ((((((coronary AND (disease* OR vessel* OR arter* OR aneurysm* OR stenos* OR 
restenos* OR thrombos* OR vasospasm))) OR ((coronary AND vasospasm*)))) AND 
((angiograph* AND tomograph*)) AND ("last 5 years"[PDat]))) AND (((((multi-slice)) OR 
((multislice OR multirow))) OR ((slice OR row)))) (938) 
#20 
Search autonomy (24249) 
#21 
Search autonomy or information* (546059) 
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#22 
Search autonomy OR information (541259) 
#23 
Search consent (41774) 
#24 
Search consent OR informed (58551) 
#25 
Search (#19) AND (#24) (18) 
#26 
Search medical file (2895) 
#27 
Search medical (file OR data) (378851) 
#28 
Search advance directive (5300) 
#29 
Search (#19) AND ((#27) OR (#28)) (64) 
#30 
Search privacy (11001) 
#31 
Search (#19) AND (#30) (0) 
#32 
Search tourism (1205) 
#33 
Search touris* (2556) 
#34 
Search (#33) AND (#19) (0) 
#35 
Search safety (191984) 
#36 
Search (safety) AND (#19) (13) 
#37 
Search ownership OR liability (40361) 
#38 
Search ((#37)) AND (#19) (1) 
#39 
Search property (42504) 
#40 
Search (property) AND (#19) (0) 
#41 
Search guarantee (6449) 
#42 
Search (guarantee ) AND (#19) (0) 
#43 
Search market (27402) 
#44 
Search (market) AND (#19) (1) 
#45 
Search (#19) AND ((#43) OR (#41) OR (#39) OR (#37) OR (#35) OR (#33) OR (#30) OR 
(#28) OR (#27) OR (#24) OR (#21)) (171) 
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Appendix 2  Search Strategy: CINAHL 
(Day of search: 18.06.2008) 
 
CINAHL Plus with Full Text, NHS Economic Evaluation Database (Trial), Health 
Technology Assessments (Trial), Cochrane Central Register of Controlled Trials (Trial), 
Cochrane Database of Systematic Reviews (Trial), Database of Abstracts of Reviews of 
Effects (Trial) 
 
Limiters - Published Date from: 2000/01-2008/06; Language: English; Date Abstract 
Published from: 2000-2008; Year of Publication - Reviews from: 2000-2008; Language: 
English; Date Abstract Published from: 2000-2008; Year of Publication - Reviews from: 
2000-2008; Language: English; Language: English; Year of Publication -- Reviews from: 
2000-2008; Year of Publication -- Protocols from: 2000-2008; Date Abstract Published from: 
2000-2008; Year of Publication -- Reviews from: 2000-2008; Language: English  
Expanders - Apply additional terms to query; Also search within the full text of the articles   
 
 
Search strategy: 
  
1. coronary disease (10508)   
2. coronary and ( disease$ or vessel$ or arter$ or aneurysm$ or stenos$ or 
restenos$ or thrombos$ or vasospam$ )  (33931) 
3. coronary angiography  (4467) 
4. angiography$ and tomography$ (2476) 
5. tomography X-ray Computed (11361) 
6. (S3) and (S5)  (377) 
7. ((S4) ) or (S6)  (2475) 
8. (S2) and (S7) (819) 
9. msct or mdct (309) 
10. (slice or row) and ((S2) or (S3) or (S7)) (968) 
11. ( (S1) and (S9) ) and informed consent (1) 
12. (S1) or (S9) and informed consent (10515) 
13. multirow or multislice or "multi-slice" or "multi slice" or multidetect$ or "multi 
detect$" or "multi-detect$" or nultidetct$ (515) 
14. ((S13) or (S9)) and coronary disease (67) 
15. S14 and informed consent (2) 
16. ( (S1) or (S2) ) and patient autonomy (63) 
17. (S16) and ((S13) or (S9))  (0) 
18. S9 and patient autonomy (0) 
19. (S13) and patient autonomy (0) 
20. ( (S13) or (S9) ) and advanced directives (0) 
21. ( (S1 ) and (S2) ) and patient data (53) 
22. S21 and ( S9 or S13 ) (0) 
23. ( S9 or S13 ) and patient data (10) 
24. ( S9 or S13 ) and ( equality and access ) (0) 
25.  ( S9 or S13 ) and equality  (0) 
26. ( S9 or S13 ) and access  (0) 
27. ( S1 or S2 ) and equality (213) 
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28. (S27) and (S9 or S13) (0) 
29. (S9 or S13 ) and acceptability (0) 
30. ( S9 or S13 ) and tourism  (0) 
31. ( S1 or S2 ) and tourism (0) 
32. ( S9 or S13 ) and authorisation  (0) 
33. ( S1 or S2 ) and authorisation (0) 
34. ( S9 or S13 ) and safety (0) 
35. ( S1 or S2 ) and safety (0) 
36. ( S9 or S13 ) and property right (0) 
37. ( S9 or S13 ) and ownership (0) 
38. ( S9 or S13 ) and liability (0) 
39. ( S9 or S13 ) and patent (0) 
40. ( S9 or S13 ) and licensing fee (0) 
41. ( S9 or S13 ) and price control (0) 
42. ( S9 or S13 ) and guarantee (0) 
43. ( S9 or S13 ) and market$ (0) 
44.  ( S9 or S13 ) and experiment$ (0) 
45. ( S9 or S13 ) and ( legislation or legal rules ) (0) 
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Appendix 3  Search Strategy: Emerald 
(Day of search: 17.07.2008) 
 
Search strategy: 
1. coronary disease (765) 
2. (1) AND computed tomography OR CT (35) 
3. (1) AND (2) AND patient informed consent (0) 
4. (1) AND (2) AND patient autonomy (2) 
5. (1) AND (2) AND advances directive  (0) 
6. (1) AND (2) AND patient data (14) 
7.  (1) AND (2) AND equality OR access (6) 
8. (1) AND (2) AND acceptability (0) 
9. (1) AND (2) AND medical tourism (0) 
10. (1) AND (2) AND authorization (0) 
11. (1) AND (2) AND safety (0) 
12. (1) AND (2) AND property right (0) 
13. (1) AND (2) AND ownership (0) 
14. (1) AND (2) AND liability (0) 
15. (1) AND (2) AND patent (0) 
16. (1) AND (2) AND licensing fee (0) 
17. (1) AND (2) AND price control (0) 
18. (1) AND (2) AND guarantee (0) 
19. (1) AND (2) AND market$ (2) 
20. (1) AND (2) AND legislation (0) 
 
 
 
 
